FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Cruz, TA
   Pinho, MB
   Castilho, LR
AF Cruz, Thayana A.
   Pinho, Marcos B.
   Castilho, Leda R.
TI Evaluation of different IRES-mediated tricistronic plasmid designs for
   expression of an anti-PCSK9 biosimilar monoclonal antibody in CHO cells
SO BIOTECHNOLOGY LETTERS
LA English
DT Article
DE Anti-PCSK9 monoclonal antibody; Biosimilar development; CHO cells;
   Critical quality attributes; IRES-mediated tricistronic plasmids
ID SELECTION
AB Objectives To compare different approaches for the expression of an anti-PCSK9 biosimilar monoclonal antibody (mAb) in CHO cells using IRES-mediated tricistronic plasmid vectors combining different signal peptides, IRES elements and selection markers. Results Transient transfection indicated a similar level of secreted mAb 48 h post-transfection for all constructs. However, transfections carried out with circular plasmids showed a higher expression than with linearized plasmids. After two months under selection pressure, only part of the transfected pools recovered. The cultures co-transfected using two antibiotics as selection markers for double selection did not recover. Growth, metabolism and mAb production profiles of the only part of the transfected pools recovered resulting stable pools were compared and the stable pool transfected with circular L1-LC-IRES-H7-HC-IRES-NEO plasmid was chosen for further studies, due to higher cell growth and mAb production. Critical quality attributes of the protein A-purified mAb such as purity, homogeneity, binding affinity to PCSK9, and amino acid sequence were assessed confirming the success of the approach adopted in this study. Conclusions The expression platform proposed showed to be efficient to produce a high-quality anti-PCSK9 mAb in stable CHO cell pools and provides benchmarks for fast production of different mAbs for characterization, formulation studies and pre-clinical investigation.
C1 [Cruz, Thayana A.; Pinho, Marcos B.; Castilho, Leda R.] Fed Univ Rio de Janeiro UFRJ, COPPE, Cell Culture Engn Lab LECC, Chem Engn Program, Cx Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
   [Cruz, Thayana A.; Castilho, Leda R.] Fed Univ Rio de Janeiro UFRJ, Biochem Program, IQ, BR-21941909 Rio De Janeiro, Brazil.
   [Cruz, Thayana A.] Libbs Farmaceut, BR-06807461 Sao Paulo, SP, Brazil.
   [Pinho, Marcos B.] Caris Life Sci Inc, 4610 South 44th Pl, Phoenix, AZ 85040 USA.
RP Castilho, LR (corresponding author), Fed Univ Rio de Janeiro UFRJ, COPPE, Cell Culture Engn Lab LECC, Chem Engn Program, Cx Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
EM leda@peq.coppe.ufrj.br
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX The authors would like to acknowledge the Brazilian research funding
   agencies CAPES, CNPq, and FAPERJ for financial support. The authors also
   thank Augusto Vieira (UEMP/UFRJ) and Eduardo Matos (CEMBIO/UFRJ) for
   support in the peptide mapping assay.
CR Ahmadi S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179902
   Balasubramanian S, 2016, BIOTECHNOL BIOENG, V113, P1234, DOI 10.1002/bit.25888
   Bayat H, 2018, PREP BIOCHEM BIOTECH, V48, P160, DOI 10.1080/10826068.2017.1421966
   Berkowitz SA, 2012, NAT REV DRUG DISCOV, V11, P527, DOI 10.1038/nrd3746
   Catapano AL, 2017, VASC HEALTH RISK MAN, V13, P343, DOI 10.2147/VHRM.S130338
   EMA, 2015, COMM MED PROD HUM US
   Haryadi R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116878
   Ho SCL, 2013, J BIOTECHNOL, V165, P157, DOI 10.1016/j.jbiotec.2013.03.019
   Ho SCL, 2012, J BIOTECHNOL, V157, P130, DOI 10.1016/j.jbiotec.2011.09.023
   Kirchhoff CF, 2017, BIOTECHNOL BIOENG, V114, P2696, DOI 10.1002/bit.26438
   Kunert R, 2016, APPL MICROBIOL BIOT, V100, P3451, DOI 10.1007/s00253-016-7388-9
   McLenachan S, 2007, GENOMICS, V89, P708, DOI 10.1016/j.ygeno.2007.02.006
   Ng SK, 2010, BIOTECHNOL PROGR, V26, P11, DOI 10.1002/btpr.281
   Noh SM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23720-9
   Rahimpour A, 2016, BIOL MED ALIGARH, V8, P341
   Stuchbury G, 2010, CYTOTECHNOLOGY, V62, P189, DOI 10.1007/s10616-010-9273-1
   von Groll A, 2006, BIOTECHNOL PROGR, V22, P1220, DOI 10.1021/bp060029s
   WHO, 2013, WHO DRUG INFORM, V27
   Wirth M, 1997, MAMMALIAN CELL BIOTECHNOLOGY IN PROTEIN PRODUCTION, P121
   Yang Y, 2018, J BIOCHEM, V163, P391, DOI 10.1093/jb/mvy007
   Yeo JHM, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201700175
   Zagari F, 2013, NEW BIOTECHNOL, V30, P238, DOI 10.1016/j.nbt.2012.05.021
NR 22
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-5492
EI 1573-6776
J9 BIOTECHNOL LETT
JI Biotechnol. Lett.
PD DEC
PY 2020
VL 42
IS 12
BP 2511
EP 2522
DI 10.1007/s10529-020-02952-8
EA JUL 2020
PG 12
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA OG6AO
UT WOS:000549311200002
PM 32676798
DA 2020-12-08
ER

PT J
AU Bettinardi, IW
   Castan, A
   Medronho, RA
   Castilho, LR
AF Bettinardi, Iona W.
   Castan, Andreas
   Medronho, Ricardo A.
   Castilho, Leda R.
TI Hydrocyclones as cell retention device for CHO perfusion processes in
   single-use bioreactors
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE CHO cells; hydrocyclone; perfusion; separation efficiency; single-use
   bioreactor
ID HIGH-DENSITY; SEPARATION EFFICIENCY; SUSPENSION-CULTURE; HYBRIDOMA
   CELLS; TFF; ATF; GLYCOSYLATION; PERFORMANCE; REDUCTION; VIABILITY
AB In this study, a hydrocyclone (HC) especially designed for mammalian cell separation was applied for the separation of Chinese hamster ovary cells. The effect of key features on the separation efficiency, such as type of pumphead in the peristaltic feed pump, use of an auxiliary pump to control the perfusate flow rate, and tubing size in the recirculation loop were evaluated in batch separation tests. Based on these preliminary batch tests, the HC was then integrated to 50-L disposable bioreactor bags. Three perfusion runs were performed, including one where perfusion was started from a low-viability late fed-batch culture, and viability was restored. The successive runs allowed optimization of the HC-bag configuration, and cultivations with 20-25 days duration at cell concentrations up to 50 x 10(6)cells/ml were performed. Separation efficiencies up to 96% were achieved at pressure drops up to 2.5 bar, with no issues of product retention. To our knowledge, this is the first report in literature of high cell densities obtained with a HC integrated to a disposable perfusion bioreactor.
C1 [Bettinardi, Iona W.; Castilho, Leda R.] Fed Univ Rio de Janeiro UFRJ, COPPE PEQ, Cell Culture Engn Lab LECC, Rio De Janeiro, RJ, Brazil.
   [Castan, Andreas] GE Healthcare Biosci AB, BioProc R&D, Uppsala, Sweden.
   [Medronho, Ricardo A.] Fed Univ Rio de Janeiro UFRJ, Sch Chem, Dept Chem Engn, Rio De Janeiro, RJ, Brazil.
RP Castilho, LR (corresponding author), PEQ COPPE UFRJ, Cx Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
EM leda@peq.coppe.ufrj.br
RI ; Medronho, Ricardo/Q-1762-2015
OI Castan, Andreas/0000-0002-5210-6558; Walter Bettinardi,
   Iona/0000-0002-9596-2848; Medronho, Ricardo/0000-0001-5603-9762
FU GE HealthcareGE Healthcare [Coppetec-PEQ20761] Funding Source: Medline;
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior [Programa de
   Excelencia Academica - PROEX] Funding Source: Medline; Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico [Doutorado GD
   /140752/2017-0, PQ-1D / 312328/2013-3] Funding Source: Medline; Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro
   [Cientistas do Nosso Estado / 202.973/2015] Funding Source: Medline
CR BATT BC, 1990, BIOTECHNOL PROGR, V6, P458, DOI 10.1021/bp00006a600
   Bhardwaj P, 2011, LAB CHIP, V11, P4012, DOI 10.1039/c1lc20606k
   Castilho L., 2008, ANIMAL CELL TECHNOLO
   Castilho LR, 2015, CONTINUOUS PROCESSING IN PHARMACEUTICAL MANUFACTURING, P115
   Castilho Leda R, 2002, Adv Biochem Eng Biotechnol, V74, P129
   Chotteau V, 2015, CELL ENG, V9, P407, DOI 10.1007/978-3-319-10320-4_13
   Clincke MF, 2013, BIOTECHNOL PROGR, V29, P754, DOI 10.1002/btpr.1704
   Dalm MCF, 2004, BIOTECHNOL BIOENG, V88, P547, DOI 10.1002/bit.20287
   Davailles A, 2012, SEP PURIF TECHNOL, V92, P152, DOI 10.1016/j.seppur.2011.12.011
   Deckwer W. D., 2005, US Patent Application, Patent No. [6,878,545 B2, 6878545]
   Elsayed EA, 2006, ENG LIFE SCI, V6, P347, DOI 10.1002/elsc.200620137
   Elsayed E. A., 2005, THESIS
   Elsayed EA, 2012, ESACT PROCEED, V5, P341, DOI 10.1007/978-94-007-0884-6_53
   Gagnon M, 2018, BIOTECHNOL PROGR, V34, P1472, DOI 10.1002/btpr.2723
   Golovanchikov AB, 2018, CHEM PETROL ENG+, V54, P118, DOI 10.1007/s10556-018-0449-4
   HILLER GW, 1993, BIOTECHNOL BIOENG, V42, P185, DOI 10.1002/bit.260420206
   Hossler P, 2009, GLYCOBIOLOGY, V19, P936, DOI 10.1093/glycob/cwp079
   Jockwer A, 2001, ESACT PROCEED, V1, P301
   Karst DJ, 2016, BIOCHEM ENG J, V110, P17, DOI 10.1016/j.bej.2016.02.003
   Karst DJ, 2018, CURR OPIN BIOTECH, V53, P76, DOI 10.1016/j.copbio.2017.12.015
   Konstantinov K, 2006, ADV BIOCHEM ENG BIOT, V101, P75, DOI 10.1007/10_016
   Kwon T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06949-8
   Luebberstedt M., 2000, P WORLD C BIOT, P460
   Mayrhofer P., 2019, P 26 ANN M EUR SOC A, P1190
   Medronho RA, 2005, LAT AM APPL RES, V35, P1
   MERCILLE S, 1994, BIOTECHNOL BIOENG, V43, P833, DOI 10.1002/bit.260430902
   Mognon JL, 2016, SEP SCI TECHNOL, V51, P370, DOI 10.1080/01496395.2015.1086374
   Ortega-Rivas E, 2004, ENG LIFE SCI, V4, P119, DOI 10.1002/elsc.200402004
   Patil R., 2017, NEW BIOPROCESSING ST, P277, DOI 10.1007/10_2016_58
   Pinto RCV, 2008, CYTOTECHNOLOGY, V56, P57, DOI 10.1007/s10616-007-9108-x
   Reinhart D, 2018, J BIOTECHNOL, V285, P23, DOI 10.1016/j.jbiotec.2018.08.013
   RICKWOOD D, 1992, FLUID MEC A, V12, P109
   Ryll T, 2000, BIOTECHNOL BIOENG, V69, P440, DOI 10.1002/1097-0290(20000820)69:4<440::AID-BIT10>3.0.CO;2-0
   Sanchez-De Melo I, 2015, J PROTEOMICS, V127, P225, DOI 10.1016/j.jprot.2015.04.012
   Schroder B, 2010, ESACT PROCEED, V4, P657, DOI 10.1007/978-90-481-3419-9_113
   Sieck J. B., 2017, CONTINUOUS BIOMANUFA, P171, DOI 10.1002/9783527699902.ch7
   Syed MS, 2017, LAB CHIP, V17, P2459, DOI 10.1039/c7lc00294g
   Takagi M, 2000, J BIOSCI BIOENG, V89, P340, DOI 10.1016/S1389-1723(00)88956-2
   Voisard D, 2003, BIOTECHNOL BIOENG, V82, P751, DOI 10.1002/bit.10629
   Wagner R., 2011, BMC P S8, V5, pP65
   Walker N., 2017, PERFUSION APPEARS BE
   Wang S, 2017, J BIOTECHNOL, V246, P52, DOI 10.1016/j.jbiotec.2017.01.020
   Woodside SM, 1998, CYTOTECHNOLOGY, V28, P163, DOI 10.1023/A:1008050202561
   Xu S, 2016, J BIOTECHNOL, V231, P149, DOI 10.1016/j.jbiotec.2016.06.019
   Yu JF, 2020, SEP SCI TECHNOL, V55, P313, DOI 10.1080/01496395.2019.1565772
   Zhang Y, 2015, J BIOTECHNOL, V213, P28, DOI 10.1016/j.jbiotec.2015.07.006
NR 46
TC 0
Z9 0
U1 8
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-3592
EI 1097-0290
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD JUL
PY 2020
VL 117
IS 7
BP 1915
EP 1928
DI 10.1002/bit.27335
PG 14
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA LX7QT
UT WOS:000540022600001
PM 32181883
DA 2020-12-08
ER

PT J
AU Alvim, RGF
   Itabaiana, I
   Castilho, LR
AF Alvim, Renata G. F.
   Itabaiana Jr, Ivaldo
   Castilho, Leda R.
TI Zika virus-like particles (VLPs): Stable cell lines and continuous
   perfusion processes as a new potential vaccine manufacturing platform
SO VACCINE
LA English
DT Article
DE Virus-like particles (VLPs); Zika virus; HEK293 cells; Stable
   expression; Perfusion; Upstream process
ID SECRETION; OUTBREAK; ANTIBODY; FUSION; REGION
AB Zika virus (ZIKV) was first detected in Brazil in 2015 and then rapidly spread to more than 80 countries in Africa, Asia and the Americas. ZIKV infection was correlated with severe congenital malformations in newborns from infected mothers, as well as with Guillain-Barre syndrome in adults. Although the number of infected people has declined in the affected countries lately, the development of a vaccine for ZIKV is of great importance to avoid the future resurgence of the virus in endemic areas or the future spread to currently non-endemic regions. Among many different platforms currently under study, virus-like particles (VLPs) are a promising alternative for the development of vaccines, since tridimensional particles mimicking the virus - but lacking its genome - can be produced and present the antigen in a repetitive way, potentially eliciting robust immune responses. In this work, we demonstrated the generation of stably transfected HEK293 cells constitutively expressing Zika VLPs. Small-scale shake flask studies using a stable cell pool enriched by Fluorescence-Activated Cell Sorting (FACS) showed that daily medium exchange (intermittent perfusion) significantly enhances viable cell density and VLP production (similar to 4-fold) over batch cultures. Continuous perfusion in a controlled bioreactor coupled to an ATF-2 cell retention device resulted in maximum VLP titers similar to those obtained under small-scale intermittent perfusion. Our results show that the use of cell lines constitutively expressing Zika VLPs, cultured in stirred-tank perfusion bioreactors, represents a promising system for the production of a VLP-based Zika vaccine candidate. (C) 2019 Elsevier Ltd.
C1 [Alvim, Renata G. F.; Castilho, Leda R.] Fed Univ Rio de Janeiro UFRJ, Cell Culture Engn Lab, COPPE, Cx Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
   [Alvim, Renata G. F.; Itabaiana Jr, Ivaldo] Fed Univ Rio de Janeiro UFRJ, Sch Chem EQ, Dept Biochem Engn, BR-21941909 Rio De Janeiro, RJ, Brazil.
RP Castilho, LR (corresponding author), Fed Univ Rio de Janeiro UFRJ, Cell Culture Engn Lab, COPPE, Cx Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
EM leda@peq.coppe.ufrj.br
RI Itabaiana, Ivaldo/A-6308-2014
OI Itabaiana, Ivaldo/0000-0003-0725-0881
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); Janssen Brazil; JLabs
FX The authors wish to acknowledge financial support from the Brazilian
   funding agencies CNPq, CAPES and FAPERJ; financial support granted by
   JLabs and Janssen Brazil in the context of the "Latin-America Quick Fire
   Challenge 2016"; reagents and media donated by GE Healthcare, Xell AG
   and Merck Millipore; and the HEK293-3F6 cell line provided by NRC
   Canada. The authors also thank T. Brunswick and T. Gonsalves (CENABIO,
   Federal University of Rio de Janeiro) for technical help during cell
   sorting experiments, and B. S. Graham (Vaccine Research Center, NIH) for
   sharing analytical reagents.; All authors attest they meet the ICMJE
   criteria for authorship.
CR Boigard H, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005608
   Brezinsky SCG, 2003, J IMMUNOL METHODS, V277, P141, DOI 10.1016/S0022-1759(03)00108-X
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Castilho LR, 2015, CONTINUOUS PROCESSING IN PHARMACEUTICAL MANUFACTURING, P115
   Chackerian B, 2007, EXPERT REV VACCINES, V6, P381, DOI 10.1586/14760584.6.3.381
   Chang G.J.J., 1998, Patent, Patent No. [US8221768132, 8221768132]
   Chang GJJ, 2003, VIROLOGY, V306, P170, DOI 10.1016/S0042-6822(02)00028-4
   Crill WD, 2007, J GEN VIROL, V88, P1169, DOI 10.1099/vir.0.82640-0
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dowd KA, 2016, SCIENCE, V354, P237, DOI 10.1126/science.aai9137
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Espinosa D, 2018, EBIOMEDICINE, V27, P61, DOI 10.1016/j.ebiom.2017.12.010
   Esposito DLA, 2015, J GEN VIROL, V96, P1702, DOI 10.1099/vir.0.000113
   Fontana D, 2015, VACCINE, V33, P4238, DOI 10.1016/j.vaccine.2015.03.088
   Fuenmayor J, 2017, NEW BIOTECHNOL, V39, P174, DOI 10.1016/j.nbt.2017.07.010
   Fuenmayor J, 2019, J CHEM TECHNOL BIOT, V94, P302, DOI 10.1002/jctb.5777
   Goudar CT, 2015, J BIOTECHNOL, V213, P1, DOI 10.1016/j.jbiotec.2015.08.015
   Gutierrez-Granados S, 2018, CURR OPIN CHEM ENG, V22, P107, DOI 10.1016/j.coche.2018.09.009
   Heukelbach J, 2016, J INFECT DEV COUNTR, V10, P116, DOI 10.3855/jidc.8217
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lima TM, 2019, VACCINE, V37, P7071
   Lin HH, 2018, BIOTECHNOL ADV, V36, P47, DOI 10.1016/j.biotechadv.2017.09.004
   Nikolay A, 2018, APPL MICROBIOL BIOT, V102, P8725, DOI 10.1007/s00253-018-9275-z
   Nikolay A, 2018, VACCINE, V36, P3140, DOI 10.1016/j.vaccine.2017.03.018
   Oehler E., 2014, Eurosurveillance, V19, P20720
   Okumura T, 2015, J BIOSCI BIOENG, V120, P340, DOI 10.1016/j.jbiosc.2015.01.007
   Pierson TC, 2008, CELL HOST MICROBE, V4, P229, DOI 10.1016/j.chom.2008.08.004
   Pijlman GP, 2015, BIOTECHNOL J, V10, P659, DOI 10.1002/biot.201400427
   Purdy DE, 2005, VIROLOGY, V333, P239, DOI 10.1016/j.virol.2004.12.036
   Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI 10.1586/ERV.10.115
   Song M, 2011, J CHEM TECHNOL BIOT, V86, P935, DOI 10.1002/jctb.2618
   Trainor NB, 2007, VIROLOGY, V360, P398, DOI 10.1016/j.virol.2006.10.033
   Venereo-Sanchez A, 2017, VACCINE, V35, P4220, DOI 10.1016/j.vaccine.2017.06.024
   Wilder-Smith A, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1067-x
   World Health Organization, 2017, ZIK VIR MICR GUILL B
   World Health Organization, WHO ZIK VIR COMPL 20
NR 37
TC 3
Z9 3
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 8
PY 2019
VL 37
IS 47
SI SI
BP 6970
EP 6977
DI 10.1016/j.vaccine.2019.05.064
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JN4GT
UT WOS:000496858100006
PM 31164305
OA Other Gold
DA 2020-12-08
ER

PT J
AU Lima, TM
   Souza, MO
   Castilho, LR
AF Lima, Tulio M.
   Souza, Matheus O.
   Castilho, Leda R.
TI Purification of flavivirus VLPs by a two-step chomatographic process
SO VACCINE
LA English
DT Article
DE Virus-like particles (VLPs); Yellow fever virus; Zika virus; Downstream
   processing; Chromatographic purification
ID VIRUS-LIKE PARTICLES; EXCHANGE MEMBRANE CHROMATOGRAPHY; YELLOW-FEVER;
   OUTBREAK
AB Flaviviruses are enveloped viruses with positive-sense, single-stranded RNA, which are most commonly transmitted by infected mosquitoes. Zika virus (ZIKV) and yellow fever virus (YFV) are flaviviruses that have caused significant outbreaks in the last few years. Since there is no approved vaccine against ZIKV, and since the existing YF attenuated vaccine presents disadvantages related to limited supply and to rare, but fatal adverse effects, there is an urgent need for new vaccines to control these diseases. Virus-like particles (VLPs) represent a recombinant platform to produce safe and immunogenic vaccines. Thus, based on our experience of expressing in recombinant mammalian cells VLPs of most flaviviruses circulating in the Americas, this work focused on the evaluation of chromatographic purification processes for zika and yellow-fever VLPs. The clarified cell culture supernatant was processed by a membrane-based anion-exchange chromatography and then a multimodal chromatographic step. With this process, it was possible to obtain the purified VLPs with a yield (including the clarification step) of 66.4% for zika and 68.1% for yellow fever. DNA clearance was in the range of 99.8-99.9%, providing VLP preparations that meet the WHO limit for this critical contaminant. Correct size and morphology of the purified VLPs were confirmed by dynamic light scattering (DLS) and transmission electron microscopy (TEM). The promising results obtained for both zika and yellow fever VLPs indicate that this process could be potentially applied also to VLPs of other flaviviruses. (C) 2019 Elsevier Ltd.
C1 [Lima, Tulio M.; Souza, Matheus O.; Castilho, Leda R.] Fed Univ Rio Janeiro UFRJ, COPPE, Cell Culture Engn Lab, Av Horacio Macedo,2030 Sl G115,Cidade Univ, BR-21941598 Rio De Janeiro, Brazil.
   [Lima, Tulio M.] Fed Univ Rio Janeiro UFRJ, EQ, EPQB Grad Program, Av Horacio Macedo,2030 Sl E206,Cidade Univ, BR-21941598 Rio De Janeiro, Brazil.
   [Souza, Matheus O.] Univ Kansas, Dept Pharmaceut Chem, Immune Engn Lab, 2095 Constant Ave, Lawrence, KS 66047 USA.
RP Castilho, LR (corresponding author), Fed Univ Rio Janeiro UFRJ, COPPE, Cell Culture Engn Lab, Av Horacio Macedo,2030 Sl G115,Cidade Univ, BR-21941598 Rio De Janeiro, Brazil.
EM leda@peq.coppe.ufrj.br
FU Brazilian research funding agency CNPq; Brazilian research funding
   agency CapesCAPES; Brazilian research funding agency Faperj
FX Financial support from the Brazilian research funding agencies CNPq,
   Capes and Faperj is gratefully acknowledged.
CR Alvim RGF, 2019, VACCINE, V37, P6970, DOI 10.1016/j.vaccine.2019.05.064
   Barzon L, 2017, EXPERT OPIN BIOL TH, V17, P1185, DOI 10.1080/14712598.2017.1346081
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Soler JC, 2009, GAC SANIT, V23, P295, DOI 10.1016/j.gaceta.2008.09.008
   Chang C, 2016, J AUTOIMMUN, V68, P1, DOI 10.1016/j.jaut.2016.02.006
   Chen Y, 2015, VACCINE, V33, P4300, DOI 10.1016/j.vaccine.2015.03.078
   DAI S, 2018, J IMMUNOL SCI, V2, P36, DOI DOI 10.29245/2578-3009/2018/2.1118
   Effio CL, 2016, J CHROMATOGR A, V1429, P142, DOI 10.1016/j.chroma.2015.12.006
   ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405
   Espinosa D, 2018, EBIOMEDICINE, V27, P61, DOI 10.1016/j.ebiom.2017.12.010
   Foster KR, 1998, SCI AM, V279, P88, DOI 10.1038/scientificamerican0898-88
   Gardner CL, 2010, CLIN LAB MED, V30, P237, DOI 10.1016/j.cll.2010.01.001
   Goldani LZ, 2017, BRAZ J INFECT DIS, V21, P123, DOI 10.1016/j.bjid.2017.02.004
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Hughson MD, 2017, BIOTECHNOL PROGR, V33, P931, DOI 10.1002/btpr.2501
   Kaaijk P, 2018, HUM VACC IMMUNOTHER, V14, P337, DOI 10.1080/21645515.2017.1389363
   Klitting R, 2018, GENES-BASEL, V9, DOI 10.3390/genes9060291
   Litvoc MN, 2018, REV ASSOC MED BRAS, V64, P106, DOI 10.1590/1806-9282.64.02.106
   Martins RD, 2018, VACCINE, V36, P4112, DOI 10.1016/j.vaccine.2018.05.041
   Middelberg PJA, 2013, PHARM BIOPROCESS, V1, P407
   Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067
   Native Antigen Company (NAC), 2019, ZIK VIR VLP CERT AN
   Native Antigen Company (NAC), 2019, DENG VIR SER 2 ENV P
   Nestola P, 2015, J CHROMATOGR A, V1426, P91, DOI 10.1016/j.chroma.2015.11.037
   O'Higgins T, 2014, ECOL SOC, V19, DOI 10.5751/ES-06507-190446
   Ohtaki N, 2011, J VIROL METHODS, V174, P131, DOI 10.1016/j.jviromet.2011.03.021
   PAHO/WHO, 2015, ZIK CAS CONG SYNDR A
   Pato TP, 2019, VACCINE, V37, P3214, DOI 10.1016/j.vaccine.2019.04.077
   Pato TP, 2014, VACCINE, V32, P2789, DOI 10.1016/j.vaccine.2014.02.036
   Paules CI, 2017, NEW ENGL J MED, V376, P1397, DOI 10.1056/NEJMp1702172
   Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI 10.1586/ERV.10.115
   Shearer FM, 2017, LANCET INFECT DIS, V17, P1209, DOI 10.1016/S1473-3099(17)30419-X
   Shi L, 2005, J PHARM SCI-US, V94, P1538, DOI 10.1002/jps.20377
   Song BH, 2017, J NEUROIMMUNOL, V308, P50, DOI 10.1016/j.jneuroim.2017.03.001
   Vicente T, 2008, J MEMBRANE SCI, V311, P270, DOI 10.1016/j.memsci.2007.12.021
   Vicente T, 2011, J INVERTEBR PATHOL, V107, pS42, DOI 10.1016/j.jip.2011.05.004
   Vogel JH, 2012, BIOTECHNOL BIOENG, V109, P3049, DOI 10.1002/bit.24578
   Wasserman S, 2016, INT J INFECT DIS, V48, P98, DOI 10.1016/j.ijid.2016.04.025
   World Health Organization, 2007, WHO STUD GROUP CELL
   World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069
   Zhao D, 2015, J APPL MICROBIOL, V119, P1196, DOI 10.1111/jam.12922
NR 41
TC 4
Z9 5
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 8
PY 2019
VL 37
IS 47
SI SI
BP 7061
EP 7069
DI 10.1016/j.vaccine.2019.05.066
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JN4GT
UT WOS:000496858100016
PM 31201056
OA Other Gold
DA 2020-12-08
ER

PT J
AU Silva, JD
   Mascarin, GM
   de Castro, RDV
   Castilho, LR
   Freire, DMG
AF Silva, Jaqueline do Nascimento
   Mascarin, Gabriel M.
   Vieira de Castro, Rui de Paula
   Castilho, Leda R.
   Freire, Denise M. G.
TI Novel combination of a biosurfactant with entomopathogenic fungi
   enhances efficacy against Bemisia whitefly
SO PEST MANAGEMENT SCIENCE
LA English
DT Article
DE Rhamnolipid; biological control; Cordycipitaceae; Bemisia tabaci;
   conidia
ID HEMIPTERA ALEYRODIDAE; BEAUVERIA-BASSIANA; VIRULENCE; BIOTYPE;
   REPRODUCTION; SURFACTANTS; OIL
AB BACKGROUND Microbial surfactants are multifunctional surface-active molecules that have been overlooked in formulating microbial biopesticides. We report a novel approach using the biosurfactant rhamnolipid (RML) against the destructive cosmopolitan insect pest Bemisia tabaci, as well as the combined action of RML with aerial conidia of two entomopathogenic fungi, Cordyceps javanica and Beauveria bassiana. RML was also tested as a suspension agent to improve the recovery rate of conidia from solid substrate for fungal preparations. RESULTS The recovery rate of conidia increased dramatically (two to five times) with RML compared with a standard surfactant (Tween 80). Spraying solutions of 0.075% and 0.1% (w/v) RML on B. tabaci third instar nymphs induced 100% mortality within 4 days. Conidial suspensions at 5 x 10(6) conidia/mL amended with RML at 0.01% or 0.05% markedly increased nymphal mortalities and considerably reduced LC50. Conidial suspensions of B. bassiana with 0.05% RML added were more effective against whitefly nymphs (87.3% mortality) than C. javanica + RML (51.4% mortality). CONCLUSION Our results show that this bacterium-based RML improved the recovery rate of hydrophobic conidia, and that mixtures of RML with fungal spore suspensions increased their insecticidal activity. (c) 2019 Society of Chemical Industry
C1 [Silva, Jaqueline do Nascimento; Castilho, Leda R.] Univ Fed Rio de Janeiro, Chem Engn Program, COPPE, Rio De Janeiro, Brazil.
   [Mascarin, Gabriel M.] Embrapa Meio Ambiente, Rodovia SP-340,Km 127-5 S-N, BR-13820000 Jaguariuna, SP, Brazil.
   [Vieira de Castro, Rui de Paula; Freire, Denise M. G.] Univ Fed Rio de Janeiro, Dept Biochem, Inst Chem, Rio De Janeiro, Brazil.
RP Mascarin, GM (corresponding author), Embrapa Meio Ambiente, Rodovia SP-340,Km 127-5 S-N, BR-13820000 Jaguariuna, SP, Brazil.
EM gabriel.mascarin@embrapa.br
RI Mascarin, Gabriel Moura/E-4646-2015
OI Mascarin, Gabriel Moura/0000-0003-3517-6826
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ) [200.369/2016] Funding Source: Medline
CR Anna LMS, 2001, APPL BIOCHEM BIOTECH, V91-3, P459
   Awada S. M., 2005, CA, Patent No. [2566864 C, 2566864, CA 2566864]
   Burnham KP, 2002, MODEL SELECTION MULT
   Chong HQ, 2017, MICROB CELL FACT, V16, DOI 10.1186/s12934-017-0753-2
   de Araujo LV, 2016, FOOD CONTROL, V63, P171, DOI 10.1016/j.foodcont.2015.11.036
   Gasic S., 2013, Pesticidi i Fitomedicina, V28, P97
   Gatarayiha MC, 2010, EXP APPL ACAROL, V50, P217, DOI 10.1007/s10493-009-9307-6
   Glare T, 2012, TRENDS BIOTECHNOL, V30, P250, DOI 10.1016/j.tibtech.2012.01.003
   Griffin W.C, 1949, J SOC COSMET CHEM, V1, P311
   Hardin J.W., 2012, GEN LINEAR MODELS EX
   James RR, 2001, J INVERTEBR PATHOL, V77, P99, DOI 10.1006/jipa.2000.5001
   Jin XX, 2008, BIOL CONTROL, V46, P226, DOI 10.1016/j.biocontrol.2008.03.008
   Kamal A, 2012, J MICROBIOL BIOTECHN, V22, P69, DOI 10.4014/jmb.1105.05008
   Kepler RM, 2017, IMA FUNGUS, V8, P335, DOI 10.5598/imafungus.2017.08.02.08
   Kim JS, 2010, J INVERTEBR PATHOL, V105, P322, DOI 10.1016/j.jip.2010.08.008
   Kim SK, 2011, J AGR FOOD CHEM, V59, P934, DOI 10.1021/jf104027x
   Lesnoff M, 2013, ANAL OVERDISPERSED D
   Liu TX, 2000, PEST MANAG SCI, V56, P861, DOI 10.1002/1526-4998(200010)56:10<861::AID-PS217>3.0.CO;2-Y
   Maier RM, 2000, APPL MICROBIOL BIOT, V54, P625, DOI 10.1007/s002530000443
   Mascarin GM, 2018, MICROBIOL RES, V216, P12, DOI 10.1016/j.micres.2018.08.002
   Mascarin GM, 2014, BIOCONTROL, V59, P111, DOI 10.1007/s10526-013-9543-x
   Mascarin GM, 2013, BIOL CONTROL, V66, P209, DOI 10.1016/j.biocontrol.2013.05.001
   Mitchell DA, 2006, SOLID-STATE FERMENTATION BIOREACTORS: FUNDAMENTALS OF DESIGN AND OPERATION, P45, DOI 10.1007/3-540-31286-2_4
   Navas-Castillo J, 2011, ANNU REV PHYTOPATHOL, V49, P219, DOI 10.1146/annurev-phyto-072910-095235
   Pedrini N, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00024
   Oliveira DGP, 2015, J MICROBIOL METH, V119, P44, DOI 10.1016/j.mimet.2015.09.021
   Quintela ED, 2016, PEST MANAG SCI, V72, P2181, DOI 10.1002/ps.4259
   R Core Team, 2014, LANG ENV STAT COMP
   Reddy KS, 2016, BIORESOURCE TECHNOL, V221, P291, DOI 10.1016/j.biortech.2016.09.041
   Reis RS, 2010, PROCESS BIOCHEM, V45, P1504, DOI 10.1016/j.procbio.2010.05.032
   Ritz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146021
   Santos AS, 2002, PEERJ, V4, pe2078
   Silva JD, 2018, APPL MICROBIOL BIOT, V102, P2595, DOI 10.1007/s00253-018-8805-z
   Silva VL, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00088
   Thakore Y., 2006, Industrial biotechnology, V2, P194, DOI 10.1089/ind.2006.2.194
   Varjani SJ, 2017, BIORESOURCE TECHNOL, V223, P277, DOI 10.1016/j.biortech.2016.10.037
   Vatsa P, 2010, INT J MOL SCI, V11, P5096, DOI 10.3390/ijms11125095
   Viccini G, 2007, PROCESS BIOCHEM, V42, P275, DOI 10.1016/j.procbio.2006.07.006
   Wheeler MW, 2006, ENVIRON TOXICOL CHEM, V25, P1441, DOI 10.1897/05-320R.1
   Yan P, 2012, BIORESOURCE TECHNOL, V116, P24, DOI 10.1016/j.biortech.2012.04.024
NR 40
TC 3
Z9 3
U1 3
U2 33
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1526-498X
EI 1526-4998
J9 PEST MANAG SCI
JI Pest Manag. Sci.
PD NOV
PY 2019
VL 75
IS 11
BP 2882
EP 2891
DI 10.1002/ps.5458
PG 10
WC Agronomy; Entomology
SC Agriculture; Entomology
GA JC0RS
UT WOS:000488988100004
PM 31038255
DA 2020-12-08
ER

PT J
AU Coronel, J
   Heinrich, C
   Klausing, S
   Noll, T
   Figueredo-Cardero, A
   Castilho, LR
AF Coronel, Juliana
   Heinrich, Christoph
   Klausing, Sandra
   Noll, Thomas
   Figueredo-Cardero, Alvio
   Castilho, Leda R.
TI Perfusion process combining low temperature and valeric acid for
   enhanced recombinant factor VIII production
SO BIOTECHNOLOGY PROGRESS
LA English
DT Article
DE CHO perfusion cultivation; mild hypothermia; productivity; recombinant
   factor VIII; valeric acid
ID LOW CULTURE TEMPERATURE; HAMSTER OVARY CELLS; HIGH-DENSITY;
   SODIUM-BUTYRATE; HEMOPHILIA-A; CHO-CELLS; EXPRESSION; SHIFT; LINES; PH
AB Perfusion operation mode remains the preferred platform for production of labile biopharmaceuticals (e.g., blood factors) and is also being increasingly adopted for production of stable products (e.g., monoclonal antibodies). Regardless of the product, process development typically aims at maximizing production capacity. In this work, we investigated the impact of perfusion cultivation conditions on process productivity for production of human factor VIII (FVIII). Recombinant CHO cells were cultivated in bioreactors coupled to inclined settlers and the effects of reducing the temperature to 31 degrees C with or without valeric acid (VA) supplementation were evaluated. Increases in cell specific productivity (q(p)) up to 2.4-fold (FVIII concentration) and up to 3.0-fold (FVIII biological activity) were obtained at 31 degrees C with VA compared to the control at 37 degrees C. Biological activity is the most important quality attribute for FVIII and was positively affected by mild hypothermia in combination with the chemical inducer. The low temperature conditions resulted in enhanced product transcript levels, suggesting that the higher q(p) is related to the increased mRNA levels. Furthermore, a high-producer subclone was evaluated under the perfusion conditions optimized for the parental clone (31 degrees C with VA), yielding increases in q(p) of 6-fold and 15-fold compared to the parental clone cultivated under the same condition and at 37 degrees C, respectively. The proposed perfusion strategy enables increased product formation without increasing production costs, being potentially applicable to perfusion production of other CHO-derived biopharmaceuticals. To the best of our knowledge, this is the first report showing the benefits of perfusion combining mild hypothermia with VA supplementation.
C1 [Coronel, Juliana; Castilho, Leda R.] Fed Univ Rio de Janeiro UFRJ, COPPE, Cell Culture Engn Lab, Rio De Janeiro, RJ, Brazil.
   [Heinrich, Christoph; Klausing, Sandra] Xell AG, Alte Verler Str 1, Bielefeld, Germany.
   [Noll, Thomas] Bielefeld Univ, Inst Cell Culture Technol, Univ Str 25, Bielefeld, Germany.
   [Figueredo-Cardero, Alvio] Biomanguinhos, Fiocruz, Rio De Janeiro, RJ, Brazil.
   [Coronel, Juliana] CEVEC Pharmaceut GmbH, Gottfried Hagen Str 60-62, D-51105 Cologne, Germany.
RP Castilho, LR (corresponding author), Fed Univ Rio de Janeiro UFRJ, COPPE, Cell Culture Engn Lab, Rio De Janeiro, RJ, Brazil.
EM leda@peq.coppe.ufrj.br
RI Noll, Thomas/A-3539-2012
OI Noll, Thomas/0000-0003-0748-3423; Coronel de Lima Lages,
   Juliana/0000-0002-1349-2310
FU Federal University of Rio de Janeiro
FX Federal University of Rio de Janeiro
CR Al-Fageeh MB, 2006, BIOCHEM J, V397, P247, DOI 10.1042/BJ20060166
   Avello V, 2017, ELECTRON J BIOTECHN, V27, P55, DOI 10.1016/j.ejbt.2017.03.008
   Becerra S, 2012, BIOCHEM ENG J, V60, P1, DOI 10.1016/j.bej.2011.10.003
   Beckmann TF, 2015, BMC P S9, V9, P27, DOI [10.1186/1753-6561-9-S9-P27, DOI 10.1186/1753-6561-9-S9-P27]
   Boedeker BGD, 2001, SEMIN THROMB HEMOST, V27, P385
   Buchsteiner M, 2018, BIOTECHNOL BIOENG, V115, P2315, DOI 10.1002/bit.26724
   Castilho LR, 2015, CONTINUOUS PROCESSING IN PHARMACEUTICAL MANUFACTURING, P115
   Chen F, 2011, BIOTECHNOL BIOPROC E, V16, P1157, DOI 10.1007/s12257-011-0069-8
   Chen KM, 2017, APPL MICROBIOL BIOT, V101, P5785, DOI 10.1007/s00253-017-8331-4
   Chen ZL, 2004, J BIOSCI BIOENG, V97, P239, DOI 10.1016/S1389-1723(04)70198-X
   Chuppa S, 1997, BIOTECHNOL BIOENG, V55, P328, DOI 10.1002/(SICI)1097-0290(19970720)55:2<328::AID-BIT10>3.0.CO;2-D
   Clincke MF, 2013, BIOTECHNOL PROGR, V29, P754, DOI 10.1002/btpr.1704
   Coppola A, 2010, J BLOOD MED, V1, P183, DOI 10.2147/JBM.S6885
   Coronel J, 2017, 25 ESACT M CELL T EC
   Coronel J, 2016, BIOCHEM ENG J, V114, P104, DOI 10.1016/j.bej.2016.06.031
   Delignat S, 2018, CELL IMMUNOL, V331, P22, DOI 10.1016/j.cellimm.2018.05.002
   Fischer S, 2015, BIOTECHNOL ADV, V33, P1878, DOI 10.1016/j.biotechadv.2015.10.015
   Fox SR, 2005, BIOTECHNOL APPL BIOC, V41, P255, DOI 10.1042/BA20040066
   Goyal MMZA, 2005, BIOTECHNOL PROGR, V21, P70, DOI 10.1021/bp049815s
   HARRIS RJ, 1993, BIO-TECHNOL, V11, P1293
   Hendrick V, 2001, CYTOTECHNOLOGY, V36, P71, DOI 10.1023/A:1014088919546
   Hiller GW, 2017, BIOTECHNOL BIOENG, V114, P1438, DOI 10.1002/bit.26259
   Hughson MD, 2017, BIOTECHNOL PROGR, V33, P931, DOI 10.1002/btpr.2501
   Jiang R, 2002, HAEMOPHILIA, V8, P1, DOI 10.1046/j.1351-8216.2001.00115.x
   Kantardjieff A, 2010, J BIOTECHNOL, V145, P143, DOI 10.1016/j.jbiotec.2009.09.008
   Kim SH, 2007, J MICROBIOL BIOTECHN, V17, P712
   Ko P, 2018, BIOTECHNOL PROGR, V34, P624, DOI 10.1002/btpr.2594
   Konstantinov KB, 2015, J PHARM SCI-US, V104, P813, DOI 10.1002/jps.24268
   Kou TC, 2011, J BIOSCI BIOENG, V111, P365, DOI 10.1016/j.jbiosc.2010.11.016
   Kumar N, 2007, CYTOTECHNOLOGY, V53, P33, DOI 10.1007/s10616-007-9047-6
   Lieuw K, 2017, J BLOOD MED, V8, P67, DOI 10.2147/JBM.S103796
   Park JH, 2016, BIOTECHNOL J, V11, P487, DOI 10.1002/biot.201500327
   Pipe SW, 2009, HAEMOPHILIA, V15, P1187, DOI 10.1111/j.1365-2516.2009.02026.x
   Spencer S, 2015, J BIOTECHNOL, V195, P15, DOI 10.1016/j.jbiotec.2014.12.009
   Sunley K, 2010, BIOTECHNOL ADV, V28, P385, DOI 10.1016/j.biotechadv.2010.02.003
   Trummer E, 2006, BIOTECHNOL BIOENG, V94, P1033, DOI 10.1002/bit.21013
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Vcelar S, 2018, BIOTECHNOL J, V13, DOI 10.1002/biot.201700495
   Vergara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093865
   Wippermann A, 2017, J BIOTECHNOL, V257, P150, DOI 10.1016/j.jbiotec.2016.11.020
   Wolf MKF, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201700722
   Yee JC, 2008, BIOTECHNOL BIOENG, V99, P1186, DOI 10.1002/bit.21665
   Yoon SK, 2005, BIOTECHNOL BIOENG, V89, P345, DOI 10.1002/bit.20353
   Yoon SK, 2004, BIOTECHNOL PROGR, V20, P1683, DOI 10.1021/bp049847f
NR 44
TC 1
Z9 1
U1 2
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8756-7938
EI 1520-6033
J9 BIOTECHNOL PROGR
JI Biotechnol. Prog.
PD JAN
PY 2020
VL 36
IS 1
AR e2915
DI 10.1002/btpr.2915
EA OCT 2019
PG 11
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA KM7BN
UT WOS:000494112700001
PM 31587517
OA Bronze
DA 2020-12-08
ER

PT J
AU Pato, TP
   Souza, MCO
   Mattos, DA
   Caride, E
   Ferreira, DF
   Gaspar, LP
   Freire, MS
   Castilho, LR
AF Pato, Tania P.
   Souza, Marta C. O.
   Mattos, Diogo A.
   Caride, Elena
   Ferreira, Davis F.
   Gaspar, Luciane P.
   Freire, Marcos S.
   Castilho, Leda R.
TI Purification of yellow fever virus produced in Vero cells for
   inactivated vaccine manufacture
SO VACCINE
LA English
DT Article
DE Yellow fever virus (YFV); Downstream processing; Virus purification;
   Inactivated vaccine; Chromatographic techniques
ID INFLUENZA-A; IMMUNOGENICITY; CHROMATOGRAPHY; PROTEINS; VECTORS; CAPTURE
AB Yellow fever (YF) is a high-lethality viral disease, endemic in tropical regions of South America and Africa, with a population of over 900 million people under risk. A highly effective attenuated vaccine, produced in embryonated eggs, has been used for about 80 years. However, egg-based production limits manufacturing capacity, and vaccine shortage led to the emergency use of a fractional dose (1/5) by the WHO in an outbreak in Africa in 2016 and by Brazilian authorities during an outbreak in 2018. In addition, rare but fatal adverse events of this vaccine have been reported since 2001. These two aspects make clear the need for the development of a new vaccine. In an effort to develop an inactivated YF vaccine, Bio-Manguinhos/FIOCRUZ started developing a new vaccine based on the production of the attenuated 17DD virus in serum-free conditions in Vero cells propagated in bioreactors, followed by chromatography-based purification and beta-propiolactone inactivation.
   Virus purification was studied in this work. Capture was performed using an anion-exchange membrane adsorber (Sartobind (R) Q), resulting in a virus recovery of 80.2 +/- 4.8% and a residual DNA level of 1.3 +/- 1.6 ng/dose, thus in accordance with the recommendations of the WHO (<10 ng/dose). However, the level of host cell proteins (HCP) was still high for a human vaccine, so a second chromatography step was developed based on a multimodal resin (Capto (TM) Core 700). This step resulted in a virus recovery of 65.7 +/- 4.8% and decreased HCP levels to 345 +/- 25 ppm. The overall virus recovery in these chromatography steps was 52.7%. SDS-PAGE of the purified sample showed a band with molecular mass of 56 kDa, thus consistent with the virus envelope protein (E) and corresponding to 96.7% of identified proteins. A Western blot stained with an antibody against the E protein showed a single band, confirming the identity of the sample. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Pato, Tania P.; Souza, Marta C. O.; Mattos, Diogo A.; Caride, Elena; Gaspar, Luciane P.; Freire, Marcos S.] Biomanguinhos, Oswaldo Cruz Fdn FIOCRUZ, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Pato, Tania P.; Castilho, Leda R.] Fed Univ Rio de Janeiro UFRJ, Inst Chem, Biochem Program, Av Athos Silveira Ramos 149,Bl A, BR-21941909 Rio De Janeiro, RJ, Brazil.
   [Ferreira, Davis F.] Fed Univ Rio de Janeiro UFRJ, Inst Microbiol, Virol Dept, Av Carlos Chagas 373,Bl 1, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Castilho, Leda R.] Fed Univ Rio de Janeiro UFRJ, COPPE, Cell Culture Engn Lab, Cx Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
RP Pato, TP (corresponding author), Biomanguinhos, Oswaldo Cruz Fdn FIOCRUZ, Ave Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM tania@bio.fiocruz.br
FU FaperjCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq); CapesCAPES
FX The authors wish to thank the Brazilian research funding agencies
   Faperj, CNPq and Capes for financial support.
CR Blom H, 2014, VACCINE, V32, P3721, DOI 10.1016/j.vaccine.2014.04.033
   BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203
   Bonaldo MC, 2017, MEM I OSWALDO CRUZ, V112, P447, DOI 10.1590/0074-02760170134
   Caufour PS, 2001, VIRUS RES, V79, P1, DOI 10.1016/S0168-1702(01)00273-8
   CDC, 2018, YELL FEV MAPS
   Chagas MP, 2013, THESIS
   FDA, 2010, CHAR QUAL CELL SUBST
   Garske T, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001638
   GE HEALTHCARE, 2012, 28998307 AA GE HEALT
   Hayes EB, 2010, VACCINE, V28, P8073, DOI 10.1016/j.vaccine.2010.10.015
   Kalbfuss B, 2007, J MEMBRANE SCI, V299, P251, DOI 10.1016/j.memsci.2007.04.048
   Mattos DA, 2015, VACCINE, V33, P4288, DOI 10.1016/j.vaccine.2015.04.050
   Monath TP, 2012, EXPERT REV VACCINES, V11, P427, DOI [10.1586/erv.12.6, 10.1586/ERV.12.6]
   Monath TP, 2010, VACCINE, V28, P3827, DOI 10.1016/j.vaccine.2010.03.023
   Morenweiser R, 2005, GENE THER, V12, pS103, DOI 10.1038/sj.gt.3302624
   Nestola P, 2015, BIOTECHNOL BIOENG, V112, P843, DOI 10.1002/bit.25545
   Ohtake S, 2015, WILEY SER BIOTECHNOL, P287
   PAHO, 2018, BRAZ LAUNCH WORLDS L
   PATH Vaccine and Pharmaceutical Technologies Group, 2012, SUMM STAB DAT INV FO
   Pato TP, 2014, VACCINE, V32, P2789, DOI 10.1016/j.vaccine.2014.02.036
   Pato TP, 2014, THESIS
   Paules CI, 2017, NEW ENGL J MED, V376, P1397, DOI 10.1056/NEJMp1702172
   Peixoto C, 2008, BIOTECHNOL PROGR, V24, P1290, DOI 10.1002/btpr.25
   Pereira RC, 2015, VACCINE, V33, P4261, DOI 10.1016/j.vaccine.2015.03.077
   Souza MCO, 2009, VACCINE, V27, P6420, DOI 10.1016/j.vaccine.2009.06.023
   Vicente T, 2009, GENE THER, V16, P766, DOI 10.1038/gt.2009.33
   Vicente T, 2008, J MEMBRANE SCI, V311, P270, DOI 10.1016/j.memsci.2007.12.021
   Wang X, 2009, BIOTECHNOL BIOENG, V103, P446, DOI 10.1002/bit.22304
   Weigel T, 2014, J VIROL METHODS, V207, P45, DOI 10.1016/j.jviromet.2014.06.019
   WHO, 2019, YELL FEV BRAZ
   WHO, 2013, YELL FEV VACC BOOST
   WHO, 2007, STUD GROUP CELL SUBS
   WHO, 2018, EL YELL FEV EP EYE S
   World Health Organization, 2016, 14 WHO
   World Health Organization, 2017, 32 WHO
NR 35
TC 7
Z9 8
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 27
PY 2019
VL 37
IS 24
BP 3214
EP 3220
DI 10.1016/j.vaccine.2019.04.077
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IA9UZ
UT WOS:000469903700012
PM 31047674
DA 2020-12-08
ER

PT J
AU Nikolay, A
   Castilho, LR
   Reichl, U
   Genzel, Y
AF Nikolay, Alexander
   Castilho, Leda R.
   Reichl, Udo
   Genzel, Yvonne
TI Propagation of Brazilian Zika virus strains in static and suspension
   cultures using Vero and BHK cells
SO VACCINE
LA English
DT Article; Proceedings Paper
CT 6th Conference of Vaccine Technology
CY JUN, 2016
CL Albufeira, PORTUGAL
DE Brazilian Zika virus; BHK-21 Suspension cell line; High cell density;
   Perfusion process; Process intensification
ID RABIES VACCINE
AB The recent spread of Zika virus (ZIKV) in the Americas and the Pacific has reached alarming levels in more than 60 countries. However, relatively little is known about the disease on a virological and epidemiological level and its consequences for humans. Accordingly, a large demand for in vitro derived Brazilian ZIKV material to support in vitro and in vivo studies has arisen. However, a prompt supply of ZIKV and ZIKV antigens cannot be guaranteed as the production of this virus typically using Vero or C6/36 cell lines remains challenging.
   Here we present a production platform based on BHK-21 suspension (BHK-21(sus)) cells to propagate Brazilian ZIKV at larger quantities in perfusion bioreactors. Scouting experiments performed in tissue culture flasks using adherent BHK-21 and Vero cells have demonstrated similar permissivity and virus yields for four different Brazilian ZIKV isolates. The cell-specific yield of infectious virus particles varied between respective virus strains (1-48 PFU/cell), and the ZIKV isolate from the Brazilian state Pernambuco (ZIKV(PE)) showed to be a best performing isolate for both cell lines. However, infection studies of BHK-21sus cells with ZIKVPE in shake flasks resulted in poor virus replication, with a maximum titer of 8.9 x 10(3) PFU/mL. Additional RT-qPCR measurements of intracellular and extracellular viral RNA levels revealed high viral copy numbers within the cell, but poor virus release. Subsequent cultivation in a perfusion bioreactor using an alternating tangential flow filtration system (ATF) under controlled process conditions enabled cell concentrations of about 1.2 x 10(7) cells/mI, and virus titers of 3.9 x 10(7) PFU/mL. However, while the total number of infectious virus particles was increased, the cell-specific yield (3.3 PFU/cell) remained lower than determined in adherent cell lines. Nevertheless, the established perfusion process allows to provide large amounts of ZIKV material for research and is a first step towards process development for manufacturing inactivated or live-attenuated ZIKV vaccines. (C) 2017 The Author(s). Published by Elsevier Ltd.
C1 [Nikolay, Alexander; Reichl, Udo; Genzel, Yvonne] Max Planck Inst Dynam Complex Tech Syst, Bioproc Engn, Sandtorstr 1, D-39106 Magdeburg, Germany.
   [Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Cell Culture Engn Lab, Cx Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
   [Reichl, Udo] Otto von Guericke Univ, Bioproc Engn, Univ Pl 2, D-39106 Magdeburg, Germany.
RP Nikolay, A (corresponding author), Max Planck Inst Dynam Complex Tech Syst, Bioproc Engn, Sandtorstr 1, D-39106 Magdeburg, Germany.
EM nikolay@mpi-magdeburg.mpg.de; leda@peq.coppe.ufrj.br;
   ureichl@mpi-magdeburg.mpg.de; genzel@mpi-magdeburg.mpg.de
OI Nikolay, Alexander/0000-0003-4475-9556
FU Brazilian funding agency CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian funding agency CAPESCAPES;
   Brazilian funding agency FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
FX Financial support from the Brazilian funding agencies CNPq, CAPES and
   FAPERJ are gratefully acknowledged.
CR Bae HG, 2003, J VIROL METHODS, V110, P185, DOI 10.1016/S0166-0934(03)00129-0
   Barreto-Vieira DF, 2016, MEM I OSWALDO CRUZ, V111, P532, DOI 10.1590/0074-02760160104
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Frensing T, 2016, APPL MICROBIOL BIOT, V100, P7181, DOI 10.1007/s00253-016-7542-4
   Gallo-Ramirez LE, 2015, EXPERT REV VACCINES, V14, P1181, DOI 10.1586/14760584.2015.1067144
   Genzel Y, 2014, VACCINE, V32, P2770, DOI 10.1016/j.vaccine.2014.02.016
   Hierholzer J. C., 1996, P25, DOI 10.1016/B978-012465330-6/50003-8
   Janis A. M., 2016, EMERG INFECT DIS J, V22
   Kindhauser MK, 2016, B WHO
   Lalosevic D, 2008, DEV BIOLOGICALS, V131, P421
   Lalosevic D, 1998, Med Pregl, V51 Suppl 1, P17
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000
   PAY TWF, 1985, DEV BIOL STAND, V60, P171
   RADLETT PJ, 1985, DEV BIOL STAND, V60, P163
   REID LM, 1979, J GEN VIROL, V42, P609, DOI 10.1099/0022-1317-42-3-609
   Walker T, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-382
   WHO, 2013, WHO TECHN REP SER, V982
   World Health Organization, 2016, ON YEAR ZIK OUTBR OB
NR 21
TC 11
Z9 12
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 24
PY 2018
VL 36
IS 22
SI SI
BP 3140
EP 3145
DI 10.1016/j.vaccine.2017.03.018
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA GH7QD
UT WOS:000433647600010
PM 28343780
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Silva, JD
   Mascarin, GM
   Gomes, ICD
   Tinoco, RS
   Quintela, ED
   Castilho, LD
   Freire, DMG
AF Silva, Jaqueline do Nascimento
   Mascarin, Gabriel Moura
   dos Santos Gomes, Isabel Cristina
   Tinoco, Ricardo Salles
   Quintela, Eliane Dias
   Castilho, Leda dos Reis
   Guimaraes Freire, Denise Maria
TI New cost-effective bioconversion process of palm kernel cake into
   bioinsecticides based on Beauveria bassiana and Isaria javanica
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE Solid-state fermentation; Agro-industrial by-products; Entomopathogenic
   fungi; Cordycipitaceae; Biological control; Bemisia tabaci
ID TABACI HEMIPTERA ALEYRODIDAE; SOLID-STATE FERMENTATION; BEMISIA-TABACI;
   ENTOMOPATHOGENIC FUNGI; BIOLOGICAL-CONTROL; METARHIZIUM-ANISOPLIAE;
   BIOTYPE B; PAECILOMYCES-FUMOSOROSEUS; SUBSTRATE FERMENTATION; HOST
   PLANTS
AB The present study aimed to add value to palm oil by-products as substrates to efficiently produce conidia of Beauveria bassiana and Isaria javanica (Hypocreales: Cordycipitaceae) for biological control of the whitefly Bemisia tabaci (Hemiptera: Aleyrodidae), through a solid-state fermentation process using palm kernel cake and palm fiber as nutrient source and solid matrix, respectively. The optimum culture conditions yielded high concentrations of viable conidia after air-drying, when the fungi were grown on palm kernel cake (B. bassiana 7.65 x 10(9) and I. javanica 2.91 x 10(9) conidia g(-1) dry substrate) after 6 days under optimal growth conditions set to 60% substrate moisture and 32 A degrees C. Both fungal strains exhibited high efficacy against third-instar whitefly nymphs, inducing mortality up to 62.9 and 56.6% by B. bassiana and I. javanica, respectively, assessed after 9 days post-application in a screenhouse. Furthermore, we noted that insect mortality was strongly correlated with high atmospheric moisture, while B. bassiana appeared to require shorter accumulative hours under high moisture to kill whitefly nymphs compared to I. javanica. Our results underpin a feasible and cost-effective mass production method for aerial conidia, using palm kernel as the main substrate in order to produce efficacious fungal bioinsecticides against an invasive whitefly species in Brazil. Finally, our fermentation process may offer a sustainable and cost-effective means to produce eco-friendly mycoinsecticides, using an abundant agro-industrial by-product from Brazil that will ultimately assist in the integrated management of agricultural insect pests.
C1 [Silva, Jaqueline do Nascimento; Castilho, Leda dos Reis] Univ Fed Rio de Janeiro, Programa Engn Quim, COPPE, Ave Horacio Macedo 2030, BR-21941598 Rio De Janeiro, RJ, Brazil.
   [Mascarin, Gabriel Moura] Embrapa Meio Ambiente, Rodovia SP-340,Km 127-5 S-N, BR-13820000 Jaguariuna, SP, Brazil.
   [dos Santos Gomes, Isabel Cristina; Guimaraes Freire, Denise Maria] Univ Fed Rio de Janeiro, Inst Quim, Dept Bioquim, Ave Athos da Silveira Ramos 149, BR-21941909 Rio De Janeiro, RJ, Brazil.
   [Tinoco, Ricardo Salles] Agropalma, Rodovia PA-150,Km 74,Caixa Postal 108, BR-68695000 Tailandia, PA, Brazil.
   [Quintela, Eliane Dias] Embrapa Arroz & Feijao, Rodovia GO-462,Km 12, BR-75375000 Santo Antonio De Goias, Go, Brazil.
RP Silva, JD (corresponding author), Univ Fed Rio de Janeiro, Programa Engn Quim, COPPE, Ave Horacio Macedo 2030, BR-21941598 Rio De Janeiro, RJ, Brazil.; Mascarin, GM (corresponding author), Embrapa Meio Ambiente, Rodovia SP-340,Km 127-5 S-N, BR-13820000 Jaguariuna, SP, Brazil.; Freire, DMG (corresponding author), Univ Fed Rio de Janeiro, Inst Quim, Dept Bioquim, Ave Athos da Silveira Ramos 149, BR-21941909 Rio De Janeiro, RJ, Brazil.
EM jaque.ufrj@gmail.com; gabriel.mascarin@embrapa.br;
   isabel.cristina.rj@gmail.com; ricardo.tinoco@agropalma.com.br;
   eliane.quintela@embrapa.br; leda@peq.coppe.ufrj.br; freire@iq.ufrj.br
RI Castilho, Leda/I-8939-2014; Mascarin, Gabriel Moura/E-4646-2015; Freire,
   Denise Maria Guimaraes/D-8699-2014
OI Mascarin, Gabriel Moura/0000-0003-3517-6826; Freire, Denise Maria
   Guimaraes/0000-0002-8298-5936
FU Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro - FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ) [200.369/2016]
FX We thank the Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro -
   FAPERJ (grant number 200.369/2016) for supporting this research. We are
   also grateful to Dr. Homero dos Santos Sousa of Agropalma S.A. for
   supplying the wastes for the solid-state fermentation process and
   associated production data. We deeply appreciate the two anonymous
   reviewers for their suggestions and comments.
CR Abd-Rabou S, 2010, ENTOMOL NEWS, V121, P456, DOI 10.3157/021.121.0507
   Agrofit-Sistema de agrotoxicos fitossanitarios-Ministerio da Agricultura, AGR SIST AGR FIT
   AIDOO KE, 1981, EUR J APPL MICROBIOL, V12, P6, DOI 10.1007/BF00508111
   Angel-Cuapio A, 2015, APPL BIOCHEM BIOTECH, V177, P446, DOI 10.1007/s12010-015-1754-4
   Burnham KP, 2002, MODEL SELECTION MULT
   Cabanillas HE, 2009, CROP PROT, V28, P333, DOI 10.1016/j.cropro.2008.11.015
   Champagne P, 2008, ENVIRON PROG, V27, P51, DOI 10.1002/ep.10242
   Chen XR, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896-015-0170-8
   de Faria MR, 2007, BIOL CONTROL, V43, P237, DOI 10.1016/j.biocontrol.2007.08.001
   DESGRANGES C, 1993, BIOTECHNOL ADV, V11, P577, DOI 10.1016/0734-9750(93)90026-J
   Dorta B, 1996, ENZYME MICROB TECH, V19, P434, DOI 10.1016/S0141-0229(96)00017-8
   dos Santos MM, 2004, BIORESOURCE TECHNOL, V93, P261, DOI 10.1016/j.biortech.2003.11.007
   Essery M, 2014, BIOPESTICIDES GROW 4
   Estrada Gutarra Melissa Limoeiro, 2009, Biotechnology Journal, V4, P1450, DOI 10.1002/biot.200800298
   Furlan Junior JF, 2006, DENDE MANEJO USO SUB
   Gao TN, 2017, SCI REP-UK, V7, DOI 10.1038/srep42727
   Hardin J.W., 2012, GEN LINEAR MODELS EX
   Hunter WB, 2011, FLA ENTOMOL, V94, P1051, DOI 10.1653/024.094.0444
   James RR, 2003, J INVERTEBR PATHOL, V84, P67, DOI 10.1016/j.jip.2003.08.006
   Jaronski ST, 2014, MASS PRODUCTION BENE, P357
   Jaronski ST, 2010, BIOCONTROL, V55, P159, DOI 10.1007/s10526-009-9248-3
   Kessler P, 2003, J INVERTEBR PATHOL, V84, P15, DOI 10.1016/j.jip.2003.08.003
   Kim JS, 2010, J IND MICROBIOL BIOT, V37, P419, DOI 10.1007/s10295-010-0692-y
   Lacey LA, 2015, J INVERTEBR PATHOL, V132, P1, DOI 10.1016/j.jip.2015.07.009
   Lacey Lawrence A., 2008, V4, P33, DOI 10.1007/978-1-4020-6740-2_3
   Markets & Markets, 2016, BIOP MARK TYP BIOINS
   Mascarin GM, 2015, APPL MICROBIOL BIOT, V99, P6653, DOI 10.1007/s00253-015-6620-3
   Mascarin GM, 2014, BIOCONTROL, V59, P111, DOI 10.1007/s10526-013-9543-x
   Mascarin GM, 2013, BIOL CONTROL, V66, P209, DOI 10.1016/j.biocontrol.2013.05.001
   Mascarin GM, 2018, J INVERTEBR PATHOL
   Moo-Young M, 1983, FILAMENTOUS FUNGI, V4, P117, DOI DOI 10.1016/0167-7799(84)90009-X
   Moslim R., 2005, P PIPOC 2005 INT PAL, P928
   Moslim R, 2014, J OIL PALM RES, V26, P133
   Navas-Castillo J, 2011, ANNU REV PHYTOPATHOL, V49, P219, DOI 10.1146/annurev-phyto-072910-095235
   Osborne L.S., 1990, Bulletin SROP, V13, P153
   Oliveira DGP, 2015, J MICROBIOL METH, V119, P44, DOI 10.1016/j.mimet.2015.09.021
   Posada-Florez FJ, 2008, J INSECT SCI, V8, DOI 10.1673/031.008.4101
   Quintela ED, 2016, PEST MANAG SCI, V72, P2181, DOI 10.1002/ps.4259
   R Core Team, 2015, R LANG ENV STAT COMP
   Raimbault M, 1998, ELECTRON J BIOTECHN, V1, P174, DOI DOI 10.2225/VOL1-ISSUE3-FULLTEXT-9
   ROCHE N, 1993, BIOTECHNOL ADV, V11, P677, DOI 10.1016/0734-9750(93)90036-M
   Rodrigues M.I., 2014, EXPT DESIGN PROCESS
   Shipp JL, 2003, ENVIRON ENTOMOL, V32, P1154, DOI 10.1603/0046-225X-32.5.1154
   Tian J, 2016, BIOCONTROL SCI TECHN, V26, P528, DOI 10.1080/09583157.2015.1129393
   Vasconcelos HGR, 2010, POTENCIAL NUTR TORTA
   Wraight SP, 2016, BIOL CONTROL, V97, P31, DOI 10.1016/j.biocontrol.2016.02.016
   Wraight SP, 1998, J INVERTEBR PATHOL, V71, P217, DOI 10.1006/jipa.1997.4734
   Zimmermann G, 2008, BIOCONTROL SCI TECHN, V18, P865, DOI 10.1080/09583150802471812
NR 48
TC 5
Z9 7
U1 0
U2 35
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
EI 1432-0614
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD MAR
PY 2018
VL 102
IS 6
BP 2595
EP 2606
DI 10.1007/s00253-018-8805-z
PG 12
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA FX5CU
UT WOS:000426096500009
PM 29417198
DA 2020-12-08
ER

PT J
AU Ribeiro, DA
   Passos, DF
   Ferraz, HC
   Castilho, LR
AF Ribeiro, Daniel A.
   Passos, Douglas F.
   Ferraz, Helen C.
   Castilho, Leda R.
TI Intermediate purification of CHO-derived recombinant human Factor IX
   using hydrophobic interaction membrane-based chromatography and its
   comparison to a sulfated resin
SO ELECTROPHORESIS
LA English
DT Article
DE affinity chromatography resins; hydrophobic interaction chromatography;
   intermediate purification; membrane adsorbers; recombinant human Factor
   IX
ID CLOTTING FACTOR-IX; MONOCLONAL-ANTIBODY; ENDOTOXIN REMOVAL; EXCHANGE;
   COMBINATION; EXPRESSION; CHALLENGES; PROTEINS
AB This work investigated the use of hydrophobic interaction membrane chromatography for intermediate purification of recombinant human Factor IX (rFIX) produced by CHO cells. The first purification step was based on a strong anion exchange monolith, thus forming a purification process fully based on convective media, which allow operation at high flow rates and low pressure drops, as well as modular scale-up. Although the starting material was challenging (CHO cell culture supernatant harvested at 70% cell viability), the two-step purification process showed promising results, with a global purification factor of 298, a global recovery of 69%, and DNA and endotoxin levels close to regulatory limits. Final host cell DNA (68.8ng per dose of 500 IU), endotoxins (60 EU per dose of 500 IU) and activated FIX (FIXa/FIX=2.33%) were in levels close to those recommended by regulatory authorities. HCP removal was of 99.98%, decreasing from 9 424 358ppm in the supernatant to a final HCP value of 2071ppm. The use of a supernatant harvested at higher viability and/or the addition of a third polishing step focusing on HCP removal could allow meeting the desired HCP range of 50-100ppm, as well as the regulatory requirements for the other critical contaminants.
C1 [Ribeiro, Daniel A.; Passos, Douglas F.; Ferraz, Helen C.; Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, Rio de Janeiro, RJ, Brazil.
   [Ribeiro, Daniel A.] Biomanguinhos, FIOCRUZ, Ave Brasil 4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
RP Castilho, LR (corresponding author), Univ Fed Rio de Janeiro, COPPE, PEQ, Cx Postal 68502, BR-21941972 Rio de Janeiro, RJ, Brazil.
EM leda@peq.coppe.ufrj.br
RI Ferraz, Helen/AAF-1060-2019; Martinovic, Tamara/R-5117-2018; Castilho,
   Leda/I-8939-2014
OI Martinovic, Tamara/0000-0001-7099-9524; 
FU Hemobras; Brazilian Development Bank (BNDES); CNPqNational Council for
   Scientific and Technological Development (CNPq); CapesCAPES;
   FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ)
FX The authors gratefully acknowledge the financial support fromHemobras,
   the Brazilian Development Bank (BNDES) and the Brazilian funding
   agencies CNPq, Capes and FAPERJ.
CR [Anonymous], 2011, EUROPEAN PHARMACOPOE
   Anspach FB, 2001, J BIOCHEM BIOPH METH, V49, P665, DOI 10.1016/S0165-022X(01)00228-7
   Belattar N, 2007, MAT SCI ENG C-BIO S, V27, P849, DOI 10.1016/j.msec.2006.10.003
   Butler M, 2005, APPL MICROBIOL BIOT, V68, P283, DOI 10.1007/s00253-005-1980-8
   Castilho LR, 2002, J MEMBRANE SCI, V207, P253, DOI 10.1016/S0376-7388(02)00257-0
   Chen RH, 2009, PROTEIN EXPRES PURIF, V64, P76, DOI 10.1016/j.pep.2008.10.006
   DePhillips P, 2001, J CHROMATOGR A, V933, P57, DOI 10.1016/S0021-9673(01)01275-4
   Dimartino S, 2015, J MOL RECOGNIT, V28, P180, DOI 10.1002/jmr.2406
   Diogo MM, 2005, J CHROMATOGR A, V1069, P3, DOI 10.1016/j.chroma.2004.09.050
   Fan JX, 2015, J CHROMATOGR A, V1423, P63, DOI 10.1016/j.chroma.2015.10.050
   GUSE AH, 1994, J CHROMATOGR A, V661, P13, DOI 10.1016/0021-9673(94)85173-5
   Hallgren KW, 2002, BIOCHEMISTRY-US, V41, P15045, DOI 10.1021/bi026016e
   Hallgrenk W., 2006, BIOCHEM, V45, P5587
   Harrison S, 1998, SEMIN HEMATOL, V35, P4
   Hoffer L, 1999, J CHROMATOGR A, V844, P119, DOI 10.1016/S0021-9673(99)00348-9
   Hughson M. D., 2017, BIOTECHNOL PROGR
   Husi H, 1999, J CHROMATOGR B, V736, P77, DOI 10.1016/S0378-4347(99)00437-5
   Jaffray J., 2015, Clinical Investigation, V5, P205, DOI 10.4155/cli.14.118
   Jungbauer A, 2013, TRENDS BIOTECHNOL, V31, P479, DOI 10.1016/j.tibtech.2013.05.011
   KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622
   Kuczewski M, 2010, BIOTECHNOL BIOENG, V105, P296, DOI 10.1002/bit.22538
   Kumar SR, 2015, BIOTECHNOL J, V10, P995, DOI 10.1002/biot.201400666
   Liu HF, 2011, J CHROMATOGR A, V1218, P6943, DOI 10.1016/j.chroma.2011.08.008
   Lopes AG, 2015, FOOD BIOPROD PROCESS, V93, P98, DOI 10.1016/j.fbp.2013.12.002
   Lowe GDO, 2001, BRIT J HAEMATOL, V115, P507, DOI 10.1046/j.1365-2141.2001.03186.x
   Matthews M. A., 2016, Patent US, Patent No. 9296981
   Opitz L, 2009, BIOTECHNOL BIOENG, V103, P1144, DOI 10.1002/bit.22345
   Queiroz JA, 2001, J BIOTECHNOL, V87, P143, DOI 10.1016/S0168-1656(01)00237-1
   Ribeiro DA, 2013, J CHROMATOGR B, V938, P111, DOI 10.1016/j.jchromb.2013.09.002
   Riddel JP, 2007, J PEDIATR ONCOL NURS, V24, P123, DOI 10.1177/1043454206298693
   Sakoda Y, 2012, MICROBIOL IMMUNOL, V56, P490, DOI 10.1111/j.1348-0421.2012.00468.x
   Smrekar V, 2013, J CHROMATOGR A, V1276, P58, DOI 10.1016/j.chroma.2012.12.029
   Sun YL, 2012, J CHROMATOGR B, V898, P78, DOI 10.1016/j.jchromb.2012.04.022
   van Reis R, 2007, J MEMBRANE SCI, V297, P16, DOI 10.1016/j.memsci.2007.02.045
   Wajih N, 2005, J BIOL CHEM, V280, P31603, DOI 10.1074/jbc.M505373200
   WAJIHN OJ, 2008, THROMB RES, V122, P405, DOI DOI 10.1016/J.THROMRES.2007.11.002
   Yoshida N., 2007, US patent, Patent No. 0049746
   Zydney AL, 2016, BIOTECHNOL BIOENG, V113, P465, DOI 10.1002/bit.25695
NR 38
TC 0
Z9 0
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0173-0835
EI 1522-2683
J9 ELECTROPHORESIS
JI Electrophoresis
PD NOV
PY 2017
VL 38
IS 22-23
SI SI
BP 2900
EP 2908
DI 10.1002/elps.201700226
PG 9
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA FO5CS
UT WOS:000416867300011
PM 28869668
DA 2020-12-08
ER

PT J
AU Almeida, AG
   Pinto, RCV
   Smales, CM
   Castilho, LR
AF Almeida, Aline G.
   Pinto, Rodrigo C. V.
   Smales, C. Mark
   Castilho, Leda R.
TI Investigations into, and development of, a lyophilized and formulated
   recombinant human factor IX produced from CHO cells
SO BIOTECHNOLOGY LETTERS
LA English
DT Article
DE Excipients; Formulation; Freeze-drying; Lyophilization; Recombinant
   factor IX; Stability study
ID INFLUENCE PROTEIN INTEGRITY; FACTOR-VIII; PHARMACEUTICALS; STABILITY;
   VARIABLES; SUCROSE
AB Objectives To develop a recombinant human factor IX (rFIX) formulation equivalent to commercially available products in terms of cake appearance, residual moisture, proportion of soluble aggregates and activity maintenance for 3 months at 4-8 degrees C.
   Results NaCl and low bulking agent/cryoprotectant mass ratio had a negative impact on cake quality upon lyophilisation for a wide range of formulations tested. Particular devised formulations maintained rFIX activity after lyophilization with a similar performance when compared with the rFIX formulated using the excipients reported for a commercially available FIX formulation (Benefix). rFIX remained active after 3 months when stored at 4 degrees C, though this was not the case with samples stored at 40 degrees C. Interestingly, particular formulations had an increase in residual moisture after 3 months storage, but not above a 3% threshold. All four formulations tested were equivalent to the Benefix formulation in terms of particle size distribution and cake appearance.
   Conclusions Three specific formulations, consisting of surfactant polysorbate-80, sucrose or trehalose as cryoprotectant, mannitol or glycine as bulking agent, L-histidine as buffering agent, and NaCl added in the reconstitution liquid at 0.234% (w/v) were suitable for use with a CHO cell-derived recombinant FIX.
C1 [Almeida, Aline G.; Castilho, Leda R.] Univ Fed Rio de Janeiro, PEQ, COPPE, Cell Culture Engn Lab, Cx Postal 68502, BR-21941972 Rio de Janeiro, RJ, Brazil.
   [Almeida, Aline G.; Castilho, Leda R.] Univ Fed Rio de Janeiro, Biochem Program, IQ, Ave Athos da Silveira Ramos 149, BR-21941909 Rio de Janeiro, RJ, Brazil.
   [Pinto, Rodrigo C. V.] Fiocruz MS, Biomanguinhos, Ave Brasil 4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Smales, C. Mark] Univ Kent, Ind Biotechnol Ctr, Canterbury CT2 7NJ, Kent, England.
   [Smales, C. Mark] Univ Kent, Sch Biosci, Canterbury CT2 7NJ, Kent, England.
RP Smales, CM (corresponding author), Univ Kent, Ind Biotechnol Ctr, Canterbury CT2 7NJ, Kent, England.; Smales, CM (corresponding author), Univ Kent, Sch Biosci, Canterbury CT2 7NJ, Kent, England.
EM c.m.smales@kent.ac.uk
RI Castilho, Leda/I-8939-2014
OI Hughson, Aline/0000-0002-3938-1694; Smales, Christopher
   Mark/0000-0002-2762-4724
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CapesCAPES; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); BNDES; Hemobras;
   University of Kent; Royal SocietyRoyal Society of London [IF130004]
FX The authors would like to thank CNPq, Capes, FAPERJ, BNDES, and Hemobras
   for the financial support of this research project, and the University
   of Kent for their support and laboratory facilities to enable these
   experiments. CMS thanks the Royal Society for an Industrial Fellowship
   (IF130004).
CR Amaral RL, 2016, BIOTECHNOL LETT, V38, P385
   Baxalta Canada Corporation, 2015, PROD MON RIX REC COA
   Bush L, 1998, SEMIN HEMATOL, V35, P18
   *EMEA, 2005, SCI DISC
   Gourbatsi E, 2016, BIOTECHNOL LETT, V38, P589, DOI 10.1007/s10529-015-2014-y
   Jameel F, 2010, FORMULATION PROCESS, P459
   Johnson RE, 2002, J PHARM SCI, V91, P914, DOI 10.1002/jps.10094
   Kasper JC, 2011, EUR J PHARM BIOPHARM, V78, P248, DOI 10.1016/j.ejpb.2011.03.010
   Lambert T, 2007, HAEMOPHILIA, V13, P233, DOI 10.1111/j.1365-2516.2007.01458.x
   Liao XM, 2005, PHARM RES-DORDR, V22, P1978, DOI 10.1007/s11095-005-7625-x
   Lim I, 2010, ESACT PROCEED, V4, P613, DOI 10.1007/978-90-481-3419-9_104
   Lim Jun Yeul, 2016, Journal of Pharmaceutical Investigation, V46, P519, DOI 10.1007/s40005-016-0275-7
   Pansare SK, 2016, AAPS PHARMSCITECH, V17, P805, DOI 10.1208/s12249-016-0551-x
   Passot S, 2010, FREEZE DRYING LYOPHI, P136
   Pfizer, 2012, PROD MON BEN COAG FA
   Povey JF, 2009, BIOTECHNOL PROGR, V25, P1217, DOI 10.1002/btpr.207
   RIBEIRO D. E., 2013, THESIS
   Ribeiro DA, 2013, J CHROMATOGR B, V938, P111, DOI 10.1016/j.jchromb.2013.09.002
   Ronzi E, 2003, CHEM ENG PROCESS, V42, P751, DOI 10.1016/S0255-2701(02)00080-6
   Smales CM, 2002, BIOTECHNOL BIOENG, V77, P37, DOI 10.1002/bit.10161
   Tang XL, 2004, PHARM RES-DORDR, V21, P191, DOI 10.1023/B:PHAM.0000016234.73023.75
   Wang W, 2000, INT J PHARMACEUT, V203, P1, DOI 10.1016/S0378-5173(00)00423-3
   Webb C, 1997, Patent WO, Patent No. [1997026909: A1, 1997026909]
NR 23
TC 1
Z9 1
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-5492
EI 1573-6776
J9 BIOTECHNOL LETT
JI Biotechnol. Lett.
PD AUG
PY 2017
VL 39
IS 8
BP 1109
EP 1120
DI 10.1007/s10529-017-2353-y
PG 12
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA FA4UP
UT WOS:000405439000002
PM 28484912
OA Green Accepted
DA 2020-12-08
ER

PT J
AU Hughson, MD
   Cruz, TA
   Carvalho, RJ
   Castilho, LR
AF Hughson, Michael D.
   Cruz, Thayana A.
   Carvalho, Rimenys J.
   Castilho, Leda R.
TI Development of a 3-Step Straight-Through Purification Strategy Combining
   Membrane Adsorbers and Resins
SO BIOTECHNOLOGY PROGRESS
LA English
DT Article
DE process development; protein liquid chromatography; membrane adsorbers;
   integrated processing; straight-through processing; CHO derived
   biopharmaceutical glycoprotein
ID RECOMBINANT MONOCLONAL-ANTIBODIES; CELL-CULTURE SUPERNATANT; SIMULATED
   MOVING-BED; MANUFACTURING PROCESS; CHROMATOGRAPHY; PROTEIN;
   BIOPHARMACEUTICALS; DESIGN; TECHNOLOGY; PLATFORM
AB The pressures to efficiently produce complex biopharmaceuticals at reduced costs are driving the development of novel techniques, such as in downstream processing with straight-through processing (STP). This method involves directly and sequentially purifying a particular target with minimal holding steps. This work developed and compared six different 3-step STP strategies, combining membrane adsorbers, monoliths, and resins, to purify a large, complex, and labile glycoprotein from Chinese hamster ovary cell culture supernatant. The best performing pathway was cation exchange chromatography to hydrophobic interaction chromatography to affinity chromatography with an overall product recovery of up to 88% across the process and significant clearance of DNA and protein impurities. This work establishes a platform and considerations for the development of STP of biopharmaceutical products and highlights its suitability for integration with single-use technologies and continuous production methods. (C) 2017 American Institute of Chemical Engineers
C1 [Hughson, Michael D.; Cruz, Thayana A.; Carvalho, Rimenys J.; Castilho, Leda R.] Fed Univ Rio Janeiro UFRJ, COPPE, Chem Engn Program, Cell Culture Engn Lab, BR-21941972 Rio De Janeiro, Brazil.
   [Cruz, Thayana A.; Castilho, Leda R.] Fed Univ Rio Janeiro UFRJ, IQ, Biochem Program, BR-21941909 Rio De Janeiro, Brazil.
RP Cruz, TA (corresponding author), Fed Univ Rio Janeiro UFRJ, COPPE, Chem Engn Program, Cell Culture Engn Lab, BR-21941972 Rio De Janeiro, Brazil.; Cruz, TA (corresponding author), Fed Univ Rio Janeiro UFRJ, IQ, Biochem Program, BR-21941909 Rio De Janeiro, Brazil.
EM tac@peq.coppe.ufrj.br
RI Castilho, Leda/I-8939-2014
OI Araujo da Cruz, Thayana/0000-0002-2087-1490
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CapesCAPES; BNDES; CNPqNational Council for
   Scientific and Technological Development (CNPq); Hemobras
FX The authors would like to thank Hemobras and the Brazilian research
   funding agencies FAPERJ, Capes, BNDES and CNPq for financial support,
   and Renata Alvim and Juliana Coronel for providing the target protein
   containing cell culture supernatants.
CR Andersson N, 2017, BIOTECHNOL PROGR, V33, P923, DOI 10.1002/btpr.2434
   Angarita M, 2015, J CHROMATOGR A, V1389, P85, DOI 10.1016/j.chroma.2015.02.046
   Barker G, 2015, BIOTECHNOL J, V10, P1493, DOI 10.1002/biot.201400671
   Butler M, 2012, APPL MICROBIOL BIOT, V96, P885, DOI 10.1007/s00253-012-4451-z
   Carvalho RJ, 2014, BIOTECHNOL J, V9, P1250, DOI 10.1002/biot.201400170
   Castilho L., 2008, ANIMAL CELL TECHNOLO
   Castilho LR, 2015, CONTINUOUS PROCESSING IN PHARMACEUTICAL MANUFACTURING, P115
   Castilho LR, 2002, J MEMBRANE SCI, V207, P253, DOI 10.1016/S0376-7388(02)00257-0
   Cramer SM, 2011, CURR OPIN CHEM ENG, V1, P27, DOI 10.1016/j.coche.2011.08.008
   Desai SG, 2015, J BIOTECHNOL, V213, P20, DOI 10.1016/j.jbiotec.2015.02.021
   dos Santos R, 2017, BIOTECHNOL ADV, V35, P41, DOI 10.1016/j.biotechadv.2016.11.005
   Dutta AK, 2015, J BIOTECHNOL, V213, P54, DOI 10.1016/j.jbiotec.2015.02.026
   Fan JX, 2015, J CHROMATOGR A, V1423, P63, DOI 10.1016/j.chroma.2015.10.050
   Faria RPV, 2015, J CHROMATOGR A, V1421, P82, DOI 10.1016/j.chroma.2015.08.045
   GE Healthcare, 2015, CONT CHROM DOWNSTR P
   Girard V, 2015, J BIOTECHNOL, V213, P65, DOI 10.1016/j.jbiotec.2015.04.026
   Godawat R, 2015, J BIOTECHNOL, V213, P13, DOI 10.1016/j.jbiotec.2015.06.393
   Gottschalk U, 2012, NAT BIOTECHNOL, V30, P489, DOI 10.1038/nbt.2263
   Guiochon G, 2011, J CHROMATOGR A, V1218, P8836, DOI 10.1016/j.chroma.2011.09.008
   Hanke AT, 2014, TRENDS BIOTECHNOL, V32, P210, DOI 10.1016/j.tibtech.2014.02.001
   Hinderer W., 2011, Patent No. [WO2011035914, 2011035914, W02011035914]
   Hou Y, 2015, BIOTECHNOL PROGR, V31, P974, DOI 10.1002/btpr.2113
   Hunt B, 2001, BIOCHEM ENG J, V9, P135, DOI 10.1016/S1369-703X(01)00136-X
   Jungbauer A, 2013, TRENDS BIOTECHNOL, V31, P479, DOI 10.1016/j.tibtech.2013.05.011
   Kelley B, 2010, HAEMOPHILIA, V16, P717, DOI 10.1111/j.1365-2516.2009.02160.x
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lai TF, 2013, PHARMACEUTICALS, V6, P579, DOI 10.3390/ph6050579
   Liu HF, 2010, MABS-AUSTIN, V2, P480, DOI 10.4161/mabs.2.5.12645
   Maria S, 2015, J CHROMATOGR A, V1393, P57, DOI 10.1016/j.chroma.2015.03.018
   McCue J, 2014, HAEMOPHILIA, V20, pe327, DOI 10.1111/hae.12451
   Mccue J, 2015, BIOLOGICALS, V43, P213, DOI 10.1016/j.biologicals.2015.05.012
   Nestola P, 2015, J BIOTECHNOL, V213, P109, DOI 10.1016/j.jbiotec.2015.01.030
   OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4
   Orr V, 2013, BIOTECHNOL ADV, V31, P450, DOI 10.1016/j.biotechadv.2013.01.007
   Pato TP, 2014, VACCINE, V32, P2789, DOI 10.1016/j.vaccine.2014.02.036
   Rege K, 2006, BIOTECHNOL BIOENG, V93, P618, DOI 10.1002/bit.20702
   RIBEIRO D. E., 2013, THESIS
   Ribeiro DA, 2013, J CHROMATOGR B, V938, P111, DOI 10.1016/j.jchromb.2013.09.002
   Rosa PAJ, 2013, BIOTECHNOL J, V8, P352, DOI 10.1002/biot.201200031
   Sanaie N, 2012, BIOTECHNOL J, V7, P1242, DOI 10.1002/biot.201200170
   van Reis R, 2007, J MEMBRANE SCI, V297, P16, DOI 10.1016/j.memsci.2007.02.045
   Vicente T, 2011, BIOTECHNOL ADV, V29, P869, DOI 10.1016/j.biotechadv.2011.07.004
   Vogel JH, 2012, BIOTECHNOL BIOENG, V109, P3049, DOI 10.1002/bit.24578
   Walther J, 2015, J BIOTECHNOL, V213, P3, DOI 10.1016/j.jbiotec.2015.05.010
   Warikoo V, 2012, BIOTECHNOL BIOENG, V109, P3018, DOI 10.1002/bit.24584
   Xenopoulos A, 2015, J BIOTECHNOL, V213, P42, DOI 10.1016/j.jbiotec.2015.04.020
   Zhou JX, 2006, BIOTECHNOL PROGR, V22, P341, DOI 10.1021/bp050425v
   Zou HF, 2001, J BIOCHEM BIOPH METH, V49, P199, DOI 10.1016/S0165-022X(01)00200-7
NR 48
TC 11
Z9 11
U1 2
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8756-7938
EI 1520-6033
J9 BIOTECHNOL PROGR
JI Biotechnol. Prog.
PD JUL-AUG
PY 2017
VL 33
IS 4
BP 931
EP 940
DI 10.1002/btpr.2501
PG 10
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA FO3GF
UT WOS:000416710400009
PM 28556541
DA 2020-12-08
ER

PT J
AU Coronel, J
   Klausing, S
   Heinrich, C
   Noll, T
   Figueredo-Cardero, A
   Castilho, LR
AF Coronel, Juliana
   Klausing, Sandra
   Heinrich, Christoph
   Noll, Thomas
   Figueredo-Cardero, Alvio
   Castilho, Leda R.
TI Valeric acid supplementation combined to mild hypothermia increases
   productivity in CHO cell cultivations
SO BIOCHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE CHO cell culture; Cultivation temperature; Butyrate and valerate
   supplementation; Valeric acid and mild hypothermia; Cell viability and
   product titre; Cell specific productivity (q(P))
ID HAMSTER OVARY CELLS; RECOMBINANT INTERFERON-BETA; LOW CULTURE
   TEMPERATURE; MAMMALIAN-CELLS; SODIUM-BUTYRATE; PERFUSION CULTURE;
   MESSENGER-RNA; VALPROIC ACID; ANTIBODY-PRODUCTION; T-PA
AB Aiming at increasing productivity in mammalian cell processes, mild hypothermia and supplementation with short-chain fatty acids have been investigated in literature, but usually separately. The combined effects of butyric acid and hypothermia were investigated in a few studies, but despite the lower cytotoxicity of valeric acid no reports were found on its use under low temperatures. In this work, DOE was used to compare supplementation with both butyrate and valerate at 31,34 and 37 degrees C to enhance recombinant protein productivity in a CHO cell process. Due to the promising results obtained with valerate, this fatty acid was further investigated. According to the results obtained, 1 mM valeric acid at 31 degrees C enables high cell viabilities, higher product titres and increases cell specific productivity (q(P)) by approximately 4-fold. Cell cycle analysis showed that at 31 degrees C, especially with valerate, a higher percentage of cells was in G(0)+G(1) phase. Overall, an inverse relation between q(P) and cell proliferation state [S/(G(0)+G(1)) ratio] was observed. To our knowledge, this is the first work describing the effects of valeric acid under mild hypothermia on CHO cell cultivations. The results provide a promising tool to increase q(P) under lower proliferation rates, which can be very useful to develop robust high-cell-density, high-productivity perfusion processes. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Coronel, Juliana; Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Cell Culture Engn Lab, Caixa Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
   [Klausing, Sandra; Heinrich, Christoph] Xell AG, Alte Verler Str 1, D-33689 Bielefeld, Germany.
   [Noll, Thomas] Univ Bielefeld, Fac Technol, Inst Cell Culture Technol, Univ Str 25, D-33615 Bielefeld, Germany.
   [Figueredo-Cardero, Alvio] Ctr Mol Immunol, Calle 216 Esq 15,POB 16040, Havana 11600, Cuba.
   [Figueredo-Cardero, Alvio] Fiocruz MS, Biomanguinhos, Ave Brasil 4365, BR-21040900 Rio De Janeiro, RJ, Brazil.
RP Coronel, J (corresponding author), Univ Fed Rio de Janeiro, COPPE, Cell Culture Engn Lab, Caixa Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
EM jcl@peq.coppe.ufrj.br; sandra.klausing@xell.ag;
   christoph.heinrich@xell.ag; thomas.noll@uni-bielefeld.de;
   alvio.figueredo@bio.fiocruz.br; leda@peq.coppe.ufrj.br
RI Noll, Thomas/A-3539-2012; Castilho, Leda/I-8939-2014
OI Noll, Thomas/0000-0003-0748-3423; Coronel de Lima Lages,
   Juliana/0000-0002-1349-2310
FU Brazilian institution CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian institution CAPESCAPES;
   Brazilian institution FAPERJ; Brazilian institution BNDES; Brazilian
   institution HEMOBRAS; CNPqNational Council for Scientific and
   Technological Development (CNPq); CAPES-PDSE
FX Financial support from the Brazilian institutions CNPq, CAPES, FAPERJ,
   BNDES and HEMOBRAS is gratefully acknowledged. J. Coronel is grateful
   for the Ph.D. scholarships received from CNPq and CAPES-PDSE.
CR Backliwal G, 2008, BIOTECHNOL BIOENG, V101, P182, DOI 10.1002/bit.21882
   Becerra S, 2012, BIOCHEM ENG J, V60, P1, DOI 10.1016/j.bej.2011.10.003
   Berrios J, 2009, BIOTECHNOL LETT, V31, P1493, DOI 10.1007/s10529-009-0050-1
   Butler M, 2012, APPL MICROBIOL BIOT, V96, P885, DOI 10.1007/s00253-012-4451-z
   Carinhas N, 2013, BIOTECHNOL BIOENG, V110, P3244, DOI 10.1002/bit.24983
   Carvalhal AV, 2003, BIOTECHNOL PROGR, V19, P69, DOI 10.1021/bp0255917
   Castilho LR, 2015, CONTINUOUS PROCESSING IN PHARMACEUTICAL MANUFACTURING, P115
   Chen F, 2011, BIOTECHNOL BIOPROC E, V16, P1157, DOI 10.1007/s12257-011-0069-8
   Chen ZL, 2004, J BIOSCI BIOENG, V97, P239, DOI 10.1016/S1389-1723(04)70198-X
   Chuppa S, 1997, BIOTECHNOL BIOENG, V55, P328, DOI 10.1002/(SICI)1097-0290(19970720)55:2<328::AID-BIT10>3.0.CO;2-D
   DORNER AJ, 1989, J BIOL CHEM, V264, P20602
   Du ZM, 2015, BIOTECHNOL BIOENG, V112, P141, DOI 10.1002/bit.25332
   Fox SR, 2005, BIOTECHNOL APPL BIOC, V41, P265, DOI 10.1042/BA20040067
   Fox SR, 2005, BIOTECHNOL APPL BIOC, V41, P255, DOI 10.1042/BA20040066
   Goudar CT, 2011, BIOTECHNOL PROGR, V27, P1347, DOI 10.1002/btpr.646
   Hendrick V, 2001, CYTOTECHNOLOGY, V36, P71, DOI 10.1023/A:1014088919546
   Kantardjieff A, 2010, J BIOTECHNOL, V145, P143, DOI 10.1016/j.jbiotec.2009.09.008
   KAPTEIN A, 1991, BIOCHEM J, V278, P557, DOI 10.1042/bj2780557
   Kaufmann H, 1999, BIOTECHNOL BIOENG, V63, P573, DOI 10.1002/(SICI)1097-0290(19990605)63:5<573::AID-BIT7>3.0.CO;2-Y
   Konstantinov KB, 1996, BIOTECHNOL PROGR, V12, P100, DOI 10.1021/bp950044p
   Kou TC, 2011, J BIOSCI BIOENG, V111, P365, DOI 10.1016/j.jbiosc.2010.11.016
   Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315
   Kumar N, 2007, CYTOTECHNOLOGY, V53, P33, DOI 10.1007/s10616-007-9047-6
   Liu CH, 2001, J BIOSCI BIOENG, V91, P71, DOI 10.1263/jbb.91.71
   Marchant RJ, 2008, MOL BIOTECHNOL, V39, P69, DOI 10.1007/s12033-008-9032-0
   MATSUHISA T, 1989, EXP CELL RES, V180, P1, DOI 10.1016/0014-4827(89)90206-1
   McMurray-Beaulieu V, 2009, J BIOSCI BIOENG, V108, P160, DOI 10.1016/j.jbiosc.2009.03.001
   Mimura Y, 2001, J IMMUNOL METHODS, V247, P205, DOI 10.1016/S0022-1759(00)00308-2
   Ozturk SS, 1996, CYTOTECHNOLOGY, V22, P3, DOI 10.1007/BF00353919
   REUVENY S, 1986, J IMMUNOL METHODS, V86, P53, DOI 10.1016/0022-1759(86)90264-4
   Rodrigues-Goulart H., 2010, J BIOMED BIOTECHNOL, V2010
   Rodriguez J, 2010, J BIOTECHNOL, V150, P509, DOI 10.1016/j.jbiotec.2010.09.959
   Sunley K, 2008, BIOTECHNOL PROGR, V24, P898, DOI [10.1002/btpr.9, 10.1021/bp.9]
   Sunley K, 2010, BIOTECHNOL ADV, V28, P385, DOI 10.1016/j.biotechadv.2010.02.003
   Trummer E, 2006, BIOTECHNOL BIOENG, V94, P1033, DOI 10.1002/bit.21013
   Wippermann A, 2014, APPL MICROBIOL BIOT, V98, P579, DOI 10.1007/s00253-013-5282-2
   Wulhfard S, 2010, J BIOTECHNOL, V148, P128, DOI 10.1016/j.jbiotec.2010.05.003
   Wurm FM, 2004, NAT BIOTECHNOL, V22, P1393, DOI 10.1038/nbt1026
   Yee JC, 2008, BIOTECHNOL BIOENG, V99, P1186, DOI 10.1002/bit.21665
   Yoon SK, 2006, J BIOTECHNOL, V122, P463, DOI 10.1016/j.jbiotec.2005.09.010
   Yoon SK, 2005, BIOTECHNOL BIOENG, V89, P345, DOI 10.1002/bit.20353
   Zagari F, 2013, NEW BIOTECHNOL, V30, P238, DOI 10.1016/j.nbt.2012.05.021
NR 42
TC 11
Z9 12
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1369-703X
EI 1873-295X
J9 BIOCHEM ENG J
JI Biochem. Eng. J.
PD OCT 15
PY 2016
VL 114
BP 104
EP 112
DI 10.1016/j.bej.2016.06.031
PG 9
WC Biotechnology & Applied Microbiology; Engineering, Chemical
SC Biotechnology & Applied Microbiology; Engineering
GA EB6UV
UT WOS:000387522000012
DA 2020-12-08
ER

PT J
AU Dowd, KA
   Ko, SY
   Morabito, KM
   Yang, ES
   Pelc, RS
   DeMaso, CR
   Castilho, LR
   Abbink, P
   Boyd, M
   Nityanandam, R
   Gordon, DN
   Gallagher, JR
   Chen, XJ
   Todd, JP
   Tsybovsky, Y
   Harris, A
   Huang, YJS
   Higgs, S
   Vanlandingham, DL
   Andersen, H
   Lewis, MG
   De La Barrera, R
   Eckels, KH
   Jarman, RG
   Nason, MC
   Barouch, DH
   Roederer, M
   Kong, WP
   Mascola, JR
   Pierson, TC
   Graham, BS
AF Dowd, Kimberly A.
   Ko, Sung-Youl
   Morabito, Kaitlyn M.
   Yang, Eun Sung
   Pelc, Rebecca S.
   DeMaso, Christina R.
   Castilho, Leda R.
   Abbink, Peter
   Boyd, Michael
   Nityanandam, Ramya
   Gordon, David N.
   Gallagher, John Robert
   Chen, Xuejun
   Todd, John-Paul
   Tsybovsky, Yaroslav
   Harris, Audray
   Huang, Yan-Jang S.
   Higgs, Stephen
   Vanlandingham, Dana L.
   Andersen, Hanne
   Lewis, Mark G.
   De La Barrera, Rafael
   Eckels, Kenneth H.
   Jarman, Richard G.
   Nason, Martha C.
   Barouch, Dan H.
   Roederer, Mario
   Kong, Wing-Pui
   Mascola, John R.
   Pierson, Theodore C.
   Graham, Barney S.
TI Rapid development of a DNA vaccine for Zika virus
SO SCIENCE
LA English
DT Article
ID JAPANESE ENCEPHALITIS-VIRUS; TICK-BORNE ENCEPHALITIS; DENGUE VIRUS;
   CANDIDATE VACCINE; HEALTHY-ADULTS; ANTIBODY; NEUTRALIZATION;
   PREMEMBRANE; PROTECTION; CHALLENGE
AB Zika virus (ZIKV) was identified as a cause of congenital disease during the explosive outbreak in the Americas and Caribbean that began in 2015. Because of the ongoing fetal risk from endemic disease and travel-related exposures, a vaccine to prevent viremia in women of childbearing age and their partners is imperative. We found that vaccination with DNA expressing the premembrane and envelope proteins of ZIKV was immunogenic in mice and nonhuman primates, and protection against viremia after ZIKV challenge correlated with serum neutralizing activity. These data not only indicate that DNA vaccination could be a successful approach to protect against ZIKV infection, but also suggest a protective threshold of vaccine induced neutralizing activity that prevents viremia after acute infection.
C1 [Dowd, Kimberly A.; Pelc, Rebecca S.; DeMaso, Christina R.; Gordon, David N.; Pierson, Theodore C.] NIAID, Viral Pathogenesis Sect, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Ko, Sung-Youl; Morabito, Kaitlyn M.; Yang, Eun Sung; Castilho, Leda R.; Chen, Xuejun; Todd, John-Paul; Roederer, Mario; Kong, Wing-Pui; Mascola, John R.; Graham, Barney S.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, Inst Alberto Luiz Coimbra Posgrad & Pesquisa Engn, Rio De Janeiro, Brazil.
   [Abbink, Peter; Boyd, Michael; Nityanandam, Ramya; Barouch, Dan H.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.
   [Gallagher, John Robert; Harris, Audray] NIAID, Struct Informat Unit, Infect Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Tsybovsky, Yaroslav] Frederick Natl Lab Canc Res, Electron Microscopy Lab, Canc Res Technol Program, Frederick, MD 21702 USA.
   [Huang, Yan-Jang S.; Higgs, Stephen; Vanlandingham, Dana L.] Kansas State Univ, Coll Vet Med, Dept Diagnost Med Pathobiol, Manhattan, KS 66506 USA.
   [Andersen, Hanne; Lewis, Mark G.] Bioqual, Rockville, MD 20852 USA.
   [De La Barrera, Rafael; Eckels, Kenneth H.] Walter Reed Army Inst Res, Translat Med Branch, Silver Spring, MD 20910 USA.
   [Jarman, Richard G.] Walter Reed Army Inst Res, Viral Dis Branch, Silver Spring, MD 20910 USA.
   [Nason, Martha C.] NIAID, Biostat Res Branch, Div Clin Res, NIH, Bethesda, MD 20852 USA.
RP Pierson, TC (corresponding author), NIAID, Viral Pathogenesis Sect, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.; Graham, BS (corresponding author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM piersontc@niaid.nih.gov; bgraham@mail.nih.gov
RI Castilho, Leda/I-8939-2014; Graham, Barney S./AAC-5898-2019; Barouch,
   Dan/Y-3918-2019
OI Graham, Barney S./0000-0001-8112-0853; Elyard,
   Hanne/0000-0003-1103-9608; Morabito, Kaitlyn/0000-0002-4849-4690; Nason,
   Martha/0000-0002-0110-881X; Pelc, Rebecca/0000-0001-5080-4945
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [VRC5283, VRC5288, VRC8400, VRC8111,
   VRC4974]; National Institute of Allergy and Infectious DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID); Department of Diagnostic Medicine and Pathobiology,
   College of Veterinary Medicine, Kansas State University; Frederick
   National Laboratory for Cancer Research, NIH [HHSN261200800001E]; Leidos
   Biomedical Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [ZIAAI005128, ZIAAI001180, ZIAAI005128,
   ZIAAI005128, ZIAAI005128, ZIAAI001209, ZIAAI001209, ZIAAI001180,
   ZIAAI001209, ZIAAI001209, ZIAAI001180, ZIAAI001180, ZIAAI001180,
   ZIAAI001180, ZIAAI001180] Funding Source: NIH RePORTER
FX We thank A. Fauci, H. Marston, J. Ledgerwood, S. Whitehead, N. Michael,
   and M. Crank for scientific advice and comments; J. Stein and M. Young
   for coordinating collaborations; A. Cook and A. Dodson for the macaque
   work; K. Leung, L. Wang, W. Shi, K. Foulds, M. Donaldson, B. Fisher, A.
   Creanga, D. Scorpio, and B. Dekosky for laboratory and animal study
   support; M. Diamond for ZIKV-specific antibodies provided before
   publication; N. Bourne and A. Barrett for scientific advice and murine
   experiments; E. Moseley for serological assays; T. Pato for scientific
   discussion on the purification of SVPs; B. Hartman for help with figure
   optimization; R. Larocca and A. Badamchi-Zadeh for murine experiments;
   and N. Mercado for shipping and coordination. The data are tabulated in
   the main paper and in the supplementary materials. The opinions or
   assertions contained herein are the private views of the authors and are
   not to be construed as reflecting the official views of the U.S. Army or
   Department of Defense. VRC5283, VRC5288, VRC8400, VRC8111, and VRC4974
   are available from NIH under a material transfer agreement. ZIKV strain
   PRVABC59 challenge stock is available from Kansas State University under
   a material transfer agreement. A patent application describing candidate
   ZIKV vaccines has been filed with the following authors listed as
   inventors: B.S.G., T.C.P., W.-P. K., S.-Y.K., K. A. D., E.S.Y., R.S.P.,
   C.R.D., L.R.C., and J. R. M. This work was supported by intramural
   funding from the National Institute of Allergy and Infectious Diseases;
   startup funding from the Department of Diagnostic Medicine and
   Pathobiology, College of Veterinary Medicine, Kansas State University
   (to D.L.V.); and federal funds from the Frederick National Laboratory
   for Cancer Research, NIH, under contract HHSN261200800001E with Leidos
   Biomedical Research (Y.T.).
CR Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157
   ALLISON SL, 1995, J VIROL, V69, P5816, DOI 10.1128/JVI.69.9.5816-5820.1995
   Arora U, 2013, VACCINE, V31, P873, DOI 10.1016/j.vaccine.2012.12.016
   Catanzaro AT, 2007, VACCINE, V25, P4085, DOI 10.1016/j.vaccine.2007.02.050
   Chang GJJ, 2003, VIROLOGY, V306, P170, DOI 10.1016/S0042-6822(02)00028-4
   Chang GJJ, 2001, ANN NY ACAD SCI, V951, P272
   Davis BS, 2001, J VIROL, V75, P4040, DOI 10.1128/JVI.75.9.4040-4047.2001
   Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058
   Dowd KA, 2016, CELL REP, V16, P1485, DOI 10.1016/j.celrep.2016.07.049
   Ferlenghi I, 2001, MOL CELL, V7, P593, DOI 10.1016/S1097-2765(01)00206-4
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   Harrower J, 2016, EMERG INFECT DIS, V22, P1855, DOI 10.3201/eid2210.160951
   KONISHI E, 1993, J VIROL, V67, P1672, DOI 10.1128/JVI.67.3.1672-1675.1993
   Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952
   Ledgerwood JE, 2011, J INFECT DIS, V203, P1396, DOI 10.1093/infdis/jir054
   Ledgerwood JE, 2009, HUM VACCINES, V5, P623, DOI 10.4161/hv.8627
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   OKUNO Y, 1978, BIKEN J, V21, P137
   Pierson TC, 2008, CELL HOST MICROBE, V4, P229, DOI 10.1016/j.chom.2008.08.004
   Rouvinski A, 2015, NATURE, V520, P109, DOI 10.1038/nature14130
   Thomas SJ, 2013, AM J TROP MED HYG, V88, P73, DOI 10.4269/ajtmh.2012.12-0361
   Wang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8712
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   Zhao HY, 2016, CELL, V166, P1016, DOI 10.1016/j.cell.2016.07.020
NR 24
TC 213
Z9 222
U1 3
U2 93
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD OCT 14
PY 2016
VL 354
IS 6309
BP 237
EP 240
DI 10.1126/science.aai9137
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EC0UN
UT WOS:000387816500047
PM 27708058
OA Bronze, Green Accepted
DA 2020-12-08
ER

PT J
AU de Castro, AM
   Castilho, LD
   Freire, DMG
AF de Castro, Aline Machado
   Castilho, Leda dos Reis
   Guimaraes Freire, Denise Maria
TI Characterization of babassu, canola, castor seed and sunflower residual
   cakes for use as raw materials for fermentation processes
SO INDUSTRIAL CROPS AND PRODUCTS
LA English
DT Article
DE Specific heat profile; Solid-state fermentation; Biomass porosity;
   Biomass surface area; Bed properties; Elemental analysis
ID SOLID-STATE FERMENTATION; PARTICLE-SIZE; ACID; HYDROLYSIS; EXTRACTION;
   SUBSTRATE; WASTE
AB Four oil cakes obtained from different industries were characterized in terms of their physical, thermal and chemical properties. The particle size distributions were mathematically modeled to Gates-Gaudin-Schumann (GGS), Rosin-Rammler-Bennett (RRB) and sigmoid models, and the last one best described most of the materials. Castor seed cake showed the lowest (375.6 kg m(-3)) and sunflower cake the highest (619.2 kg m(-3)) bulk densities. Elemental analysis was performed and babassu cake was determined to present a C/N ratio of 11.37, which was considered the most suitable for some fermentation for enzyme production. The compositional analysis corroborated elemental analysis, indicating canola and castor seed cakes as those with the highest protein contents (34.8 and 43.5% m/m, respectively). The properties determined in this study can be useful for a wide range of applications of the biomasses. (c) 2015 Elsevier B.V. All rights reserved.
C1 [de Castro, Aline Machado] Petrobras SA, Div Biotechnol, Ctr Res & Dev, Petrobras, Brazil.
   [Castilho, Leda dos Reis] Univ Fed Rio de Janeiro, Chem Engn Program, COPPE, BR-21941909 Rio De Janeiro, Brazil.
   [Guimaraes Freire, Denise Maria] Univ Fed Rio de Janeiro, Inst Chem, BR-21941909 Rio De Janeiro, Brazil.
RP de Castro, AM (corresponding author), Ilha Fundao, Div Biotechnol, Ctr Res & Dev, PETROBRAS, Ave Horacio Macedo 950, BR-21941915 Rio De Janeiro, Brazil.; Freire, DMG (corresponding author), Univ Fed Rio de Janeiro, Dept Biochem, Inst Chem, Ilha Fundao, Ave Athos da Silveira Ramos 149 CT,Lab 549-1, BR-21941909 Rio De Janeiro, Brazil.
EM alinebio@petrobras.com.br; freire@iq.ufrj.br
RI FREIRE, Denise Maria/D-8699-2014; Castilho, Leda/I-8939-2014; CASTRO,
   ALINE/C-4984-2015
OI FREIRE, Denise Maria/0000-0002-8298-5936; CASTRO,
   ALINE/0000-0002-1355-8455
FU PETROBRAS/ANP; CAPESCAPES; CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ)
FX To Professor Magali Cammarota (Laboratory of Environmental Technology,
   School of Chemistry, Federal University of Rio de Janeiro) for the
   infrastructure for lipid content analysis. To Alessandra Rangel Cassela
   (PETROBRAS R&D Center) for elemental and DSC analyses. To Denise Costa
   (PETROBRAS R&D Center) for BET analysis. To PETROBRAS/ANP, CAPES, CNPq
   and FAPERJ for financial support.
CR Akhtar J, 2014, APPL MICROBIOL BIOT, V98, P987, DOI 10.1007/s00253-013-5319-6
   Alcantara S. R., 2007, Revista Brasileira de Produtos Agroindustriais, V9, P137
   Barga M. C., 2007, THESIS U FEDERAL PAR
   Bastos R.G., 2006, THESIS U CAMPINAS BR
   Brijwani Khushal, 2011, Enzyme Res, V2011, P860134, DOI 10.4061/2011/860134
   Casciatori FP, 2016, CHEM ENG J, V287, P103, DOI 10.1016/j.cej.2015.10.108
   Casciatori FP, 2014, CHEM ENG J, V255, P214, DOI 10.1016/j.cej.2014.06.040
   Castro A.M., 2005, 2 MERC C CHEM ENG
   Cinelli BA, 2014, FUEL, V124, P41, DOI 10.1016/j.fuel.2014.01.076
   Cunniff P., 1995, OFFICIAL METHODS A S
   de Castro AM, 2011, WASTE BIOMASS VALORI, V2, P291, DOI 10.1007/s12649-011-9075-5
   Figueroa-Montero A, 2011, J CHEM TECHNOL BIOT, V86, P1321, DOI 10.1002/jctb.2637
   FRARE LM, 2000, ACTA SCI, V22, P1235
   Gema H, 2002, APPL MICROBIOL BIOT, V58, P303, DOI 10.1007/s00253-001-0910-7
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   Gottipati R, 2010, BRAZ J CHEM ENG, V27, P357, DOI 10.1590/S0104-66322010000200014
   Guan J., 2014, AM J AGR FOR, V2, P1
   Heerd D, 2012, FOOD BIOPROD PROCESS, V90, P102, DOI 10.1016/j.fbp.2011.08.003
   Hidayat H., 2014, THESIS U GRONINGEN
   IBGE, 2015, QUANT PROD EXTR VEG
   Isahak W.N.R.W., 2013, J CHEM, V2013, P6
   Itavo L.C.V., 2015, FOOD CHEM
   KHALIL CN, 2001, Patent No. 01058886
   KHALIL CN, 2006, Patent No. 7112229
   Klockeman DM, 1997, J AGR FOOD CHEM, V45, P3867, DOI 10.1021/jf970026i
   Konwar LJ, 2015, APPL CATAL B-ENVIRON, V176, P20, DOI 10.1016/j.apcatb.2015.03.005
   Krishna Murthy TP, 2013, AM J FOOD SCI TECHNO, V1, P70
   Kucinskas V., 2012, Journal of Research and Applications in Agricultural Engineering, V57, P14
   Lacerda RS, 2014, CHEM ENGINEER TRANS, V37, P775, DOI 10.3303/CET1437130
   Liu J, 2007, FOOD TECHNOL BIOTECH, V45, P420
   Lopez J.A., 2012, 4 INT C ENG WAST BIO
   Manikandan K., 2010, International Journal of ChemTech Research, V2, P947
   Martin C, 2010, BIOMASS BIOENERG, V34, P533, DOI 10.1016/j.biombioe.2009.12.019
   McCusker LB, 2001, PURE APPL CHEM, V73, P381, DOI 10.1351/pac200173020381
   McKendry P, 2002, BIORESOURCE TECHNOL, V83, P37, DOI 10.1016/S0960-8524(01)00118-3
   Melo WC, 2008, J BRAZIL CHEM SOC, V19, P418, DOI 10.1590/S0103-50532008000300008
   Membrillo I, 2008, BIORESOURCE TECHNOL, V99, P7842, DOI 10.1016/j.biortech.2008.01.083
   MENDLOWITZ M, 1985, CLIN HEMORHEOL, V5, P123
   Miranda M.R.S., 2011, THESIS FEDERAL U UBE
   Normas analiticas do Instituto Aldolfo Lutz, 2005, MET QUIM FIS AN AL, P1018
   Obernberger I, 2004, BIOMASS BIOENERG, V27, P653, DOI 10.1016/j.biombioe.2003.07.006
   PANDEY A, 1991, BIORESOURCE TECHNOL, V37, P169, DOI 10.1016/0960-8524(91)90206-Y
   PARRADO J, 1993, J AGR FOOD CHEM, V41, P1821, DOI 10.1021/jf00035a003
   Perez EE, 2004, J AM OIL CHEM SOC, V81, P245, DOI 10.1007/s11746-004-0890-y
   Rahardjo YSP, 2006, BIOTECHNOL ADV, V24, P161, DOI 10.1016/j.biotechadv.2005.09.002
   Raimbault M, 1998, ELECTRON J BIOTECHN, V1, P174, DOI DOI 10.2225/vol1-issue3-fulltext-9
   Ramachandran S, 2007, BIORESOURCE TECHNOL, V98, P2000, DOI 10.1016/j.biortech.2006.08.002
   Ren J, 2012, ADV INTEL SOFT COMPU, V134, P441
   Rodriguez-Fernandez DE, 2012, BIORESOURCE TECHNOL, V118, P603, DOI 10.1016/j.biortech.2012.05.032
   Schmidt CG, 2012, BIORESOURCE TECHNOL, V123, P36, DOI 10.1016/j.biortech.2012.07.081
   Silveira C.L., 2015, J CHEM TECHNOL BIOTE
   SMAIL T, 1995, WORLD J MICROB BIOT, V11, P171, DOI 10.1007/BF00704642
   VANSOEST PJ, 1963, J ASSOC OFF AGR CHEM, V46, P825
   Vassilev SV, 2013, FUEL, V105, P40, DOI 10.1016/j.fuel.2012.09.041
   Vassilev SV, 2012, FUEL, V94, P1, DOI 10.1016/j.fuel.2011.09.030
   Vassilev SV, 2010, FUEL, V89, P913, DOI 10.1016/j.fuel.2009.10.022
   Vivekanandhan S, 2013, LIQUID GASEOUS SOLID, P491
   Zadrazil F, 1995, BIORESOURCE TECHNOL, V54, P85, DOI 10.1016/0960-8524(95)00119-0
   Zielinski J.M., 2015, INTERTEK WHITEPAPER
NR 59
TC 17
Z9 17
U1 2
U2 32
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0926-6690
EI 1872-633X
J9 IND CROP PROD
JI Ind. Crop. Prod.
PD MAY
PY 2016
VL 83
BP 140
EP 148
DI 10.1016/j.indcrop.2015.12.050
PG 9
WC Agricultural Engineering; Agronomy
SC Agriculture
GA DE8NX
UT WOS:000370894000020
DA 2020-12-08
ER

PT J
AU Lages, YM
   Nascimento, JM
   Lemos, GA
   Galina, A
   Castilho, LR
   Rehen, SK
AF Lages, Yury M.
   Nascimento, Juliana M.
   Lemos, Gabriela A.
   Galina, Antonio
   Castilho, Leda R.
   Rehen, Stevens K.
TI Low oxygen alters mitochondrial function and response to oxidative
   stress in human neural progenitor cells
SO PEERJ
LA English
DT Article
DE Low oxygen; Cell metabolism; Reactive oxygen species; DNA damage;
   Mitochondria; Human neural progenitor cells
ID STEM-CELLS; HUMAN ES; IN-VIVO; DIFFERENTIATION; SURVIVAL; PROLIFERATION;
   PEROXIREDOXIN; PRECURSORS; EXPRESSION; EFFICIENT
AB Oxygen concentration should be carefully regulated in all living tissues, beginning at the early embryonic stages. Unbalances in oxygen regulation can lead to cell death and disease. However, to date, few studies have investigated the consequences of variations in oxygen levels for fetal-like cells. Therefore, in the present work, human neural progenitor cells (NPCs) derived from pluripotent stem cells grown in 3% oxygen (v/v) were compared with NPCs cultured in 21% (v/v) oxygen. Low oxygen concentrations altered the mitochondrial content and oxidative functions of the cells, which led to improved ATP production, while reducing generation of reactive oxygen species (ROS). NPCs cultured in both conditions showed no differences in proliferation and glucose metabolism. Furthermore, antioxidant enzymatic activity was not altered in NPCs cultured in 3% oxygen under normal conditions, however, when exposed to external agents known to induce oxidative stress, greater susceptibility to DNA damage was observed. Our findings indicate that the management of oxygen levels should be considered for in vitro models of neuronal development and drug screening.
C1 [Lages, Yury M.; Rehen, Stevens K.] Univ Fed Rio de Janeiro, Inst Biomed Sci, Rio De Janeiro, Brazil.
   [Nascimento, Juliana M.; Rehen, Stevens K.] DOr Inst Res & Educ, IDOR, Rio De Janeiro, RJ, Brazil.
   [Lemos, Gabriela A.; Galina, Antonio] Univ Fed Rio de Janeiro, Inst Med Biochem Leopoldo De Meis, Rio De Janeiro, RJ, Brazil.
   [Castilho, Leda R.] Univ Fed Rio de Janeiro, Chem Engn Program, COPPE, Rio De Janeiro, RJ, Brazil.
RP Rehen, SK (corresponding author), Univ Fed Rio de Janeiro, Inst Biomed Sci, Rio De Janeiro, Brazil.
EM srehen@lance-ufrj.org
RI de Lemos, Gabriela A/C-1743-2019; Rehen, Stevens K/J-5874-2012;
   Nascimento, Juliana/B-8764-2009; Castilho, Leda/I-8939-2014
OI de Lemos, Gabriela A/0000-0002-2804-3163; Rehen, Stevens
   K/0000-0003-4216-9501; Nascimento, Juliana/0000-0003-3126-4984; Lages,
   Yury/0000-0003-4100-4510
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); CAPESCAPES; FINEPCiencia Tecnologia e
   Inovacao (FINEP); BNDES
FX This study was funded by the following Brazilian funding agencies: CNPq,
   FAPERJ, CAPES, FINEP, and BNDES. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bae D, 2012, STEM CELLS DEV, V21, P1344, DOI 10.1089/scd.2011.0225
   Becker NP, 2014, METALLOMICS, V6, P1079, DOI 10.1039/c4mt00004h
   Brennand K, 2015, MOL PSYCHIATR, V20, P361, DOI 10.1038/mp.2014.22
   Carreau A, 2011, J CELL MOL MED, V15, P1239, DOI 10.1111/j.1582-4934.2011.01258.x
   Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529
   Chan DC, 2012, ANNU REV GENET, V46, P265, DOI 10.1146/annurev-genet-110410-132529
   Chen HL, 2007, STEM CELLS, V25, P2291, DOI 10.1634/stemcells.2006-0609
   Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200
   Cheng AW, 2010, ASN NEURO, V2, P243, DOI 10.1042/AN20100019
   Chiba M, 2014, TUMOR BIOL, V35, P12689, DOI 10.1007/s13277-014-2593-6
   Clanton TL, 2013, COMPR PHYSIOL, V3, P1135, DOI 10.1002/cphy.c120030
   Drose S, 2008, J BIOL CHEM, V283, P21649, DOI 10.1074/jbc.M803236200
   Duranton C, 2012, AM J PATHOL, V181, P1367, DOI 10.1016/j.ajpath.2012.06.017
   Eliasson P, 2010, J CELL PHYSIOL, V222, P17, DOI 10.1002/jcp.21908
   Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004
   Forristal CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062507
   Forristal CE, 2013, BLOOD, V121, P759, DOI 10.1182/blood-2012-02-408419
   Fraga AM, 2011, CELL TRANSPLANT, V20, P431, DOI 10.3727/096368910X522261
   Giedt RJ, 2012, ANN BIOMED ENG, V40, P1903, DOI 10.1007/s10439-012-0568-6
   Hidalgo M, 2014, CELL PHYSIOL BIOCHEM, V33, P67, DOI 10.1159/000356650
   Janc OA, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00056
   Jang YY, 2007, BLOOD, V110, P3056, DOI 10.1182/blood-2007-05-087759
   Jastroch M, 2010, ESSAYS BIOCHEM, V47, P53, DOI [10.1042/BSE0470053, 10.1042/bse0470053]
   Konyalioglu S, 2013, NEURAL REGEN RES, V8, P485, DOI 10.3969/j.issn.1673-5374.2013.06.001
   Kubota Y, 2008, BIOCHEM BIOPH RES CO, V366, P335, DOI 10.1016/j.bbrc.2007.11.086
   Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003
   Li Zhuyin, 2014, Curr Chem Genom Transl Med, V8, P1, DOI 10.2174/2213988501408010001
   Mitozo PA, 2011, FREE RADICAL BIO MED, V51, P69, DOI 10.1016/j.freeradbiomed.2011.03.017
   Narva E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078847
   Paulsen BD, 2013, ARCH BIOCHEM BIOPHYS, V534, P3, DOI 10.1016/j.abb.2012.10.009
   Pereira SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082095
   REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015
   Rosafio K, 2014, GLIA, V62, P477, DOI 10.1002/glia.22618
   Rosova I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007-1104
   Ross HH, 2012, EXP NEUROL, V235, P238, DOI 10.1016/j.expneurol.2012.01.027
   Song XR, 2006, CANCER CHEMOTH PHARM, V58, P776, DOI 10.1007/s00280-006-0224-7
   Stacpoole SRL, 2011, CELL DEATH DIFFER, V18, P1016, DOI 10.1038/cdd.2010.171
   Studer L, 2000, J NEUROSCI, V20, P7377
   Tait SWG, 2012, J CELL SCI, V125, P807, DOI 10.1242/jcs.099234
   Tiede LM, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.128
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Xi H, 2014, FEBS LETT, V588, P3390, DOI 10.1016/j.febslet.2014.07.030
   Yan MH, 2013, FREE RADICAL BIO MED, V62, P90, DOI 10.1016/j.freeradbiomed.2012.11.014
   Zachar V, 2010, IN VITRO CELL DEV-AN, V46, P276, DOI 10.1007/s11626-010-9305-3
NR 44
TC 6
Z9 6
U1 0
U2 12
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD DEC 10
PY 2015
VL 3
AR e1486
DI 10.7717/peerj.1486
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CY4XU
UT WOS:000366413000005
PM 26713239
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Mattos, DA
   Silva, MV
   Gaspar, LP
   Castilho, LR
AF Mattos, Diogo A.
   Silva, Marlon V.
   Gaspar, Luciane P.
   Castilho, Leda R.
TI Increasing Vero viable cell densities for yellow fever virus production
   in stirred-tank bioreactors using serum-free medium
SO VACCINE
LA English
DT Article; Proceedings Paper
CT Vaccine Technology V - ECI Conference
CY JUN 08-13, 2014
CL Playa del Carmen, MEXICO
DE Yellow fever virus production; Vero cells; Serum-free medium;
   Bioreactors
ID INFLUENZA-VIRUSES; 17DD VACCINE; IMMUNOGENICITY; POLIOVIRUS; YIELDS;
   LINES
AB In this work, changes in Vero. cell cultivation methods have been employed in order to improve cell growth conditions to obtain higher viable cell densities and to increase viral titers. The propagation of the 17DD yellow fever virus (YFV) in Vero cells grown on Cytodex I microcarriers was evaluated in 3-L bioreactor vessels. Prior to the current changes, Vero cells were repeatedly displaying insufficient microcarrier colonization. A modified cultivation process with four changes has resulted in higher cell densities and higher virus titers than previously observed for 17DD YFV. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Mattos, Diogo A.; Silva, Marlon V.; Gaspar, Luciane P.] Biomanguinhos FIOCRUZ, Technol Dev Vice Directory, Rio De Janeiro, RJ, Brazil.
   [Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21945 Rio De Janeiro, RJ, Brazil.
RP Gaspar, LP (corresponding author), Biomanguinhos FIOCRUZ, Technol Dev Vice Directory, Rio De Janeiro, RJ, Brazil.
EM lgaspar@bio.fiocruz.br
RI Castilho, Leda/I-8939-2014
FU Programa de Desenvolvimento Tecnologico em Insumos para Saude Publica
   (PDTSP) from FIOCRUZ; government funding agency Financiadora de Estudos
   e Projetos (FINEP)
FX We thank Bio-Manguinhos/FIOCRUZ for the continued interest and support
   to this work. We also thank Sheila Maria Barbosa de Lima for the use of
   the Virological Facility at Bio-Manguinhos and YF inactivated vaccine
   team of Bio-Manguinhos for continuous technical support. This work was
   supported in part by the Programa de Desenvolvimento Tecnologico em
   Insumos para Saude Publica (PDTSP) from FIOCRUZ and by the government
   funding agency Financiadora de Estudos e Projetos (FINEP).
CR Arifin MA, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/586363
   Barrett ADT, 2009, CURR OPIN IMMUNOL, V21, P308, DOI 10.1016/j.coi.2009.05.018
   Caufour PS, 2001, VIRUS RES, V79, P1, DOI 10.1016/S0168-1702(01)00273-8
   Donis RO, 2014, VACCINE, V32, P6583, DOI 10.1016/j.vaccine.2014.06.045
   Freire MS, 2005, VACCINE, V23, P2501, DOI 10.1016/j.vaccine.2004.10.035
   Gardner CL, 2010, CLIN LAB MED, V30, P237, DOI 10.1016/j.cll.2010.01.001
   Genzel Y, 2014, METHODS MOL BIOL, V1104, P371, DOI 10.1007/978-1-62703-733-4_23
   Genzel Y, 2010, APPL MICROBIOL BIOT, V88, P461, DOI 10.1007/s00253-010-2742-9
   Guertin PM., 2010, US Patent, Patent No. 043013
   Hayes EB, 2010, VACCINE, V28, P8073, DOI 10.1016/j.vaccine.2010.10.015
   Kummerer BM., 2006, MOL BIOL FLAVIVIRUS, P1
   Lohr V, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-79
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   Monath TP, 2010, VACCINE, V28, P3827, DOI 10.1016/j.vaccine.2010.03.023
   Paillet C, 2009, VACCINE, V27, P6464, DOI 10.1016/j.vaccine.2009.06.020
   Pato TP, 2014, VACCINE, V32, P2789, DOI 10.1016/j.vaccine.2014.02.036
   Rourou S, 2009, APPL MICROBIOL BIOT, V85, P53, DOI 10.1007/s00253-009-2064-y
   Sanders BP, 2013, VACCINE, V31, P850, DOI 10.1016/j.vaccine.2012.10.070
   SANFORD KK, 1951, J NATL CANCER I, V11, P773
   Souza MCO, 2009, VACCINE, V27, P6420, DOI 10.1016/j.vaccine.2009.06.023
   Thomassen YE, 2014, VACCINE, V32, P2782, DOI 10.1016/j.vaccine.2014.02.022
   Vasconcelos PFC, 2001, LANCET, V358, P91, DOI 10.1016/S0140-6736(01)05326-0
NR 22
TC 8
Z9 11
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 20
PY 2015
VL 33
IS 35
SI SI
BP 4288
EP 4291
DI 10.1016/j.vaccine.2015.04.050
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA CQ8PK
UT WOS:000360870500010
PM 25930117
DA 2020-12-08
ER

PT J
AU Cinelli, BA
   Castilho, LR
   Freire, DMG
   Castro, AM
AF Cinelli, Bernardo A.
   Castilho, Leda R.
   Freire, Denise M. G.
   Castro, Aline M.
TI A brief review on the emerging technology of ethanol production by cold
   hydrolysis of raw starch
SO FUEL
LA English
DT Review
DE Ethanol; Starch; Amylase; Saccharomyces cerevisiae; Cold hydrolysis
ID SWEET-POTATO STARCHES; SACCHAROMYCES-CEREVISIAE; ALPHA-AMYLASE; CORN
   STARCH; SIMULTANEOUS SACCHARIFICATION; ENZYMATIC-HYDROLYSIS; NATIVE
   TRITICALE; SMALL GRANULES; BY-PRODUCTS; FERMENTATION
AB Ethanol is one of the main biobased molecule produced worldwide, mainly from corn and other starchy crops. In the past few years, one promising technology that has been claimed to reduce capital and operational costs of industrial plants and increase overall yields for ethanol is named 'cold starch hydrolysis'. The saccharification is carried out at low temperatures (under starch gelatinization point) but require the use of accessory enzymes to achieve high conversions. The best result achieved so far is 98.6% of starch conversion into glucose. This review briefly states the main concepts of this technology, discussing recent literature data for ethanol production and finally presenting future trends in the field of ethanol production from starchy raw materials. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Cinelli, Bernardo A.; Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21941 Rio De Janeiro, Brazil.
   [Freire, Denise M. G.] Univ Fed Rio de Janeiro, Inst Chem, BR-21941 Rio De Janeiro, Brazil.
   [Castro, Aline M.] Petrobras SA, Ctr Res & Dev, Div Biotechnol, BR-21941915 Rio De Janeiro, RJ, Brazil.
RP Freire, DMG (corresponding author), IQ UFRJ, Dept Biochem, Av Athos Silveira Ramos 149,CT,Lab 549-1, BR-21941909 Rio De Janeiro, RJ, Brazil.
EM freire@iq.ufrj.br; alinebio@petrobras.com.br
RI Castilho, Leda/I-8939-2014; CASTRO, ALINE/C-4984-2015; FREIRE, Denise
   Maria/D-8699-2014
OI CASTRO, ALINE/0000-0002-1355-8455; FREIRE, Denise
   Maria/0000-0002-8298-5936
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CapesCAPES; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); CENPES/PETROBRAS
FX The authors gratefully acknowledge CNPq, Capes, FAPERJ and
   CENPES/PETROBRAS for financial support.
CR Bai FW, 2008, BIOTECHNOL ADV, V26, P89, DOI 10.1016/j.biotechadv.2007.09.002
   Balcerek M, 2013, J CHEM TECHNOL BIOT, V88, P615, DOI 10.1002/jctb.3873
   Balls AK, 1944, J BIOL CHEM, V156, P203
   BERVEN D, 2005, ETHANOL PROD MAG, V11, P67
   Bialas W, 2010, BIORESOURCE TECHNOL, V101, P3126, DOI 10.1016/j.biortech.2009.12.090
   Blazek J, 2010, BIOMACROMOLECULES, V11, P3275, DOI 10.1021/bm101124t
   Castro AM, 2011, BIOMASS CONVERS BIOR, V1, DOI 10.1007/s13399-011-0023-1
   Chen G, 2012, J CEREAL SCI, V56, P316, DOI 10.1016/j.jcs.2012.01.011
   Cinelli BA, 2014, FUEL, V124, P41, DOI 10.1016/j.fuel.2014.01.076
   Clark JH, 2006, GREEN CHEM, V8, P853, DOI 10.1039/b604483m
   de Castro AM, 2011, WASTE BIOMASS VALORI, V2, P291, DOI 10.1007/s12649-011-9075-5
   de Castro AM, 2010, APPL BIOCHEM BIOTECH, V162, P1612, DOI [10.1007/s12010-010-8986-0, 10.1007/s12010-010-8942-z]
   den Haan R, 2013, J CHEM TECHNOL BIOT, V88, P983, DOI 10.1002/jctb.4068
   Devantier R, 2005, APPL MICROBIOL BIOT, V68, P622, DOI 10.1007/s00253-005-1902-9
   Farrell AE, 2006, SCIENCE, V311, P506, DOI 10.1126/science.1121416
   GALVEZ A, 2005, ETHANOL PRODUCER, V11, P58
   Ghang DM, 2007, BIOTECHNOL LETT, V29, P1203, DOI 10.1007/s10529-007-9371-0
   Harris PV, 2014, CURR OPIN CHEM BIOL, V19, P162, DOI 10.1016/j.cbpa.2014.02.015
   Helbert W, 1996, INT J BIOL MACROMOL, V19, P165, DOI 10.1016/0141-8130(96)01123-3
   Holm-Nielsen JB, 2006, WORLD BIOEN 2006 C B
   Huston Adrienne L., 2008, P347, DOI 10.1007/978-3-540-74335-4_20
   Johnston DB, 2014, BIORESOURCE TECHNOL, V154, P18, DOI 10.1016/j.biortech.2013.11.043
   Kawa-Rygielska J, 2012, BIOMASS BIOENERG, V44, P17, DOI 10.1016/j.biombioe.2012.04.016
   Kelsall DR, 2003, GRAIN DRY MILLING CO
   Kim JH, 2010, BIOTECHNOL LETT, V32, P713, DOI 10.1007/s10529-010-0212-1
   Kim Y, 2008, BIORESOURCE TECHNOL, V99, P5165, DOI 10.1016/j.biortech.2007.09.028
   Klosowski G, 2010, J BIOSCI BIOENG, V109, P466, DOI 10.1016/j.jbiosc.2009.10.024
   Kopnieczny-Janda G, 2008, Patent application, Patent No. [WO2008112282 A1, 2008112282]
   Koutinas AA, 2007, BIOTECHNOL BIOENG, V97, P61, DOI 10.1002/bit.21206
   Lamsal BP, 2011, BIORESOURCE TECHNOL, V102, P6680, DOI 10.1016/j.biortech.2011.03.040
   Lewis S, 2004, United States patent, Patent No. [US 2004/0234,649, 20040234649]
   Li JH, 2012, CARBOHYD POLYM, V87, P1649, DOI 10.1016/j.carbpol.2011.09.061
   Marrone P, ETHANOL PRODUCER MAG
   Murthy G., 2007, DEV CONTROLLER FERME
   Naguleswaran S, 2013, FOOD RES INT, V51, P771, DOI 10.1016/j.foodres.2013.01.057
   Naguleswaran S, 2012, CARBOHYD POLYM, V88, P864, DOI 10.1016/j.carbpol.2012.01.027
   Nghiem NP, 2010, BIOTECHNOL BIOFUELS, V3, P1
   Oates CG, 1997, TRENDS FOOD SCI TECH, V8, P375, DOI 10.1016/S0924-2244(97)01090-X
   Oner ET, 2005, APPL ENVIRON MICROB, V71, P6443, DOI 10.1128/AEM.71.10.6443-6445.2005
   Pereira FB, 2010, BIORESOURCE TECHNOL, V101, P7856, DOI 10.1016/j.biortech.2010.04.082
   Perez-Carrillo E, 2012, BIOCHEM ENG J, V67, P1, DOI 10.1016/j.bej.2012.04.010
   Pickens CE, 1986, PROCESS ENZYMATIC HY
   PRANAMUDA H, 1995, STARCH-STARKE, V47, P277, DOI 10.1002/star.19950470708
   Ragauskas AJ, 2006, SCIENCE, V311, P484, DOI 10.1126/science.1114736
   Rattanachomsri U, 2009, J BIOSCI BIOENG, V108, P357, DOI 10.1016/j.jbiosc.2009.06.012
   Reddy LVA, 2009, YEAST BIOTECHNOLOGY, P515
   Robertson GH, 2006, J AGR FOOD CHEM, V54, P353, DOI 10.1021/jf051883m
   Sainz MB, 2009, IN VITRO CELL DEV-PL, V45, P314, DOI 10.1007/s11627-009-9210-1
   Sapinska E, 2014, J I BREWING, V120, P105, DOI 10.1002/jib.119
   Sarian FD, 2012, APPL MICROBIOL BIOT, V93, P645, DOI 10.1007/s00253-011-3436-7
   Schill S. R., ETHANOL PRODUCER MAG
   Schill SR, 2008, ETHANOL PRODUCER MAG
   Shariffa YN, 2009, FOOD HYDROCOLLOID, V23, P434, DOI 10.1016/j.foodhyd.2008.03.009
   Shigechi H, 2004, APPL ENVIRON MICROB, V70, P5037, DOI 10.1128/AEM.70.8.5037-5040.2004
   Shrestha AK, 2012, CARBOHYD POLYM, V90, P23, DOI 10.1016/j.carbpol.2012.04.041
   Sugimoto T, 2012, J IND MICROBIOL BIOT, V39, P605, DOI 10.1007/s10295-011-1053-1
   Sun HY, 2010, APPL BIOCHEM BIOTECH, V160, P988, DOI 10.1007/s12010-009-8579-y
   Sun HY, 2009, AFR J BIOTECHNOL, V8, P1734
   Szymanowska Daria, 2011, Biotechnologia (Poznan), V92, P85
   Szymanowska-Powalowska D, 2012, BIOTECHNOL J BIOTECH, V93, P645
   Szymanowska-Powalowska D, 2014, FUEL, V119, P328, DOI 10.1016/j.fuel.2013.11.034
   Tatsumi H, 2005, J AGR FOOD CHEM, V53, P8123, DOI 10.1021/jf050934c
   Tester RF, 2006, ANIM FEED SCI TECH, V130, P39, DOI 10.1016/j.anifeedsci.2006.01.016
   Textor SD, 1998, CAN J CHEM ENG, V76, P87, DOI 10.1002/cjce.5450760111
   Uthumporn U, 2013, IND CROP PROD, V43, P441, DOI 10.1016/j.indcrop.2012.07.060
   Uthumporn U, 2012, APPL BIOCHEM BIOTECH, V166, P1167, DOI 10.1007/s12010-011-9502-x
   Uthumporn U, 2010, FOOD BIOPROD PROCESS, V88, P47, DOI 10.1016/j.fbp.2009.10.001
   van Zyl WH, 2012, APPL MICROBIOL BIOT, V95, P1377, DOI 10.1007/s00253-012-4248-0
   Vidal BC, 2009, STARCH-STARKE, V61, P448, DOI 10.1002/star.200800091
   Vidal BC, 2009, CEREAL CHEM, V86, P323, DOI 10.1094/CCHEM-86-3-0323
   Thang VH, 2014, APPL BIOCHEM BIOTECH, V172, P1818, DOI 10.1007/s12010-013-0620-5
   Wang P, 2005, CEREAL CHEM, V82, P734, DOI 10.1094/CC-82-0734
   Wang P, 2009, CEREAL CHEM, V86, P319, DOI 10.1094/CCHEM-86-3-0319
   Wang R, 2009, ENZYME MICROB TECH, V44, P223, DOI 10.1016/j.enzmictec.2008.10.002
   Warren FJ, 2011, CARBOHYD POLYM, V86, P1038, DOI 10.1016/j.carbpol.2011.05.062
   WELLER CL, 1983, BIOTECHNOL BIOENG, P437
   Williams J., 2006, ETHANOL PRODUCER MAG
   Wood C, 2014, IND CROP PROD, V56, P145, DOI 10.1016/j.indcrop.2014.03.001
   Yussof NS, 2013, STARCH-STARKE, V65, P285, DOI 10.1002/star.201200002
NR 79
TC 49
Z9 52
U1 2
U2 102
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0016-2361
EI 1873-7153
J9 FUEL
JI Fuel
PD JUN 15
PY 2015
VL 150
BP 721
EP 729
DI 10.1016/j.fuel.2015.02.063
PG 9
WC Energy & Fuels; Engineering, Chemical
SC Energy & Fuels; Engineering
GA CE3FA
UT WOS:000351710400084
DA 2020-12-08
ER

PT J
AU de Castro, AM
   Castilho, LR
   Freire, DMG
AF de Castro, Aline Machado
   Castilho, Leda R.
   Guimares Freire, Denise Maria
TI Multivariate Optimization and Supplementation Strategies for the
   Simultaneous Production of Amylases, Cellulases, Xylanases, and
   Proteases by Aspergillus awamori Under Solid-State Fermentation
   Conditions
SO APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
LA English
DT Article
DE Amylases; Proteases; Cellulases; Xylanases; Multivariate optimization by
   desirability analysis
ID LIPASE PRODUCTION; HYDROLYSIS; RESIDUE; DESIGN; WASTE; CAKE
AB The production of extracts containing a pool of enzymes for extensive biomass deconstruction can lead to significant advantages in biorefinery applications. In this work, a strain of Aspergillus awamori IOC-3914 was used for the simultaneous production of five groups of hydrolases by solid-state fermentation of babassu cake. Sequential experimental design strategies and multivariate optimization using the desirability function were first used to study temperature, moisture content, and granulometry. After that, further improvements in product yields were achieved by supplementation with other agro-industrial materials. At the end of the study, the production of enzymes was up to 3.3-fold increased, and brewer's spent grains and babassu flour showed to be the best supplements. Maximum activities for endoamylases, exoamylases, cellulases (CMCases), xylanases, and proteases achieved were 197, 106, 20, 835, and 57 U g(-1), respectively. The strain was also able to produce beta-glucosidases and debranching amylases (up to 35 and 43 U g(-1), respectively), indicating the potential of its enzyme pool for cellulose and starch degradation.
C1 [de Castro, Aline Machado] Petrobras SA, Ctr Res & Dev, Div Biotechnol, BR-21941915 Rio De Janeiro, Brazil.
   [Guimares Freire, Denise Maria] Univ Fed Rio de Janeiro, Inst Chem, Rio De Janeiro, Brazil.
   [de Castro, Aline Machado; Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21945 Rio De Janeiro, Brazil.
RP de Castro, AM (corresponding author), Petrobras SA, Ctr Res & Dev, Div Biotechnol, Ave Horacio Macedo,950 Ilha Fundao, BR-21941915 Rio De Janeiro, Brazil.
EM alinebio@petrobras.com.br
RI FREIRE, Denise Maria/D-8699-2014; Castilho, Leda/I-8939-2014; CASTRO,
   ALINE/C-4984-2015
OI FREIRE, Denise Maria/0000-0002-8298-5936; CASTRO,
   ALINE/0000-0002-1355-8455
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); ANP/PETROBRAS
FX The authors wish to thank Dr. Edmond Baruque (Tocantins Babacu S.A.) for
   kindly providing babassu cake and Daniele Fernandes and Mariana Teixeira
   for their technical assistance. The financial support from CNPq, CAPES,
   FAPERJ, and ANP/PETROBRAS are also gratefully acknowledged.
CR Balkan B, 2011, ROM BIOTECH LETT, V16, P6591
   Castilho LR, 2000, BIOCHEM ENG J, V4, P239, DOI 10.1016/S1369-703X(99)00052-2
   Castro A. M., 2011, ENZYME RES, DOI [10.4061/2011/457392, DOI 10.4061/2011/457392]
   Castro A. M., 2010, THESIS FEDERAL U RIO
   Castro A. M. de, 2010, Journal of Industrial Microbiology & Biotechnology, V37, P151
   Castro AM, 2011, BIOMASS CONVERS BIOR, V1, DOI 10.1007/s13399-011-0023-1
   Cinelli BA, 2014, FUEL, V124, P41, DOI 10.1016/j.fuel.2014.01.076
   de Castro AM, 2010, QUIM NOVA, V33, P181, DOI 10.1590/S0100-40422010000100031
   Garlapati VK, 2010, APPL BIOCHEM BIOTECH, V162, P1350, DOI 10.1007/s12010-009-8895-2
   Gervais P, 2003, BIOCHEM ENG J, V13, P85, DOI 10.1016/S1369-703X(02)00122-5
   Gutarra MLE, 2007, J CHEM TECHNOL BIOT, V82, P313, DOI 10.1002/jctb.1674
   Gutarra MLE, 2009, BIORESOURCE TECHNOL, V100, P5249, DOI 10.1016/j.biortech.2008.08.050
   Holker U, 2005, CURR OPIN MICROBIOL, V8, P301, DOI 10.1016/j.mib.2005.04.006
   Kareem SO, 2009, AFR J MICROBIOL RES, V3, P974
   Lopez J.A., 2012, 4 INT C ENG WAST BIO
   Lopez JA, 2013, BIOCHEM ENG J, V77, P231, DOI 10.1016/j.bej.2013.06.006
   Martin C, 2010, BIOMASS BIOENERG, V34, P533, DOI 10.1016/j.biombioe.2009.12.019
   Moftah OAS, 2012, APPL BIOCHEM BIOTECH, V166, P348, DOI 10.1007/s12010-011-9429-2
   Mohamed SA, 2013, J MICROBIOL, V51, P605, DOI 10.1007/s12275-013-3016-x
   Mussatto SI, 2006, J CEREAL SCI, V43, P1, DOI 10.1016/j.jcs.2005.06.001
   Pal A, 2010, BIORESOURCE TECHNOL, V101, P7563, DOI 10.1016/j.biortech.2010.04.033
   Paris L. D., 2012, ACTA SCI-TECHNOL, V34, P193
   Priyanka P., 2013, International Journal of Chemical Sciences, V11, P291
   Ragauskas AJ, 2006, SCIENCE, V311, P484, DOI 10.1126/science.1114736
   Rodrigues M. I., 2005, PLANEJAMENTO EXPT OT
   Vassilev SV, 2012, FUEL, V94, P1, DOI 10.1016/j.fuel.2011.09.030
   Viniegra-Gonzalez G, 2003, BIOCHEM ENG J, V13, P157, DOI 10.1016/S1369-703X(02)00128-6
   Walia A, 2013, ANN MICROBIOL, V63, P187, DOI 10.1007/s13213-012-0460-5
   Xu J, 2005, PROCESS BIOCHEM, V40, P3075, DOI 10.1016/j.procbio.2005.03.011
   YOUNG DL, 1991, IEEE T COMPUT AID D, V10, P103, DOI 10.1109/43.62796
NR 30
TC 9
Z9 9
U1 0
U2 35
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0273-2289
EI 1559-0291
J9 APPL BIOCHEM BIOTECH
JI Appl. Biochem. Biotechnol.
PD FEB
PY 2015
VL 175
IS 3
BP 1588
EP 1602
DI 10.1007/s12010-014-1368-2
PG 15
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA CB1PA
UT WOS:000349398800026
PM 25413792
DA 2020-12-08
ER

PT J
AU Castro, AM
   Castilho, LR
   Freire, DMG
AF Castro, Aline M.
   Castilho, Leda R.
   Freire, Denise M. G.
TI Performance of a fixed-bed solid-state fermentation bioreactor with
   forced aeration for the production of hydrolases by Aspergillus awamori
SO BIOCHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Production of amylases; proteases, xylanases and cellulases; Solid-state
   fermentation; Fixed-bed bioreactors; Filamentous fungi; Temperature
   gradients and heat transfer
ID HYDROLYSIS; GROWTH; NIGER; CAKE
AB In order to overcome scale-up limitations of conventional tray-type solid-state fermentation (SSF) bioreactors, a cylindrical fixed-bed bioreactor with forced aeration was investigated for the production of a pool of industrially relevant enzymes by Aspergillus awamori IOC-3914 using babassu cake as raw material. Significant internal radial and axial temperature gradients were observed (up to 2.4 degrees C cm(-1)), but despite of this, good titers of the production of the six enzyme groups evaluated was observed in all three bed layers sampled. Maximum activities of exoamylases, endoamylases, proteases, xylanases and cellulases (CMCase) were, respectively, 73.4, 55.7, 31.8, 23.8 and 6.2 U g(-1). Moreover, a considerable production of isoamylases (27.0 U g(-1)) was observed, although the production of starch-debranching enzymes by SSF is rarely reported. Productivities were highest for endoamylases (0.95 U g(-1) h(-1)) and exoamylases (0.67 U g(-1) h(-1)). The present results show that despite considerable axial and radial temperature gradients, significant levels of different enzymes can be obtained, giving evidence that fixed-bed bioreactors with forced aeration present a promising alternative in terms of instrumented bioreactors for SSF processes. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Castro, Aline M.] Petrobras SA, Ctr Res & Dev, Div Biotechnol, Rio De Janeiro, RJ, Brazil.
   [Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, Rio De Janeiro, RJ, Brazil.
   [Freire, Denise M. G.] Univ Fed Rio de Janeiro, Inst Chem, Rio De Janeiro, RJ, Brazil.
RP Freire, DMG (corresponding author), Univ Fed Rio de Janeiro, Inst Chem, Rio De Janeiro, RJ, Brazil.
EM freire@iq.ufrj.br
RI CASTRO, ALINE/C-4984-2015; FREIRE, Denise Maria/D-8699-2014; Castilho,
   Leda/I-8939-2014
OI CASTRO, ALINE/0000-0002-1355-8455; FREIRE, Denise
   Maria/0000-0002-8298-5936; 
FU PETROBRAS; Brazilian agency CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian agency CAPESCAPES; Brazilian
   agency FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); Brazilian agency ANP
FX The authors gratefully acknowledge Daniele Carvalho, Mariana Teixeira
   and Carolina Lazar for technical assistance, as well as funding by
   PETROBRAS and the Brazilian agencies CNPq, CAPES, FAPERJ and ANP.
CR AIDOO KE, 1981, EUR J APPL MICROBIOL, V12, P6, DOI 10.1007/BF00508111
   Astolfi V, 2011, BIOCHEM ENG J, V58-59, P39, DOI 10.1016/j.bej.2011.08.012
   Castro A.M., 2011, ENZYME RES
   Castro A. M., 2010, THESIS FEDERAL U RIO
   Castro A.M., 2010, ENZYME RES
   Chen H., 2013, MODERN SOLID STATE F
   Cinelli BA, 2014, FUEL, V124, P41, DOI 10.1016/j.fuel.2014.01.076
   de Castro AM, 2011, WASTE BIOMASS VALORI, V2, P291, DOI 10.1007/s12649-011-9075-5
   de Castro AM, 2010, APPL BIOCHEM BIOTECH, V162, P1612, DOI [10.1007/s12010-010-8986-0, 10.1007/s12010-010-8942-z]
   Diaz-Godinez G, 2001, J IND MICROBIOL BIOT, V26, P271, DOI 10.1038/sj.jim.7000113
   Figueroa-Montero A, 2011, J CHEM TECHNOL BIOT, V86, P1321, DOI 10.1002/jctb.2637
   Flodman HR, 2013, BIOCHEM ENG J, V81, P24, DOI 10.1016/j.bej.2013.09.011
   Ghosh B, 2011, BRAZ ARCH BIOL TECHN, V54, P867, DOI 10.1590/S1516-89132011000500003
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   Jian L, 2006, CHEM BIOCHEM ENG Q, V20, P449
   Lopez JA, 2013, BIOCHEM ENG J, V77, P231, DOI 10.1016/j.bej.2013.06.006
   Mitchell DA, 2004, BIOCHEM ENG J, V17, P15, DOI 10.1016/S1369-703X(03)00120-7
   Rodriguez-Duran LV, 2011, J MICROBIOL BIOTECHN, V21, P960, DOI 10.4014/jmb.1103.03025
   Rodriguez-Zuniga UF, 2013, BIOENERG RES, V6, P142, DOI 10.1007/s12155-012-9242-y
   Silveira C.L., 2014, BIOSYST ENG, V37, P1945
   Singhania RR, 2009, BIOCHEM ENG J, V44, P13, DOI 10.1016/j.bej.2008.10.019
   Sukumprasertsri M, 2013, J MICROBIOL BIOTECHN, V23, P335, DOI 10.4014/jmb.1204.04038
   Thomas L, 2013, BIOCHEM ENG J, V81, P146, DOI 10.1016/j.bej.2013.10.013
   van de Lagemaat J, 2004, BIOTECHNOL BIOENG, V87, P924, DOI 10.1002/bit.20206
   Weber FJ, 2002, BIOTECHNOL BIOENG, V77, P381, DOI 10.1002/bit.10087
NR 25
TC 26
Z9 27
U1 1
U2 39
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1369-703X
EI 1873-295X
J9 BIOCHEM ENG J
JI Biochem. Eng. J.
PD JAN 15
PY 2015
VL 93
BP 303
EP 308
DI 10.1016/j.bej.2014.10.016
PG 6
WC Biotechnology & Applied Microbiology; Engineering, Chemical
SC Biotechnology & Applied Microbiology; Engineering
GA AY1OL
UT WOS:000347362100037
DA 2020-12-08
ER

PT J
AU Figueredo-Cardero, A
   Martinez, E
   Chico, E
   Castilho, LR
   Medronho, RA
AF Figueredo-Cardero, Alvio
   Martinez, Edel
   Chico, Ernesto
   Castilho, Leda R.
   Medronho, Ricardo A.
TI Rotating Cylindrical Filters Used in Perfusion Cultures: CFD Simulations
   and Experiments
SO BIOTECHNOLOGY PROGRESS
LA English
DT Article
DE animal cell retention devices for perfusion cultures; rotating
   cylindrical filters; external spin-filters; computational fluid dynamics
   simulation; exchange flow and particle lateral migration
ID FILTRATION; PARAMETERS; PERFORMANCE; SPINFILTER; REDUCTION; RETENTION;
   DESIGN; FLOW
AB The particle and fluid dynamics in a rotating cylindrical filtration (RCF) system used for animal cell retention in perfusion processes was studied. A validated CFD model was used and the results gave numerical evidence of phenomena that had been earlier claimed, but not proven for this kind of application under turbulent and high mesh permeability conditions, such as bidirectional radial exchange flow (EF) through the filter mesh and particle (cells) lateral migration. Taylor vortices were shown to cause EF 10-100 times higher than perfusion flow, indicating that EF is the main drag source, at least in early stages of RCF operation. Particle lateral migration caused a cell concentration reduction (CCR) near the filter surface of approximately 10%, contributing significantly to cell separation in RCF systems and giving evidence that the mesh sieving effect is not the sole phenomenon underlying cell retention in RCF systems. Filter rotation rate was shown to significantly affect both EF and CCR. A higher separation efficiency (measured experimentally at 2,000-L bioreactor scale) and an enhanced CCR (predicted by the numerical simulations) were found for the same rotation rate range, indicating that there is an optimal operational space with practical consequences on RCF performance. Experimental data of a large-scale perfusion run employing the simulated RCF showed high cell viabilities for over 100 days, which is probably related to the fact that the computed shear stress level in the system was shown to be relatively low (below 20 Pa under all tested conditions). (C) 2014 American Institute of Chemical Engineers
C1 [Figueredo-Cardero, Alvio; Martinez, Edel; Chico, Ernesto] Ctr Mol Immunol, Therapeut Antibody Unit, Havana 11600, Cuba.
   [Figueredo-Cardero, Alvio; Medronho, Ricardo A.] Univ Fed Rio de Janeiro, Sch Chem, Dept Chem Engn, Rio De Janeiro, Brazil.
   [Castilho, Leda R.] Univ Fed Rio de Janeiro, Chem Engn Program, COPPE, Rio De Janeiro, Brazil.
RP Figueredo-Cardero, A (corresponding author), Ctr Mol Immunol, Therapeut Antibody Unit, AP 16040, Havana 11600, Cuba.
EM alvio@cim.sld.cu
RI Medronho, Ricardo/Q-1762-2015; Castilho, Leda/I-8939-2014
OI Medronho, Ricardo/0000-0001-5603-9762; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ)
FX The authors thank Yaritza Galvez, Maria C. Duarte, Jose A. Fernandez
   Duniet Mesa, and the operators of the Therapeutic Antibody Unit upstream
   group at CIM (Cuba) for their support on the execution of the
   large-scale perfusion bioreactor runs. The authors are also grateful to
   Ihosvany Romero, from CIM (Cuba), for drawing the large-scale RCF shown
   in Figure 1, as well as to Bioengineering AG (Switzerland) for providing
   the original drawings and sketches. Financial support from the Brazilian
   research funding agencies CNPq and FAPERJ is gratefully acknowledged.
CR Akonur A, 2003, PHYS FLUIDS, V15, P947, DOI 10.1063/1.1556615
   BELFORT G, 1993, J MEMBRANE SCI, V77, P1, DOI 10.1016/0376-7388(93)85231-K
   Castilho Leda R, 2002, Adv Biochem Eng Biotechnol, V74, P129
   Castilho LR, 2003, BIOTECHNOL BIOENG, V83, P514, DOI 10.1002/bit.10697
   FENGE C, 1993, CYTOTECHNOLOGY, V11, P233, DOI 10.1007/BF00749874
   FIELD RW, 1995, J MEMBRANE SCI, V100, P259, DOI 10.1016/0376-7388(94)00265-Z
   Figueredo-Cardero A, 2010, THESIS ESCOLA QUIMIC
   Figueredo-Cardero A, 2012, BIOTECHNOL PROGR, V28, P1491, DOI 10.1002/btpr.1618
   Figueredo-Cardero A, 2009, CYTOTECHNOLOGY, V61, P55, DOI 10.1007/s10616-009-9242-8
   HALLSTROM B, 1978, DESALINATION, V24, P273
   HAWRYLIK SJ, 1994, CYTOTECHNOLOGY, V15, P253, DOI 10.1007/BF00762400
   Iding K, 2000, CYTOTECHNOLOGY, V34, P141, DOI 10.1023/A:1008183508439
   Jaffrin MY, 2008, J MEMBRANE SCI, V324, P7, DOI 10.1016/j.memsci.2008.06.050
   Ku H. H., 1966, J RES NBS C ENG INST, V1, P331
   Lee S, 2004, DESALINATION, V169, P109, DOI 10.1016/j.desal.2004.08.012
   Martinand D, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3243976
   MENTER FR, 1994, AIAA J, V32, P1598, DOI 10.2514/3.12149
   MERCILLE S, 1994, BIOTECHNOL BIOENG, V43, P833, DOI 10.1002/bit.260430902
   Montgomery D.C., 2009, DESIGN ANAL EXPT
   Pollock J, 2013, BIOTECHNOL BIOENG, V110, P206, DOI 10.1002/bit.24608
   Schwille JA, 2002, J MEMBRANE SCI, V204, P53, DOI 10.1016/S0376-7388(02)00016-9
   SMITH GP, 1982, J FLUID MECH, V123, P187, DOI 10.1017/S0022112082003024
   Trocha M, 1997, ANIMAL CELL TECHNOLOGY, P405
   Vallez-Chetreanu F, 2007, J BIOTECHNOL, V130, P265, DOI 10.1016/j.jbiotec.2007.04.007
   Vallez-Chetreanu F, 2006, THESIS ECOLE POLYTEC
   Versteeg H.K., 1995, INTRO COMPUTATIONAL
   Wereley ST, 2002, J MEMBRANE SCI, V209, P469, DOI 10.1016/S0376-7388(02)00365-4
   Wereley ST, 1999, PHYS FLUIDS, V11, P325, DOI 10.1063/1.869882
   YABANNAVAR VM, 1992, BIOTECHNOL BIOENG, V40, P925, DOI 10.1002/bit.260400809
   Yang YM, 2012, J BIOTECHNOL, V161, P250, DOI 10.1016/j.jbiotec.2012.07.007
NR 30
TC 2
Z9 2
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8756-7938
EI 1520-6033
J9 BIOTECHNOL PROGR
JI Biotechnol. Prog.
PD SEP-OCT
PY 2014
VL 30
IS 5
BP 1093
EP 1102
DI 10.1002/btpr.1945
PG 10
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA AU3IE
UT WOS:000345505000013
PM 25059206
DA 2020-12-08
ER

PT J
AU Pato, TP
   Souza, MCO
   Silva, ANMR
   Pereira, RC
   Silva, MV
   Caride, E
   Gaspar, LP
   Freire, MS
   Castilho, LR
AF Pato, Tania P.
   Souza, Marta Cristina O.
   Silva, Andrea N. M. R.
   Pereira, Renata C.
   Silva, Marlon V.
   Caride, Elena
   Gaspar, Luciane P.
   Freire, Marcos S.
   Castilho, Leda R.
TI Development of a membrane adsorber based capture step for the
   purification of yellow fever virus
SO VACCINE
LA English
DT Article; Proceedings Paper
CT 4th Vaccine Technology Conference in the Engineering Conferences
   International (ECI)
CT 4th Vaccine Technology Conference in the Engineering Conferences
   International (ECI)
CY MAY 20-24, 2012
CY MAY 20-24, 2012
CL Albufeira, PORTUGAL
CL Albufeira, PORTUGAL
ID IMMUNOGENICITY; PARTICLES; CULTURE
AB Yellow fever (YF) is an endemic disease in some tropical areas of South America and Africa that presents lethality rate between 20 and 50%. There is no specific treatment and to control this disease a highly effective live-attenuated egg based vaccine is widely used for travelers and residents of areas where YF is endemic. However, recent reports of rare, sometimes fatal, adverse events post-vaccination have raised concerns. In order to increase safety records, alternative strategies should be considered, such as developing a new inactivated vaccine using a cell culture based technology, capable of meeting the demands in cases of epidemic. With this goal, the production of YF virus in Vero cells grown on microcarriers and its subsequent purification by chromatographic techniques was studied. In this work we investigate the capture step of the purification process of the YF virus. At first, virus stability was studied over a wide pH range, showing best results for the alkaline region. Considering this result and the pI of the envelope protein previously determined in silico, a strong anion exchanger was considered most suitable. Due to the easy scalability, simplicity to handle, absence of diffusional limitations and suitability for virus handling of membrane adsorbers, a Q membrane was evaluated. The amount of antigen adsorbed onto the membrane was investigated within the pH range for virus stability, and the best pH for virus adsorption was considered to be 8.5. Finally, studies on gradient and step elution allowed to determine the most adequate salt concentration for washing (0.15 M) and virus elution (0.30 M). Under these operating conditions, it was shown that this capture step is quite efficient, showing high product recovery (93.2 +/- 30.3%) and efficient DNA clearance (0.9 +/- 0.3 ng/dose). (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Pato, Tania P.; Souza, Marta Cristina O.; Silva, Andrea N. M. R.; Pereira, Renata C.; Silva, Marlon V.; Caride, Elena; Gaspar, Luciane P.; Freire, Marcos S.] Fiocruz MS, Oswaldo Cruz Fdn, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Cell Culture Engn Lab, BR-21941972 Rio De Janeiro, RJ, Brazil.
   [Pato, Tania P.; Castilho, Leda R.] Univ Fed Rio de Janeiro, IQ, Biochem Program, BR-21941909 Rio De Janeiro, RJ, Brazil.
RP Castilho, LR (corresponding author), Univ Fed Rio de Janeiro, COPPE, Cell Culture Engn Lab, Cx Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
EM leda@peq.coppe.ufrj.br
RI Castilho, Leda/I-8939-2014
CR [Anonymous], 2010, GE HEALTHCARE STRATE
   [Anonymous], 2007, VACCINE, V25, P2758
   Caufour PS, 2001, VIRUS RES, V79, P1, DOI 10.1016/S0168-1702(01)00273-8
   Champion K, 2005, BIOPROCESS INT   SEP
   Czermak P, 2008, DESALINATION, V224, P23, DOI 10.1016/j.desal.2007.04.074
   Fields BN, 2007, FIELDS VIROLOGY, Vxix, P3091
   Forcic D, 2011, J CHROMATOGR B, V879, P981, DOI 10.1016/j.jchromb.2011.03.012
   Freire MS, 2005, VACCINE, V23, P2501, DOI 10.1016/j.vaccine.2004.10.035
   Gardner CL, 2010, CLIN LAB MED, V30, P237, DOI 10.1016/j.cll.2010.01.001
   Kalbfuss B, 2007, J MEMBRANE SCI, V299, P251, DOI 10.1016/j.memsci.2007.04.048
   Monath TP, 2010, VACCINE, V28, P3827, DOI 10.1016/j.vaccine.2010.03.023
   Rodrigues T, 2007, J BIOTECHNOL, V127, P520, DOI 10.1016/j.jbiotec.2006.07.028
   Souza MCO, 2009, VACCINE, V27, P6420, DOI 10.1016/j.vaccine.2009.06.023
   Vicente T, 2008, J MEMBRANE SCI, V311, P270, DOI 10.1016/j.memsci.2007.12.021
   Vicente T, 2011, BIOTECHNOL ADV, V29, P869, DOI 10.1016/j.biotechadv.2011.07.004
   Vogel JH, 2012, BIOTECHNOL BIOENG, V109, P3049, DOI 10.1002/bit.24578
   Wolter T, 2005, BIOPROCESS INT   FEB
   World Health Organization, 2007, WHO STUD GROUP CELL
NR 18
TC 11
Z9 11
U1 0
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAY 19
PY 2014
VL 32
IS 24
SI SI
BP 2789
EP 2793
DI 10.1016/j.vaccine.2014.02.036
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AI2RD
UT WOS:000336704900005
PM 24631080
OA Green Published
DA 2020-12-08
ER

PT J
AU Cinelli, BA
   Lopez, JA
   Castilho, LR
   Freire, DMG
   Castro, AM
AF Cinelli, Bernardo A.
   Lopez, Jimmy A.
   Castilho, Leda R.
   Freire, Denise M. G.
   Castro, Aline M.
TI Granular starch hydrolysis of babassu agroindustrial residue: A
   bioprocess within the context of biorefinery
SO FUEL
LA English
DT Article
DE Enzyme production; Solid-state fermentation; Cold hydrolysis;
   Simultaneous saccharification and fermentation (SSF); Ethanol
ID FUEL ETHANOL-PRODUCTION; COCONUT STARCH; ALPHA-AMYLASE; CORN;
   FERMENTATION; CONVERSION
AB The conversion of renewable feedstocks into a range of commercial products and energy is the principle underlying the concept of biorefinery. In this work, two agroindustrial by-products from babassu were used as unconventional biomasses to develop a sustainable process. Babassu cake was used to produce a multienzyme complex, which was able to hydrolyse starch granules and to release free amino nitrogen from babassu flour, yielding a hydrolysate rich in carbon and nitrogen nutrients. To exemplify its possible applications, different strategies for ethanol production by simultaneous saccharification and fermentation (SSF) were investigated and that comprising a 4-h hydrolysis step at 50 degrees C followed by 44 h of SSF at 32 degrees C showed the most promising results (53.6 g/L ethanol, 83% efficiency of starch into ethanol and productivity of 1.12 g/(L h)). On-site enzymes promoted better results than a commercial enzyme product (110.9 +/- 6.6 g/L versus 74.5 +/- 1.8 g/L glucose releases, respectively), and showed high efficiency and productivity also on corn flour, either similar or superior to those reported for the industrial-scale dry-grind process. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Cinelli, Bernardo A.; Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21941909 Rio De Janeiro, Brazil.
   [Lopez, Jimmy A.; Freire, Denise M. G.] Univ Fed Rio de Janeiro, Inst Chem, BR-21941909 Rio De Janeiro, Brazil.
   [Castro, Aline M.] Petrobras SA, Ctr Res & Dev, Rio De Janeiro, Brazil.
RP Freire, DMG (corresponding author), Univ Fed Rio de Janeiro, Dept Biochem, Inst Chem, Ilha Fundao,CT,Lab 549 1, Av Athos da Silveira Ramos 149,Cidade Univ, BR-21941909 Rio De Janeiro, Brazil.
EM freire@iq.ufrj.br
RI FREIRE, Denise Maria/D-8699-2014; CASTRO, ALINE/C-4984-2015; Castilho,
   Leda/I-8939-2014
OI FREIRE, Denise Maria/0000-0002-8298-5936; CASTRO,
   ALINE/0000-0002-1355-8455; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CapesCAPES; FAPERJ ANPCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ);
   CENPES/PETROBRAS
FX The authors wish to thank Tocantins Babacu S.A. for providing the
   babassu cake and babassu flour used in the experiments, the Membrane
   Separation Processes and Polymer Laboratory, PAM/COPPE, Federal
   University of Rio de Janeiro for technical assistance in SEM analyses
   and Laboratorio de Controle Bromatologico (LabCBrom) for babassu
   analysis. The authors also gratefully acknowledge CNPq, Capes, FAPERJ
   ANP and CENPES/PETROBRAS for financial support.
CR Baruque EA, 1998, APPL BIOCHEM BIOTECH, V70-2, P877, DOI 10.1007/BF02920198
   Baruque EA, 2000, BIORESOURCE TECHNOL, V75, P49, DOI 10.1016/S0960-8524(00)00026-2
   Bialas W, 2010, BIORESOURCE TECHNOL, V101, P3126, DOI 10.1016/j.biortech.2009.12.090
   Bothast RJ, 2005, APPL MICROBIOL BIOT, V67, P19, DOI 10.1007/s00253-004-1819-8
   Bozic N, 2011, BIOCHEM ENG J, V53, P203, DOI 10.1016/j.bej.2010.10.014
   Castro A.M., 2010, ENZYME RES
   Castro AM, 2011, BIOMASS CONVERS BIOR, V1, DOI 10.1007/s13399-011-0023-1
   de Almeida RR, 2011, THERMOCHIM ACTA, V519, P50, DOI 10.1016/j.tca.2011.02.029
   de Castro AM, 2010, APPL BIOCHEM BIOTECH, V162, P1612, DOI [10.1007/s12010-010-8986-0, 10.1007/s12010-010-8942-z]
   DESER, 2007, CAD PROD BAB EST EXP
   Helbert W, 1996, INT J BIOL MACROMOL, V19, P165, DOI 10.1016/0141-8130(96)01123-3
   IBGE, 2011, QUANT PROD EXTR VEG
   INSTITUTO ADOLFO LUTZ, 2005, MET QUIM FIS AN AL
   INTERNACIONAL A., 1995, OFFICIAL METHODS ANA
   Kamm B, 2007, ADV BIOCHEM ENG BIOT, V105, P175, DOI 10.1007/10_2006_040
   Lehmann U, 2007, TRENDS FOOD SCI TECH, V18, P346, DOI 10.1016/j.tifs.2007.02.009
   Lewis S, 2004, United States patent, Patent No. [US 2004/0234,649, 20040234649]
   Li JH, 2012, CARBOHYD POLYM, V87, P1649, DOI 10.1016/j.carbpol.2011.09.061
   Lopez JA, 2013, BIOCHEM ENG J, V77, P231, DOI 10.1016/j.bej.2013.06.006
   MENDLOWITZ M, 1985, CLIN HEMORHEOL, V5, P123
   Nichols NN, 2008, PRODUCTION ETHANOL C
   Novo MT, 2005, APPL MICROBIOL BIOT, V66, P560, DOI 10.1007/s00253-004-1676-5
   Pandey A, 2000, BIORESOURCE TECHNOL, V74, P81, DOI 10.1016/S0960-8524(99)00143-1
   Pickens CE, 1986, PROCESS ENZYMATIC HY
   PRANAMUDA H, 1995, STARCH-STARKE, V47, P277, DOI 10.1002/star.19950470708
   Quintero JA, 2008, ENERGY, V33, P385, DOI 10.1016/j.energy.2007.10.001
   Rattanachomsri U, 2009, J BIOSCI BIOENG, V107, P488, DOI 10.1016/j.jbiosc.2008.12.024
   Robertson GH, 2006, J AGR FOOD CHEM, V54, P353, DOI 10.1021/jf051883m
   Roehr M, 2001, BIOTECHNOLOGY ETHANO
   Sarikaya E, 2000, PROCESS BIOCHEM, V35, P711, DOI 10.1016/S0032-9592(99)00133-8
   Textor SD, 1998, CAN J CHEM ENG, V76, P87, DOI 10.1002/cjce.5450760111
   Uthumporn U, 2010, FOOD BIOPROD PROCESS, V88, P47, DOI 10.1016/j.fbp.2009.10.001
   Vidal BC, 2009, STARCH-STARKE, V61, P448, DOI 10.1002/star.200800091
   Wang P, 2005, CEREAL CHEM, V82, P734, DOI 10.1094/CC-82-0734
   Wang P, 2009, CEREAL CHEM, V86, P319, DOI 10.1094/CCHEM-86-3-0319
   WELLER CL, 1983, BIOTECHNOL BIOENG, P437
NR 36
TC 23
Z9 23
U1 0
U2 45
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0016-2361
EI 1873-7153
J9 FUEL
JI Fuel
PD MAY 15
PY 2014
VL 124
BP 41
EP 48
DI 10.1016/j.fuel.2014.01.076
PG 8
WC Energy & Fuels; Engineering, Chemical
SC Energy & Fuels; Engineering
GA AC3GH
UT WOS:000332403600005
DA 2020-12-08
ER

PT J
AU Ribeiro, DA
   Passos, DF
   Ferraz, HC
   Castilho, LR
AF Ribeiro, Daniel A.
   Passos, Douglas F.
   Ferraz, Helen C.
   Castilho, Leda R.
TI Anion-exchange purification of recombinant factor IX from cell culture
   supernatant using different chromatography supports
SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES
LA English
DT Article
DE Anion exchange chromatography; Recombinant factor IX (rFIX); Activated
   factor IX (FIXa); Resins, monoliths and membrane adsorbers;
   Pseudoaffinity elution with calcium chloride; Host-cell protein and
   residual DNA clearance
ID CLOTTING FACTOR-IX; MONOLITHIC COLUMNS; FACTOR-VII; EXPRESSION;
   PROTEINS; CARBOXYLATION; DESIGN; VKORC1
AB Both recombinant and plasma-derived factor IX concentrates are used in replacement therapies for the treatment of haemophilia B. In the present work, the capture step for a recombinant FIX (rFIX) purification process was investigated. Different strong anion-exchange chromatography media (the resins Q Sepharose (R) FF and Fractogel (R) TMAE, the monolith CIM (R) QA and the membrane adsorber Sartobind (R) Q) were tested for their rFIX binding capacity under dynamic conditions. In these experiments, crude supernatant from CHO cells was used, thus in the presence of supernatant contaminants and mimicking process conditions. The highest dynamic binding capacity was obtained for the monolith, which was then further investigated. To study pseudoaffinity elution of functional rFIX with Ca2+ ions, a design of experiments to evaluate the effects of pH, NaCl and CaCl2 on yield and purification factor was carried out. The effect of pH was not statistically significant, and a combination of no NaCl and 45 mM CaCl2 yielded a good purification factor combined with a high yield of active rFIX. Under these conditions, activity yield of rFIX was higher than the mass yield, confirming selective elution of functional, gamma-carboxylated rFIX. Scaling-up of this process 8 fold resulted in very similar process performance. Monitoring of the undesired activated FIX (FIXa) revealed that the FIXa/FIX ratio (1.94%) was higher in the eluate than in the loaded sample, but was still within an acceptable range. HCP and DNA clearances were high (1256 and 7182 fold, respectively), indicating that the proposed process is adequate for the intended rFIX capture step. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Ribeiro, Daniel A.; Passos, Douglas F.; Ferraz, Helen C.; Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21941972 Rio De Janeiro, RJ, Brazil.
RP Castilho, LR (corresponding author), Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, Caixa Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
EM leda@peq.coppe.ufrj.br
RI Castilho, Leda/I-8939-2014; Ferraz, Helen/AAF-1060-2019
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CapesCAPES; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); BNDES; Hemobras
FX The authors gratefully acknowledge CNPq, Capes, FAPERJ, BNDES and
   Hemobras for research funding, as well as BioManguinhos/FIOCRUZ for the
   use of the Qubit (TM) DNA quantification system. The authors would like
   to dedicate this article to Prof. Alberto Luiz Coimbra, in the 50th
   anniversary of COPPE (1963-2013), the Graduate School of Engineering of
   the Federal University of Rio de Janeiro.
CR Arrua RD, 2012, ANAL CHIM ACTA, V738, P1, DOI 10.1016/j.aca.2012.05.052
   Bond M, 1998, SEMIN HEMATOL, V35, P11
   Branovic K, 2003, J CHROMATOGR B, V790, P175, DOI 10.1016/S1570-0232(03)00095-3
   Branovic K, 2000, J CHROMATOGR A, V903, P21, DOI 10.1016/S0021-9673(00)00899-2
   Brgles M, 2011, J CHROMATOGR A, V1218, P2389, DOI 10.1016/j.chroma.2010.11.059
   Choudhari PB, 2013, MED CHEM RES, V22, P976, DOI 10.1007/s00044-012-0091-1
   Dismer F, 2008, J CHROMATOGR A, V1194, P11, DOI 10.1016/j.chroma.2007.12.085
   Doneanu CE, 2012, MABS-AUSTIN, V4, P24, DOI 10.4161/mabs.4.1.18748
   El-Sayed MMH, 2010, BIOCHEM ENG J, V49, P221, DOI 10.1016/j.bej.2009.12.017
   Gagnon P., 2006, GENET ENG NEWS, V26
   Gajdosik MS, 2012, J CHROMATOGR A, V1239, P1, DOI 10.1016/j.chroma.2012.03.046
   Gillis S, 1997, PROTEIN SCI, V6, P185
   Gutierrez A.H., 2012, ACM BCB, P637
   Hallgren KW, 2006, BIOCHEMISTRY-US, V45, P5587, DOI 10.1021/bi051986y
   Hallgren KW, 2002, BIOCHEMISTRY-US, V41, P15045, DOI 10.1021/bi026016e
   Harrison S, 1998, SEMIN HEMATOL, V35, P4
   Jin M, 2010, BIOTECHNOL BIOENG, V105, P306, DOI 10.1002/bit.22532
   Josic D, 2003, J CHROMATOGR B, V790, P183, DOI 10.1016/S1570-0232(03)00082-5
   Jungbauer A, 2008, J CHROMATOGR A, V1184, P62, DOI 10.1016/j.chroma.2007.12.087
   KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622
   Kim WH, 2009, J BIOTECHNOL, V142, P275, DOI 10.1016/j.jbiotec.2009.06.001
   KURACHI K, 1993, BLOOD COAGUL FIBRIN, V4, P953, DOI 10.1097/00001721-199304060-00013
   Levison PR, 1999, J CHROMATOGR A, V865, P3, DOI 10.1016/S0021-9673(99)00784-0
   Lowe GDO, 2001, BRIT J HAEMATOL, V115, P507, DOI 10.1046/j.1365-2141.2001.03186.x
   Podgornik A, 2004, J BIOCHEM BIOPH METH, V60, P179, DOI 10.1016/j.jbbm.2004.01.002
   Riddel JP, 2007, J PEDIATR ONCOL NURS, V24, P123, DOI 10.1177/1043454206298693
   Rivieccio V, 2007, PROTEIN EXPRES PURIF, V51, P49, DOI 10.1016/j.pep.2006.07.009
   Sheng-Fowler L, 2009, BIOLOGICALS, V37, P190, DOI 10.1016/j.biologicals.2009.02.015
   Staby A, 2000, J CHROMATOGR A, V897, P99, DOI 10.1016/S0021-9673(00)00780-9
   Sun YL, 2012, J CHROMATOGR B, V898, P78, DOI 10.1016/j.jchromb.2012.04.022
   van Reis R, 2007, J MEMBRANE SCI, V297, P16, DOI 10.1016/j.memsci.2007.02.045
   Vlakh EG, 2009, J CHROMATOGR A, V1216, P2637, DOI 10.1016/j.chroma.2008.09.090
   Wajih N, 2005, J BIOL CHEM, V280, P31603, DOI 10.1074/jbc.M505373200
   Wajih N, 2008, THROMB RES, V122, P405, DOI 10.1016/j.thromres.2007.11.002
   Weaver J, 2013, BIOTECHNOL BIOENG, V110, P500, DOI 10.1002/bit.24724
   Winkler ME, 2000, BIOTECHNOL & BIOPROC, V25, P143
   Yan S.B., 1991, US patent, Patent No. [4,981,952, 4981952]
NR 37
TC 10
Z9 10
U1 0
U2 33
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1570-0232
EI 1873-376X
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD NOV 1
PY 2013
VL 938
BP 111
EP 118
DI 10.1016/j.jchromb.2013.09.002
PG 8
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 235QC
UT WOS:000325734800016
PM 24076525
DA 2020-12-08
ER

PT J
AU Lopez, JA
   Lazaro, CD
   Castilho, LD
   Freire, DMG
   de Castro, AM
AF Lopez, Jimmy A.
   Lazaro, Carolina da Costa
   Castilho, Leda dos Reis
   Guimaraes Freire, Denise Maria
   de Castro, Aline Machado
TI Characterization of multienzyme solutions produced by solid-state
   fermentation of babassu cake, for use in cold hydrolysis of raw biomass
SO BIOCHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Aspergillus awamori; Crude enzyme solutions; Solid-state fermentation;
   Cold hydrolysis
ID ENZYMATIC-HYDROLYSIS; ASPERGILLUS-AWAMORI; PROTEASE TREATMENT;
   ALPHA-AMYLASE; STARCH; XYLOSE; ETHANOL; SACCHARIFICATION; PURIFICATION;
   XYLANASE
AB The production of multienzyme solutions containing diverse hydrolytic enzymes has attracted increasing interest, because of their potential for simultaneously hydrolyzing different biological macromolecules. When these crude enzyme solutions are produced by solid-state fermentation (SSF) in agricultural byproducts, production costs are considerably lower than those of conventional submerged fermentation processes. Crude enzyme solutions containing mainly exo- and endoamylases, proteases, xylanases, and cellulases were produced under standardized procedures by means of SSF of babassu cake by Aspergillus awamori IOC-3914. Central composite designs were implemented and revealed optimal activities of the enzymes produced between pH 4.4-5.0 and 45-51 degrees C. Based on the application of a global desirability analysis on all the group of enzymes detected in the multienzyme solution, an overall optimal activity was observed at 53 degrees C and pH 4.7. These conditions were used for the separate hydrolysis of babassu cake and babassu flour, in order to evaluate the ability to simultaneously hydrolyze crude starch, cellulose, hemicelluloses, and protein. Under optimal global conditions, high levels of glucose, xylose, and free amino nitrogen (FAN) (up to 44, 19 and 0.75 g L-1, respectively) were obtained. Finally, the use of Tween 80 was found to activate both exo- and endoamylases (up to 50% increase). (C) 2013 Elsevier B.V. All rights reserved.
C1 [Lopez, Jimmy A.; Lazaro, Carolina da Costa; Guimaraes Freire, Denise Maria] Univ Fed Rio de Janeiro, Inst Chem, BR-21941 Rio De Janeiro, Brazil.
   [Castilho, Leda dos Reis] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21941 Rio De Janeiro, Brazil.
   [de Castro, Aline Machado] Petrobras SA, Div Biotechnol, Ctr Res & Dev, Ilha Fundao, Rio De Janeiro, Brazil.
RP de Castro, AM (corresponding author), Petrobras SA, Div Biotechnol, Ctr Res & Dev, Ilha Fundao, Av Horacio Macedo 950, Rio De Janeiro, Brazil.
EM alinebio@petrobras.com.br
RI FREIRE, Denise Maria/D-8699-2014; Castilho, Leda/I-8939-2014; CASTRO,
   ALINE/C-4984-2015
OI FREIRE, Denise Maria/0000-0002-8298-5936; CASTRO,
   ALINE/0000-0002-1355-8455
FU ANP/PETROBRAS; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX The study was financially supported by ANP/PETROBRAS, CNPq and FAPERJ.
   The authors also acknowledge Mariana Teixeira, Arthur Lima and Bruno
   Dias for their technical assistance.
CR Agbogbo FK, 2006, PROCESS BIOCHEM, V41, P2333, DOI 10.1016/j.procbio.2006.05.004
   Alvarez MM, 2010, J CHEM TECHNOL BIOT, V85, P1122, DOI 10.1002/jctb.2408
   Alvira P, 2010, BIORESOURCE TECHNOL, V101, P4851, DOI 10.1016/j.biortech.2009.11.093
   [Anonymous], 2008, MATLAB VERS 7 6 0 32
   Bakalova NG, 2002, BIOTECHNOL BIOTEC EQ, V16, P91, DOI 10.1080/13102818.2002.10819161
   Baruque EA, 1998, APPL BIOCHEM BIOTECH, V70-2, P877, DOI 10.1007/BF02920198
   BERVEN D, 2005, ETHANOL PROD MAG, V11, P67
   BHELLA RS, 1985, CAN J MICROBIOL, V31, P149, DOI 10.1139/m85-029
   Blazek J, 2010, BIOMACROMOLECULES, V11, P3275, DOI 10.1021/bm101124t
   Bruns R.E., 2006, STAT DESIGN CHEMOMET
   Champagne CP, 1999, FOOD RES INT, V32, P575, DOI 10.1016/S0963-9969(99)00133-7
   Chen L, 2010, APPL BIOCHEM BIOTECH, V162, P252, DOI 10.1007/s12010-009-8744-3
   Cheremisinoff N.P., 1987, PRACTICAL STAT ENG S
   Cui YQ, 1998, ENZYME MICROB TECH, V23, P168, DOI 10.1016/S0141-0229(98)00038-6
   Damaso MCT, 2004, APPL BIOCHEM BIOTECH, V113, P1003
   Dartora AB, 2002, Z NATURFORSCH C, V57, P666
   de Barros Neto B., 2007, COMO FAZER EXPT PESQ
   de Castro A.M., 2010, THESIS U FEDERAL RIO
   de Castro AM, 2011, WASTE BIOMASS VALORI, V2, P291, DOI 10.1007/s12649-011-9075-5
   de Castro AM, 2010, APPL BIOCHEM BIOTECH, V162, P1612, DOI [10.1007/s12010-010-8986-0, 10.1007/s12010-010-8942-z]
   GALVEZ A, 2005, ETHANOL PRODUCER, V11, P58
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   Hargreaves PL, 2013, BIORESOURCE TECHNOL, V134, P257, DOI 10.1016/j.biortech.2013.02.002
   HELLE SS, 1993, BIOTECHNOL BIOENG, V42, P611, DOI 10.1002/bit.260420509
   HOURS RA, 1994, J FERMENT BIOENG, V78, P426, DOI 10.1016/0922-338X(94)90041-8
   Ji XJ, 2009, BIORESOURCE TECHNOL, V100, P5214, DOI 10.1016/j.biortech.2009.05.036
   Khuri AI, 1987, RESPONSE SURFACES DE
   Koutinas AA, 2007, BIOTECHNOL BIOENG, V97, P61, DOI 10.1002/bit.21206
   Lemos JLS, 2000, BRAZ J MICROBIOL, V31, P206
   Li JH, 2012, CARBOHYD POLYM, V87, P1649, DOI 10.1016/j.carbpol.2011.09.061
   LIE S, 1973, J I BREWING, V79, P37, DOI 10.1002/j.2050-0416.1973.tb03495.x
   Liu XG, 2006, PROCESS BIOCHEM, V41, P801, DOI 10.1016/j.procbio.2005.10.009
   Mathews J.H., 2008, NUMERICAL METHODS US
   McIlvaine TC, 1921, J BIOL CHEM, V49, P183
   Mezo-Villanueva M, 2004, STARCH-STARKE, V56, P371, DOI 10.1002/star.200300264
   Myers R. H., 2002, RESPONSE SURFACE MET
   Negi S, 2009, FOOD RES INT, V42, P443, DOI 10.1016/j.foodres.2009.01.004
   Ohgren K, 2006, J BIOTECHNOL, V126, P488, DOI 10.1016/j.jbiotec.2006.05.001
   OngenBaysal G, 1996, BIOTECHNOL LETT, V18, P1431, DOI 10.1007/BF00129349
   Perevozchenko I.I., 1972, APPL BIOCHEM MICROB, V8, P7
   Perez-Carrillo E, 2007, CEREAL CHEM, V84, P607, DOI 10.1094/CCHEM-84-6-0607
   Perez-Carrillo E, 2006, STARCH-STARKE, V58, P338, DOI 10.1002/star.200500483
   Rattanachomsri U, 2009, J BIOSCI BIOENG, V107, P488, DOI 10.1016/j.jbiosc.2008.12.024
   Sanchez S, 2008, WORLD J MICROB BIOT, V24, P709, DOI 10.1007/s11274-007-9527-z
   Sharma A, 2001, BIORESOURCE TECHNOL, V78, P281, DOI 10.1016/S0960-8524(01)00010-4
   SINGH S, 2003, AAPS PHARMSCITECH, V4, P101, DOI DOI 10.1208/pt040342
   Sirisansaneeyakul S, 2007, WORLD J MICROB BIOT, V23, P543, DOI 10.1007/s11274-006-9258-6
   Teixeira RSS, 2010, J IND MICROBIOL BIOT, V37, P1041, DOI 10.1007/s10295-010-0751-4
   Sohail M, 2009, NEW BIOTECHNOL, V25, P437, DOI 10.1016/j.nbt.2009.02.002
   Teixeira MA, 2008, BIOMASS BIOENERG, V32, P857, DOI 10.1016/j.biombioe.2007.12.016
   Uthumporn U, 2010, FOOD BIOPROD PROCESS, V88, P47, DOI 10.1016/j.fbp.2009.10.001
   Vazquez MJ, 2001, WORLD J MICROB BIOT, V17, P817, DOI 10.1023/A:1013563628882
   Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001
   Viniegra-Gonzalez G, 2003, BIOCHEM ENG J, V13, P157, DOI 10.1016/S1369-703X(02)00128-6
   Wang RH, 2010, ENZYME MICROB TECH, V47, P77, DOI 10.1016/j.enzmictec.2010.05.005
   Wang R, 2009, ENZYME MICROB TECH, V44, P223, DOI 10.1016/j.enzmictec.2008.10.002
   Xia LM, 1999, PROCESS BIOCHEM, V34, P909, DOI 10.1016/S0032-9592(99)00015-1
   You C, 2010, AFR J BIOTECHNOL, V9, P1288
   YOUNG DL, 1991, IEEE T COMPUT AID D, V10, P103, DOI 10.1109/43.62796
   Zeng GM, 2006, ENZYME MICROB TECH, V39, P1451, DOI 10.1016/j.enzmictec.2006.03.035
   Zhang ZG, 2010, APPL BIOCHEM BIOTECH, V160, P1653, DOI 10.1007/s12010-009-8668-y
NR 61
TC 19
Z9 19
U1 1
U2 35
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1369-703X
EI 1873-295X
J9 BIOCHEM ENG J
JI Biochem. Eng. J.
PD AUG 15
PY 2013
VL 77
BP 231
EP 239
DI 10.1016/j.bej.2013.06.006
PG 9
WC Biotechnology & Applied Microbiology; Engineering, Chemical
SC Biotechnology & Applied Microbiology; Engineering
GA 207JE
UT WOS:000323593900030
DA 2020-12-08
ER

PT J
AU Marinho, PAN
   Vareschini, DT
   Gomes, IC
   Paulsen, BD
   Furtado, DR
   Castilho, LD
   Rehen, SK
AF Nobrega Marinho, Paulo Andre
   Vareschini, Daniel Tait
   Gomes, Ismael Carlos
   Paulsen, Bruna da Silveira
   Furtado, Daniel Rodrigues
   Castilho, Leda dos Reis
   Rehen, Stevens Kastrup
TI Xeno-Free Production of Human Embryonic Stem Cells in Stirred
   Microcarrier Systems Using a Novel Animal/Human-Component-Free Medium
SO TISSUE ENGINEERING PART C-METHODS
LA English
DT Article
ID LONG-TERM EXPANSION; SUSPENSION; CULTURE; LINES; DIFFERENTIATION
AB Currently, stem cell research faces a major bottleneck related to the low efficiency of methods to produce large quantities of human embryonic stem cells (ESC) for use in clinical trials. Most culture media currently employed for human ESC cultivation contain animal compounds, and cells are grown in static flasks. Besides the immediate contamination with nonhuman compounds, cell expansion in flasks tends to be laborious and nonefficient. Here we cultured human ESC in stirred microcarrier (MC) systems using an animal/human-component-free medium, to overcome both issues. The method developed to culture cells on suspended beads combined the use of polymeric MCs in stirred vessels with an optimized culture medium free of supplements of animal and human origin. This approach generated approximately 160 million cells within 6 days, which were shown to remain pluripotent. The process developed herein provides a step forward toward therapy due to the economic advantages in the production of human ESC and to their consequent low immunogenic potential.
C1 [Nobrega Marinho, Paulo Andre; Vareschini, Daniel Tait; Gomes, Ismael Carlos; Paulsen, Bruna da Silveira; Furtado, Daniel Rodrigues; Rehen, Stevens Kastrup] Univ Fed Rio de Janeiro, Inst Biomed Sci, Natl Lab Embryon Stem Cell Res, Rio De Janeiro, Brazil.
   [Castilho, Leda dos Reis] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, Cell Culture Engn Lab, BR-21945 Rio De Janeiro, Brazil.
RP Rehen, SK (corresponding author), Hosp Clementino Fraga Filho, LaNCE RJ, Lab Nacl Celulas Tronco Embrionarias, Rua Rodolpho Paulo Rocco,255-4 Andar,CEPEDIP Ilha, BR-21941913 Rio De Janeiro, RJ, Brazil.
EM srehen@lance-ufrj.org
RI Castilho, Leda/I-8939-2014; Furtado, Daniel/B-8697-2008; Vareschini,
   Daniel Tait/ABD-4549-2020; Vareschini, Daniel T/C-6742-2014; Rehen,
   Stevens K/J-5874-2012
OI Furtado, Daniel/0000-0001-7072-7879; Vareschini, Daniel
   Tait/0000-0002-7495-3299; Rehen, Stevens K/0000-0003-4216-9501
FU CAPESCAPES; FAPERJCarlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); CNPqNational Council for
   Scientific and Technological Development (CNPq); FINEPCiencia Tecnologia
   e Inovacao (FINEP); BNDES
FX The authors acknowledge funding from the Brazilian public agencies
   CAPES, FAPERJ, CNPq, FINEP, and BNDES. Special thanks also to Dr. Sylvie
   Devalle (National Laboratory for Embryonic Stem Cell Research, Brazil)
   for reviewing the article and Dr. Marcia Sader (Metallurgical and
   Materials Engineering-COPPE/UFRJ) for assistance with scanning electron
   microscopy.
CR Abranches E, 2007, BIOTECHNOL BIOENG, V96, P1211, DOI 10.1002/bit.21191
   Alfred R, 2011, BIOMATERIALS, V32, P6006, DOI 10.1016/j.biomaterials.2011.04.015
   Chen XL, 2010, STEM CELLS DEV, V19, P1781, DOI 10.1089/scd.2010.0077
   Chin ACP, 2010, STEM CELLS DEV, V19, P753, DOI 10.1089/scd.2009.0210
   Codamo G., 2010, THESIS U QUEENSLAND
   Cormier JT, 2006, TISSUE ENG, V12, P3233, DOI 10.1089/ten.2006.12.3233
   Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330
   Ellis J, 2011, CLIN PHARMACOL THER, V89, P639, DOI 10.1038/clpt.2011.22
   Fernandes AM, 2010, CELL TRANSPLANT, V19, P509, DOI 10.3727/096368909X485067
   Fernandes AM, 2009, BRAZ J MED BIOL RES, V42, P515, DOI 10.1590/S0100-879X2009000600007
   Fernandes TG, 2010, BIOTECHNOL LETT, V32, P171, DOI 10.1007/s10529-009-0108-0
   Fok EYL, 2005, STEM CELLS, V23, P1333, DOI 10.1634/stemcells.2005-0112
   Garcia-Gonzalo FR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001384
   Israel MA, 2012, NATURE, V482, P216, DOI 10.1038/nature10821
   Kehoe DE, 2008, BIOTECHNOL PROGR, V24, P1342, DOI 10.1002/btpr.57
   Krawetz R, 2010, TISSUE ENG PART C-ME, V16, P573, DOI [10.1089/ten.tec.2009.0228, 10.1089/ten.TEC.2009.0228]
   Lerou PH, 2005, BLOOD REV, V19, P321, DOI 10.1016/j.blre.2005.01.005
   Lock LT, 2009, TISSUE ENG PT A, V15, P2051, DOI 10.1089/ten.tea.2008.0455
   Marchetto MCN, 2010, CELL, V143, P527, DOI 10.1016/j.cell.2010.10.016
   Marinho P.A.N., 2010, THESIS U FEDERAL RIO
   Marinho PAN, 2010, BIOTECHNOL PROGR, V26, P548, DOI 10.1002/btpr.328
   Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181
   Mountford JC, 2008, TRANSFUSION MED, V18, P1, DOI 10.1111/j.1365-3148.2007.00807.x
   Muotri A., 2011, International patient, Patent No. [WO 2011/140397 A2, 2011140397]
   Nie Y, 2009, BIOTECHNOL PROGR, V25, P20, DOI 10.1002/btpr.110
   Oh SKW, 2009, STEM CELL RES, V2, P219, DOI 10.1016/j.scr.2009.02.005
   Olmer R, 2010, STEM CELL RES, V5, P51, DOI 10.1016/j.scr.2010.03.005
   Paulsen BD, 2012, CELL TRANSPLANT, V21, P1547, DOI 10.3727/096368911X600957
   Phillips BW, 2008, J BIOTECHNOL, V138, P24, DOI 10.1016/j.jbiotec.2008.07.1997
   Pouton CW, 2007, NAT REV DRUG DISCOV, V6, P605, DOI 10.1038/nrd2194
   Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399
   Ronsyn MW, 2008, SPINAL CORD, V46, P532, DOI 10.1038/sc.2008.13
   Serra M, 2010, J BIOTECHNOL, V148, P208, DOI 10.1016/j.jbiotec.2010.06.015
   Shi B, 2010, CELL PROLIFERAT, V43, P275, DOI 10.1111/j.1365-2184.2010.00677.x
   Singh H, 2010, STEM CELL RES, V4, P165, DOI 10.1016/j.scr.2010.03.001
   Storm MP, 2010, BIOTECHNOL BIOENG, V107, P683, DOI 10.1002/bit.22850
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Varki A, 2001, YEARB PHYS ANTHROPOL, V44, P54, DOI 10.1002/ajpa.10018
   Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   zur Nieden NI, 2007, J BIOTECHNOL, V129, P421, DOI 10.1016/j.jbiotec.2007.01.006
NR 42
TC 27
Z9 27
U1 0
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3384
EI 1937-3392
J9 TISSUE ENG PART C-ME
JI Tissue Eng. Part C-Methods
PD FEB
PY 2013
VL 19
IS 2
BP 146
EP 155
DI 10.1089/ten.tec.2012.0141
PG 10
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
SC Cell Biology; Engineering; Materials Science
GA 069ID
UT WOS:000313427600006
PM 22834864
DA 2020-12-08
ER

PT J
AU Figueredo-Cardero, A
   Chico, E
   Castilho, L
   Medronho, RD
AF Figueredo-Cardero, Alvio
   Chico, Ernesto
   Castilho, Leda
   Medronho, Ricardo de Andrade
TI Particle image velocimetry (PIV) study of rotating cylindrical filters
   for animal cell perfusion processes
SO BIOTECHNOLOGY PROGRESS
LA English
DT Article
DE rotating cylindrical filter (RCF); particle image velocimetry (PIV);
   animal cell perfusion culture; slip velocity; turbulence statistics
ID DIRECT NUMERICAL-SIMULATION; BOUNDARY-CONDITIONS; REVERSE-OSMOSIS; FLOW;
   FILTRATION; STABILITY; VELOCITY; RETENTION; CYLINDERS; CULTURE
AB In the present work, the main fluid flow features inside a rotating cylindrical filtration (RCF) system used as external cell retention device for animal cell perfusion processes were investigated using particle image velocimetry (PIV). The motivation behind this work was to provide experimental fluid dynamic data for such turbulent flow using a high-permeability filter, given the lack of information about this system in the literature. The results shown herein gave evidence that, at the boundary between the filter mesh and the fluid, a slip velocity condition in the tangential direction does exist, which had not been reported in the literature so far. In the RCF system tested, this accounted for a fluid velocity 10% lower than that of the filter tip, which could be important for the cake formation kinetics during filtration. Evidence confirming the existence of Taylor vortices under conditions of turbulent flow and high permeability, typical of animal cell perfusion RCF systems, was obtained. Second-order turbulence statistics were successfully calculated. The radial behavior of the second-order turbulent moments revealed that turbulence in this system is highly anisotropic, which is relevant for performing numerical simulations of this system. (C) 2012 American Institute of Chemical Engineers Biotechnol. Prog., 2012
C1 [Figueredo-Cardero, Alvio; Chico, Ernesto] Ctr Mol Immunol, Havana 11600, Cuba.
   [Figueredo-Cardero, Alvio; Medronho, Ricardo de Andrade] Univ Fed Rio de Janeiro, Sch Chem, Dept Chem Engn, BR-21941909 Rio De Janeiro, RJ, Brazil.
   [Castilho, Leda] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21941972 Rio De Janeiro, RJ, Brazil.
RP Figueredo-Cardero, A (corresponding author), Ctr Mol Immunol, AP 16040, Havana 11600, Cuba.
EM alvio@cim.sld.cu
RI Medronho, Ricardo/Q-1762-2015; Castilho, Leda/I-8939-2014
OI Medronho, Ricardo/0000-0001-5603-9762; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CapesCAPES; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX The authors acknowledge A. P. S. Freire, D. Greco, J. Zotin, and R.
   Balian for their assistance at "Laboratorio de Mecanica da Turbulencia"
   at PEM/COPPE/UFRJ. They thank L. P. M Marins, from CENPES/Petrobras, for
   kindly providing the PIV system, and I. Romero, from CIM, for the CAD
   drawings. Funding from the Brazilian agencies CNPq, Capes, and FAPERJ is
   gratefully acknowledged.
CR Akonur A, 2003, PHYS FLUIDS, V15, P947, DOI 10.1063/1.1556615
   BEAVERS GS, 1967, J FLUID MECH, V30, P197, DOI 10.1017/S0022112067001375
   BELFORT G, 1993, J MEMBRANE SCI, V77, P1, DOI 10.1016/0376-7388(93)85231-K
   Castilho Leda R, 2002, Adv Biochem Eng Biotechnol, V74, P129
   Castilho LR, 2008, ANIMAL CELL TECHNOLO, P389
   Dabiri D, 2006, CROSS CORRELATION DI, P115
   di Prima RC, 1979, TOPIC APPL PHYS, P139
   Dong S, 2007, J FLUID MECH, V587, P373, DOI 10.1017/S0022112007007367
   Figueredo-Cardero A, 2010, THESIS U FEDERAL RIO
   Figueredo-Cardero A, 2009, CYTOTECHNOLOGY, V61, P55, DOI 10.1007/s10616-009-9242-8
   Goyeau B, 2003, INT J HEAT MASS TRAN, V46, P4071, DOI 10.1016/S0017-9310(03)00241-2
   Jaffrin MY, 2008, J MEMBRANE SCI, V324, P7, DOI 10.1016/j.memsci.2008.06.050
   Johnson EC, 1997, PHYS FLUIDS, V9, P3687, DOI 10.1063/1.869506
   Kim MM, 2006, J MEMBRANE SCI, V281, P666, DOI 10.1016/j.memsci.2006.04.037
   Krahe M, 2003, ULLMANNS ENCY IND CH
   Lee S, 2004, DESALINATION, V169, P109, DOI 10.1016/j.desal.2004.08.012
   Lee S, 2001, J MEMBRANE SCI, V192, P129, DOI 10.1016/S0376-7388(01)00493-8
   Liu QL, 2011, J FLUID MECH, V679, P77, DOI 10.1017/jfm.2011.124
   Pirro D, 2008, EUR J MECH B-FLUID, V27, P552, DOI 10.1016/j.euromechflu.2007.10.005
   Pozrikidis C, 2005, J FLUID STRUCT, V20, P177, DOI 10.1016/j.jfluidstructs.2004.10.013
   Pozrikidis C, 2004, COMPUT FLUIDS, V33, P1, DOI 10.1016/S0045-7930(03)00030-6
   Shah MK, 2008, EXP THERM FLUID SCI, V32, P725, DOI 10.1016/j.expthermflusci.2007.09.004
   SMITH GP, 1982, J FLUID MECH, V123, P187, DOI 10.1017/S0022112082003024
   Sobolik V, 2000, INT J HEAT MASS TRAN, V43, P4381, DOI 10.1016/S0017-9310(00)00067-3
   Taylor GI, 1923, PHILOS T R SOC LOND, V223, P289, DOI 10.1098/rsta.1923.0008
   Tilton N, 2008, J FLUID MECH, V604, P411, DOI 10.1017/S0022112008001341
   Vallez-Chetreanu F, 2007, J BIOTECHNOL, V130, P265, DOI 10.1016/j.jbiotec.2007.04.007
   Vallez-Chetreanu F, 2006, THESIS ECOLE POLYTEC
   Versteeg H.K., 1995, INTRO COMPUTATIONAL
   Voisard D, 2003, BIOTECHNOL BIOENG, V82, P751, DOI 10.1002/bit.10629
   Walsh G, 2010, NAT BIOTECHNOL, V28, P917, DOI 10.1038/nbt0910-917
   Wang W, 1995, CHEM ENG J BIOCH ENG, V60, P55, DOI 10.1016/0923-0467(95)02989-3
   Wereley ST, 2002, J MEMBRANE SCI, V209, P469, DOI 10.1016/S0376-7388(02)00365-4
   WERELEY ST, 1994, EXP FLUIDS, V18, P1
   Wereley ST, 1999, PHYS FLUIDS, V11, P325, DOI 10.1063/1.869882
   YABANNAVAR VM, 1992, BIOTECHNOL BIOENG, V40, P925, DOI 10.1002/bit.260400809
   Zotin JLZ, 2010, THESIS U FEDERAL RIO
NR 37
TC 4
Z9 4
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8756-7938
EI 1520-6033
J9 BIOTECHNOL PROGR
JI Biotechnol. Prog.
PD NOV-DEC
PY 2012
VL 28
IS 6
BP 1491
EP 1498
DI 10.1002/btpr.1618
PG 8
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 051VX
UT WOS:000312157100013
PM 22915477
DA 2020-12-08
ER

PT J
AU Langier, S
   Galvani, RG
   Alves, APG
   Fidelis, R
   Nunes, PHC
   Silva, MH
   Castilho, LR
   Monteiro, JP
   Bonomo, A
AF Langier, S.
   Galvani, R. G.
   Alves, A. P. G.
   Fidelis, R.
   Nunes, P. H. C.
   Silva, M. H.
   Castilho, L. R.
   Monteiro, J. P.
   Bonomo, A.
TI Prolonged acceptance of skin grafts induced by B cells places regulatory
   T cells on the histopathology scene
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Skin graft; Tolerance; B cells; Treg; Histopathology
ID TOLERANCE; AUTOIMMUNITY; ANTIGEN; TRANSPLANTATION; REJECTION; INDUCTION
AB The participation of regulatory T (Treg) cells in B cell-induced T cell tolerance has been claimed in different models. In skin grafts, naive B cells were shown to induce graft tolerance. However, neither the contribution of Treg cells to B cell-induced skin tolerance nor their contribution to the histopathological diagnosis of graft acceptance has been addressed. Here, using male C57BL/6 naive B cells to tolerize female animals, we show that skin graft tolerance is dependent on CD25(+) Treg cell activity and independent of B cell-derived IL-10. In fact, B cells from IL-10-deficient mice were able to induce skin graft tolerance while Treg depletion of the host inhibited 100% graft survival. We questioned how Treg cell-mediated tolerance would impact on histopathology. B cell-tolerized skin grafts showed pathological scores as high as a rejected skin from naive, non-tolerized mice due to loss of skin appendages, reduced keratinization and mononuclear cell infiltrate. However, in tolerized mice, 40% of graft infiltrating CD4(+) cells were FoxP3(+) Treg cells with a high Treg:Teff (effector T cell) ratio (6:1) as compared to non-tolerized mice where Tregs comprise less than 8% of total infiltrating CD4 cells with a Treg:Teff ratio below 1:1. These results render Treg cells an obligatory target for histopathological studies on tissue rejection that may help to diagnose and predict the outcome of a transplanted organ.
C1 [Langier, S.; Galvani, R. G.; Alves, A. P. G.; Fidelis, R.; Nunes, P. H. C.; Monteiro, J. P.; Bonomo, A.] Inst Nacl Canc, Programa Med Expt, BR-20231050 Rio De Janeiro, RJ, Brazil.
   [Galvani, R. G.; Silva, M. H.; Bonomo, A.] Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol Prof Paulo de Goes, Rio De Janeiro, RJ, Brazil.
   [Langier, S.] Univ Fed Rio de Janeiro, Programa Posgrad Ciencias Morfol, Inst Ciencias Biomed, Rio De Janeiro, RJ, Brazil.
   [Castilho, L. R.] Univ Fed Rio de Janeiro, Programa Engn Quim, Rio De Janeiro, RJ, Brazil.
RP Bonomo, A (corresponding author), Inst Nacl Canc, Programa Med Expt, Rua Andre Cavalcanti 37, BR-20231050 Rio De Janeiro, RJ, Brazil.
EM acbonomo@gmail.com
RI Castilho, Leda/I-8939-2014
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [30.8961/2007-2, 47.1108/2007-3, 47.4519/2004-0]; FAPERJCarlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ) [E-26/102.798/2008, E-26/110.949/2008]; Swiss Bridge Foundation
   [2301500]
FX We thank Fabricio dos Santos for help with the purification of the
   anti-CD25, 7D4, monoclonal antibody. Research supported by CNPq
   (#30.8961/2007-2, #47.1108/2007-3 and #47.4519/2004-0), FAPERJ
   (#E-26/102.798/2008 and #E-26/110.949/2008), and the Swiss Bridge
   Foundation (#2301500).
CR Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816
   Ashour HM, 2007, J LEUKOCYTE BIOL, V82, P1033, DOI 10.1189/jlb.0507310
   Bestard O, 2011, AM J TRANSPLANT, V11, P2162, DOI 10.1111/j.1600-6143.2011.03633.x
   Bestard O, 2008, J AM SOC NEPHROL, V19, P2020, DOI 10.1681/ASN.2007111174
   Braun MY, 2001, J IMMUNOL, V166, P4879, DOI 10.4049/jimmunol.166.8.4879
   Castilho LR, 2002, J MEMBRANE SCI, V207, P253, DOI 10.1016/S0376-7388(02)00257-0
   FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825
   Golshayan D, 2009, INT IMMUNOPHARMACOL, V9, P683, DOI 10.1016/j.intimp.2008.12.006
   KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X
   Monteiro JP, 2008, J IMMUNOL, V181, P5895, DOI 10.4049/jimmunol.181.9.5895
   Parekh VV, 2003, J IMMUNOL, V170, P5897, DOI 10.4049/jimmunol.170.12.5897
   Scott DW, 2011, CURR STEM CELL RES T, V6, P38
   Tarbell KV, 2006, SEMIN IMMUNOL, V18, P93, DOI 10.1016/j.smim.2006.01.009
   Tu WW, 2008, BLOOD, V112, P2554, DOI 10.1182/blood-2008-04-152041
   von Bubnoff D, 2002, ALLERGY, V57, P2, DOI 10.1034/j.1398-9995.2002.01150.x
   Waldmann H, 2006, SEMIN IMMUNOL, V18, P111, DOI 10.1016/j.smim.2006.01.010
   Watanabe R, 2010, J IMMUNOL, V184, P4801, DOI 10.4049/jimmunol.0902385
   Yi TS, 2009, BLOOD, V114, P3101, DOI 10.1182/blood-2009-05-219402
NR 18
TC 3
Z9 3
U1 0
U2 3
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD OCT
PY 2012
VL 45
IS 10
BP 942
EP 947
DI 10.1590/S0100-879X2012007500089
PG 6
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 000SM
UT WOS:000308408600009
PM 22641417
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT B
AU Elsayed, EA
   Ramalho, LAG
   Castilho, LR
   Medronho, RA
AF Elsayed, Elsayed A.
   Ramalho, Leonardo A. G.
   Castilho, Leda R.
   Medronho, Ricardo A.
BE Jenkins, N
   Barron, N
   Alves, PM
TI Feed Flow Pulsation in the Separation of CHO Cells in Hydrocyclones:
   Effects of Pressure Drop and Pumphead Type on Separation Efficiency and
   Cell Viability
SO PROCEEDINGS OF THE 21ST ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR
   ANIMAL CELL TECHNOLOGY (ESACT), 2009
SE ESACT Proceedings
LA English
DT Proceedings Paper
CT 21st Annual Meeting of the European-Society-for-Animal-Cell-Technology
   (ESACT)
CY JUN 07-10, 2009
CL Dublin, IRELAND
SP European Soc Animal Cell Technol
AB The effect of pumphead type and operating pressure on cell viability and cell separation efficiency was investigated during hydrocyclone separation of recombinant CHO cells producing human GM-CSF. The conventional pulsating pumphead gave comparable results to the pulsation-free pumphead usually adopted so far in hydrocyclone separation systems. Separation efficiencies above 93% were obtained for viable cells for both types of pumpheads over the whole pressure range tested (0.25-1.0 bar).
C1 [Ramalho, Leonardo A. G.; Medronho, Ricardo A.] Fed Univ Rio de Janeiro UFRJ, Sch Chem, BR-21941900 Rio De Janeiro, RJ, Brazil.
   [Elsayed, Elsayed A.] King Saud Univ, Adv Chair Prote & Cytom Res, Fac Sci, Riyadh 1145, Saudi Arabia.
   [Ramalho, Leonardo A. G.; Castilho, Leda R.] Fed Univ Rio de Janeiro UFRJ, Cell Culture Engn Lab LECC, COPPE, BR-21941972 Rio De Janeiro, RJ, Brazil.
RP Medronho, RA (corresponding author), Fed Univ Rio de Janeiro UFRJ, Sch Chem, BR-21941900 Rio De Janeiro, RJ, Brazil.
EM eaelsayed@ksu.edu.sa; medronho@eq.ufrj.br
RI Medronho, Ricardo/Q-1762-2015
OI Medronho, Ricardo/0000-0001-5603-9762
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); FINEPCiencia Tecnologia e Inovacao
   (FINEP)
FX The authors gratefully acknowledge CNPq, FAPERJ and FINEP for financial
   support.
CR Castilho Leda R, 2002, Adv Biochem Eng Biotechnol, V74, P129
   Castilho LR, 2008, ANIMAL CELL TECHNOLO, P273
   Deckwer W. D., 2005, US Patent Application, Patent No. [6,878,545 B2, 6878545]
   Elsayed EA, 2006, ENG LIFE SCI, V6, P347, DOI 10.1002/elsc.200620137
   Pinto RCV, 2008, CYTOTECHNOLOGY, V56, P57, DOI 10.1007/s10616-007-9108-x
NR 5
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
BN 978-94-007-0883-9
J9 ESACT PROCEED
PY 2012
VL 5
BP 341
EP 344
DI 10.1007/978-94-007-0884-6_53
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA BH1NK
UT WOS:000398249100053
DA 2020-12-08
ER

PT J
AU de Castro, AM
   de Andrea, TV
   Carvalho, DF
   Teixeira, MMP
   Castilho, LD
   Freire, DMG
AF de Castro, Aline Machado
   de Andrea, Thiago Vetter
   Carvalho, Daniele Fernandes
   Pereira Teixeira, Mariana Martins
   Castilho, Leda dos Reis
   Guimaraes Freire, Denise Maria
TI Valorization of Residual Agroindustrial Cakes by Fungal Production of
   Multienzyme Complexes and Their Use in Cold Hydrolysis of Raw Starch
SO WASTE AND BIOMASS VALORIZATION
LA English
DT Article
DE Fungal amylases; Hydrolases; Agroindustrial oil cakes; Aspergillus and
   Penicillium strains; Solid-state fermentation; Cold starch hydrolysis
ID SOLID-STATE FERMENTATION; ALPHA-AMYLASE; LIPASE PRODUCTION;
   PENICILLIUM-RESTRICTUM; BIOETHANOL PRODUCTION; ENZYMATIC-HYDROLYSIS; OIL
   CAKE; DEGRADATION; CULTURE; ACID
AB In this work four agroindustrial cakes were used as raw material both for production of enzyme pools containing amylases and accessory hydrolases by solid-state fermentation (SSF) and for cold starch hydrolysis. Eight fungal strains from the genera Aspergillus and Penicillium were screened for enzyme production, and their enzyme extracts were then evaluated in the hydrolysis of raw cakes. Babassu cake was the most suitable raw material for endoamylases, exoamylases and proteases production. The highest activities of these three enzymes were produced by A. awamori IOC-3914 (29.8 U g(-1)), A. wentii (47.8 U g(-1)) and P. verrucosum (27.5 U g(-1)), respectively. Regarding cellulases and xylanases, maximum activities (12.8 and 598.0 U g(-1), respectively) were obtained by A. awamori IOC-3915 in castor seed residue. Saccharification studies showed a flexible applicability of the raw extracts to hydrolyze different cakes. A maximum total reducing sugars concentration of 13.9 g L-1 was obtained from babassu cake using a raw enzyme extract produced by A. awamori IOC-3915, without any concentration or purification steps. The present results demonstrate that a low-cost SSF process can supply enzyme extracts with a high potential for application in the cold hydrolysis of raw starch from agroindustrial cakes.
C1 [de Castro, Aline Machado] Ilha Fundao, PETROBRAS, Ctr Res & Dev, Renewable Energy Div, BR-21941915 Rio De Janeiro, Brazil.
   [de Castro, Aline Machado; de Andrea, Thiago Vetter; Carvalho, Daniele Fernandes; Pereira Teixeira, Mariana Martins; Castilho, Leda dos Reis] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21945 Rio De Janeiro, Brazil.
   [Guimaraes Freire, Denise Maria] Univ Fed Rio de Janeiro, Inst Chem, Rio De Janeiro, Brazil.
RP de Castro, AM (corresponding author), Ilha Fundao, PETROBRAS, Ctr Res & Dev, Renewable Energy Div, Av Horacio Macedo 950, BR-21941915 Rio De Janeiro, Brazil.
EM alinebio@petrobras.com.br; thiagovetter@gmail.com;
   danielefernandes@gmail.com; marybiology@gmail.com;
   leda@peq.coppe.ufrj.br; freire@iq.ufrj.br
RI Castilho, Leda/I-8939-2014; Freire, Denise Maria Guimaraes/D-8699-2014;
   CASTRO, ALINE/C-4984-2015
OI Freire, Denise Maria Guimaraes/0000-0002-8298-5936; CASTRO,
   ALINE/0000-0002-1355-8455
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); ANP/PETROBRAS
FX The authors wish to thank Dr. Edmond Baruque (Tocantis Babacu S.A.) for
   kindly providing babassu cake and Ms. Mariana Paixao (Membrane
   Separation Processes and Polymer Laboratory, PAM/COPPE, Federal
   University of Rio de Janeiro) for her technical assistance in SEM
   analyses. The authors also gratefully acknowledge the financial support
   from CNPq, FAPERJ and ANP/PETROBRAS.
CR Alva S, 2007, AFR J BIOTECHNOL, V6, P576
   AOAC, 1995, OFF METH AN AOAC INT
   Balan V, 2009, J AM OIL CHEM SOC, V86, P157, DOI 10.1007/s11746-008-1329-4
   Baruque EA, 2000, BIORESOURCE TECHNOL, V75, P49, DOI 10.1016/S0960-8524(00)00026-2
   Bendicho S, 2002, FOOD CHEM, V79, P245, DOI 10.1016/S0308-8146(02)00126-7
   BERVEN D, 2005, ETHANOL PROD MAG, V11, P67
   Britton HTS, 1931, J CHEM SOC, P1456, DOI 10.1039/jr9310001456
   Castilho LR, 2000, BIOCHEM ENG J, V4, P239, DOI 10.1016/S1369-703X(99)00052-2
   Costa JAV, 2007, BRAZ ARCH BIOL TECHN, V50, P759, DOI 10.1590/S1516-89132007000500003
   de Castro Aline Machado, 2010, Enzyme Res, V2010, P576872, DOI 10.4061/2010/576872
   de Castro AM, 2010, APPL BIOCHEM BIOTECH, V162, P1612, DOI [10.1007/s12010-010-8986-0, 10.1007/s12010-010-8942-z]
   de Castro AM, 2010, QUIM NOVA, V33, P181, DOI 10.1590/S0100-40422010000100031
   de Castro AM, 2010, J IND MICROBIOL BIOT, V37, P151, DOI 10.1007/s10295-009-0656-2
   de Vries RP, 2001, MICROBIOL MOL BIOL R, V65, P497, DOI 10.1128/MMBR.65.4.497-522.2001
   Ertan F, 2006, PREP BIOCHEM BIOTECH, V36, P81, DOI 10.1080/10826060500388553
   Estrada Gutarra Melissa Limoeiro, 2009, Biotechnology Journal, V4, P1450, DOI 10.1002/biot.200800298
   Faulds CB, 2008, J AGR FOOD CHEM, V56, P7038, DOI 10.1021/jf800433c
   FERNANDES L. P., 2007, REV ELETRONICA FARMA, VIV, P43
   Figueira ELZ, 2000, BRAZ ARCH BIOL TECHN, V43, P461, DOI 10.1590/S1516-89132000000500003
   GALVEZ A, 2005, ETHANOL PRODUCER, V11, P58
   GHOSE TK, 1987, PURE APPL CHEM, V59, P257, DOI 10.1351/pac198759020257
   Gibreel A, 2009, APPL ENVIRON MICROB, V75, P1363, DOI 10.1128/AEM.01512-08
   Godfrey T, 1996, IND ENZYMOLOGY
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   Gupta R, 2003, PROCESS BIOCHEM, V38, P1599, DOI 10.1016/S0032-9592(03)00053-0
   Holker U, 2005, CURR OPIN MICROBIOL, V8, P301, DOI 10.1016/j.mib.2005.04.006
   Kempka AP, 2008, BIOPROC BIOSYST ENG, V31, P119, DOI 10.1007/s00449-007-0154-8
   KHALIL CN, 2006, Patent No. 7112229
   Kim Y, 2008, BIORESOURCE TECHNOL, V99, P5177, DOI 10.1016/j.biortech.2007.09.035
   Kunamneni A, 2005, J BIOSCI BIOENG, V100, P168, DOI 10.1263/jbb.100.168
   Lang XS, 2001, ENERG SOURCE, V23, P417, DOI 10.1080/009083101300058408
   Matsubara T, 2004, J BIOCHEM MOL BIOL, V37, P422
   Melo WC, 2008, J BRAZIL CHEM SOC, V19, P418, DOI 10.1590/S0103-50532008000300008
   Mitchell DA, 2003, BIOCHEM ENG J, V13, P137, DOI 10.1016/S1369-703X(02)00126-2
   Muller C, 2002, APPL ENVIRON MICROB, V68, P1827, DOI 10.1128/AEM.68.4.1827-1836.2002
   Norouzian D, 2006, BIOTECHNOL ADV, V24, P80, DOI 10.1016/j.biotechadv.2005.06.003
   Olajuyigbe F.M., 2006, GLOBAL J PURE APPL S, V12, P85
   Pandey A, 2000, BIOTECHNOL APPL BIOC, V31, P135, DOI 10.1042/BA19990073
   Polaina J., 2007, IND ENZYMES STRUCTUR
   Prakasham RS, 2007, J APPL MICROBIOL, V102, P204, DOI 10.1111/j.1365-2672.2006.03058.x
   RAJAGOPALAN S, 1995, CHEM ENG SCI, V50, P803, DOI 10.1016/0009-2509(94)00452-W
   Ramachandran S, 2004, BRAZ ARCH BIOL TECHN, V47, P309, DOI 10.1590/S1516-89132004000200019
   Riaz M, 2007, ENZYME MICROB TECH, V41, P558, DOI 10.1016/j.enzmictec.2007.05.010
   Robertson GH, 2006, J AGR FOOD CHEM, V54, P353, DOI 10.1021/jf051883m
   Sarikaya E, 2000, PROCESS BIOCHEM, V35, P711, DOI 10.1016/S0032-9592(99)00133-8
   Sauer J, 2000, BBA-PROTEIN STRUCT M, V1543, P275, DOI 10.1016/S0167-4838(00)00232-6
   Sumner JB, 1921, J BIOL CHEM, V47, P5
   Textor SD, 1998, CAN J CHEM ENG, V76, P87, DOI 10.1002/cjce.5450760111
   van der Maarel MJEC, 2002, J BIOTECHNOL, V94, P137, DOI 10.1016/S0168-1656(01)00407-2
   Vidal BC, 2009, STARCH-STARKE, V61, P448, DOI 10.1002/star.200800091
   Vidal BC, 2009, CEREAL CHEM, V86, P323, DOI 10.1094/CCHEM-86-3-0323
   Viniegra-Gonzalez G, 2003, BIOCHEM ENG J, V13, P157, DOI 10.1016/S1369-703X(02)00128-6
   Wang P, 2009, CEREAL CHEM, V86, P319, DOI 10.1094/CCHEM-86-3-0319
   Zhang YHP, 2004, BIOTECHNOL BIOENG, V88, P797, DOI 10.1002/bit.20282
NR 54
TC 27
Z9 28
U1 1
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1877-2641
EI 1877-265X
J9 WASTE BIOMASS VALORI
JI Waste Biomass Valorization
PD AUG
PY 2011
VL 2
IS 3
BP 291
EP 302
DI 10.1007/s12649-011-9075-5
PG 12
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA V36ET
UT WOS:000209196700005
DA 2020-12-08
ER

PT J
AU de Castro, AM
   de Andrea, TV
   Castilho, LD
   Freire, DMG
AF de Castro, Aline Machado
   de Andrea, Thiago Vetter
   Castilho, Leda dos Reis
   Guimaraes Freire, Denise Maria
TI Use of Mesophilic Fungal Amylases Produced by Solid-state Fermentation
   in the Cold Hydrolysis of Raw Babassu Cake Starch
SO APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
LA English
DT Article
DE Mesophilic amylases; Babassu cake; Aspergillus; Filamentous fungi; Raw
   starch hydrolysis; Desirability function; Cold hydrolysis; Simultaneous
   liquefaction and saccharification
ID ALPHA-AMYLASE; ETHANOL-PRODUCTION; GLUCOAMYLASE; ACID; PURIFICATION;
   CONVERSION; ENZYMES; BINDING; CORN
AB Amylases constitute one of the most important groups of industrial enzymes, presenting several applications, such as in the food, textile, and ethanol manufacturing. In this work, a starchy residue from the Brazilian agroindustry, namely babassu cake, was used for the production of amylases by solid-state fermentation and for obtaining sugar hydrolysates, which can be used as building blocks for future bioconversions. Eight filamentous fungi from the genera Aspergillus and Penicillium were screened. Regarding amylase production, A. awamori strains showed well-balanced endoamylase and exoamylase activities, while A. wentii produced an amylolytic complex much richer in the endo-acting enzymes. Simultaneous liquefaction and saccharification using the crude enzyme extracts from the four most promising fungal strains was then investigated applying DOE techniques. The highest total reducing sugar content (24.70 g L(-1)) was obtained by the crude extract from A. awamori IOC-3914, corresponding to a hydrolysis yield of 52% of total starch in the cake, while A. awamori IOC-3915 produced the most appropriate extract in terms of glucose release (maximum of 5.52 g L(-1)). Multivariate analysis of the DOE studies indicated that these extracts showed their best performance at 50-57 A degrees C under acid conditions (pH 3.6-4.5), but were also able to act satisfactorily under milder conditions (36 A degrees C and pH 5.0), when TRS and glucose released were about 65% of the maximum values obtained. These data confirm the high potential of the enzyme extracts under study for cold hydrolysis of starch.
C1 [de Castro, Aline Machado] PETROBRAS, Ctr Res & Dev, Renewable Energy Div, BR-21941915 Rio De Janeiro, Brazil.
   [de Castro, Aline Machado; de Andrea, Thiago Vetter; Castilho, Leda dos Reis] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21945 Rio De Janeiro, Brazil.
   [Guimaraes Freire, Denise Maria] Univ Fed Rio de Janeiro, Inst Chem, Rio De Janeiro, Brazil.
RP de Castro, AM (corresponding author), PETROBRAS, Ctr Res & Dev, Renewable Energy Div, Av Horacio Macedo,950 Ilha Fundao, BR-21941915 Rio De Janeiro, Brazil.
EM alinebio@petrobras.com.br
RI Junior, Nei Pereira/H-2471-2016; Castilho, Leda/I-8939-2014; FREIRE,
   Denise Maria/D-8699-2014; CASTRO, ALINE/C-4984-2015
OI FREIRE, Denise Maria/0000-0002-8298-5936; CASTRO,
   ALINE/0000-0002-1355-8455
CR Baruque EA, 2000, BIORESOURCE TECHNOL, V75, P49, DOI 10.1016/S0960-8524(00)00026-2
   Bendicho S, 2002, FOOD CHEM, V79, P245, DOI 10.1016/S0308-8146(02)00126-7
   Bhanja T, 2007, BIOPROC BIOSYST ENG, V30, P369, DOI 10.1007/s00449-007-0133-0
   Bothast RJ, 2005, APPL MICROBIOL BIOT, V67, P19, DOI 10.1007/s00253-004-1819-8
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Britton HTS, 1931, J CHEM SOC, P1456, DOI 10.1039/jr9310001456
   Calado V, 2003, PLANEJAMENTO EXPT US
   CHARNEY J, 1947, J BIOL CHEM, V171, P501
   Costa JAV, 2007, BRAZ ARCH BIOL TECHN, V50, P759, DOI 10.1590/S1516-89132007000500003
   Lima JRD, 2007, QUIM NOVA, V30, P600, DOI 10.1590/S0100-40422007000300019
   Ertan F, 2006, PREP BIOCHEM BIOTECH, V36, P81, DOI 10.1080/10826060500388553
   FERNANDES L. P., 2007, REV ELETRONICA FARMA, VIV, P43
   Figueira ELZ, 2000, BRAZ ARCH BIOL TECHN, V43, P461, DOI 10.1590/S1516-89132000000500003
   FREIRE DMG, 1997, THESIS FEDERAL U RIO
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   Guimaraes LHS, 2006, BRAZ J MICROBIOL, V37, P474, DOI 10.1590/S1517-83822006000400014
   Gupta R, 2003, PROCESS BIOCHEM, V38, P1599, DOI 10.1016/S0032-9592(03)00053-0
   Kumari A, 2008, PLANT SOIL ENVIRON, V54, P72, DOI 10.17221/2783-PSE
   Marlida Y, 2000, FOOD CHEM, V71, P221, DOI 10.1016/S0308-8146(00)00160-6
   MCALOON A, 2000, NREL REPORT
   Melo WC, 2008, J BRAZIL CHEM SOC, V19, P418, DOI 10.1590/S0103-50532008000300008
   MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030
   Nagasaka Y, 1998, APPL MICROBIOL BIOT, V50, P323, DOI 10.1007/s002530051299
   Nahas Ely, 2002, Rev Latinoam Microbiol, V44, P5
   Norouzian D, 2006, BIOTECHNOL ADV, V24, P80, DOI 10.1016/j.biotechadv.2005.06.003
   Polaina J., 2007, IND ENZYMES STRUCTUR
   Quintero JA, 2008, ENERGY, V33, P385, DOI 10.1016/j.energy.2007.10.001
   Ramachandran S, 2004, BRAZ ARCH BIOL TECHN, V47, P309, DOI 10.1590/S1516-89132004000200019
   Riaz M, 2007, ENZYME MICROB TECH, V41, P558, DOI 10.1016/j.enzmictec.2007.05.010
   Robertson GH, 2006, J AGR FOOD CHEM, V54, P353, DOI 10.1021/jf051883m
   Roehr M, 2001, BIOTECHNOLOGY ETHANO
   Southall SM, 1999, FEBS LETT, V447, P58, DOI 10.1016/S0014-5793(99)00263-X
   Tasic MB, 2009, BIOCHEM ENG J, V43, P208, DOI 10.1016/j.bej.2008.09.019
   Tester RF, 2006, ANIM FEED SCI TECH, V130, P39, DOI 10.1016/j.anifeedsci.2006.01.016
   van der Maarel MJEC, 2002, J BIOTECHNOL, V94, P137, DOI 10.1016/S0168-1656(01)00407-2
NR 35
TC 66
Z9 67
U1 0
U2 8
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0273-2289
J9 APPL BIOCHEM BIOTECH
JI Appl. Biochem. Biotechnol.
PD NOV
PY 2010
VL 162
IS 6
BP 1612
EP 1625
DI 10.1007/s12010-010-8942-z
PG 14
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 644PL
UT WOS:000281391800010
PM 20455032
DA 2020-12-08
ER

PT J
AU Roldao, A
   Mellado, MCM
   Castilho, LR
   Carrondo, MJT
   Alves, PM
AF Roldao, Antonio
   Mellado, Maria Candida M.
   Castilho, Leda R.
   Carrondo, Manuel J. T.
   Alves, Paula M.
TI Virus-like particles in vaccine development
SO EXPERT REVIEW OF VACCINES
LA English
DT Review
DE assembly; bioprocessing challenges; chimeric VLP; clinical trials;
   disassembly; drug delivery; nanotechnology; recombinant vaccines;
   virus-like particles; VLP technology
ID HEPATITIS-B SURFACE; ROTAVIRUS-LIKE PARTICLES; PROTECTIVE
   IMMUNE-RESPONSES; BACULOVIRUS EXPRESSION SYSTEM; PAPILLOMAVIRUS-LIKE
   PARTICLES; MAJOR CAPSID PROTEIN; CHINESE-HAMSTER OVARY;
   INSECT-CELL-CULTURES; INFLUENZA-A VACCINE; HIGHLY PATHOGENIC H5N1
AB Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates. A handful of prophylactic VLP-based vaccines is currently commercialized worldwide: GlaxoSmithKline's Engerix (R) (hepatitis B virus) and Cervarix (R) (human papillomavirus), and Merck and Co., Inc.'s Recombivax HB (R) (hepatitis B virus) and Gardasil (R) (human papillomavirus) are some examples. Other VLP-based vaccine candidates are in clinical trials or undergoing preclinical evaluation, such as, influenza virus, parvovirus, Norwalk and various chimeric VLPs. Many others are still restricted to small-scale fundamental research, despite their success in preclinical tests. This article focuses on the essential role of VLP technology in new-generation vaccines against prevalent and emergent diseases. The implications of large-scale VLP production are discussed in the context of process control, monitorization and optimization. The main up- and down-stream technical challenges are identified and discussed accordingly. Successful VLP-based vaccine blockbusters are briefly presented concomitantly with the latest results from clinical trials and the recent developments in chimeric VLP-based technology for either therapeutic or prophylactic vaccination.
C1 [Roldao, Antonio; Alves, Paula M.] Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal.
   [Roldao, Antonio; Mellado, Maria Candida M.; Carrondo, Manuel J. T.; Alves, Paula M.] Inst Biol Expt & Tecnol, P-2781901 Oeiras, Portugal.
   [Mellado, Maria Candida M.; Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Cell Culture Engn Lab, BR-21941972 Rio De Janeiro, Brazil.
   [Carrondo, Manuel J. T.] Univ Nova Lisboa, Fac Ciencias & Tecnol, P-2825 Monte De Caparica, Portugal.
RP Alves, PM (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Apartado 127, P-2781901 Oeiras, Portugal.
EM marques@itqb.unl.pt
RI Castilho, Leda/I-8939-2014; Alves, Paula M/C-1070-2008; Roldao,
   Antonio/J-2396-2013; Carrondo, Manuel/C-8155-2011
OI Alves, Paula M/0000-0003-1445-3556; Roldao, Antonio/0000-0003-0414-4899;
   Carrondo, Manuel/0000-0002-4550-4574
FU Portuguese Foundation for Science and TechnologyPortuguese Foundation
   for Science and Technology [SFRH/BD/2191012005, SFRH/BD/28323/2006];
   European CommissionEuropean CommissionEuropean Commission Joint Research
   Centre [LSHB-CT-2006-018933, LSHB-2006-037541]
FX The authors acknowledge the financial support received from the
   Portuguese Foundation for Science and Technology (SFRH/BD/2191012005 and
   SFRH/BD/28323/2006) and from the European Commission (Clinigene Network
   of Excellence, LSHB-CT-2006-018933; Baculogenes, LSHB-2006-037541). The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR ABOUD M, 1982, ARCH VIROL, V71, P185, DOI 10.1007/BF01314870
   ADAMS SE, 1987, NATURE, V329, P68, DOI 10.1038/329068a0
   AGRAWAL DK, 1995, VIROLOGY, V207, P89, DOI 10.1006/viro.1995.1054
   Almanza H, 2008, J CLIN MICROBIOL, V46, P3971, DOI 10.1128/JCM.01204-08
   Ambuhl PM, 2007, J HYPERTENS, V25, P63, DOI 10.1097/HJH.0b013e32800ff5d6
   Amexis G, 2006, J INFECT DIS, V194, P790, DOI 10.1086/506361
   Aucoin Marc G., 2007, V388, P281
   BAKER TS, 1991, BIOPHYS J, V60, P1445, DOI 10.1016/S0006-3495(91)82181-6
   Bazan SB, 2009, ARCH VIROL, V154, P1609, DOI 10.1007/s00705-009-0484-8
   Bengt W, 2008, ALZHEIMERS DEMENT, V4, pT128
   Bernal V, 2009, BIOTECHNOL BIOENG, V104, P162, DOI 10.1002/bit.22364
   Bertram J, 2006, CURR PHARM BIOTECHNO, V7, P277, DOI 10.2174/138920106777950825
   BETENBAUGH M, 1995, VIRUS RES, V38, P111, DOI 10.1016/0168-1702(95)00053-S
   Bisht H, 2002, J BIOTECHNOL, V99, P97, DOI 10.1016/S0168-1656(02)00181-5
   Boijoux O, 2005, MOL PHARMACOL, V67, P1829, DOI 10.1124/mol.105.011163
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Bragard C, 2000, J GEN VIROL, V81, P267, DOI 10.1099/0022-1317-81-1-267
   Bright RA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001501
   Bright RA, 2007, VACCINE, V25, P3871, DOI 10.1016/j.vaccine.2007.01.106
   Brinkman M, 2005, CANCER IMMUNOL IMMUN, V54, P611, DOI 10.1007/s00262-004-0655-0
   BUCHER B, 1994, EUR J CLIN MICROBIOL, V13, P212, DOI 10.1007/BF01974539
   Buckland BC, 2005, NAT MED, V11, pS16, DOI 10.1038/nm1218
   Bundy BC, 2008, BIOTECHNOL BIOENG, V100, P28, DOI 10.1002/bit.21716
   Buonaguro L, 2001, ANTIVIR RES, V49, P35, DOI 10.1016/S0166-3542(00)00136-4
   BURRELL CJ, 1979, NATURE, V279, P43, DOI 10.1038/279043a0
   Canady MA, 2000, J MOL BIOL, V299, P573, DOI 10.1006/jmbi.2000.3723
   Carinhas N, 2010, METAB ENG, V12, P39, DOI 10.1016/j.ymben.2009.08.008
   CARON AW, 1994, BIOTECHNOL BIOENG, V43, P881, DOI 10.1002/bit.260430907
   Chackerian B, 2002, J IMMUNOL, V169, P6120, DOI 10.4049/jimmunol.169.11.6120
   Chackerian B, 2001, J CLIN INVEST, V108, P415, DOI 10.1172/JCI11849
   Chackerian B, 2006, VACCINE, V24, P6321, DOI 10.1016/j.vaccine.2006.05.059
   Chandran D, 2009, VACCINE, V28, P132, DOI 10.1016/j.vaccine.2009.09.093
   CHARNAY P, 1979, P NATL ACAD SCI USA, V76, P2222, DOI 10.1073/pnas.76.5.2222
   Chen XJS, 2000, MOL CELL, V5, P557, DOI 10.1016/S1097-2765(00)80449-9
   Chen YH, 2005, J BIOTECHNOL, V118, P135, DOI 10.1016/j.jbiotec.2005.02.018
   Chong KWY, 2006, J NEUROSCI METH, V158, P56, DOI 10.1016/j.jneumeth.2006.05.017
   Chromy LR, 2003, P NATL ACAD SCI USA, V100, P10477, DOI 10.1073/pnas.1832245100
   Chung YC, 2006, WORLD J GASTROENTERO, V12, P921, DOI 10.3748/wjg.v12.i6.921
   Citkowicz A, 2008, ANAL BIOCHEM, V376, P163, DOI 10.1016/j.ab.2008.02.011
   Cornuz J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002547
   Coroadinha AS, 2006, J BIOTECHNOL, V124, P457, DOI 10.1016/j.jbiotec.2006.01.037
   CREGG JM, 1987, BIO-TECHNOL, V5, P479, DOI 10.1038/nbt0587-479
   Crevar CJ, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-131
   Cruz PE, 1998, J CHEM TECHNOL BIOT, V72, P149
   Cruz PE, 1998, BIOTECHNOL BIOENG, V60, P408, DOI 10.1002/(SICI)1097-0290(19981120)60:4<408::AID-BIT2>3.0.CO;2-Q
   D'Aoust MA, 2008, PLANT BIOTECHNOL J, V6, P930, DOI 10.1111/j.1467-7652.2008.00384.x
   D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497
   Dale CJ, 2002, VIROLOGY, V301, P176, DOI 10.1006/viro.2002.1589
   DAVIS TR, 1995, IN VITRO CELL DEV-AN, V31, P659
   De Filette M, 2005, VIROLOGY, V337, P149, DOI 10.1016/j.virol.2005.04.004
   Deml L, 2005, MOL IMMUNOL, V42, P259, DOI 10.1016/j.molimm.2004.06.028
   Doan LX, 2005, REV MED VIROL, V15, P75, DOI 10.1002/rmv.449
   Eckhart L, 1996, J GEN VIROL, V77, P2001, DOI 10.1099/0022-1317-77-9-2001
   Ehsani P, 1997, GENE, V190, P107, DOI 10.1016/S0378-1119(96)00647-6
   Emeny RT, 2002, J VIROL, V76, P7832, DOI 10.1128/JVI.76.15.7832-7842.2002
   Fernandez-Arias A, 1998, J GEN VIROL, V79, P1047, DOI 10.1099/0022-1317-79-5-1047
   Ferreira TB, 2007, J BIOTECHNOL, V129, P433, DOI 10.1016/j.jbiotec.2007.01.010
   Ferreira TB, 2005, J BIOTECHNOL, V119, P272, DOI 10.1016/j.jbiotec.2005.03.009
   Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007
   Franco CF, 2010, TALANTA, V80, P1561, DOI 10.1016/j.talanta.2009.06.081
   Frazer IH, 2004, VACCINE, V23, P172, DOI 10.1016/j.vaccine.2004.05.013
   FRENCH TJ, 1990, J VIROL, V64, P5695, DOI 10.1128/JVI.64.12.5695-5700.1990
   FRITSCH A, 1978, CR ACAD SCI D NAT, V287, P1453
   Fromentin R, 2007, ANAL BIOCHEM, V366, P37, DOI 10.1016/j.ab.2007.03.033
   Galarza JM, 2005, VIRAL IMMUNOL, V18, P244, DOI 10.1089/vim.2005.18.244
   Gleiter S, 2001, PROTEIN SCI, V10, P434, DOI 10.1110/ps.31101
   Goldmann C, 1999, J VIROL, V73, P4465, DOI 10.1128/JVI.73.5.4465-4469.1999
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   GU MB, 1991, APPL MICROBIOL BIOT, V35, P46
   Guo LZ, 2003, VIROLOGY, V313, P502, DOI 10.1016/S0042-6822(03)00372-6
   HAGENSEE ME, 1993, J VIROL, V67, P315, DOI 10.1128/JVI.67.1.315-322.1993
   Haglund K, 2000, VIROLOGY, V268, P112, DOI 10.1006/viro.1999.0120
   Hammonds J, 2007, VACCINE, V25, P8036, DOI 10.1016/j.vaccine.2007.09.016
   Hardy E, 2000, J BIOTECHNOL, V77, P157, DOI 10.1016/S0168-1656(99)00201-1
   Harvey TJ, 2004, J VIROL, V78, P531, DOI [10.1128/JVI.78.1.531-538.2004, 10.1128/JVI.78.22.12225-12235.2004]
   Haynes JR, 2009, VACCINE, V27, P530, DOI 10.1016/j.vaccine.2008.11.011
   Hervas-Stubbs S, 2007, J IMMUNOL, V178, P2361, DOI 10.4049/jimmunol.178.4.2361
   Holzer GW, 2003, PROTEIN EXPRES PURIF, V29, P58, DOI 10.1016/S1046-5928(03)00011-1
   Hong S, 2007, MOL THER, V15, P1630, DOI 10.1038/sj.mt.6300251
   Hooker JM, 2004, J AM CHEM SOC, V126, P3718, DOI 10.1021/ja031790q
   Hou LH, 2009, ARCH VIROL, V154, P547, DOI 10.1007/s00705-009-0336-6
   Hu YC, 2001, BIOTECHNOL BIOENG, V75, P104, DOI 10.1002/bit.1170
   Huang Z, 2006, VACCINE, V24, P2506, DOI 10.1016/j.vaccine.2005.12.024
   Huang Z, 2005, VACCINE, V23, P1851, DOI 10.1016/j.vaccine.2004.11.017
   Huang Z, 2004, PLANT BIOTECHNOL J, V2, P241, DOI 10.1111/j.1467-7652.2004.00068.x
   Ionescu RM, 2006, J PHARM SCI-US, V95, P70, DOI 10.1002/jps.20493
   Jacobsen LB, 2004, METHODS, V33, P104, DOI 10.1016/j.ymeth.2003.11.002
   James ER, 2007, APPL MICROBIOL BIOT, V75, P279, DOI 10.1007/s00253-006-0812-9
   JANOWICZ ZA, 1991, YEAST, V7, P431, DOI 10.1002/yea.320070502
   Jegerlehner A, 2002, EUR J IMMUNOL, V32, P3305, DOI 10.1002/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J
   Jegerlehner A, 2002, VACCINE, V20, P3104, DOI 10.1016/S0264-410X(02)00266-9
   Jennings GT, 2008, BIOL CHEM, V389, P521, DOI 10.1515/BC.2008.064
   Jiang BM, 1998, BIOTECHNOL BIOENG, V60, P369, DOI 10.1002/(SICI)1097-0290(19981105)60:3<369::AID-BIT14>3.0.CO;2-H
   Jin HL, 2007, VIRAL IMMUNOL, V20, P429, DOI 10.1089/vim.2007.0031
   Jones JW, 2008, J BIOMOL SCREEN, V13, P424, DOI 10.1177/1087057108318332
   Kallstrom G, 2005, J VIROL METHODS, V127, P1, DOI 10.1016/j.jviromet.2005.02.015
   Kane MA, 2002, CURR OPIN INFECT DIS, V15, P465, DOI 10.1097/00001432-200210000-00002
   Kane MA, 2006, VACCINE, V24, P132, DOI 10.1016/j.vaccine.2006.05.128
   Kanesashi SN, 2003, J GEN VIROL, V84, P1899, DOI 10.1099/vir.0.19067-0
   Kang SM, 2009, VIRUS RES, V143, P140, DOI 10.1016/j.virusres.2009.04.005
   Kang SM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004667
   Kao JH, 2002, LANCET INFECT DIS, V2, P395, DOI 10.1016/S1473-3099(02)00315-8
   Kapusta J, 1999, FASEB J, V13, P1796
   Kee GS, 2010, BIOTECHNOL PROGR, V26, P26, DOI 10.1002/btpr.307
   Kim Y, 2002, VIROLOGY, V302, P1, DOI 10.1006/viro.2002.1610
   Kimchi-Sarfaty C, 2004, CURR PHARM BIOTECHNO, V5, P451, DOI 10.2174/1389201043376670
   KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180
   KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395
   Ko YJ, 2005, CLIN DIAGN LAB IMMUN, V12, P922, DOI 10.1128/CDLI.12.8.922-929.2005
   KOMPIER R, 1988, BIOTECHNOL LETT, V10, P849, DOI 10.1007/BF01026994
   Konz JO, 1998, BIOTECHNOL PROGR, V14, P393, DOI 10.1021/bp980021l
   Krammer F, 2010, J VIROL METHODS, V167, P17, DOI 10.1016/j.jviromet.2010.03.003
   Krammer F, 2010, MOL BIOTECHNOL, V45, P226, DOI 10.1007/s12033-010-9268-3
   Krammer F, 2010, BIOTECHNOL J, V5, P17, DOI 10.1002/biot.200900267
   Kratz PA, 1999, P NATL ACAD SCI USA, V96, P1915, DOI 10.1073/pnas.96.5.1915
   Kumar N, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-42
   Lai CY, 2008, J BIOMED SCI, V15, P15, DOI 10.1007/s11373-007-9204-0
   Lai WB, 2002, BIOPROC BIOSYST ENG, V25, P121, DOI 10.1007/s00449-002-0289-6
   Latham T, 2001, J VIROL, V75, P6154, DOI 10.1128/JVI.75.13.6154-6165.2001
   LAURENT S, 1994, J VIROL, V68, P6794, DOI 10.1128/JVI.68.10.6794-6798.1994
   LEAVITT AD, 1985, J BIOL CHEM, V260, P2803
   Lechmann M, 2001, HEPATOLOGY, V34, P417, DOI 10.1053/jhep.2001.26523
   Lechner F, 2002, INTERVIROLOGY, V45, P212, DOI 10.1159/000067912
   Lee KW, 2008, J VIROL METHODS, V151, P172, DOI 10.1016/j.jviromet.2008.05.025
   LEE T, 1989, ARCH VIROL, V106, P151, DOI 10.1007/BF01311047
   Lee YY, 2007, METAB ENG, V9, P52, DOI 10.1016/j.ymben.2006.08.006
   Legendre D, 2005, J BIOTECHNOL, V117, P183, DOI 10.1016/j.jbiotec.2005.01.010
   Levy HC, 2009, J STRUCT BIOL, V165, P146, DOI 10.1016/j.jsb.2008.12.002
   LIM GMA, 2007, TRANSGENIC PLANT J, V1, P256
   Lisziewicz J, 2003, VACCINE, V21, P620, DOI 10.1016/S0264-410X(02)00569-8
   Liu CT, 2008, MOL BIOTECHNOL, V39, P141, DOI 10.1007/s12033-008-9051-x
   Liu L, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-82
   Liu WJ, 2000, VIROLOGY, V273, P374, DOI 10.1006/viro.2000.0435
   Ludwig C, 2007, CURR OPIN BIOTECH, V18, P537, DOI 10.1016/j.copbio.2007.10.013
   Mellado MCM, 2008, J CHROMATOGR A, V1192, P166, DOI 10.1016/j.chroma.2008.03.035
   Ma ZY, 2008, PROCESS BIOCHEM, V43, P690, DOI 10.1016/j.procbio.2008.02.012
   Madalinski K, 2001, VACCINE, V20, P92, DOI 10.1016/S0264-410X(01)00312-7
   Mahmood K, 2008, VACCINE, V26, P5393, DOI 10.1016/j.vaccine.2008.07.084
   Maloney BJ, 2005, VACCINE, V23, P1870, DOI 10.1016/j.vaccine.2004.11.020
   Maranga L, 2004, J BIOTECHNOL, V107, P55, DOI 10.1016/j.jbiotec.2003.09.012
   Maranga L, 2003, BIOTECHNOL BIOENG, V84, P245, DOI 10.1002/bit.10773
   Maranga L, 2002, APPL MICROBIOL BIOT, V59, P45, DOI 10.1007/s00253-002-0976-x
   Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335
   Masotti A, 2009, COLLOID SURFACE B, V68, P136, DOI 10.1016/j.colsurfb.2008.09.017
   Matassov D, 2007, VIRAL IMMUNOL, V20, P441, DOI 10.1089/vim.2007.0027
   Matsuo E, 2006, BIOCHEM BIOPH RES CO, V340, P200, DOI 10.1016/j.bbrc.2005.12.001
   Matthias S, 2006, ALZHEIMERS DEMENT, V2, pS20
   Maurer P, 2005, EUR J IMMUNOL, V35, P2031, DOI 10.1002/eji.200526285
   Maurer P, 2006, CURR OPIN MOL THER, V8, P11
   McGinnes LW, 2010, J VIROL, V84, P4513, DOI 10.1128/JVI.01931-09
   Meghrous J, 2005, BIOTECHNOL PROGR, V21, P154, DOI 10.1021/bp049802e
   Mellado MCM, 2008, J CHROMATOGR B, V874, P89, DOI 10.1016/j.jchromb.2008.09.002
   Mellado MCM, 2009, BIOTECHNOL BIOENG, V104, P674, DOI 10.1002/bit.22430
   Mena JA, 2005, J CHROMATOGR B, V824, P267, DOI 10.1016/j.jchromb.2005.07.034
   Michel ML, 2010, PATHOL BIOL, V58, P288, DOI 10.1016/j.patbio.2010.01.006
   MICHEL ML, 1984, P NATL ACAD SCI-BIOL, V81, P7708, DOI 10.1073/pnas.81.24.7708
   Mihailova M, 2006, VACCINE, V24, P4369, DOI 10.1016/j.vaccine.2006.02.051
   MIYANOHARA A, 1983, P NATL ACAD SCI-BIOL, V80, P1, DOI 10.1073/pnas.80.1.1
   Molinari P, 2008, J VIROL METHODS, V147, P364, DOI 10.1016/j.jviromet.2007.09.002
   MOLINAS MMB, 2003, 18 ESACT M AN CELL T, P83
   MONTROSS L, 1991, J VIROL, V65, P4991, DOI 10.1128/JVI.65.9.4991-4998.1991
   Moorthy Vasee, 2007, Vaccine, V25, P5115, DOI 10.1016/j.vaccine.2007.01.085
   MOREIRA JL, 1995, ENZYME MICROB TECH, V17, P437, DOI 10.1016/0141-0229(94)00071-X
   Morenweiser R, 2005, GENE THER, V12, pS103, DOI 10.1038/sj.gt.3302624
   MORRIS TD, 1992, J VIROL, V66, P7397, DOI 10.1128/JVI.66.12.7397-7405.1992
   Mortola E, 2004, FEBS LETT, V576, P174, DOI 10.1016/j.febslet.2004.09.009
   Murawski MR, 2010, J VIROL, V84, P1110, DOI 10.1128/JVI.01709-09
   MURHAMMER DW, 1988, BIO-TECHNOL, V6, P1411, DOI 10.1038/nbt1288-1411
   NAGY E, 1991, J GEN VIROL, V72, P753, DOI 10.1099/0022-1317-72-3-753
   Nardin EH, 2004, INFECT IMMUN, V72, P6519, DOI 10.1128/IAI.72.11.6519-6527.2004
   Negrete A, 2007, PROCESS BIOCHEM, V42, P1107, DOI 10.1016/j.procbio.2007.05.004
   Neirynck S, 1999, NAT MED, V5, P1157
   Netter HJ, 2001, J VIROL, V75, P2130, DOI 10.1128/JVI.75.5.2130-2141.2001
   Niikura M, 2002, VIROLOGY, V293, P273, DOI 10.1006/viro.2001.1240
   Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7
   Oh YK, 2004, VIROLOGY, V328, P266, DOI 10.1016/j.virol.2004.06.047
   Ohtake N, 2010, CHEMBIOCHEM, V11, P959, DOI 10.1002/cbic.201000094
   Oliveira GA, 2005, INFECT IMMUN, V73, P3587, DOI 10.1128/IAI.73.6.3587-3597.2005
   Pajot-Augy E, 1999, EUR J BIOCHEM, V260, P635, DOI 10.1046/j.1432-1327.1999.00241.x
   Park MA, 2008, PROTEIN EXPRES PURIF, V59, P175, DOI 10.1016/j.pep.2008.01.021
   Parkin J, 1906, ANN ROY BOT GARD, V3, P11
   De la Rosa GP, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-2
   Peacey M, 2007, BIOTECHNOL BIOENG, V98, P968, DOI 10.1002/bit.21518
   Peixoto C, 2007, J BIOTECHNOL, V127, P452, DOI 10.1016/j.jbiotec.2006.08.002
   Peixoto C, 2008, BIOTECHNOL PROGR, V24, P1290, DOI 10.1002/btpr.25
   Peters BS, 1997, J INFECTION, V35, P231, DOI 10.1016/S0163-4453(97)92814-0
   Pillay S, 2009, BIOTECHNOL PROGR, V25, P1153, DOI 10.1002/btpr.187
   Pinto LA, 2003, J INFECT DIS, V188, P327, DOI 10.1086/376505
   POWER JF, 1994, BIOTECHNOL BIOENG, V44, P710, DOI 10.1002/bit.260440607
   Prel A, 2008, AVIAN PATHOL, V37, P513, DOI 10.1080/03079450802357001
   Pumpens P, 2002, INTERVIROLOGY, V45, P24, DOI 10.1159/000050084
   Pumpens P, 2001, INTERVIROLOGY, V44, P98, DOI 10.1159/000050037
   Pushko P, 2005, VACCINE, V23, P5751, DOI 10.1016/j.vaccine.2005.07.098
   Pushko P, 2007, VACCINE, V25, P4283, DOI 10.1016/j.vaccine.2007.02.059
   Quan FS, 2008, J VIROL, V82, P1350, DOI 10.1128/JVI.01615-07
   Quan FS, 2007, J VIROL, V81, P3514, DOI 10.1128/JVI.02052-06
   Quan FS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009161
   Ramqvist T, 2007, EXPERT OPIN BIOL TH, V7, P997, DOI 10.1517/14712598.7.7.997
   RODGERS RED, 1994, J VIROL, V68, P3386, DOI 10.1128/JVI.68.5.3386-3390.1994
   Rodrigues T, 2007, J GENE MED, V9, P233, DOI 10.1002/jgm.1021
   ROLDAO A, 2010, BIOPHYS J IN PRESS
   Roldao A, 2008, COMPUT CHEM ENG, V32, P68, DOI 10.1016/j.compchemeng.2007.04.017
   Roos AK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007226
   ROSE RC, 1993, J VIROL, V67, P1936, DOI 10.1128/JVI.67.4.1936-1944.1993
   Rueda P, 2000, VACCINE, V19, P726, DOI 10.1016/S0264-410X(00)00259-0
   RUTGERS T, 1988, BIO-TECHNOL, V6, P1065, DOI 10.1038/nbt0988-1065
   Sadeyen JR, 2003, VIROLOGY, V309, P32, DOI 10.1016/S0042-6822(02)00134-4
   Sakuragi S, 2002, P NATL ACAD SCI USA, V99, P7956, DOI 10.1073/pnas.082281199
   Sasnauskas K, 2002, INTERVIROLOGY, V45, P308, DOI 10.1159/000067922
   Sastri M, 1997, J MOL BIOL, V272, P541, DOI 10.1006/jmbi.1997.1258
   Schadlicha L, 2009, VACCINE, V27, P1511, DOI 10.1016/j.vaccine.2009.01.014
   Schiller JT, 2008, VACCINE, V26, pK53, DOI 10.1016/j.vaccine.2008.06.002
   SCHLIENGER K, 1992, J VIROL, V66, P2570, DOI 10.1128/JVI.66.4.2570-2576.1992
   SCHODEL F, 1994, J EXP MED, V180, P1037, DOI 10.1084/jem.180.3.1037
   Shapira MY, 2001, J HEPATOL, V34, P123, DOI 10.1016/S0168-8278(00)00082-9
   Shelly DA, 2009, GENET ENG BIOTECHN N, V29, P50
   SHIODA T, 1990, VIROLOGY, V175, P139, DOI 10.1016/0042-6822(90)90194-V
   Slupetzky K, 2007, VACCINE, V25, P2001, DOI 10.1016/j.vaccine.2006.11.049
   Smith D, 2001, HIV Med, V2, P272, DOI 10.1046/j.1468-1293.2001.00080.x
   Smith JF, 2007, HUM VACCINES, V3, P109, DOI 10.4161/hv.3.4.4058
   Smith ML, 2002, BIOTECHNOL BIOENG, V80, P812, DOI 10.1002/bit.10444
   SNINSKY JJ, 1979, NATURE, V279, P346, DOI 10.1038/279346a0
   Sojikul P, 2003, P NATL ACAD SCI USA, V100, P2209, DOI 10.1073/pnas.0438037100
   Spohn G, 2008, EUR J IMMUNOL, V38, P877, DOI 10.1002/eji.200737989
   Storni T, 2004, J IMMUNOL, V172, P1777, DOI 10.4049/jimmunol.172.3.1777
   Sun YL, 2009, VIROLOGY, V383, P12, DOI 10.1016/j.virol.2008.09.020
   SUZICH JA, 1995, P NATL ACAD SCI USA, V92, P11553, DOI 10.1073/pnas.92.25.11553
   Swenson DL, 2005, VACCINE, V23, P3033, DOI 10.1016/j.vaccine.2004.11.070
   Szecsi J, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-70
   Tacket CO, 2003, CLIN IMMUNOL, V108, P241, DOI 10.1016/S1521-6616(03)00120-7
   Takahashi R, 2008, J BIOTECHNOL, V135, P385, DOI 10.1016/j.jbiotec.2008.05.012
   TAKEHARA K, 1988, J GEN VIROL, V69, P2763, DOI 10.1099/0022-1317-69-11-2763
   Tan M, 2004, J MED VIROL, V74, P641, DOI 10.1002/jmv.20228
   TATMAN JD, 1994, J GEN VIROL, V75, P1101, DOI 10.1099/0022-1317-75-5-1101
   Taube S, 2005, ARCH VIROL, V150, P1425, DOI 10.1007/s00705-005-0517-x
   Teixeira AP, 2009, BIOTECHNOL ADV, V27, P726, DOI 10.1016/j.biotechadv.2009.05.003
   Teixeira AP, 2009, BIOTECHNOL BIOENG, V102, P1098, DOI 10.1002/bit.22125
   Tissot AC, 2008, LANCET, V371, P821, DOI 10.1016/S0140-6736(08)60381-5
   TSUCHIDA N, 1973, Intervirology, V1, P27, DOI 10.1159/000148829
   VALENZUELA P, 1979, NATURE, V280, P815, DOI 10.1038/280815a0
   VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0
   VANLIER FLJ, 1994, BIOTECHNOL PROGR, V10, P60, DOI 10.1021/bp00025a007
   Vassileva A, 2001, PROTEIN EXPRES PURIF, V21, P71, DOI 10.1006/prep.2000.1335
   Vicente T, 2009, GENE THER, V16, P766, DOI 10.1038/gt.2009.33
   Vicente T, 2008, J MEMBRANE SCI, V311, P270, DOI 10.1016/j.memsci.2007.12.021
   Vieira HLA, 2005, J BIOTECHNOL, V120, P72, DOI 10.1016/j.jbiotec.2005.03.026
   Villa LL, 2006, VACCINE, V24, P23, DOI 10.1016/j.vaccine.2005.09.001
   Wagner R, 1996, INTERVIROLOGY, V39, P93, DOI 10.1159/000150480
   Wakabayashi MT, 2002, INTERVIROLOGY, V45, P300, DOI 10.1159/000067921
   Wang BZ, 2008, J VIROL, V82, P11813, DOI 10.1128/JVI.01076-08
   Wang KC, 2005, BIOTECHNOL BIOENG, V89, P464, DOI 10.1002/bit.20385
   Wang MY, 1996, J BIOTECHNOL, V46, P243, DOI 10.1016/0168-1656(96)00003-X
   Warfield KL, 2007, J INFECT DIS, V196, pS421, DOI 10.1086/520612
   Warzecha H, 2003, J VIROL, V77, P8702, DOI 10.1128/JVI.77.16.8702-8711.2003
   WEBER J, 1995, VACCINE, V13, P831, DOI 10.1016/0264-410X(94)00061-Q
   Willis S, 2008, BIOCHEMISTRY-US, V47, P6988, DOI 10.1021/bi800540b
   Wu CY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009784
   XI JA, 1992, J VIROL, V66, P6527, DOI 10.1128/JVI.66.11.6527-6532.1992
   XI SZ, 1991, J GEN VIROL, V72, P2981, DOI 10.1099/0022-1317-72-12-2981
   Xia M, 2007, J MED VIROL, V79, P74, DOI 10.1002/jmv.20762
   Xie LZ, 2003, BIOTECHNOL BIOENG, V83, P45, DOI 10.1002/bit.10644
   YAMSHCHIKOV GV, 1995, VIROLOGY, V214, P50, DOI 10.1006/viro.1995.9955
   Yu F, 2001, J VIROL, V75, P2753, DOI 10.1128/JVI.75.6.2753-2764.2001
   Zamora E, 2006, J IMMUNOL, V177, P2662, DOI 10.4049/jimmunol.177.4.2662
   Zhang W, 1998, VIROLOGY, V243, P423, DOI 10.1006/viro.1998.9050
   Zhao QQ, 2009, BIOL PHARM BULL, V32, P706, DOI 10.1248/bpb.32.706
   Zheng XZ, 2009, BOSNIAN J BASIC MED, V9, P174
   Zhou WB, 2006, J CHROMATOGR B, V838, P71, DOI 10.1016/j.jchromb.2006.03.064
   Zielonka A, 2006, VIRUS RES, V120, P128, DOI 10.1016/j.virusres.2006.02.010
   Zlotnick A, 1996, BIOCHEMISTRY-US, V35, P7412, DOI 10.1021/bi9604800
NR 270
TC 381
Z9 409
U1 10
U2 203
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-0584
EI 1744-8395
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD OCT
PY 2010
VL 9
IS 10
BP 1149
EP 1176
DI 10.1586/ERV.10.115
PG 28
WC Immunology
SC Immunology
GA 667PA
UT WOS:000283204800009
PM 20923267
DA 2020-12-08
ER

PT J
AU Marinho, PAN
   Fernandes, AM
   Cruz, JC
   Rehen, SK
   Castilho, LR
AF Marinho, Paulo A. N.
   Fernandes, Aline M.
   Cruz, Juliana C.
   Rehen, Stevens K.
   Castilho, Leda R.
TI Maintenance of Pluripotency in Mouse Embryonic Stem Cells Cultivated in
   Stirred Microcarrier Cultures
SO BIOTECHNOLOGY PROGRESS
LA English
DT Article
DE mouse embryonic stem cells; pluripotency; microcarriers; stirred culture
   systems; differentiation capability
ID EXPANSION; ESTABLISHMENT; LINE; CRYOPRESERVATION; DIFFERENTIATION;
   INHIBITION; ANEUPLOIDY; LACTATE; MODELS
AB The development of efficient and reproducible culture systems for embryonic stem (ES) cells is an essential pre-requisite for regenerative medicine. Culture scale-up ensuring maintenance of cell pluripotency is a central issue, because large amounts of pluripotent cells must be generated to warrant that differentiated cells deriving thereof are transplanted in great amounts and survive the procedure. This study aimed to develop a robust scalable cell expansion system, using a murine embryonic stem cell line that is feeder-dependent and adapted to serum-free medium, thus representing a more realistic model for human ES cells. We showed that high concentrations of murine ES cells can be obtained in stirred microcarrier-based spinner cultures, with a 10-fold concentration of cells per volume of medium and a 5-fold greater cell concentration per surface area, as compared to static cultures. No differences in terms of pluripotency and differentiation capability were observed between cells grown in traditional static systems and cells that were replated onto the traditional system after being expanded on microcarriers in the stirred system. This was verified by morphological analyses, quantification of cells expressing important pluripotency markers (Oct-4, SSEA-I, and SOX2), karyotype profile, and the ability to form embryoid bodies with similar sizes, and maintaining their intrinsic ability to differentiate into all three germ layers. (C) 2009 American Institute of Chemical Engineers Biotechnol. Prog., 26: 548-555, 2010
C1 [Marinho, Paulo A. N.; Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Cell Culture Engn Lab, Chem Engn Program, BR-21941914 Rio De Janeiro, Brazil.
   [Marinho, Paulo A. N.; Fernandes, Aline M.; Cruz, Juliana C.; Rehen, Stevens K.] Univ Fed Rio de Janeiro, Inst Biomed Sci, BR-21941902 Rio De Janeiro, Brazil.
RP Castilho, LR (corresponding author), Univ Fed Rio de Janeiro, COPPE, Cell Culture Engn Lab, Chem Engn Program, BR-21941914 Rio De Janeiro, Brazil.
EM leda@peq.coppe.ufrj.br
RI Fernandes, Aline/H-3799-2017; Castilho, Leda/I-8939-2014; Rehen, Stevens
   K/J-5874-2012
OI Fernandes, Aline/0000-0003-0460-1738; Rehen, Stevens
   K/0000-0003-4216-9501
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq); CapesCAPES
FX The authors acknowledge Prof. L. Pereira (University of Sao Paulo,
   Brazil) and Dr. I. Kerkis (Butantan Institute, Brazil) for providing the
   USP-1 murine embryonic stem cell line, Stacie Ngo Abdalla for
   proofreading, and the Brazilian funding agencies FAPERJ, CNPq, and Capes
   for the financial support.
CR Abranches E, 2007, BIOTECHNOL BIOENG, V96, P1211, DOI 10.1002/bit.21191
   CONLEY JB, 2003, INT J BIOCHEM CELL B, V36, P555
   Coutts M, 2008, EXP NEUROL, V209, P368, DOI 10.1016/j.expneurol.2007.09.002
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Fernandes AM, 2007, J BIOTECHNOL, V132, P227, DOI 10.1016/j.jbiotec.2007.05.031
   Fernandes AM, 2009, BRAZ J MED BIOL RES, V42, P515, DOI 10.1590/S0100-879X2009000600007
   Filip S, 2005, FOLIA BIOL-PRAGUE, V51, P180
   Fok EYL, 2005, STEM CELLS, V23, P1333, DOI 10.1634/stemcells.2005-0112
   Fong WJ, 2005, BIOPROC BIOSYST ENG, V27, P381, DOI 10.1007/s00449-005-0421-5
   Hagell P, 2001, J NEUROPATH EXP NEUR, V60, P741, DOI 10.1093/jnen/60.8.741
   HASSELL T, 1991, APPL BIOCHEM BIOTECH, V30, P29, DOI 10.1007/BF02922022
   Lock LT, 2009, TISSUE ENG PT A, V15, P2051, DOI 10.1089/ten.tea.2008.0455
   MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634
   McLenachan S, 2007, GENOMICS, V89, P708, DOI 10.1016/j.ygeno.2007.02.006
   McNeish J, 2004, NAT REV DRUG DISCOV, V3, P70, DOI 10.1038/nrd1281
   NICHOLS J, 1990, DEVELOPMENT, V110, P1341
   Nie Y, 2009, BIOTECHNOL PROGR, V25, P20, DOI 10.1002/btpr.110
   Oh SKW, 2005, BIOTECHNOL BIOENG, V91, P523, DOI 10.1002/bit.20650
   Ouyang A, 2007, STEM CELLS, V25, P447, DOI 10.1634/stemcells.2006-0322
   Park MH, 2008, EXP MOL MED, V40, P92, DOI 10.3858/emm.2008.40.1.92
   Patel SD, 2000, BIOTECHNOL PROGR, V16, P885, DOI 10.1021/bp000080a
   Pouton CW, 2007, NAT REV DRUG DISCOV, V6, P605, DOI 10.1038/nrd2194
   Rasnick D, 1999, BIOCHEM J, V340, P621, DOI 10.1042/0264-6021:3400621
   Rebuzzini P, 2008, CYTOGENET GENOME RES, V121, P18, DOI 10.1159/000124377
   Rehen SK, 2005, J NEUROSCI, V25, P2176, DOI 10.1523/JNEUROSCI.4560-04.2005
   Reubinoff BE, 2001, HUM REPROD, V16, P2187, DOI 10.1093/humrep/16.10.2187
   Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435
   SOARES M, 2006, Patent No. 00077765
   Sukoyan MA, 2002, BRAZ J MED BIOL RES, V35, P535, DOI 10.1590/S0100-879X2002000500004
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   zur Nieden NI, 2007, J BIOTECHNOL, V129, P421, DOI 10.1016/j.jbiotec.2007.01.006
NR 31
TC 12
Z9 12
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8756-7938
EI 1520-6033
J9 BIOTECHNOL PROGR
JI Biotechnol. Prog.
PD MAR-APR
PY 2010
VL 26
IS 2
BP 548
EP 555
DI 10.1002/btpr.328
PG 8
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 587IV
UT WOS:000276985400027
PM 20014096
DA 2020-12-08
ER

PT B
AU Figueredo, A
   Chico, E
   Castilho, LR
   Medronho, RA
AF Figueredo, Alvio
   Chico, Ernesto
   Castilho, Leda R.
   Medronho, Ricardo A.
BE Noll, T
TI CFD Study of the Fluid and Particle Dynamics in a Spin-Filter Perfusion
   Bioreactor
SO CELLS AND CULTURE
SE ESACT Proceedings
LA English
DT Proceedings Paper
CT 20th ESACT Meeting
CY JUN 17-OCT 05, 2007
CL Dresden, GERMANY
SP ESACT
DE Animal cells; CFD - computational fluid dynamics; Perfusion bioreactor;
   Spin-filter
AB In this work, simulations of a spin-filter bioreactor were carried out using computational fluid dynamics (CFD). Bi-directional radial exchange of fluid through the filter mesh and lateral migration were observed in the simulations. The fluid exchange might explain the observations of cell accumulation also on the internal side of the mesh. Moreover, lower cell concentrations were observed in the vicinity of the filter mesh, indicating that lateral migration could be related to the ability of spin-filters to delay clogging.
   The current results show that CFD modelling allows improving the current understanding of the principles that underlie spin-filter operation. The use of computational fluid dynamics could lead to a reduction in the number of experiments needed to optimize spin-filter operation and could help in the design of improved spin-filter devices.
C1 [Figueredo, Alvio] Ctr Mol Immunol, Calle 15 Esq 216, Havana, Cuba.
   [Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, PEQ, Cell Culture Engn Lab LECC, BR-21941972 Rio De Janeiro, RJ, Brazil.
   [Medronho, Ricardo A.] Univ Fed Rio de Janeiro, CT Bl E, Ilha Fundao, UFRJ, BR-21941914 Rio De Janeiro, RJ, Brazil.
RP Figueredo, A (corresponding author), Ctr Mol Immunol, Calle 15 Esq 216, Havana, Cuba.
EM alvio@cim.sld.cu
RI Medronho, Ricardo/Q-1762-2015
OI Medronho, Ricardo/0000-0001-5603-9762
CR Castilho Leda R, 2002, Adv Biochem Eng Biotechnol, V74, P129
   Figueredo A, 2005, Animal Cell Technology Meets Genomics, P683
   HALOW JS, 1970, AICHE J, V16, P281, DOI 10.1002/aic.690160222
   Vallez-Chetreanu F., 2006, THESIS
   WERELEY ST, 1994, EXP FLUIDS, V18, P1
   YABANNAVAR VM, 1992, BIOTECHNOL BIOENG, V40, P925, DOI 10.1002/bit.260400809
NR 6
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
BN 978-90-481-3419-9; 978-90-481-3418-2
J9 ESACT PROCEED
PY 2010
VL 4
BP 233
EP 238
DI 10.1007/978-90-481-3419-9_40
PG 6
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA BH3JS
UT WOS:000399748800040
DA 2020-12-08
ER

PT B
AU Pinto, RCV
   Marinho, PAN
   Oliveira, AB
   Esteban, G
   Melo, PA
   Medronho, RA
   Castilho, LR
AF Pinto, Rodrigo C. V.
   Marinho, Paulo A. N.
   Oliveira, Aline B.
   Esteban, Geoffrey
   Melo, Priamo A.
   Medronho, Ricardo A.
   Castilho, Leda R.
BE Noll, T
TI Biomass Monitoring and CHO Cell Culture Optimization Using Capacitance
   Spectroscopy
SO CELLS AND CULTURE
SE ESACT Proceedings
LA English
DT Proceedings Paper
CT 20th ESACT Meeting
CY JUN 17-OCT 05, 2007
CL Dresden, GERMANY
SP ESACT
DE Capacitance spectroscopy; CHO cells; Online determination of cell size
   distribution; Online determination of viable cell concentration;
   Perfusion cultivation
AB Viable cell concentration is one key variable to monitor during animal cell culture processes and is strongly linked to process productivity. In batch and fed-batch cultures, on-line viable cell density data can be used to determine the most adequate harvest time. Furthermore, in fed-batch and perfusion cultivations, on-line biomass data can be used to define the bioreactor feeding strategy and to maximize productivity.
   Among the technologies available for on-line determining cell density, the permittivity-based technology, which relies on the correlation of the capacitance signal at fixed frequencies with the concentration of viable cells, is probably the most reliable technique available currently. Moreover, measuring the cell capacitance spectra over a frequency range allows to correlate the signal with cell size variation and so to monitor changes in cell morphology and physiology.
   Thus, in this work, online measurement of permittivity and capacitance spectroscopy were shown to allow for continuous monitoring of viable cell density and cell size distribution, respectively, of recombinant CHO cells cultivated in a lab-scale perfusion bioreactor.
C1 [Pinto, Rodrigo C. V.; Marinho, Paulo A. N.; Oliveira, Aline B.; Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, PEQ, Cell Culture Engn Lab LECC, Caixa Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
   [Oliveira, Aline B.] Univ Fed Rio de Janeiro, Sch Chem, Rio De Janeiro, Brazil.
   [Esteban, Geoffrey] FOGALE Nanotech, Nimes, France.
   [Melo, Priamo A.] Bio Sidus SA, Buenos Aires, DF, Argentina.
   [Medronho, Ricardo A.] Univ Fed Rio de Janeiro, UFRJ, CT Bl E, BR-21941914 Rio De Janeiro, RJ, Brazil.
RP Castilho, LR (corresponding author), Univ Fed Rio de Janeiro, COPPE, PEQ, Cell Culture Engn Lab LECC, Caixa Postal 68502, BR-21941972 Rio De Janeiro, RJ, Brazil.
EM leda@peq.coppe.ufrj.br
RI Medronho, Ricardo/Q-1762-2015
OI Medronho, Ricardo/0000-0001-5603-9762
FU Brazilian funding agency CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian funding agency FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ)
FX The authors wish to thank the Brazilian funding agencies CNPq and
   FAPERJ, as well as Mrs. Isis C. Baptista for the excellent technical
   assistance.
CR Esteban G., 2006, CELL CULT ENG 10 WHI
   Soares M., 2006, PARTICLE SIZE DISTRI
NR 2
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
BN 978-90-481-3419-9; 978-90-481-3418-2
J9 ESACT PROCEED
PY 2010
VL 4
BP 343
EP 348
DI 10.1007/978-90-481-3419-9_60
PG 6
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA BH3JS
UT WOS:000399748800060
DA 2020-12-08
ER

PT J
AU Castilho, LR
   Mitchel, DA
   Freire, DMG
AF Castilho, Leda R.
   Mitchel, David A.
   Freire, Denise M. G.
TI Production of polyhydroxyalkanoates (PHAs) from waste materials and
   by-products by submerged and solid-state fermentation
SO BIORESOURCE TECHNOLOGY
LA English
DT Review
DE Biodegradable polymers; Bacterial polyesters; Polyhydroxyalkanoates
   (PHAs); Submerged fermentation; Solid-state fermentation
ID RECOMBINANT ESCHERICHIA-COLI; FED-BATCH CULTURE;
   POLY-BETA-HYDROXYBUTYRATE; POLY(3-HYDROXYBUTYRATE) PRODUCTION;
   RALSTONIA-EUTROPHA; PHB PRODUCTION; BIOTECHNOLOGICAL PRODUCTION;
   MICROBIAL-DEGRADATION; ALCALIGENES-EUTROPHUS; ACTIVATED-SLUDGE
AB Polyhydroxyalkanoates are biodegradable polymers produced by prokaryotic organisms from renewable resources. The production of PHAs by submerged fermentation processes has been intensively studied over the last 30 years. In recent years, alternative strategies have been proposed, such as the use of solid-state fermentation or the production of PHAs in transgenic plants. This paper gives an overview of submerged and solid-state fermentation processes used to produce PHAs from waste materials and by-products. The use of these low-cost raw materials has the potential to reduce PHA production costs, because the raw material costs contribute a significant part of production costs in traditional PHA production processes. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21941972 Rio De Janeiro, Brazil.
   [Mitchel, David A.] Univ Fed Parana, Dept Biochem, BR-81531990 Curitiba, Parana, Brazil.
   [Freire, Denise M. G.] Univ Fed Rio de Janeiro, IQ, Dept Biochem, BR-21949900 Rio De Janeiro, Brazil.
RP Castilho, LR (corresponding author), Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, Caixa Postal 68502, BR-21941972 Rio De Janeiro, Brazil.
EM leda@peq.coppe.ufrj.br
RI Castilho, Leda/I-8939-2014; FREIRE, Denise Maria/D-8699-2014; Mitchell,
   David/A-8935-2008
OI FREIRE, Denise Maria/0000-0002-8298-5936; Mitchell,
   David/0000-0001-9355-5520
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CapesCAPES; Rio de Janeiro State research agency FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ)
FX Financial support from the Brazilian Government research agencies CNPq
   and Capes, and from the Rio de Janeiro State research agency FAPERJ is
   gratefully acknowledged.
CR Ahn WS, 2000, APPL ENVIRON MICROB, V66, P3624, DOI 10.1128/AEM.66.8.3624-3627.2000
   Aldor AS, 2003, CURR OPIN BIOTECH, V14, P475, DOI 10.1016/j.copbio.2003.09.002
   ANDERSON AJ, 1990, MICROBIOL REV, V54, P450, DOI 10.1128/MMBR.54.4.450-472.1990
   ANDERSON AJ, 1992, FEMS MICROBIOL LETT, V103, P93, DOI 10.1111/j.1574-6968.1992.tb05826.x
   Ashby RD, 2004, J POLYM ENVIRON, V12, P105, DOI 10.1023/B:JOOE.0000038541.54263.d9
   Beccari M, 1998, WATER RES, V32, P3403, DOI 10.1016/S0043-1354(98)00100-6
   Ben Rebah F, 2009, APPL BIOCHEM BIOTECH, V158, P155, DOI 10.1007/s12010-008-8358-1
   Bohlmann GM, 2006, ACS SYM SER, V921, P253
   Bonatto D, 2004, WORLD J MICROB BIOT, V20, P395, DOI 10.1023/B:WIBI.0000033063.55133.e1
   Bormann EJ, 1999, BIOTECHNOL LETT, V21, P1059, DOI 10.1023/A:1005640712329
   CACHUM M, 2006, IND PLASTICO CAMINHO
   Cavalheiro JMBT, 2009, PROCESS BIOCHEM, V44, P509, DOI 10.1016/j.procbio.2009.01.008
   *CHEM INN, 2008, REN CHEM
   Chen GQ, 2005, KEY ENG MATER, V288-289, P437, DOI 10.4028/www.scientific.net/KEM.288-289.437
   Cho KS, 1997, BIOTECHNOL LETT, V19, P7
   Choi J, 1999, APPL MICROBIOL BIOT, V51, P13, DOI 10.1007/s002530051357
   Choi JI, 1999, BIOTECHNOL BIOENG, V62, P546, DOI 10.1002/(SICI)1097-0290(19990305)62:5<546::AID-BIT6>3.0.CO;2-0
   Choi JI, 1997, BIOPROCESS ENG, V17, P335, DOI 10.1007/s004490050394
   *CMAI GLOB, 2009, GLOB PLAST POL MARK
   CRANK M, 2004, TECHNOECONOMIC FEASI
   Cromwick AM, 1996, APPL MICROBIOL BIOT, V46, P464, DOI 10.1007/s002530050845
   Dias JML, 2006, MACROMOL BIOSCI, V6, P885, DOI 10.1002/mabi.200600112
   Dionisi D, 2001, IND ENG CHEM RES, V40, P5110, DOI 10.1021/ie001008k
   Du GC, 2004, J POLYM ENVIRON, V12, P89, DOI 10.1023/B:JOOE.0000010054.58019.21
   ESPOSITO F, 2008, RESIN SUPPLIERS TURN
   Flieger M, 2003, FOLIA MICROBIOL, V48, P27, DOI 10.1007/BF02931273
   Fuchtenbusch B, 2000, APPL MICROBIOL BIOT, V53, P167, DOI 10.1007/s002530050004
   Fukui T, 1998, APPL MICROBIOL BIOT, V49, P333, DOI 10.1007/s002530051178
   Fukui T, 1998, J BACTERIOL, V180, P667, DOI 10.1128/JB.180.3.667-673.1998
   Fukui T, 1997, J BACTERIOL, V179, P4821, DOI 10.1128/jb.179.15.4821-4830.1997
   Full TD, 2006, LETT APPL MICROBIOL, V43, P377, DOI 10.1111/j.1472-765X.2006.01981.x
   Ganz MB, 1999, EXP NEPHROL, V7, P413
   Gross RA, 2002, SCIENCE, V297, P803, DOI 10.1126/science.297.5582.803
   Grothe E, 1999, ENZYME MICROB TECH, V25, P132, DOI 10.1016/S0141-0229(99)00023-X
   Hahn Sei Kwang, 1993, Biotechnology Techniques, V7, P209, DOI 10.1007/BF02566149
   Halami PM, 2008, WORLD J MICROB BIOT, V24, P805, DOI 10.1007/s11274-007-9543-z
   HANGGI UJ, 2004, P PACKT SEM GENT 3 S
   ISHIZAKI A, 1993, J CHEM ENG JPN, V26, P225, DOI 10.1252/jcej.26.225
   Ishizaki A, 2001, APPL MICROBIOL BIOT, V57, P6
   Jendrossek D, 2001, ADV BIOCHEM ENG BIOT, V71, P293
   Jiang YJ, 2008, ENZYME MICROB TECH, V42, P167, DOI 10.1016/j.enzmictec.2007.09.003
   Johnstone B., 1990, FAR EASTERN ECONOMIC, V147, P62
   Kahar P, 2004, POLYM DEGRAD STABIL, V83, P79, DOI 10.1016/S0141-3910(03)00227-1
   Kapritchkoff FM, 2006, J BIOTECHNOL, V122, P453, DOI 10.1016/j.jbiotec.2005.09.009
   KHALIL CN, 2001, Patent No. 01058886
   Khanna S, 2009, APPL BIOCHEM BIOTECH, V157, P237, DOI 10.1007/s12010-008-8395-9
   Khardenavis AA, 2007, BIORESOURCE TECHNOL, V98, P3579, DOI 10.1016/j.biortech.2006.11.024
   Kim BS, 1998, BIOTECHNOL LETT, V20, P109, DOI 10.1023/A:1005307903684
   Kim BS, 2000, ENZYME MICROB TECH, V27, P774, DOI 10.1016/S0141-0229(00)00299-4
   KIM BS, 1994, ENZYME MICROB TECH, V16, P556, DOI 10.1016/0141-0229(94)90118-X
   Kim YB, 2001, ADV BIOCHEM ENG BIOT, V71, P51
   Koller M, 2005, BIOMACROMOLECULES, V6, P561, DOI 10.1021/bm049478b
   Koller M, 2008, BIORESOURCE TECHNOL, V99, P4854, DOI 10.1016/j.biortech.2007.09.049
   Koutinas AA, 2004, BIOTECHNOL BIOENG, V85, P524, DOI 10.1002/bit.10888
   Koutinas AA, 2007, ENZYME MICROB TECH, V40, P1035, DOI 10.1016/j.enzmictec.2006.08.002
   KRAM JW, 2008, BIOMASS MAGAZINE OCT
   Kusaka S, 1997, APPL MICROBIOL BIOT, V47, P140, DOI 10.1007/s002530050902
   Kusaka S, 1998, J MACROMOL SCI PURE, VA35, P319, DOI 10.1080/10601329808001980
   Law KH, 2003, BIOCHEM ENG J, V16, P203, DOI 10.1016/S1369-703X(03)00039-1
   Leal MCMR, 2006, PROCESS BIOCHEM, V41, P1173, DOI 10.1016/j.procbio.2005.12.014
   Lee S Y, 1995, Adv Biochem Eng Biotechnol, V52, P27
   Lee SY, 1997, BIOTECHNOL LETT, V19, P1033, DOI 10.1023/A:1018411820580
   Lee SY, 1996, TRENDS BIOTECHNOL, V14, P431, DOI 10.1016/0167-7799(96)10061-5
   Lee SY, 1998, BIOPROCESS ENG, V18, P397
   Lemoigne M, 1926, B SOC CHIM BIOL, V8, P770
   Lemos PC, 2004, WATER SCI TECHNOL, V50, P189
   Listewnik HF, 2007, ENG LIFE SCI, V7, P278, DOI 10.1002/elsc.200620193
   Liu F, 1998, BIOTECHNOL LETT, V20, P345, DOI 10.1023/A:1005367011378
   Liu XW, 2009, BIOCHEM ENG J, V43, P72, DOI 10.1016/j.bej.2008.09.001
   *LOND MET EXCH, 2009, IND OV
   MERGAERT J, 1993, APPL ENVIRON MICROB, V59, P3233, DOI 10.1128/AEM.59.10.3233-3238.1993
   MERGAERT J, 1992, FEMS MICROBIOL LETT, V103, P317, DOI 10.1111/j.1574-6968.1992.tb05853.x
   Mergaert Joris, 1994, Journal of Environmental Polymer Degradation, V2, P177, DOI 10.1007/BF02067443
   *MGC, 2009, BIOGR BIOD PLAST
   Mitchell D. A., 2006, SOLID STATE FERMENTA
   Mitchell DA, 2000, BIOTECHNOL BIOENG, V68, P127, DOI 10.1002/(SICI)1097-0290(20000420)68:2<127::AID-BIT1>3.0.CO;2-K
   Mitchell DA, 2003, BIOCHEM ENG J, V13, P137, DOI 10.1016/S1369-703X(02)00126-2
   Moo-Young M, 1983, FILAMENTOUS FUNGI, V4, P117, DOI DOI 10.1016/0167-7799(84)90009-X
   Nath A, 2008, BIORESOURCE TECHNOL, V99, P5749, DOI 10.1016/j.biortech.2007.10.017
   Nikel PI, 2006, APPL ENVIRON MICROB, V72, P3949, DOI 10.1128/AEM.00044-06
   Nonato RV, 2001, APPL MICROBIOL BIOT, V57, P1, DOI 10.1007/s002530100732
   Ojumu TV, 2004, AFR J BIOTECHNOL, V3, P18, DOI DOI 10.5897/AJB2004.000-2004
   Oliveira F C., 2004, Patent application, Patent No. [PI0400116-8, 04001168]
   Oliveira FC, 2007, BIORESOURCE TECHNOL, V98, P633, DOI 10.1016/j.biortech.2006.02.022
   Oliveira FC, 2004, BIOTECHNOL LETT, V26, P1851, DOI 10.1007/s10529-004-5315-0
   OLIVEIRA FC, 2004, THESIS FEDERAL U RIO, P116
   PAGE WJ, 1992, APPL ENVIRON MICROB, V58, P2866, DOI 10.1128/AEM.58.9.2866-2873.1992
   Pandey A, 2000, PROCESS BIOCHEM, V35, P1153, DOI 10.1016/S0032-9592(00)00152-7
   Park SJ, 2002, BIOTECHNOL LETT, V24, P185, DOI 10.1023/A:1014196906095
   Quillaguaman J, 2008, APPL MICROBIOL BIOT, V78, P227, DOI 10.1007/s00253-007-1297-x
   Reddy CSK, 2003, BIORESOURCE TECHNOL, V87, P137, DOI 10.1016/S0960-8524(02)00212-2
   Reis MAM, 2003, BIOPROC BIOSYST ENG, V25, P377, DOI 10.1007/s00449-003-0322-4
   Reusch RN, 2000, BIOCHEMISTRY-MOSCOW+, V65, P280
   RIBEIRO CMS, 2008, Patent No. 08041016
   RIBERA RG, 2001, ELECTRON J BIOTECHN, V4, P116
   ROCHA PRS, 2005, THESIS FEDERAL U RIO, P95
   Rusendi D, 1995, BIORESOURCE TECHNOL, V54, P191, DOI 10.1016/0960-8524(95)00124-7
   Salehizadeh H, 2004, BIOTECHNOL ADV, V22, P261, DOI 10.1016/j.biotechadv.2003.09.003
   Satoh H, 1998, WATER SCI TECHNOL, V38, P103, DOI 10.1016/S0273-1223(98)00435-1
   Silva LF, 2004, J IND MICROBIOL BIOT, V31, P245, DOI 10.1007/s10295-004-0136-7
   Snell KD, 2002, METAB ENG, V4, P29, DOI 10.1006/mben.2001.0214
   Steinbuchel A, 2003, BIOCHEM ENG J, V16, P81, DOI 10.1016/S1369-703X(03)00036-6
   Steinbuchel A, 2001, MACROMOL BIOSCI, V1, P1
   Sudesh K, 2000, PROG POLYM SCI, V25, P1503, DOI 10.1016/S0079-6700(00)00035-6
   Taga N, 1997, BIOTECHNOL BIOENG, V53, P529
   TATE L, 2006, MOLASSES MONTHLY MAR
   *US SUG CORP, 2009, MOL COMP
   van der Walle GAM, 2001, ADV BIOCHEM ENG BIOT, V71, P263
   Vandamme P, 2004, INT J SYST EVOL MICR, V54, P2285, DOI 10.1099/ijs.0.63247-0
   Vaneechoutte M, 2004, INT J SYST EVOL MICR, V54, P317, DOI 10.1099/ijs.0.02754-0
   von Meien OF, 2002, BIOTECHNOL BIOENG, V79, P416, DOI 10.1002/bit.10268
   WALLEN LL, 1974, ENVIRON SCI TECHNOL, V8, P576, DOI 10.1021/es60091a007
   Wang FL, 1997, APPL ENVIRON MICROB, V63, P3703, DOI 10.1128/AEM.63.9.3703-3706.1997
   Wiggam MI, 1997, DIABETES CARE, V20, P1347, DOI 10.2337/diacare.20.9.1347
   YAMANE T, 1993, BIOTECHNOL BIOENG, V41, P165, DOI 10.1002/bit.260410122
   Yilmaz M, 2005, ZUCKERINDUSTRIE, V130, P109
   Yu J, 2001, J BIOTECHNOL, V86, P105, DOI 10.1016/S0168-1656(00)00405-3
   Yu J, 2008, BIORESOURCE TECHNOL, V99, P8042, DOI 10.1016/j.biortech.2008.03.071
   Zinn M, 2001, ADV DRUG DELIVER REV, V53, P5, DOI 10.1016/S0169-409X(01)00218-6
NR 119
TC 148
Z9 157
U1 4
U2 75
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0960-8524
EI 1873-2976
J9 BIORESOURCE TECHNOL
JI Bioresour. Technol.
PD DEC
PY 2009
VL 100
IS 23
BP 5996
EP 6009
DI 10.1016/j.biortech.2009.03.088
PG 14
WC Agricultural Engineering; Biotechnology & Applied Microbiology; Energy &
   Fuels
SC Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels
GA 494KV
UT WOS:000269812600067
PM 19581084
DA 2020-12-08
ER

PT J
AU Gutarra, MLE
   Godoy, MG
   Maugeri, F
   Rodrigues, MI
   Freire, DMG
   Castilho, LR
AF Gutarra, Melissa L. E.
   Godoy, Mateus G.
   Maugeri, Francisco
   Rodrigues, Maria Isabel
   Freire, Denise M. G.
   Castilho, Leda R.
TI Production of an acidic and thermostable lipase of the mesophilic fungus
   Penicillium simplicissimum by solid-state fermentation
SO BIORESOURCE TECHNOLOGY
LA English
DT Article
DE Solid-state fermentation; Babassu cake; Penicillium simplicissimum;
   Acidic lipase; Thermal stability
ID PURIFICATION; OIL; RESTRICTUM; ENZYMES; ADVANTAGES; CAKE
AB The production of a lipase by a wild-type Brazilian strain of Penicillium simplicissimium in solid-state fermentation of babassu cake, an abundant residue of the oil industry, was studied. The enzyme production reached about 90 U/g in 72 h, with a specific activity of 4.5 U/mg of total proteins. The Crude lipase showed high activities at 35-60 degrees C and pH 4.0-6.0, with a maximum activity at 50 degrees C and pH 4.0-5.0. Enzyme stability was enhanced at pH 5.0 and 6.0, with a maximum half-life of 5.02 h at 50 degrees C and pH 5.0. Thus, this lipase shows a thermophilic and thermostable behavior, what is not common among lipases from mesophilic filamentous fungi. The crude enzyme catalysed the hydrolysis of triglycerides and p-nitrophenyl esters (C4:0-C18:0), preferably acting on substrates with medium-chain fatty acids. This non-purified lipase in addition to interesting properties showed a reduced production cost making feasible its applicability in many fields. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Freire, Denise M. G.] Univ Fed Rio de Janeiro, Ctr Tecnol 149, Inst Quim, Dept Bioquim,Lab Biotecnol Microbiana 549 1, BR-21941909 Rio De Janeiro, Brazil.
   [Maugeri, Francisco; Rodrigues, Maria Isabel] Univ Estadual Campinas UNICAMP, FEA, Dept Engn Alimentos, Campinas, SP, Brazil.
   [Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Programa Engn Quim, BR-21941909 Rio De Janeiro, Brazil.
RP Freire, DMG (corresponding author), Univ Fed Rio de Janeiro, Ctr Tecnol 149, Inst Quim, Dept Bioquim,Lab Biotecnol Microbiana 549 1, Av Athos Silveira Ramos,Bloco A, BR-21941909 Rio De Janeiro, Brazil.
EM freire@iq.ufrj.br
RI FREIRE, Denise Maria/D-8699-2014; Gutarra, Melissa/J-5706-2015;
   Castilho, Leda/I-8939-2014; de Godoy, Mateus Gomes/D-9977-2015
OI FREIRE, Denise Maria/0000-0002-8298-5936; Gutarra,
   Melissa/0000-0003-2480-7223; de Godoy, Mateus Gomes/0000-0003-2209-7993
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX This work was Supported by the Brazilian state funding agencies CAPES,
   CNPq and FAPERJ.
CR AIDOO KE, 1981, EUR J APPL MICROBIOL, V12, P6, DOI 10.1007/BF00508111
   Boutaiba S, 2006, J MOL CATAL B-ENZYM, V41, P21, DOI 10.1016/j.molcatb.2006.03.010
   Cammarota MC, 2006, BIORESOURCE TECHNOL, V97, P2195, DOI 10.1016/j.biortech.2006.02.030
   Castilho LR, 2000, BIOCHEM ENG J, V4, P239, DOI 10.1016/S1369-703X(99)00052-2
   Costa MAF, 1999, J BASIC MICROB, V39, P11, DOI 10.1002/(SICI)1521-4028(199903)39:1<11::AID-JOBM11>3.0.CO;2-8
   Di Luccio M, 2004, APPL BIOCHEM BIOTECH, V113, P173, DOI 10.1385/ABAB:113:1-3:173
   Diaz JCM, 2006, ENZYME MICROB TECH, V39, P1042, DOI 10.1016/j.enzmictec.2006.02.005
   FREIRE DMG, 1996, THESIS U FEDERAL RIO
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   Gutarra MLE, 2005, APPL BIOCHEM BIOTECH, V121, P105, DOI 10.1385/ABAB:121:1-3:0105
   Haki GD, 2003, BIORESOURCE TECHNOL, V89, P17, DOI 10.1016/S0960-8524(03)00033-6
   Holker U, 2004, APPL MICROBIOL BIOT, V64, P175, DOI 10.1007/s00253-003-1504-3
   Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315
   Jesus MFCP, 1999, BRAZ J CHEM ENG, V16, P113, DOI 10.1590/S0104-66321999000200002
   Kakugawa K, 2002, BIOSCI BIOTECH BIOCH, V66, P978, DOI 10.1271/bbb.66.978
   Kamini NR, 1998, PROCESS BIOCHEM, V33, P505, DOI 10.1016/S0032-9592(98)00005-3
   Karadzic I, 2006, J BIOSCI BIOENG, V102, P82, DOI 10.1263/jbb.102.82
   Lima VMG, 2004, BIOCHEM ENG J, V18, P65, DOI 10.1016/S1369-703X(03)00165-7
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Matsumoto Y, 2004, PROCESS BIOCHEM, V39, P665, DOI 10.1016/S0032-9592(03)00140-7
   Nawani N, 2007, ENZYME MICROB TECH, V40, P881, DOI 10.1016/j.enzmictec.2006.07.006
   Ramachandran S, 2004, BIORESOURCE TECHNOL, V93, P169, DOI 10.1016/j.biortech.2003.10.021
   Sant'Anna GL, 1997, REV MICROBIOL, V28, P6
   Sharma R, 2001, BIOTECHNOL ADV, V19, P627, DOI 10.1016/S0734-9750(01)00086-6
   STOCKLEIN W, 1993, BIOCHIM BIOPHYS ACTA, V1168, P181, DOI 10.1016/0005-2760(93)90123-Q
   SZTAJER H, 1992, BIOCHIM BIOPHYS ACTA, V1124, P253, DOI 10.1016/0005-2760(92)90137-K
   Tan TW, 2004, PROCESS BIOCHEM, V39, P1495, DOI 10.1016/S0032-9592(03)00296-6
   Viniegra-Gonzalez G, 2003, BIOCHEM ENG J, V13, P157, DOI 10.1016/S1369-703X(02)00128-6
NR 28
TC 93
Z9 99
U1 0
U2 31
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0960-8524
EI 1873-2976
J9 BIORESOURCE TECHNOL
JI Bioresour. Technol.
PD NOV
PY 2009
VL 100
IS 21
BP 5249
EP 5254
DI 10.1016/j.biortech.2008.08.050
PG 6
WC Agricultural Engineering; Biotechnology & Applied Microbiology; Energy &
   Fuels
SC Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels
GA 480NP
UT WOS:000268742800048
PM 19560339
DA 2020-12-08
ER

PT J
AU Figueredo-Cardero, A
   Chico, E
   Castilho, LR
   Medronho, RA
AF Figueredo-Cardero, Alvio
   Chico, Ernesto
   Castilho, Leda R.
   Medronho, Ricardo A.
TI CFD simulation of an internal spin-filter: evidence of lateral migration
   and exchange flow through the mesh
SO CYTOTECHNOLOGY
LA English
DT Article
DE Animal cell perfusion culture; Cell retention device; Computational
   fluid dynamics (CFD); Fluid exchange; Lateral migration; Spin-filter
ID SPINFILTER PERFUSION BIOREACTOR; MAMMALIAN-CELL RETENTION; FILTRATION;
   SUSPENSION; TURBULENCE; REDUCTION; CULTURES; SYSTEMS
AB In the present work Computational Fluid Dynamics (CFD) was used to study the flow field and particle dynamics in an internal spin-filter (SF) bioreactor system. Evidence of a radial exchange flow through the filter mesh was detected, with a magnitude up to 130-fold higher than the perfusion flow, thus significantly contributing to radial drag. The exchange flow magnitude was significantly influenced by the filter rotation rate, but not by the perfusion flow, within the ranges evaluated. Previous reports had only given indirect evidences of this exchange flow phenomenon in spin-filters, but the current simulations were able to quantify and explain it. Flow pattern inside the spin-filter bioreactor resembled a typical Taylor-Couette flow, with vortices being formed in the annular gap and eventually penetrating the internal volume of the filter, thus being the probable reason for the significant exchange flow observed. The simulations also showed that cells become depleted in the vicinity of the mesh due to lateral particle migration. Cell concentration near the filter was approximately 50% of the bulk concentration, explaining why cell separation achieved in SFs is not solely due to size exclusion. The results presented indicate the power of CFD techniques to study and better understand spin-filter systems, aiming at the establishment of effective design, operation and scale-up criteria.
C1 [Medronho, Ricardo A.] UFRJ EQ, BR-21941914 Rio De Janeiro, Brazil.
   [Figueredo-Cardero, Alvio; Chico, Ernesto] Ctr Mol Immunol, Havana, Cuba.
   [Figueredo-Cardero, Alvio; Medronho, Ricardo A.] Univ Fed Rio de Janeiro, Sch Chem, Chem Engn Program, Rio De Janeiro, Brazil.
   [Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21945 Rio De Janeiro, Brazil.
RP Medronho, RA (corresponding author), UFRJ EQ, Av Horacio Macedo 2030,CT,Bloco E, BR-21941914 Rio De Janeiro, Brazil.
EM medronho@eq.ufrj.br
RI Medronho, Ricardo/Q-1762-2015; Castilho, Leda/I-8939-2014
OI Medronho, Ricardo/0000-0001-5603-9762; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Financiadora de Estudos e Projetos (FINEP)Ciencia Tecnologia e
   Inovacao (FINEP); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
FX The authors gratefully acknowledge the financial support from the
   Brazilian funding agencies Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Financiadora de Estudos e Projetos
   (FINEP) and Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado
   do Rio de Janeiro (FAPERJ).
CR Aubin J, 2004, EXP THERM FLUID SCI, V28, P431, DOI 10.1016/j.expthermflusci.2003.04.001
   Brucato A, 1998, CHEM ENG SCI, V53, P3653, DOI 10.1016/S0009-2509(98)00149-3
   Castilho Leda R, 2002, Adv Biochem Eng Biotechnol, V74, P129
   Castilho LR, 2003, BIOTECHNOL BIOENG, V83, P514, DOI 10.1002/bit.10697
   CASTILHO LR, 2001, DEV DYNAMIC FILTER I
   Castilho LR, 2008, ANIMAL CELL TECHNOLO, P273
   Chu L, 2001, CURR OPIN BIOTECH, V12, P180, DOI 10.1016/S0958-1669(00)00197-X
   CURTIS ASG, 1967, CELL SURFACE ITS MOL
   Deo YM, 1996, BIOTECHNOL PROGR, V12, P57, DOI 10.1021/bp950079p
   DIPRIMA RC, 1979, HYDRODYNAMIC INSTABI, P139
   FAVRE E, 1992, CYTOTECHNOLOGY, V9, P11, DOI 10.1007/BF02521727
   Figueredo A, 2005, Animal Cell Technology Meets Genomics, P683
   HALOW JS, 1970, AICHE J, V16, P281, DOI 10.1002/aic.690160222
   HIMMELFA.P, 1969, SCIENCE, V164, P555, DOI 10.1126/science.164.3879.555
   MERCILLE S, 1994, BIOTECHNOL BIOENG, V43, P833, DOI 10.1002/bit.260430902
   SAFFMAN PG, 1965, J FLUID MECH, V22, P385, DOI 10.1017/S0022112065000824
   Schiller L, 1933, Z VER DTSCH ING, V77, P318
   SPEZIALE CG, 1991, J FLUID MECH, V227, P245, DOI 10.1017/S0022112091000101
   Tetlow N, 1998, J RHEOL, V42, P307, DOI 10.1122/1.550954
   Trocha M, 1997, ANIMAL CELL TECHNOLOGY, P405
   Vallez-Chetreanu F, 2007, J BIOTECHNOL, V130, P265, DOI 10.1016/j.jbiotec.2007.04.007
   Vallez-Chetreanu F, 2006, THESIS ECOLE POLYTEC
   Wereley ST, 2002, J MEMBRANE SCI, V209, P469, DOI 10.1016/S0376-7388(02)00365-4
   WERELEY ST, 1994, EXP FLUIDS, V18, P1
   YABANNAVAR VM, 1994, BIOTECHNOL BIOENG, V43, P159, DOI 10.1002/bit.260430209
   YABANNAVAR VM, 1992, BIOTECHNOL BIOENG, V40, P925, DOI 10.1002/bit.260400809
NR 26
TC 7
Z9 7
U1 0
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-9069
EI 1573-0778
J9 CYTOTECHNOLOGY
JI Cytotechnology
PD NOV
PY 2009
VL 61
IS 1-2
BP 55
EP 64
DI 10.1007/s10616-009-9242-8
PG 10
WC Biotechnology & Applied Microbiology; Cell Biology
SC Biotechnology & Applied Microbiology; Cell Biology
GA 534AR
UT WOS:000272868400007
PM 19998058
OA Green Published
DA 2020-12-08
ER

PT J
AU Gutarrra, M
   Godoy, M
   Silva, M
   Silva, J
   Castilho, L
   Freire, D
AF Gutarrra, M.
   Godoy, M.
   Silva, M.
   Silva, J.
   Castilho, L.
   Freire, D.
TI Development and operation of a multi-proposal solid-state fermentation
   bioreactor for lipase production using an agro-industrial residue as
   culture medium
SO NEW BIOTECHNOLOGY
LA English
DT Meeting Abstract
C1 [Gutarrra, M.; Godoy, M.; Silva, M.; Silva, J.; Freire, D.] Univ Fed Rio de Janeiro, Inst Quim, Rio De Janeiro, Brazil.
   [Castilho, L.] Univ Fed Rio de Janeiro, COPPE, BR-21941 Rio De Janeiro, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1871-6784
J9 NEW BIOTECHNOL
JI New Biotech.
PD SEP
PY 2009
VL 25
SU 1
BP S236
EP S237
DI 10.1016/j.nbt.2009.06.223
PG 2
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 649HU
UT WOS:000281760100572
DA 2020-12-08
ER

PT J
AU Fernandes, AM
   Marinho, PAN
   Sartore, RC
   Paulsen, BS
   Mariante, RM
   Castilho, LR
   Rehen, SK
AF Fernandes, A. M.
   Marinho, P. A. N.
   Sartore, R. C.
   Paulsen, B. S.
   Mariante, R. M.
   Castilho, L. R.
   Rehen, S. K.
TI Successful scale-up of human embryonic stem cell production in a stirred
   microcarrier culture system
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Human embryonic stem cells; Scale-up; Microcarriers; Spinner bioreactors
ID CULTIVATION SYSTEM; PROGENITOR CELLS; VIRUS PRODUCTION; DRUG DISCOVERY;
   EXPANSION; DIFFERENTIATION; BIOREACTOR; GROWTH; BODIES; LINES
AB Future clinical applications of human embryonic stem (hES) cells will require high-yield culture protocols. Currently, hES cells are mainly cultured in static tissue plates, which offer a limited surface and require repeated sub-culturing. Here we describe a stirred system with commercial dextran-based microcarriers coated with denatured collagen to scale-up hES cell production. Maintenance of pluripotency in the microcarrier-based stirred system was shown by immunocytochemical and flow cytometry analyses for pluripotency-associated markers. The formation of cavitated embryoid bodies expressing markers of endoderm, ectoderm and mesoderm was further evidence of maintenance of differentiation capability. Cell yield per volume of medium spent was more than 2-fold higher than in static plates, resulting in a significant decrease in cultivation costs. A total of 10(8) karyotypically stable hES cells were obtained from a unitary small vessel that needed virtually no manipulation during cell proliferation, decreasing risks of contamination. Spinner flasks are available up to working volumes in the range of several liters. If desired, samples from the homogenous suspension can be withdrawn to allow process validation needed in the last expansion steps prior to transplantation. Especially when thinking about clinical trials involving from dozens to hundreds of patients, the use of a small number of larger spinners instead of hundreds of plates or flasks will be beneficial. To our knowledge, this is the first description of successful scale-up of feeder-and Matrigel (TM)-free production of undifferentiated hES cells under continuous agitation, which makes this system a promising alternative for both therapy and research needs.
C1 [Fernandes, A. M.; Marinho, P. A. N.; Sartore, R. C.; Paulsen, B. S.; Rehen, S. K.] UFRJ, Inst Ciencias Biomed, BR-21941902 Rio De Janeiro, Brazil.
   [Marinho, P. A. N.; Castilho, L. R.] Univ Fed Rio de Janeiro, COPPE Programa Engn Quim, Rio De Janeiro, Brazil.
   [Mariante, R. M.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Neurogenese, BR-21941 Rio De Janeiro, Brazil.
RP Rehen, SK (corresponding author), UFRJ, Inst Ciencias Biomed, Av Carlos Chagas Filho,S-N Bloco F-F14, BR-21941902 Rio De Janeiro, Brazil.
EM srehen@anato.ufrj.br
RI Rehen, Stevens K/J-5874-2012; Fernandes, Aline/H-3799-2017; Mariante,
   Rafael/A-2971-2015; Castilho, Leda/I-8939-2014
OI Rehen, Stevens K/0000-0003-4216-9501; Fernandes,
   Aline/0000-0003-0460-1738; Mariante, Rafael/0000-0001-8024-9612;
   Sartore, Rafaela/0000-0002-1801-8650
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq); Fundacao Ary Frauzino para Pesquisa e
   Controle do Cancer (FAF); CAPESCAPES; Ministerio da Saude; Academy of
   Sciences of the Developing World
FX Research supported by FAPERJ, CNPq, Fundacao Ary Frauzino para Pesquisa
   e Controle do Cancer (FAF), CAPES, as well as Ministerio da Saude, the
   Academy of Sciences of the Developing World (TWAS), and Pew Latin
   American Fellows Program in Biomedical Sciences.
CR Abranches E, 2007, BIOTECHNOL BIOENG, V96, P1211, DOI 10.1002/bit.21191
   Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912
   Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691
   Chen X, 2006, STEM CELLS, V24, P2052, DOI 10.1634/stemcells.2005-0591
   Ellerstrom C, 2007, STEM CELLS, V25, P1690, DOI 10.1634/stemcells.2006-0607
   Erceg S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002122
   Fernandes AM, 2007, J BIOTECHNOL, V132, P227, DOI 10.1016/j.jbiotec.2007.05.031
   Fok EYL, 2005, STEM CELLS, V23, P1333, DOI 10.1634/stemcells.2005-0112
   Frauenschuh S, 2007, BIOTECHNOL PROGR, V23, P187, DOI 10.1021/bp060155w
   Genzel Y, 2004, VACCINE, V22, P2202, DOI 10.1016/j.vaccine.2003.11.041
   Gepstein L, 2002, CIRC RES, V91, P866, DOI 10.1161/01.RES.0000041435.95082.84
   Guhr A, 2006, STEM CELLS, V24, P2187, DOI 10.1634/stemcells.2006-0053
   Hoffman LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102
   Hwang YS, 2009, BIOMATERIALS, V30, P499, DOI 10.1016/j.biomaterials.2008.07.028
   Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776
   KOLLER MR, 1993, BLOOD, V82, P378
   Lemischka I, 1999, P NATL ACAD SCI USA, V96, P14193, DOI 10.1073/pnas.96.25.14193
   Lemischka I, 2002, EXP HEMATOL, V30, P848, DOI 10.1016/S0301-472X(02)00876-7
   Martin I, 2004, TRENDS BIOTECHNOL, V22, P80, DOI 10.1016/j.tibtech.2003.12.001
   McConnell MJ, 2004, J NEUROSCI, V24, P8090, DOI 10.1523/JNEUROSCI.2263-04.2004
   Mccoy MK, 2008, EXP NEUROL, V210, P14, DOI 10.1016/j.expneurol.2007.10.011
   Mountford JC, 2008, TRANSFUSION MED, V18, P1, DOI 10.1111/j.1365-3148.2007.00807.x
   Mukhida K, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E7
   Nie Y, 2009, BIOTECHNOL PROGR, V25, P20, DOI 10.1002/btpr.110
   Niebruegge S, 2008, TISSUE ENG PT A, V14, P1591, DOI 10.1089/ten.tea.2007.0247
   Oh SKW, 2006, CYTOTECHNOLOGY, V50, P181, DOI 10.1007/s10616-005-3862-4
   Phillips BW, 2008, J BIOTECHNOL, V138, P24, DOI 10.1016/j.jbiotec.2008.07.1997
   Phillips BW, 2008, J BIOTECHNOL, V134, P79, DOI 10.1016/j.jbiotec.2007.12.007
   Pouton CW, 2007, NAT REV DRUG DISCOV, V6, P605, DOI 10.1038/nrd2194
   Raffoul T, 2005, BRAZ ARCH BIOL TECHN, V48, P85, DOI 10.1590/S1516-89132005000400011
   Schop D, 2008, J TISSUE ENG REGEN M, V2, P126, DOI 10.1002/term.73
   SOUZA MCO, 2009, VACCINE IN PRESS
   Thomson H, 2007, TRENDS BIOTECHNOL, V25, P224, DOI 10.1016/j.tibtech.2007.03.003
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tian XH, 2006, STEM CELLS, V24, P1370, DOI 10.1634/stemcells.2005-0340
   Tielens S, 2007, BIOMACROMOLECULES, V8, P825, DOI 10.1021/bm060870u
   VANWEZEL AL, 1967, NATURE, V216, P64, DOI 10.1038/216064a0
   Yin CH, 2007, BIOSCI BIOTECH BIOCH, V71, P728, DOI 10.1271/bbb.60568
   Yirme G, 2008, STEM CELLS DEV, V17, P1227, DOI 10.1089/scd.2007.0272
   Yokomizo AY, 2004, BIOTECHNOL BIOENG, V85, P506, DOI 10.1002/bit.10917
NR 40
TC 83
Z9 86
U1 0
U2 32
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JUN
PY 2009
VL 42
IS 6
BP 515
EP 522
DI 10.1590/S0100-879X2009000600007
PG 8
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 446QI
UT WOS:000266135800018
PM 19448900
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Souza, MCO
   Freire, MS
   Schulze, EA
   Gaspar, LP
   Castilho, LR
AF Souza, Marta Cristina O.
   Freire, Marcos S.
   Schulze, Erica A.
   Gaspar, Luciane P.
   Castilho, Leda R.
TI Production of yellow fever virus in microcarrier-based Vero cell
   cultures
SO VACCINE
LA English
DT Article
DE Yellow fever virus; Microcarrier-based culture; Vero cells; Serum-free
   medium
ID SERUM-FREE MEDIUM; RABIES VIRUS; FREE MEDIA; BIOREACTOR; GROWTH;
   IMMUNOGENICITY
AB In this work, the propagation of the 17DD yellow fever virus in Vero cells grown on Cytodex-1 microcarriers was evaluated. After verifying that upon infection the virus adsorption step could be performed under continuous agitation, experiments were carried out in spinners and sparged lab-scale stirred-tank bioreactor to evaluate the use of a commercial serum-free medium (VP-SFM) and to investigate the effects of multiplicity of infection (MOI) and time of infection (TOI) on virus production. Virus titers as high as 8.4 x 10(8) pfu/mL were obtained upon infection with MOI of 0.02 and TOI of 3 days, using the serum-free medium in the sparged bioreactor. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Souza, Marta Cristina O.; Freire, Marcos S.; Schulze, Erica A.; Gaspar, Luciane P.] Fiocruz MS, Oswaldo Cruz Fdn, Viral Vaccine Program, BR-21045900 Rio De Janeiro, Brazil.
   [Souza, Marta Cristina O.; Schulze, Erica A.; Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Cell Culture Engn Lab, BR-21941972 Rio De Janeiro, Brazil.
RP Freire, MS (corresponding author), Fiocruz MS, Oswaldo Cruz Fdn, Viral Vaccine Program, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM freire@bio.fiocruz.br
RI Castilho, Leda/I-8939-2014
FU CapesCAPES; FIOCRUZ; CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ)
FX M.C.O. Souza gratefully acknowledges the Ph.D. scholarship received from
   the Brazilian funding agency Capes. The authors wish to thank
   Bio-Manguinhos/FIOCRUZ for the continuous interest and support to this
   work. Financial support from the PDTIS Program from FIOCRUZ and from the
   Brazilian funding agencies CNPq and FAPERJ is gratefully acknowledged.
CR Audsley JM, 2005, J VIROL METHODS, V123, P187, DOI 10.1016/j.jviromet.2004.09.015
   Belsher JL, 2007, VACCINE, V25, P8480, DOI 10.1016/j.vaccine.2007.08.061
   Butler M, 2000, BIOTECHNOL PROGR, V16, P854, DOI 10.1021/bp000110+
   Caufour PS, 2001, VIRUS RES, V79, P1, DOI 10.1016/S0168-1702(01)00273-8
   Freire MS, 2005, VACCINE, V23, P2501, DOI 10.1016/j.vaccine.2004.10.035
   Gaspar LP, 2008, J VIROL METHODS, V150, P57, DOI 10.1016/j.jviromet.2008.03.002
   Genzel Y, 2006, VACCINE, V24, P6074, DOI 10.1016/j.vaccine.2006.05.023
   Liu CC, 2007, VACCINE, V25, P19, DOI 10.1016/j.vaccine.2006.06.083
   Maranga L, 2003, BIOTECHNOL BIOENG, V84, P245, DOI 10.1002/bit.10773
   MONATH TP, 2005, MEDICINE, V33, P21
   Pugachev KV, 2005, CURR OPIN INFECT DIS, V18, P387, DOI 10.1097/01.qco.0000178823.28585.ad
   Quesney S, 2001, CYTOTECHNOLOGY, V35, P115, DOI 10.1023/A:1017589526145
   Rourou S, 2007, VACCINE, V25, P3879, DOI 10.1016/j.vaccine.2007.01.086
   SANFORD KK, 1951, J NATL CANCER I, V11, P773
   SOUZA MCO, 2007, THESIS FEDERAL U RIO
   Toriniwa H, 2007, BIOLOGICALS, V35, P221, DOI 10.1016/j.biologicals.2007.02.002
   *WHO, 1987, WHO TECH REP SER, V760, P167
   World Health Organization, 1987, WHO TECH REP SER, V745, P99
   Yasumura Y., 1963, NIPPON RINSHO, V21, P1201
   Yokomizo AY, 2004, BIOTECHNOL BIOENG, V85, P506, DOI 10.1002/bit.10917
NR 20
TC 18
Z9 24
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PY 2009
VL 27
IS 46
SI SI
BP 6420
EP 6423
DI 10.1016/j.vaccine.2009.06.023
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 521LK
UT WOS:000271922700007
PM 19559120
DA 2020-12-08
ER

PT J
AU Pinto, RCV
   Medronho, RA
   Castilho, LR
AF Pinto, Rodrigo C. V.
   Medronho, Ricardo A.
   Castilho, Leda R.
TI Separation of CHO cells using hydrocyclones
SO CYTOTECHNOLOGY
LA English
DT Article
DE animal cells; cell separation; CHO cells; hydrocyclones; perfusion;
   retention device
ID HIGH-DENSITY CULTURE; PERFUSION CULTURE; ANIMAL-CELLS; HYBRIDOMA;
   MECHANISMS; RETENTION; APOPTOSIS; SYSTEM
AB Hydrocyclones are simple and robust separation devices with no moving parts. In the past few years, their use in animal cell separation has been proposed. In this work, the use of different hydrocyclone configurations for Chinese hamster ovary (CHO) cell separation was investigated following an experimental design. It was shown that cell separation efficiencies for cultures of the wild-type CHO.K1 cell line and of a recombinant CHO cell line producing granulocyte-macrophage colony stimulating factor (GM-CSF) were kept above 97%. Low viability losses were observed, as measured by trypan blue exclusion and by determination of intracellular lactate dehydrogenase (LDH) released to the culture medium. Mathematical models were proposed to predict the flow rate, flow ratio and separation efficiency as a function of hydrocyclone geometry and pressure drop. When cells were monitored for any induction of apoptosis upon passage through the hydrocyclones, no increase in apoptotic cell concentration was observed within 48 h of hydrocycloning. Thus, based on the high separation efficiencies, the robustness of the equipment, and the absence of apoptosis induction, hydrocyclones seem to be specially suited for use as cell retention devices in long-term perfusion runs.
C1 [Medronho, Ricardo A.] Univ Fed Rio de Janeiro, Sch Chem, Dept Chem Engn, BR-21949 Rio De Janeiro, Brazil.
   [Pinto, Rodrigo C. V.; Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Chem Engn program, BR-68502 Rio De Janeiro, Brazil.
RP Medronho, RA (corresponding author), Univ Fed Rio de Janeiro, Sch Chem, Dept Chem Engn, CT, Bloco E, CEP, BR-21949 Rio De Janeiro, Brazil.
EM medronho@eq.ufr.br
RI Medronho, Ricardo/Q-1762-2015; Castilho, Leda/I-8939-2014
OI Medronho, Ricardo/0000-0001-5603-9762; 
CR al-Rubeai M, 1998, Adv Biochem Eng Biotechnol, V59, P225
   ALRUBEAI M, 1995, BIOTECHNOL BIOENG, V46, P88, DOI 10.1002/bit.260460112
   ALRUBEAI M, 1995, BIOTECHNOL BIOENG, V45, P463, DOI 10.1002/bit.260450602
   BATT BC, 1990, BIOTECHNOL PROGR, V6, P458, DOI 10.1021/bp00006a600
   BORN C, 1992, BIOTECHNOL BIOENG, V40, P1004, DOI 10.1002/bit.260400903
   Bradley D., 1959, T I CHEM ENG-LOND, V37, P34
   BUJA LM, 1993, ARCH PATHOL LAB MED, V117, P1208
   Castilho L., 2008, ANIMAL CELL TECHNOLO
   Castilho Leda R, 2002, Adv Biochem Eng Biotechnol, V74, P129
   Castilho LR, 2002, BIOTECHNOL PROGR, V18, P776, DOI 10.1021/bp0255154
   Deckwer W. D., 2005, US Patent Application, Patent No. [6,878,545 B2, 6878545]
   Deo YM, 1996, BIOTECHNOL PROGR, V12, P57, DOI 10.1021/bp950079p
   ESCLADE LRJ, 1991, BIOTECHNOL BIOENG, V38, P159, DOI 10.1002/bit.260380208
   Iding K, 2000, CYTOTECHNOLOGY, V34, P141, DOI 10.1023/A:1008183508439
   JAGER V, 1992, ANIMAL CELL TECHNOLOGY : DEVELOPMENTS, PROCESSES AND PRODUCTS, P397
   Jockwer A, 2001, ESACT PROCEED, V1, P301
   KAWAHARA H, 1994, CYTOTECHNOLOGY, V14, P61, DOI 10.1007/BF00772196
   Kretzmer G, 2002, APPL MICROBIOL BIOT, V59, P135, DOI 10.1007/s00253-002-0991-y
   KUCHLER RJ, 2000, BIOCH METHODS CELL C
   Lipscomb ML, 2004, BIOTECHNOL PROGR, V20, P1402, DOI 10.1021/bp049973j
   Lubberstedt M., 2000, CHEM ENG TECHNOL, V72, P1089
   LUBBERSTEDT M, 2000, P WORLD C BIOT BIOT, V1, P460
   MATTA VM, 2000, BIOSEPARATION, V9, P43
   Medronho RA, 2005, LAT AM APPL RES, V35, P1
   Medronho RA, 2003, BIOTECHNOL & BIOPROC, V27, P131
   MERCILLE S, 1994, BIOTECHNOL BIOENG, V43, P833, DOI 10.1002/bit.260430902
   MERCILLE S, 1994, BIOTECHNOL BIOENG, V44, P1140, DOI 10.1002/bit.260440916
   PLITT LR, 1976, CIM BULL, V69, P114
   RACHER AJ, 1990, CYTOTECHNOLOGY, V3, P301, DOI 10.1007/BF00365494
   SANFORD KK, 1951, J NATL CANCER I, V11, P773
   SEARLES JA, 1994, BIOTECHNOL PROGR, V10, P198, DOI 10.1021/bp00026a600
   Takagi M, 2000, J BIOSCI BIOENG, V89, P340, DOI 10.1016/S1389-1723(00)88956-2
   TOKASHIKI M, 1990, CYTOTECHNOLOGY, V3, P239, DOI 10.1007/BF00365487
   van Reis R, 2001, CURR OPIN BIOTECH, V12, P208, DOI 10.1016/S0958-1669(00)00201-9
   VANDERPOL L, 1990, BIOPROCESS ENG, V5, P241
   Voisard D, 2003, BIOTECHNOL BIOENG, V82, P751, DOI 10.1002/bit.10629
   Wen ZY, 2000, J BIOTECHNOL, V79, P1, DOI 10.1016/S0168-1656(00)00219-4
   Woodside SM, 1998, CYTOTECHNOLOGY, V28, P163, DOI 10.1023/A:1008050202561
NR 38
TC 32
Z9 32
U1 0
U2 26
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-9069
EI 1573-0778
J9 CYTOTECHNOLOGY
JI Cytotechnology
PD JAN
PY 2008
VL 56
IS 1
BP 57
EP 67
DI 10.1007/s10616-007-9108-x
PG 11
WC Biotechnology & Applied Microbiology; Cell Biology
SC Biotechnology & Applied Microbiology; Cell Biology
GA 244OA
UT WOS:000251874000008
PM 19002842
OA Green Published
DA 2020-12-08
ER

PT J
AU Mellado, MCM
   Curbelo, D
   Nobrega, R
   Castilho, LR
AF Mellado, Maria Candida M.
   Curbelo, David
   Nobrega, Ronaldo
   Castilho, Leda R.
TI Comparison of affinity membrane adsorbers for the purification of
   recombinant human erythropoietin (rhEPO)
SO JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE recombinant human erythropoietin (rhEPO); purification; affinity
   chromatography; membrane adsorbers
ID PROTEIN ADSORPTION; DYE-LIGAND; CHROMATOGRAPHY; SEPARATION; CELLS;
   HORSERADISH; PEROXIDASE; CELLULOSE; LECTINS; AGAROSE
AB In this work affinity membrane adsorbers were investigated for the chromatographic purification of recombinant human erythropoietin (rhEPO) produced in mammalian cells. Cibacron Blue (CB), IDA-Cu+2, wheat germ agglutinin (WGA), concanavalin A (ConA) and an anti-EPO monoclonal antibody (MAb) were tested as affinity ligands, attached to microporous Sartobind (R) membranes. In experiments carried out with cell culture supernatant, the best results were obtained with Sartobind-CB, Sartobind-WGA and Sartobind-MAb membranes. The thermodynamic parameters were determined by adsorption isotherms of rhEPO onto the membranes. Sartobind-ConA presented the lowest affinity for rhEPO, as evidenced by a lower association constant. For Sartobind-CB, Sartobind-IDA-Cu+2 and Sartobind-MAb K-A was in the order of 10(5) L mol(-1), whereas for Sartobind-WGA it was 10(6) L mol(-1). Sartobind-CB eluates were also investigated by RP-HPLC. The purity level achieved in this one-step purification strategy was 55%, indicating that the Sartobind-CB membrane is a promising affinity membrane for rhEPO purification. (c) 2007 Society of Chemical Industry.
C1 UFRJ, Chem Engn Program, COPPE, BR-21941972 Rio De Janeiro, Brazil.
   Ctr Mol Immunol, Havana 11600, Cuba.
RP Mellado, MCM (corresponding author), IBET, Apartado 12, P-2781901 Oeiras, Portugal.
EM mellado@itqb.unl.pt
RI Castilho, Leda/I-8939-2014
CR Amadeo GI, 2003, BRAZ J CHEM ENG, V20, P21, DOI 10.1590/S0104-66322003000100005
   Anspach FB, 1996, BIOSEPARATION, V6, P165
   Arica MY, 1998, J CHROMATOGR A, V799, P83, DOI 10.1016/S0021-9673(97)01079-0
   ARNOLD FH, 1985, CHEM ENG J B, V30, P9
   BEESKOW T, 1996, THESIS TU BRAUNSCHWE
   BEESKOW TC, 1995, J CHROMATOGR A, V715, P49, DOI 10.1016/0021-9673(95)00540-4
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BROUDY VC, 1988, ARCH BIOCHEM BIOPHYS, V265, P329, DOI 10.1016/0003-9861(88)90135-X
   Burns S, 2002, BLOOD, V99, P4400, DOI 10.1182/blood.V99.12.4400
   Castilho LR, 2000, J MEMBRANE SCI, V172, P269, DOI 10.1016/S0376-7388(00)00343-4
   Castilho LR, 2002, J MEMBRANE SCI, V207, P253, DOI 10.1016/S0376-7388(02)00257-0
   CHAMPLUVIER B, 1992, BIOTECHNOL BIOENG, V40, P33, DOI 10.1002/bit.260400106
   DAVIS JM, 1987, BIOCHEMISTRY-US, V26, P2633, DOI 10.1021/bi00383a034
   DEMMER W, 2003, NEW INSIGHTS MEMBRAN
   DEPAOLIS AM, 1995, J PHARM SCI-US, V84, P1280, DOI 10.1002/jps.2600841105
   Faber R, 2006, DESALINATION, V199, P553, DOI 10.1016/j.desal.2006.03.126
   Ghosh R, 2002, J CHROMATOGR A, V952, P13, DOI 10.1016/S0021-9673(02)00057-2
   Gokana A, 1997, J CHROMATOGR A, V791, P109, DOI 10.1016/S0021-9673(97)00766-8
   Guo W, 2003, J MEMBRANE SCI, V211, P101, DOI 10.1016/S0376-7388(02)00410-6
   INOUE N, 1994, BIOL PHARM BULL, V17, P180
   KLEIN E, 1994, J MEMBRANE SCI, V95, P199, DOI 10.1016/0376-7388(94)00171-5
   KRYSTAL G, 1986, BLOOD, V67, P71
   Kubota N, 1996, BIOTECHNOL PROGR, V12, P869, DOI 10.1021/bp960076s
   Ladisch M.R., 2001, BIOSEPARATIONS ENG P
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   Lasne F, 2002, ANAL BIOCHEM, V311, P119, DOI 10.1016/S0003-2697(02)00407-4
   Miranda MV, 2002, PROCESS BIOCHEM, V38, P537, DOI 10.1016/S0032-9592(02)00166-8
   Narhi LO, 2001, PROTEIN ENG, V14, P135, DOI 10.1093/protein/14.2.135
   Ohlson S, 1997, J CHROMATOGR A, V758, P199, DOI 10.1016/S0021-9673(96)00733-9
   QUELLE FW, 1989, BLOOD, V74, P652
   RUDZKI Z, 1978, Haematologica, V63, P426
   Shin HS, 2003, PROTEIN EXPRES PURIF, V28, P331, DOI 10.1016/S1046-5928(02)00685-X
   Singh RS, 1999, CRIT REV BIOTECHNOL, V19, P145, DOI 10.1080/0738-859991229224
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Walsh G, 2004, EUR J PHARM BIOPHARM, V58, P185, DOI 10.1016/j.ejpb.2004.03.012
   Wang MD, 2002, BIOTECHNOL BIOENG, V77, P194, DOI 10.1002/bit.10144
   WEN DY, 1994, J BIOL CHEM, V269, P22839
   Wu CY, 2003, J CHROMATOGR A, V996, P53, DOI 10.1016/S0021-9673(03)00531-4
   YANAGI H, 1987, J CHROMATOGR-BIOMED, V417, P178, DOI 10.1016/0378-4347(87)80105-6
   Zanette D, 2003, J BIOTECHNOL, V101, P275, DOI 10.1016/S0168-1656(02)00357-7
NR 41
TC 8
Z9 8
U1 0
U2 16
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0268-2575
J9 J CHEM TECHNOL BIOT
JI J. Chem. Technol. Biotechnol.
PD JUL
PY 2007
VL 82
IS 7
BP 636
EP 645
DI 10.1002/jctb.1720
PG 10
WC Biotechnology & Applied Microbiology; Chemistry, Multidisciplinary;
   Engineering, Environmental; Engineering, Chemical
SC Biotechnology & Applied Microbiology; Chemistry; Engineering
GA 196ZN
UT WOS:000248522300006
DA 2020-12-08
ER

PT J
AU de Azeredo, LAI
   Gomes, PM
   Sant'Anna, GL
   Castilho, LR
   Freire, DMG
AF de Azeredo, Luciana A. I.
   Gomes, Patricia M.
   Sant'Anna, Geraldo L., Jr.
   Castilho, Leda R.
   Freire, Denise M. G.
TI Production and regulation of lipase activity from Penicillium restrictum
   in submerged and solid-state fermentations
SO CURRENT MICROBIOLOGY
LA English
DT Article
ID ASPERGILLUS-NIGER; MICROBIAL LIPASES; REPRESSION; BIOTECHNOLOGY;
   AGITATION; SUBSTRATE; PHYTASE; ENZYMES
AB Different carbon (C) sources, mainly carbohydrates and lipids, have been screened for their capacity to support growth and lipase production by Penicillium restrictum in submerged fermentation (SmF) and in solid-state fermentation (SSF). Completely different physiological behaviors were observed after the addition of easily (oleic acid and glucose) and complex (olive oil and starch) assimilable C sources to the liquid and solid media. Maximal lipolytic activities (12.1 U/mL and 17.4 U/g) by P. restrictum were obtained with olive oil in SmF and in SSF, respectively. Biomass levels in SmF (12.2-14.1 mg/mL) and SSF (7.0-8.0 mg/g) did not varied greatly with the distinct C sources used. High lipase production (12.3 U/g) using glucose was only attained in SSF, perhaps due to the ability of this fermentation process to minimize catabolite repression.
C1 Univ Fed Rio de Janeiro, Ctr Technol, Inst Chem, Dept Biochem,Lab 5492, BR-21945900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, Ctr Technol, BR-21941972 Rio De Janeiro, Brazil.
RP Freire, DMG (corresponding author), Univ Fed Rio de Janeiro, Ctr Technol, Inst Chem, Dept Biochem,Lab 5492, Bloco A,, BR-21945900 Rio De Janeiro, Brazil.
EM freire@iq.ufrj.br
RI FREIRE, Denise Maria/D-8699-2014; Castilho, Leda/I-8939-2014
OI FREIRE, Denise Maria/0000-0002-8298-5936; 
CR Aguilar CN, 2001, PROCESS BIOCHEM, V36, P565
   AKHTAR MW, 1983, CAN J MICROBIOL, V29, P664, DOI 10.1139/m83-108
   Aranda C, 2006, FOOD TECHNOL BIOTECH, V44, P229
   Asther M, 2002, PROCESS BIOCHEM, V38, P685, DOI 10.1016/S0032-9592(02)00196-6
   Bornscheuer UT, 2002, TRENDS BIOTECHNOL, V20, P433, DOI 10.1016/S0167-7799(02)02046-2
   CERDAMONTALVO ML, 2005, INT J CHEM REACT ENG, V3, P1
   FENIKSOVA R V, 1960, Mikrobiologiia, V29, P745
   Ferrer P, 2001, APPL BIOCHEM BIOTECH, V95, P221, DOI 10.1385/ABAB:95:3:221
   Freire DM, 1997, APPL BIOCHEM BIOTECH, V63-5, P409, DOI 10.1007/BF02920442
   FREIRE DMG, 1997, REV MICROBIOL, V28, P6
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   Helisto P, 1998, ENZYME MICROB TECH, V23, P113, DOI 10.1016/S0141-0229(98)00024-6
   Jaeger KE, 1998, TRENDS BIOTECHNOL, V16, P396, DOI 10.1016/S0167-7799(98)01195-0
   Maldonado MC, 1998, J IND MICROBIOL BIOT, V20, P34, DOI 10.1038/sj.jim.2900470
   Mitchell David A, 2002, Biotechnol Annu Rev, V8, P183, DOI 10.1016/S1387-2656(02)08009-2
   NAHAS E, 1988, J GEN MICROBIOL, V134, P227
   Nandakumar MP, 1999, LETT APPL MICROBIOL, V29, P380, DOI 10.1046/j.1472-765X.1999.00652.x
   OTA Y, 1968, AGR BIOL CHEM TOKYO, V32, P1476, DOI 10.1080/00021369.1968.10859253
   Palma MB, 2000, APPL BIOCHEM BIOTECH, V84-6, P1137, DOI 10.1385/ABAB:84-86:1-9:1137
   Pandey A, 1999, CURR SCI INDIA, V77, P149
   Pandey A, 1999, BIOTECHNOL APPL BIOC, V29, P119
   Papagianni M, 2001, FOOD TECHNOL BIOTECH, V39, P319
   Papagianni M, 1999, PROCESS BIOCHEM, V35, P397, DOI 10.1016/S0032-9592(99)00088-6
   Perez-Guerra N, 2003, ELECT J ENV AGR FOOD, V2, P343
   Raghavarao KSMS, 2003, BIOCHEM ENG J, V13, P127, DOI 10.1016/S1369-703X(02)00125-0
   RAMESH MV, 1991, APPL MICROBIOL BIOT, V35, P591
   Rogalska E, 1997, BIOCHEM SOC T, V25, P161, DOI 10.1042/bst0250161
   SAKURAI Y, 1977, AGR BIOL CHEM TOKYO, V41, P619, DOI 10.1080/00021369.1977.10862552
   SolisPereyra S, 1996, WORLD J MICROB BIOT, V12, P257, DOI 10.1007/BF00360924
   SZTAJER H, 1989, BIOTECHNOL LETT, V11, P895, DOI 10.1007/BF01026848
NR 30
TC 46
Z9 51
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0343-8651
J9 CURR MICROBIOL
JI Curr. Microbiol.
PD MAY
PY 2007
VL 54
IS 5
BP 361
EP 365
DI 10.1007/s00284-006-0425-7
PG 5
WC Microbiology
SC Microbiology
GA 166BO
UT WOS:000246352300006
PM 17457647
DA 2020-12-08
ER

PT J
AU Gutarra, MLE
   Godoy, MG
   Castilho, LR
   Freire, DMG
AF Gutarra, Melissa L. E.
   Godoy, Mateus G.
   Castilho, Leda R.
   Freire, Denise M. G.
TI Inoculum strategies for Penicillium simplicissimum lipase production by
   solid-state fermentation using a residue from the babassu oil industry
SO JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE solid-state fermentation; lipase; inoculum strategies; Penicillium
   simplissicimum; babassu cake
ID RESTRICTUM
AB Two alternative inoculation strategies for lipase production by the fungus Penicillium simplicissimum were tested in solid-state fermentation using a residue from the babassu oil industry (babassu cake),. Conventional spore inoculation was compared with fungal pellets grown in liquid medium and with inocula consisting of fermented cake. Fungal pellets delayed lipase production whereas fermented cake accelerated enzyme synthesis, yielding a productivity of 0.45 U g(-1) h(-1), which is equivalent to the highest values obtained with conventional inocula. Therefore, a 2(2) factorial design was used to determine the best conditions for lipase production with fermented cake as inoculum strategy, varying the inoculum propagation time and inoculum concentration. Lipase activity and productivity reached 30 U g-1 and 0.63 U g(-1) h(-1), respectively, with 10% inoculum and 36 h. Thus, fermented cake inocula increased production 1.5-fold with 10 times fewer spores than in conventional inoculation, indicating that fermented solids are an interesting alternative for inoculum development in solid-state fermentation, mainly for large-scale processes. (c) 2007 Society of Chemical Industry
C1 Univ Fed Rio de Janeiro, Inst Quim, Dept Bioquim, BR-21941909 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21941909 Rio De Janeiro, Brazil.
RP Freire, DMG (corresponding author), Univ Fed Rio de Janeiro, Inst Quim, Dept Bioquim, Avenida Athos Silveira Ramos,149 Cidade Univ, BR-21941909 Rio De Janeiro, Brazil.
EM freire@iq.ufrj.br
RI FREIRE, Denise Maria/D-8699-2014; Castilho, Leda/I-8939-2014; Gutarra,
   Melissa/J-5706-2015; de Godoy, Mateus Gomes/D-9977-2015
OI FREIRE, Denise Maria/0000-0002-8298-5936; Gutarra,
   Melissa/0000-0003-2480-7223; de Godoy, Mateus Gomes/0000-0003-2209-7993
CR AIDOO KE, 1981, EUR J APPL MICROBIOL, V12, P6, DOI 10.1007/BF00508111
   Castilho LR, 2000, BIOCHEM ENG J, V4, P239, DOI 10.1016/S1369-703X(99)00052-2
   de Vrije T, 2001, APPL MICROBIOL BIOT, V56, P58, DOI 10.1007/s002530100678
   Deshpande MV, 1999, CRIT REV MICROBIOL, V25, P229, DOI 10.1080/10408419991299220
   Freire DM, 1997, APPL BIOCHEM BIOTECH, V63-5, P409, DOI 10.1007/BF02920442
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   Gutarra MLE, 2005, APPL BIOCHEM BIOTECH, V121, P105, DOI 10.1385/ABAB:121:1-3:0105
   Holker U, 2004, APPL MICROBIOL BIOT, V64, P175, DOI 10.1007/s00253-003-1504-3
   Hornbaek T, 2004, FEMS MICROBIOL LETT, V236, P145, DOI 10.1111/j.1574-6968.2004.tb09640.x
   Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315
   Kamini NR, 1998, PROCESS BIOCHEM, V33, P505, DOI 10.1016/S0032-9592(98)00005-3
   Mitchell DA, 2000, ADV BIOCHEM ENG BIOT, V68, P61
   Roncal T, 2003, RES MICROBIOL, V154, P539, DOI 10.1016/S0923-2508(03)00168-2
   Sharma R, 2001, BIOTECHNOL ADV, V19, P627, DOI 10.1016/S0734-9750(01)00086-6
NR 14
TC 33
Z9 36
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0268-2575
EI 1097-4660
J9 J CHEM TECHNOL BIOT
JI J. Chem. Technol. Biotechnol.
PD MAR
PY 2007
VL 82
IS 3
BP 313
EP 318
DI 10.1002/jctb.1674
PG 6
WC Biotechnology & Applied Microbiology; Chemistry, Multidisciplinary;
   Engineering, Environmental; Engineering, Chemical
SC Biotechnology & Applied Microbiology; Chemistry; Engineering
GA 152WZ
UT WOS:000245394300013
DA 2020-12-08
ER

PT J
AU Oliveira, FC
   Dias, ML
   Castilho, LR
   Freire, DMG
AF Oliveira, Fabiane C.
   Dias, Marcos L.
   Castilho, Leda R.
   Freire, Denise M. G.
TI Characterization of poly(3-hydroxybutyrate) produced by Cupriavidus
   necator in solid-state fermentation
SO BIORESOURCE TECHNOLOGY
LA English
DT Article
DE poly(3-hydroxybutyrate); characterization; solid-state fermentation;
   Cupriavidus necator
ID ALCALIGENES-EUTROPHUS; BETA-HYDROXYBUTYRATE; RALSTONIA-EUTROPHA
AB Solid-state fermentation (SSF) has recently been proposed as an alternative to submerged fermentation for the production of poly(hydroxyalkanoates). In the present work, X-ray diffraction, differential scanning calorimetry, nuclear magnetic resonance and infrared spectroscopy were employed to investigate the chemical structure, as well as the thermal properties and the crystalline morphology of poly(3-hydroxybutyrate) samples produced by SSF, using as raw material either soy cake or soy cake supplemented with 2.5% (m/m) sugarcane molasses. The results obtained showed that the biopolymer obtained by SSF presented the same properties as commercial PHB, except for the higher molar mass and the lower degree of crystallinity that were observed. Thus, the present data indicate that solid-state fermentation is an interesting alternative for the production of PHB, allowing the production of biopolymers with adequate properties from low-cost, renewable resources. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Fed Rio de Janeiro, COPPE, Programa Engn Quim, BR-21941972 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Inst Macromol Prof Eloisa Mano, BR-21945970 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Inst Quim, BR-21949900 Rio De Janeiro, Brazil.
RP Castilho, LR (corresponding author), Univ Fed Rio de Janeiro, COPPE, Programa Engn Quim, Caixa Postal 68502, BR-21941972 Rio De Janeiro, Brazil.
EM leda@peq.coppe.ufrj.br
RI Castilho, Leda/I-8939-2014; FREIRE, Denise Maria/D-8699-2014
OI FREIRE, Denise Maria/0000-0002-8298-5936
CR Castilho LR, 2000, BIOCHEM ENG J, V4, P239, DOI 10.1016/S1369-703X(99)00052-2
   CHEN GQ, 1994, BIOTECHNOL LETT, V16, P155, DOI 10.1007/BF01021663
   Chua H, 1998, APPL BIOCHEM BIOTECH, V70-2, P929, DOI 10.1007/BF02920203
   Chun YS, 2000, POLYMER, V41, P2305, DOI 10.1016/S0032-3861(99)00534-0
   DOI Y, 1986, MACROMOLECULES, V19, P2860, DOI 10.1021/ma00165a033
   Galego N, 2000, POLYM TEST, V19, P485, DOI 10.1016/S0142-9418(99)00011-2
   Gascue B., 2000, REV LATINOAM METAL M, V20, P47
   INOUE Y, 1992, PROG POLYM SCI, V17, P571, DOI 10.1016/0079-6700(92)90002-G
   Kahar P, 2004, POLYM DEGRAD STABIL, V83, P79, DOI 10.1016/S0141-3910(03)00227-1
   Kim BS, 2000, ENZYME MICROB TECH, V27, P774, DOI 10.1016/S0141-0229(00)00299-4
   Kong Y, 2002, POLYMER, V43, P3873, DOI 10.1016/S0032-3861(02)00235-5
   Oliveira FC, 2004, BIOTECHNOL LETT, V26, P1851, DOI 10.1007/s10529-004-5315-0
   OLIVEIRA FC, 2004, Patent No. 04001168
   PEREIRA SMF, 2002, THESIS U ESTADUAL NO
   RIIS V, 1988, J CHROMATOGR, V445, P285, DOI 10.1016/S0021-9673(01)84535-0
   Steinbuchel A, 1998, TRENDS BIOTECHNOL, V16, P419, DOI 10.1016/S0167-7799(98)01194-9
   Vandamme P, 2004, INT J SYST EVOL MICR, V54, P2285, DOI 10.1099/ijs.0.63247-0
   WITNEY RE, 1999, POLYMER, V40, P5147
NR 18
TC 84
Z9 87
U1 1
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0960-8524
J9 BIORESOURCE TECHNOL
JI Bioresour. Technol.
PD FEB
PY 2007
VL 98
IS 3
BP 633
EP 638
DI 10.1016/j.biortech.2006.02.022
PG 6
WC Agricultural Engineering; Biotechnology & Applied Microbiology; Energy &
   Fuels
SC Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels
GA 101AD
UT WOS:000241710400022
PM 16580194
DA 2020-12-08
ER

PT B
AU Pinto, RCV
   Medronho, RA
   Castilho, LR
AF Pinto, Rodrigo C. V.
   Medronho, Ricardo A.
   Castilho, Leda R.
BE Smith, R
TI The effects of cell separation with hydrocyclones on the viability of
   CHO cells
SO CELL TECHNOLOGY FOR CELL PRODUCTS
LA English
DT Proceedings Paper
CT 19th Meeting of the European-Society-for-Animal-Cell-Technology (ESACT)
CY JUN 05-08, 2005
CL Harrogate, ENGLAND
SP European Soc Anim Cell Technol
DE hydrocyclone; cell retention device; perfusion; CHO.K1 cells; separation
   efficiency; cell viability; apoptosis
AB Five different hydrocyclone geometries were tested for the separation of CHO cells and presented separation efficiencies over 97%. Cell passage through the hydrocyclone did not induce apoptosis. The high separation efficiencies coupled to the low viability losses obtained in the present work confirm that hydrocyclones are suitable for animal cell retention in perfusion processes.
C1 [Pinto, Rodrigo C. V.; Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, CxP 68502, BR-21941972 Rio De Janeiro, Brazil.
   [Medronho, Ricardo A.] Univ Fed Rio de Janeiro, Sch Chem, Dept Chem, BR-21941972 Rio De Janeiro, Brazil.
RP Pinto, RCV (corresponding author), Univ Fed Rio de Janeiro, COPPE, CxP 68502, BR-21941972 Rio De Janeiro, Brazil.
EM medronho@eq.ufrj.br; leda@peq.coppe.ufrj.br
RI Medronho, Ricardo/Q-1762-2015
OI Medronho, Ricardo/0000-0001-5603-9762
CR Castilho Leda R, 2002, Adv Biochem Eng Biotechnol, V74, P129
   ELSAYED A, 2003, ANIMAL CELL TECHNOLO, P383
   Iding K, 2000, CYTOTECHNOLOGY, V34, P141, DOI 10.1023/A:1008183508439
   Jockwer A, 2001, ESACT PROCEED, V1, P301
   Medronho RA, 2005, LAT AM APPL RES, V35, P1
   Wen ZY, 2000, J BIOTECHNOL, V79, P1, DOI 10.1016/S0168-1656(00)00219-4
NR 6
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES
BN 978-1-4020-5475-4
PY 2007
BP 745
EP +
DI 10.1007/978-1-4020-5476-1_134
PG 2
WC Biotechnology & Applied Microbiology; Cell Biology
SC Biotechnology & Applied Microbiology; Cell Biology
GA BGB45
UT WOS:000245916900134
DA 2020-12-08
ER

PT B
AU Mellado, MCM
   Curbelo, D
   Nobrega, R
   Castilho, LR
AF Mellado, Maria Candida M.
   Curbelo, David
   Nobrega, Ronaldo
   Castilho, Leda R.
BE Smith, R
TI Erythropoietin purification employing affinity membrane adsorbers
SO CELL TECHNOLOGY FOR CELL PRODUCTS
LA English
DT Proceedings Paper
CT 19th Meeting of the European-Society-for-Animal-Cell-Technology (ESACT)
CY JUN 05-08, 2005
CL Harrogate, ENGLAND
SP European Soc Anim Cell Technol
DE erythropoietin; affinity chromatography; membrane adsorbers;
   purification
AB In the present work, rhEPO was purified from crude CHO cell culture supernatant either with Sartobind..Cibacron Blue (CB) or Sartobind-IDA-Cu+2 affinity membranes. Purity degrees were of 55 and 75%, respectively.
C1 [Mellado, Maria Candida M.; Nobrega, Ronaldo; Castilho, Leda R.] Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, POB 68502, BR-21941972 Rio De Janeiro, Brazil.
   [Curbelo, David] Ctr Mol Immunol CIM, Havana 11600, Cuba.
RP Mellado, MCM (corresponding author), Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, POB 68502, BR-21941972 Rio De Janeiro, Brazil.
EM maria@peq.coppe.ufrj.br; leda@peq.coppe.ufrj.br
FU Brazilian research agencies CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ)
FX The financial support from the Brazilian research agencies CNPq and
   FAPERJ is gratefully acknowledged.
CR Castilho LR, 2002, J MEMBRANE SCI, V207, P253, DOI 10.1016/S0376-7388(02)00257-0
   Ghosh R, 2002, J CHROMATOGR A, V952, P13, DOI 10.1016/S0021-9673(02)00057-2
NR 2
TC 1
Z9 1
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES
BN 978-1-4020-5475-4
PY 2007
BP 749
EP +
DI 10.1007/978-1-4020-5476-1_135
PG 2
WC Biotechnology & Applied Microbiology; Cell Biology
SC Biotechnology & Applied Microbiology; Cell Biology
GA BGB45
UT WOS:000245916900135
DA 2020-12-08
ER

PT B
AU Souza, MCO
   Freire, MS
   Castilho, LR
AF Souza, Marta Cristina O.
   Freire, Marcos S.
   Castilho, Leda R.
BE Smith, R
TI Cultivation of Vero cells on microporous and macroporous microcarriers
SO CELL TECHNOLOGY FOR CELL PRODUCTS
LA English
DT Proceedings Paper
CT 19th Meeting of the European-Society-for-Animal-Cell-Technology (ESACT)
CY JUN 05-08, 2005
CL Harrogate, ENGLAND
SP European Soc Anim Cell Technol
DE Vero cells; microcarriers; culture conditions; immunobiologicals;
   vaccine; Cytodex 1; Cytodex 3; Cytoline; Cytopore; experimental design
AB The manufacture of immunobiologicals, such as viral vaccines, is largely based on animal cell technology. Large-scale production of viral antigens depends on efficient cell proliferation and virus replication, both in terms of quality and quantity. This can be achieved by choosing adequate culture conditions and cultivation systems. Microcarriers are a toot to provide a large adhesion area in homogeneous bioreactor systems, allowing high densities of anchorage-dependent cells to be obtained. The aim of the present work was to study the use of different microcarriers and culture conditions to obtain high-density Vero cell cultures for the production of viral antigens.
C1 Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, POB 68502, BR-21941972 Rio De Janeiro, Brazil.
RP Souza, MCO (corresponding author), Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, POB 68502, BR-21941972 Rio De Janeiro, Brazil.
EM leda@peq.coppe.ufrj.br
CR Butler M, 2000, BIOTECHNOL PROGR, V16, P854, DOI 10.1021/bp000110+
   Yokomizo AY, 2004, BIOTECHNOL BIOENG, V85, P506, DOI 10.1002/bit.10917
NR 2
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES
BN 978-1-4020-5475-4
PY 2007
BP 753
EP +
DI 10.1007/978-1-4020-5476-1_136
PG 2
WC Biotechnology & Applied Microbiology; Cell Biology
SC Biotechnology & Applied Microbiology; Cell Biology
GA BGB45
UT WOS:000245916900136
DA 2020-12-08
ER

PT B
AU Machado, RL
   Figueredo, A
   Carneiro, DGP
   Castilho, LR
   Medronho, RA
AF Machado, Romi L.
   Figueredo, Alvio
   Carneiro, Damlo G. P.
   Castilho, Leda R.
   Medronho, Ricardo A.
BE Smith, R
TI CFD-aided design of hollow fibre modules for integrated mammalian cell
   retention and product purification
SO CELL TECHNOLOGY FOR CELL PRODUCTS
LA English
DT Proceedings Paper
CT 19th Meeting of the European-Society-for-Animal-Cell-Technology (ESACT)
CY JUN 05-08, 2005
CL Harrogate, ENGLAND
SP European Soc Anim Cell Technol
DE computational fluid dynamics; CFD; hollow fibre membranes; perfusion
   processes; cell retention; product purification
AB Membrane-based affinity chromatography is a powerful technique for protein purification. The use of membrane adsorbers allows combining cell separation and primary product purification in one step. However, a challenge is to find module geometries that can avoid both membrane fouling and premature product breakthrough. In the present work, computational fluid dynamics was employed as a tool to evaluate the flow pattern and pressure profiles in hollow fibre membranes as a function of feed velocity, with the final aim of designing a membrane device that is adequate for carrying out integrated perfusion/purification processes.
C1 Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, CxP 68502, BR-21941972 Rio De Janeiro, Brazil.
   [Figueredo, Alvio; Carneiro, Damlo G. P.; Medronho, Ricardo A.] Univ Fed Rio de Janeiro, Sch Chem, Chem Engn Program, BR-21941972 Rio De Janeiro, Brazil.
   [Figueredo, Alvio] Univ Fed Rio de Janeiro, Ctr Mol Immunol CIM, BR-21941972 Rio De Janeiro, Brazil.
RP Machado, RL (corresponding author), Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, CxP 68502, BR-21941972 Rio De Janeiro, Brazil.
EM leda@peq.coppe.ufrj.br
RI Medronho, Ricardo/Q-1762-2015
OI Medronho, Ricardo/0000-0001-5603-9762
CR Bird R B., 2001, TRANSPORT PHENOMENA
   Castilho LR, 2002, BIOTECHNOL PROGR, V18, P776, DOI 10.1021/bp0255154
NR 2
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES
BN 978-1-4020-5475-4
PY 2007
BP 757
EP +
DI 10.1007/978-1-4020-5476-1_137
PG 2
WC Biotechnology & Applied Microbiology; Cell Biology
SC Biotechnology & Applied Microbiology; Cell Biology
GA BGB45
UT WOS:000245916900137
DA 2020-12-08
ER

PT J
AU Souza, MCD
   Freire, MD
   Castilho, LD
AF Souza, MCD
   Freire, MD
   Castilho, LD
TI Influence of culture conditions on Vero cell propagation on non-porous
   microcarriers
SO BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY
LA English
DT Article; Proceedings Paper
CT 15th Brazilian Congress of Chemical Engineering
CY SEP 26-29, 2004
CL Curitiba, BRAZIL
DE Vero cells; microcarriers; Cytodex 1; Cytodex 3; high-cell-density
   cultivation
ID SERUM-FREE MEDIUM; MACROPOROUS MICROCARRIERS; MAMMALIAN-CELLS;
   ATTACHMENT; CULTIVATION; BIOREACTOR; KINETICS; GROWTH; VIRUS
AB Animal cell cultures are widely employed for the production of viral vaccines and for recombinant protein expression. The cell line Vero is a continuous, adherent cell line, which has been recommended by the World Health Organization for the production of human vaccines. For the large-scale production of vaccines, microcarriers, which are microspheres that serve as support for the cells, are being increasingly used. The use of microcarriers in stirred bioreactors allows high cell densities and, consequently, high virus titres to be achieved With the aim of selecting appropriate culture conditions for the cultivation of Vero cells at high cell densities, in this work the influence of several variables (agitation rate, ratio of inoculated cells to microcarrier mass and fetal bovine serum concentration) on cell growth on Cytodex 1 microcarriers was studied. Under the best conditions determined, a comparison with Vero cell cultivation on Cytodex 3 microcarriers was carried out.
C1 Univ Fed Rio de Janeiro, COPPE, Programa Engn Quim, Ilha Fundao, BR-21941970 Rio De Janeiro, Brazil.
   Fiocruz MS, Inst Tecnol Imunobiol Bio Manguinhos, BR-21045900 Rio De Janeiro, Brazil.
RP Castilho, LD (corresponding author), Univ Fed Rio de Janeiro, COPPE, Programa Engn Quim, Ilha Fundao, CP 68502, BR-21941970 Rio De Janeiro, Brazil.
EM freire@bio.fiocruz.br; leda@peq.coppe.ufrj.br
RI Castilho, Leda/I-8939-2014
CR *AM PHARM BIOT, 1999, MICR CELL CULT PRINC
   Butler M, 2000, BIOTECHNOL PROGR, V16, P854, DOI 10.1021/bp000110+
   Cruz HJ, 1999, BIOTECHNOL BIOENG, V66, P104, DOI 10.1002/(SICI)1097-0290(1999)66:2<104::AID-BIT3>3.0.CO;2-#
   DESMYTER J, 1968, J VIROL, V2, P955, DOI 10.1128/JVI.2.10.955-961.1968
   Doyle A., 1998, CELL TISSUE CULTURE
   FORESTELL SP, 1992, BIOTECHNOL BIOENG, V39, P305, DOI 10.1002/bit.260390308
   Frazzati-Gallina NM, 2001, J BIOTECHNOL, V92, P67, DOI 10.1016/S0168-1656(01)00362-5
   KADOURI A, 1994, COLLOID SURFACE B, V2, P265, DOI 10.1016/0927-7765(94)80040-5
   Mendonca RZ, 1998, BIOPROCESS ENG, V18, P213, DOI 10.1007/s004490050433
   MENDONCA RZ, 1995, BIOPROCESS ENG, V12, P279
   MUKHOPADHYAY A, 1993, J CHEM TECHNOL BIOT, V56, P369
   Ng YC, 1996, BIOTECHNOL BIOENG, V50, P627, DOI 10.1002/(SICI)1097-0290(19960620)50:6<627::AID-BIT3>3.0.CO;2-M
   NIKOLAI TJ, 1992, ENZYME MICROB TECH, V14, P203, DOI 10.1016/0141-0229(92)90067-X
   Spier RE, 1997, ENZYME MICROB TECH, V21, P2, DOI 10.1016/S0141-0229(96)00213-X
   Sun XM, 2000, J BIOSCI BIOENG, V90, P32, DOI 10.1263/jbb.90.32
   Yasumura Y., 1963, NIPPON RINSHO, V21, P1201
NR 16
TC 6
Z9 6
U1 0
U2 5
PU INST TECNOLOGIA PARANA
PI CURITIBA-PARANA
PA RUA PROF ALGACYR MUNHOZ MADER 3775-CIC, 81350-010 CURITIBA-PARANA,
   BRAZIL
SN 1516-8913
EI 1678-4324
J9 BRAZ ARCH BIOL TECHN
JI Braz. Arch. Biol. Technol.
PD JUN
PY 2005
VL 48
SI SI
BP 71
EP 77
DI 10.1590/S1516-89132005000400009
PG 7
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 956OP
UT WOS:000231310000010
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Cavalcanti, EDC
   Gutarra, MLE
   Freire, DMG
   Castilho, LD
   Sant'Anna, GL
AF Cavalcanti, EDC
   Gutarra, MLE
   Freire, DMG
   Castilho, LD
   Sant'Anna, GL
TI Lipase production by solid-state fermentation in fixed-bed bioreactors
SO BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY
LA English
DT Article; Proceedings Paper
CT 15th Brazilian Congress of Chemical Engineering
CY SEP 26-29, 2004
CL Curitiba, BRAZIL
DE solid-state fermentation; fixed-bed bioreactors; lipase; Penicillium
   simplicissimum
ID STRATEGIES
AB In the present work, packed bed bioreactors were employed with the aim of increasing productivity and scaling up of lipase production using Penicillium simplicissimum in solid-state fermentation. The influence of temperature and air flow rate on enzyme production was evaluated employing statistical experimental design, and an empirical model was adjusted to the experimental data. It was shown that higher lipase activities could be achieved at lower temperatures and higher airflow rates. The maximum lipase activity (26.4 U/g) was obtained at the temperature of 27 degrees C and airflow rate of 0.8 L/min.
C1 Univ Fed Rio de Janeiro, COPPE, Inst Quim, Ilha Fundao,CT Lab A 549, BR-21945970 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, COPPE, Programa Engn Quim, Ilha Fundao,CT Lab A 549, BR-21945970 Rio De Janeiro, Brazil.
RP Freire, DMG (corresponding author), Univ Fed Rio de Janeiro, COPPE, Inst Quim, Ilha Fundao,CT Lab A 549, BR-21945970 Rio De Janeiro, Brazil.
EM freire@iq.ufrj.br
RI FREIRE, Denise Maria/D-8699-2014; Castilho, Leda/I-8939-2014; Gutarra,
   Melissa/J-5706-2015
OI FREIRE, Denise Maria/0000-0002-8298-5936; Gutarra,
   Melissa/0000-0003-2480-7223
CR Ashley VM, 1999, BIOCHEM ENG J, V3, P141, DOI 10.1016/S1369-703X(99)00010-8
   Couto SR, 2003, BIOCHEM ENG J, V15, P21
   Durand A, 2003, BIOCHEM ENG J, V13, P113, DOI 10.1016/S1369-703X(02)00124-9
   FREIRE DMG, 1996, THEISIS IQ UFRJ DEP
   FREIRE DMG, 2000, REV BRAS FARM, V81, P48
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   GUTARRA MLE, 2003, THESIS IQ UFRJ DEP B
   Mitchell DA, 2003, BIOCHEM ENG J, V13, P137, DOI 10.1016/S1369-703X(02)00126-2
   Mitchell DA, 1999, PROCESS BIOCHEM, V35, P167, DOI 10.1016/S0032-9592(99)00048-5
   PANDEY A, 1993, PROCESS BIOCHEM, V28, P305, DOI 10.1016/0032-9592(93)85003-X
   Pandey A, 1999, BIOTECHNOL APPL BIOC, V29, P119
   SAUCEDOCASTANED.G, 1990, BIOTECHNOL BIOENG, V35, P82
   Sharma R, 2001, BIOTECHNOL ADV, V19, P627, DOI 10.1016/S0734-9750(01)00086-6
NR 13
TC 30
Z9 31
U1 0
U2 14
PU INST TECNOLOGIA PARANA
PI CURITIBA-PARANA
PA RUA PROF ALGACYR MUNHOZ MADER 3775-CIC, 81350-010 CURITIBA-PARANA,
   BRAZIL
SN 1516-8913
EI 1678-4324
J9 BRAZ ARCH BIOL TECHN
JI Braz. Arch. Biol. Technol.
PD JUN
PY 2005
VL 48
SI SI
BP 79
EP 84
DI 10.1590/S1516-89132005000400010
PG 6
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 956OP
UT WOS:000231310000011
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Gutarra, MLE
   Cavalcanti, EDC
   Castilho, LR
   Freire, DMG
   Sant'Anna Jr, GL
AF Gutarra, MLE
   Cavalcanti, EDC
   Castilho, LR
   Freire, DMG
   Sant'Anna Jr, GL
TI Lipase production by solid-state fermentation - Cultivation conditions
   and operation of tray and packed-bed bioreactors
SO APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
LA English
DT Article; Proceedings Paper
CT 26th Symposium on Biotechnology for Fuels and Chemicals
CY MAY 09-12, 2004
CL Chattanooga, TN
SP Oak Ridge Natl Lab, Natl Renewable Energy Lab, US DOE Off Biomass Program, Abengoa Bioenergy Corp, Archer Daniels Midland, EI DuPont Nemours & Co, Genencor Int Inc, Iogen Corp, Katzen Int Inc, Nat Resources Canada, Novozymes A/S, Purevis Technol Inc, Syngenta, Tate & Lyle PLC, Tembec Inc, USDA, Agr Res Serv, Verdia Inc
DE lipase; packed-bed bioreactor; tray-type bioreactor; Penicillium
   simplicissimum; solid-state fermentation
ID PENICILLIUM-RESTRICTUM; ASPERGILLUS-NIGER; OIL CAKE; PURIFICATION;
   STRATEGIES; SUBSTRATE; AERATION
AB The production of lipase by Penicillium simplicissimum in solid-state fermentation was studied using babassu cake as the basal medium. Tray-type and packed-bed bioreactors were employed. In the former, the influence of temperature; content of the medium, and medium supplementation with olive oil, sugarcane molasses, corn steep liquor, and yeast hydrolysate was studied. For all combinations of supplements, a temperature of 30 degrees C, a moisture content of 70%, and a concentration of carbon source of 6.25% (m/m, dry basis) provided optimum conditions for lipase production. When used as single supplements olive oil and molasses also were able to provide high lipase activities (20 U/g). Using packed-bed bioreactors and molasses-supplemented medium, optimum conditions for enzyme production were air superficial velocities above 55 cm/min and temperatures below 28 degrees C. The lower temperature optimum found for these reactors is probably related to radial heat gradient formation inside the packed bed. Maximum lipase activities obtained in these bioreactors (26.4 U/g) were 30% higher than in tray-type reactors.
C1 Fed Univ Rio De Janeiro, CT, Lab 949 2, Ilha Fundao,Dept Biochem,Inst Chem, BR-21945970 Rio De Janeiro, Brazil.
   Fed Univ Rio De Janeiro, CT, Lab 949 2, Ilha Fundao,COPPE,Chem Engn Program, BR-21945970 Rio De Janeiro, Brazil.
RP Freire, DMG (corresponding author), Fed Univ Rio De Janeiro, CT, Lab 949 2, Ilha Fundao,Dept Biochem,Inst Chem, BR-21945970 Rio De Janeiro, Brazil.
EM freire@iq.ufrj.br
RI Gutarra, Melissa/J-5706-2015; Castilho, Leda/I-8939-2014; FREIRE, Denise
   Maria/D-8699-2014; Cavalcanti-Oliveira, Elisa D/G-6263-2017
OI Gutarra, Melissa/0000-0003-2480-7223; FREIRE, Denise
   Maria/0000-0002-8298-5936; Cavalcanti-Oliveira, Elisa
   D/0000-0001-5071-8238
CR Ashley VM, 1999, BIOCHEM ENG J, V3, P141, DOI 10.1016/S1369-703X(99)00010-8
   Cordova J, 1998, J MOL CATAL B-ENZYM, V5, P75, DOI 10.1016/S1381-1177(98)00067-8
   Couto SR, 2003, BIOCHEM ENG J, V15, P21
   Freire DM, 1997, APPL BIOCHEM BIOTECH, V63-5, P409, DOI 10.1007/BF02920442
   Freire DMG, 1996, THESIS FEDERAL U RIO
   FREIRE DMG, 1997, REV MICROBIOL, V28, P6
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   GUTARRA MLE, 2003, THESIS FEDERAL U RIO
   Kamini NR, 1998, PROCESS BIOCHEM, V33, P505, DOI 10.1016/S0032-9592(98)00005-3
   Mahadik ND, 2002, PROCESS BIOCHEM, V38, P715, DOI 10.1016/S0032-9592(02)00194-2
   Mitchell DA, 2003, BIOCHEM ENG J, V13, P137, DOI 10.1016/S1369-703X(02)00126-2
   Mitchell DA, 1999, PROCESS BIOCHEM, V35, P167, DOI 10.1016/S0032-9592(99)00048-5
   Mitchell David A, 2002, Biotechnol Annu Rev, V8, P183, DOI 10.1016/S1387-2656(02)08009-2
   Pandey A, 2000, PROCESS BIOCHEM, V35, P1153, DOI 10.1016/S0032-9592(00)00152-7
   RAO PV, 1993, PROCESS BIOCHEM, V28, P391
   SATO K, 1999, MANUAL IND MICROBIOL, P61
   SAUCEDOCASTANEDA G, 1990, BIOTECHNOL BIOENG, V35, P802, DOI 10.1002/bit.260350808
   Sharma R, 2001, BIOTECHNOL ADV, V19, P627, DOI 10.1016/S0734-9750(01)00086-6
   SZTAJER H, 1992, BIOCHIM BIOPHYS ACTA, V1124, P253, DOI 10.1016/0005-2760(92)90137-K
   Ul-Haq I, 2002, PROCESS BIOCHEM, V37, P637, DOI 10.1016/S0032-9592(01)00252-7
NR 20
TC 48
Z9 52
U1 0
U2 9
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0273-2289
EI 1559-0291
J9 APPL BIOCHEM BIOTECH
JI Appl. Biochem. Biotechnol.
PD SPR
PY 2005
VL 121
BP 105
EP 116
DI 10.1385/ABAB:121:1-3:0105
PG 12
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 938BP
UT WOS:000229975200011
PM 15917592
DA 2020-12-08
ER

PT J
AU Soares, VF
   Castilho, LR
   Bon, EPS
   Freire, DMG
AF Soares, VF
   Castilho, LR
   Bon, EPS
   Freire, DMG
TI High-yield Bacillus subtilis protease production by solid-state
   fermentation
SO APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
LA English
DT Article; Proceedings Paper
CT 26th Symposium on Biotechnology for Fuels and Chemicals
CY MAY 09-12, 2004
CL Chattanooga, TN
SP Oak Ridge Natl Lab, Natl Renewable Energy Lab, US DOE Off Biomass Program, Abengoa Bioenergy Corp, Archer Daniels Midland, EI DuPont Nemours & Co, Genencor Int Inc, Iogen Corp, Katzen Int Inc, Nat Resources Canada, Novozymes A/S, Purevis Technol Inc, Syngenta, Tate & Lyle PLC, Tembec Inc, USDA, Agr Res Serv, Verdia Inc
DE Bacillus subtilis; protease; solid-state fermentation; submerged
   fermentation; soy cake
ID ALKALINE PROTEASE
AB A Bacillus subtilis isolate was shown to be able to produce extracellular protease in solid-state fermentations (SSF) using soy cake as culture medium. A significant effect of inoculum concentration and physiological age on protease production was observed. Maximum activities were obtained for inocula consisting of exponentially growing cells at inoculum concentrations in the range of 0.7-2.0 mg g(-1). A comparative study on the influence of cultivation temperature and initial medium pH on protease production in SSF and in submerged fermentation (SF) revealed that in SSF a broader pH range (5-10), but the same optimum temperature (37 degrees C), is obtained when compared to SE A kinetic study showed that enzyme production is associated with bacterial growth and that enzyme inactivation begins before biomass reaches a maximum level for both SF and SSE Maximum protease activity and productivity were 960 U g(-1) and 15.4 U g(-1) h(-1) for SSF, and 12 U mL(-1) and 1.3 U mL(-1) h(-1) for SE When SSF protease activity was expressed by volume of enzyme extract, the enzyme level was 10-fold higher and the enzyme productivity 45% higher than in SE These results indicate that this bacterial strain shows a high biotechnological potential for protease production in solid-state fermentation.
C1 Univ Fed Rio de Janeiro, Dept Biochem, Inst Chem, Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21945 Rio De Janeiro, Brazil.
RP Freire, DMG (corresponding author), Univ Fed Rio de Janeiro, Dept Biochem, Inst Chem, Rio De Janeiro, Brazil.
EM freire@iq.ufrj.br
RI Bon, Elba P.S./C-5331-2013; Castilho, Leda/I-8939-2014; FREIRE, Denise
   Maria/D-8699-2014
OI FREIRE, Denise Maria/0000-0002-8298-5936; Bon, Elba/0000-0002-0385-5448
CR Agrawal D, 2004, PROCESS BIOCHEM, V39, P977, DOI 10.1016/S0032-9592(03)00212-7
   CHARNEY J, 1947, J BIOL CHEM, V171, P501
   CHU IM, 1992, ENZYME MICROB TECH, V14, P755, DOI 10.1016/0141-0229(92)90116-6
   FREIRE DMG, 1996, THESIS FED U RIO JAN
   Germano S, 2003, ENZYME MICROB TECH, V32, P246, DOI 10.1016/S0141-0229(02)00283-1
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   Mitchell David A, 2002, Biotechnol Annu Rev, V8, P183, DOI 10.1016/S1387-2656(02)08009-2
   Pandey A, 2000, PROCESS BIOCHEM, V35, P1153, DOI 10.1016/S0032-9592(00)00152-7
   Romero FJ, 2001, PROCESS BIOCHEM, V36, P507, DOI 10.1016/S0032-9592(00)00221-1
   Singh J, 2001, PROCESS BIOCHEM, V36, P781, DOI 10.1016/S0032-9592(00)00275-2
   SOARES VF, 2003, P 14 S NAC FERM FLOR, P1
   Uyar F, 2004, PROCESS BIOCHEM, V39, P1893, DOI 10.1016/j.procbio.2003.09.016
   Yang SS, 1999, BOT BULL ACAD SINICA, V40, P259
NR 13
TC 26
Z9 28
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0273-2289
EI 1559-0291
J9 APPL BIOCHEM BIOTECH
JI Appl. Biochem. Biotechnol.
PD SPR
PY 2005
VL 121
BP 311
EP 319
DI 10.1385/ABAB:121:1-3:0311
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 938BP
UT WOS:000229975200028
PM 15917609
DA 2020-12-08
ER

PT J
AU Oliveira, FC
   Freire, DMG
   Castilho, LR
AF Oliveira, FC
   Freire, DMG
   Castilho, LR
TI Production of poly(3-hydroxybutyrate) by solid-state fermentation with
   Ralstonia eutropha
SO BIOTECHNOLOGY LETTERS
LA English
DT Article
DE poly(3-hydroxybutyrate) (PHB); Ralstonia eutropha; solid-state
   fermentation
ID PENICILLIUM-RESTRICTUM; LIPASE PRODUCTION; POLY-3-HYDROXYBUTYRATE
AB The use of solid-state fermentation is examined as a low-cost technology for the production of poly(hydroxyalkanoates) (PHAs) by Ralstonia eutropha. Two agroindustrial residues (babassu and soy cake) were evaluated as culture media. The maximum poly(hydroxybutyrate) (PHB) yield was 1.2 mg g(-1) medium on soy cake in 36 h, and 0.7 mg g(-1) medium on babassu cake in 84 h. Addition of 2.5% (w/w) sugar cane molasses to soy cake increased PHB production to 4.9 mg g(-1) medium in 60 h. Under these conditions, the PHB content of the dry biomass was 39% (w/w). The present results indicate that solid-state fermentation could be a promising alternative for producing biodegradable polymers at low cost.
C1 Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21945 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Inst Chem, BR-21945 Rio De Janeiro, Brazil.
RP Castilho, LR (corresponding author), Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21945 Rio De Janeiro, Brazil.
EM leda@ufrj.br
RI Castilho, Leda/I-8939-2014; FREIRE, Denise Maria/D-8699-2014
OI FREIRE, Denise Maria/0000-0002-8298-5936
CR Castilho LR, 2000, BIOCHEM ENG J, V4, P239, DOI 10.1016/S1369-703X(99)00052-2
   Chen YG, 1999, PROCESS BIOCHEM, V34, P153, DOI 10.1016/S0032-9592(98)00082-X
   Du GC, 2001, J BIOTECHNOL, V88, P59, DOI 10.1016/S0168-1656(01)00266-8
   Ganz MB, 1999, EXP NEPHROL, V7, P413
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   Gouda MK, 2001, MICROBIOL RES, V156, P201, DOI 10.1078/0944-5013-00104
   Jung YM, 2000, J BIOSCI BIOENG, V90, P266, DOI 10.1016/S1389-1723(00)80080-8
   Kim BS, 2000, ENZYME MICROB TECH, V27, P774, DOI 10.1016/S0141-0229(00)00299-4
   Madison LL, 1999, MICROBIOL MOL BIOL R, V63, P21, DOI 10.1128/MMBR.63.1.21-53.1999
   Mitchell David A, 2002, Biotechnol Annu Rev, V8, P183, DOI 10.1016/S1387-2656(02)08009-2
   OLIVEIRA FC, 2004, BIOPOLIMEROS PROCESS
   Reddy CSK, 2003, BIORESOURCE TECHNOL, V87, P137, DOI 10.1016/S0960-8524(02)00212-2
   RIIS V, 1988, J CHROMATOGR, V445, P285, DOI 10.1016/S0021-9673(01)84535-0
   Steinbuchel A, 1998, TRENDS BIOTECHNOL, V16, P419, DOI 10.1016/S0167-7799(98)01194-9
NR 14
TC 24
Z9 28
U1 0
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-5492
EI 1573-6776
J9 BIOTECHNOL LETT
JI Biotechnol. Lett.
PD DEC
PY 2004
VL 26
IS 24
BP 1851
EP 1855
DI 10.1007/s10529-004-5315-0
PG 5
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 904CA
UT WOS:000227472500005
PM 15672227
DA 2020-12-08
ER

PT J
AU Castilho, LR
   Anspach, FB
AF Castilho, LR
   Anspach, FB
TI CFD-aided design of a dynamic filter for mammalian cell separation
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE computational fluid dynamics (CFD); dynamic filter; module design;
   membrane filtration; mammalian cells
ID MEMBRANE DISK FILTERS; ANIMAL-CELLS; SHEAR; PURIFICATION; CULTIVATION;
   VELOCITY; FLOW
AB In the present work, a rotating disk filter was designed for mammalian cell separation with the aim of avoiding both cell damage and membrane fouling. Different geometric and operational variables of the rotating disk filter were studied using computational fluid dynamics (CFD) by varying rotor radius, rotor angle, membrane-rotor distance, and angular velocity. The combinations of these variables followed a statistical design, so that an analysis of the CFD results provided correlations describing the average shear stress on the membrane surface and the maximum shear stress in the whole module as a function of the variables studied. Based on these correlations, and on the shear resistance levels of Chinese hamster ovary (CHO) and baby hamster kidney (BHK) cell lines, which were investigated using a cone-and-plate viscosimeter, it was possible to determine the geometry and angular velocity that would minimize both cell damage and membrane fouling. After construction, the filter was tested in filtration experiments at increasing permeate fluxes. Cell viability remained >90% for the duration of the experiments (2.5 h), and no indication of fouling was observed. It was shown that the designed dynamic filter is able to effectively avoid both cell damage and membrane fouling, and thus can be used for mammalian cell harvesting and perfusion. (C) 2003 Wiley Periodicals, Inc.
C1 GBF German Res Ctr Biotechnol, Div Biochem Engn, Braunschweig, Germany.
RP Castilho, LR (corresponding author), Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, Ctr Tecnol, Sala G-116, BR-21945970 Rio De Janeiro, Brazil.
EM leda@ufrj.br
RI Castilho, Leda/I-8939-2014
CR ALRUBEAI M, 1990, BIOTECHNOL LETT, V12, P323, DOI 10.1007/BF01024425
   BORN C, 1992, BIOTECHNOL BIOENG, V40, P1004, DOI 10.1002/bit.260400903
   Bouzerar R, 2000, AICHE J, V46, P257, DOI 10.1002/aic.690460206
   Buntemeyer H, 1987, MODERN APPROACHES AN, P411
   Castilho LR, 2000, J MEMBRANE SCI, V172, P269, DOI 10.1016/S0376-7388(00)00343-4
   Castilho LR, 2002, J MEMBRANE SCI, V207, P253, DOI 10.1016/S0376-7388(02)00257-0
   Castilho LR, 2001, ESACT PROCEED, V1, P379
   Castilho LR, 2002, BIOTECHNOL PROGR, V18, P776, DOI 10.1021/bp0255154
   CASTILHO LR, 2002, ADV BIOCHEM ENG BIOT, V74, P127
   Castro D, 2001, J COMPLEXITY, V17, P212, DOI 10.1006/jcom.2000.0572
   Culkin B, 1998, CHEM ENG PROG, V94, P29
   Daily JW, 1960, T ASME             D, V82, P217, DOI DOI 10.1115/1.3662532
   Darcy H., 1856, FONTAINES PUBLIQUES
   Haaland PD, 1989, EXPT DESIGN BIOTECHN
   Hauser H, 1997, MAMMALIAN CELL BIOTECHNOLOGY IN PROTEIN PRODUCTION, P3
   Joshi JB, 1996, CHEM ENG J BIOCH ENG, V62, P121, DOI 10.1016/0923-0467(95)03062-X
   KETOLA HN, 1968, T ASME, V90, P395
   Kohara Y, 1995, J CHEM ENG JPN, V28, P703, DOI 10.1252/jcej.28.703
   Lehmann J, 1988, ANIMAL CELL BIOTECHN, V3, P221
   MCQUEEN A, 1989, BIOTECHNOL LETT, V11, P531, DOI 10.1007/BF01040030
   RUDNIAK L, 1995, CHEM ENG TECHNOL, V18, P90, DOI 10.1002/ceat.270180203
   SANFORD KK, 1951, J NATL CANCER I, V11, P773
   Scharfenberg K, 1995, ANIMAL CELL TECHNOLOGY: DEVELOPMENTS TOWARDS THE 21ST CENTURY, P619
   SCHIELE B, 1979, THESIS U STUTTGART G
   Serra CA, 2000, J MEMBRANE SCI, V165, P19, DOI 10.1016/S0376-7388(99)00219-7
   Serra CA, 1999, CHEM ENG J, V72, P1, DOI 10.1016/S1385-8947(98)00128-4
   Steppan D. D., 1998, ESSENTIAL REGRESSION
   TENNANT JR, 1964, TRANSPLANTATION, V2, P685, DOI 10.1097/00007890-196411000-00001
   van der Pol L, 1998, TRENDS BIOTECHNOL, V16, P323, DOI 10.1016/S0167-7799(98)01209-8
   Vogel JH, 2002, BIOTECHNOL BIOENG, V78, P805, DOI 10.1002/bit.10262
   Vogel JH, 1999, BIOTECHNOL BIOENG, V63, P663, DOI 10.1002/(SICI)1097-0290(19990620)63:6<663::AID-BIT4>3.0.CO;2-0
   Vogel TI, 1999, DYN CONTIN DISCRET I, V5, P1
   WOLFSHTE.M, 1969, INT J HEAT MASS TRAN, V12, P301, DOI 10.1016/0017-9310(69)90012-X
NR 33
TC 9
Z9 9
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-3592
EI 1097-0290
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD SEP 5
PY 2003
VL 83
IS 5
BP 514
EP 524
DI 10.1002/bit.10697
PG 11
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 703YL
UT WOS:000184310700002
PM 12827693
DA 2020-12-08
ER

PT J
AU De Azeredo, LAI
   Castilho, LR
   Leite, SGF
   Coelho, RRR
   Freire, DMG
AF De Azeredo, LAI
   Castilho, LR
   Leite, SGF
   Coelho, RRR
   Freire, DMG
TI Protease production by Streptomyces sp isolated from Brazilian Cerrado
   soil
SO APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
LA English
DT Article; Proceedings Paper
CT 24th Symposium on Biotechnology for Fuels and Chemicals
CY APR 28-MAY 01, 2002
CL GATLINBURG, TN
DE Streptomyces; sugarcane molasses; protease production; experimental
   design
ID CLAVULIGERUS; AGENT
AB Streptomyces are important microorganisms because of their capacity to produce numerous bioactive molecules. In the present work protease production, by Streptomyces sp. 594 isolated from a Brazilian Cerrado soil, was maximized by optimizing a low-cost culture medium composition (casitone and sugarcane molasses) using statistical experimental design. The final protease activity (56 U/mL) was 2.8-fold and 58-fold higher than that obtained in the beginning of this study, and in a previous work, using an actinomycete selection medium, respectively. Protease production, not growth associated, appeared to be modulated by an inducer system, whereby the C/N ratio seemed to play a significant role.
C1 Univ Fed Rio de Janeiro, Inst Quim, Predio Ctr Tecnol, DBq, BR-21949900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Sch Chem, BR-21949900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, BR-21949900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, COPPE, Inst Microbiol Prof Paulo Goes, BR-21949900 Rio De Janeiro, Brazil.
RP Freire, DMG (corresponding author), Univ Fed Rio de Janeiro, Inst Quim, Predio Ctr Tecnol, DBq, Bloco A,Lab 549-2 Iiha Fundao, BR-21949900 Rio De Janeiro, Brazil.
EM freire@iq.ufrj.br
RI FREIRE, Denise Maria/D-8699-2014; Castilho, Leda/I-8939-2014
OI FREIRE, Denise Maria/0000-0002-8298-5936; 
CR ARETZ W, 1989, FEMS MICROBIOL LETT, V65, P31, DOI 10.1016/0378-1097(89)90361-3
   BAILLARGEON MW, 1989, APPL MICROBIOL BIOT, V30, P92
   BASCARAN V, 1990, APPL MICROBIOL BIOT, V34, P208, DOI 10.1007/BF00166782
   Brabban AD, 1996, J APPL BACTERIOL, V80, P651, DOI 10.1111/j.1365-2672.1996.tb03270.x
   Bremner J.M., 1965, METHODS SOIL ANALYSI, V9, P1149
   de Azeredo LAI, 2001, J MICROBIOL METH, V45, P207, DOI 10.1016/S0167-7012(01)00251-2
   GIBERT M, 1995, CRIT REV BIOTECHNOL, V15, P13, DOI 10.3109/07388559509150530
   Kim IS, 1996, MICROBIOL-UK, V142, P1797, DOI 10.1099/13500872-142-7-1797
   Lee D, 2000, J MICROBIOL BIOTECHN, V10, P208
   Macedo JMB, 1999, APPL BIOCHEM BIOTECH, V77-9, P735
   MACKAY SJ, 1977, APPL ENVIRON MICROB, V33, P227, DOI 10.1128/AEM.33.2.227-230.1977
   MALATHI S, 1991, APPL ENVIRON MICROB, V57, P712, DOI 10.1128/AEM.57.3.712-716.1991
   NETO BB, 1995, PLANEJAMENTO OTIMIZA, P61
   PECZYNSKACZOCH N, 1988, ACTINOMYCETE ENZYMES, P219
   Porto ALF, 1996, APPL BIOCHEM BIOTECH, V60, P115, DOI 10.1007/BF02788066
   SARATH G, 1989, PROTEOLYTIC ENZYMES, P22
   Semedo LTAS, 2001, MICROBIOL RES, V155, P291, DOI 10.1016/S0944-5013(01)80007-0
   SOMOGYI M, 1952, J BIOL CHEM, V195, P19
   Steppan D. D., 1998, ESSENTIAL REGRESSION
NR 19
TC 18
Z9 18
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0273-2289
EI 1559-0291
J9 APPL BIOCHEM BIOTECH
JI Appl. Biochem. Biotechnol.
PD SPR
PY 2003
VL 105
BP 749
EP 755
PG 7
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 675YK
UT WOS:000182725000068
PM 12721412
DA 2020-12-08
ER

PT J
AU Castilho, LR
   Anspach, FB
   Deckwer, WD
AF Castilho, LR
   Anspach, FB
   Deckwer, WD
TI Comparison of affinity membranes for the purification of immunoglobulins
SO JOURNAL OF MEMBRANE SCIENCE
LA English
DT Article
DE affinity membranes; adsorption; purification; immunoglobulins;
   monoclonal antibody; cell culture supernatant
ID IMMOBILIZED L-HISTIDINE; HOLLOW-FIBER MEMBRANES; HUMAN-IGG;
   MONOCLONAL-ANTIBODIES; SURFACE MODIFICATION; CHROMATOGRAPHY; SEPARATION;
   PERFORMANCE; ADSORPTION; ADSORBERS
AB The purification of immunoglobulins was studied by comparing 10 different affinity membranes, prepared by coupling various affinity ligands to different microfiltration membranes. Membranes carrying the synthetic peptide TG19318, histidine, the thiophilic ligand and iminodiacetic acid complexed with Zn(II) showed a weak affinity for human IgG, as expressed by apparent association constants (K(A)) in the order of 10(5) M(-1). Human IgM and rat IgG bound with high affinity to TG19318 membranes, thus, demonstrating the potential of this sorbent for the purification of immunoglobulins other than human IgG. When carrying Protein-A ligands, membranes based on Nylon 66 coated with low-molar-mass dextran or poly(v inyl alcohol), as well as commercial pre-activated polysulfone (Ultrabind(R)) and regenerated cellulose (Sartobind(R)) membranes, showed high affinity for human IgG (K(A) approximate to 10(6) M(-1)). In contrast, a nylon membrane coated with high-molar-mass dextran yielded only K(A) approximate to 10(5) M(-1), which was attributed to a low accessibility of the immobilized ligand. Besides the high association constants, Protein-A adsorbers based on polysulfone and regenerated cellulose membranes showed several other advantages, such as enhanced charge-to-charge consistency, simpler preparation procedure, membrane sterilisability, good selectivity for IgG purification from cell culture supernatant and good stability throughout repeated adsorption-elution cycles. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 GBF, German Res Ctr Biotechnol, Div Biochem Engn, D-38124 Braunschweig, Germany.
RP Castilho, LR (corresponding author), Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, Ctr Tecnol, Sala G-116,Ilha Fundao, BR-21945970 Rio De Janeiro, Brazil.
EM ledacastilho@ieg.com.br; fbanspach@aol.com; wdd@gbf.de
RI Castilho, Leda/I-8939-2014
CR Anspach FB, 1996, BIOSEPARATION, V6, P165
   Beeskow T, 1997, J COLLOID INTERF SCI, V196, P278, DOI 10.1006/jcis.1997.5199
   BEESKOW TC, 1995, J CHROMATOGR A, V715, P49, DOI 10.1016/0021-9673(95)00540-4
   BELEW M, 1987, ANAL BIOCHEM, V164, P457, DOI 10.1016/0003-2697(87)90519-7
   Boschetti E, 2001, J BIOCHEM BIOPH METH, V49, P361, DOI 10.1016/S0165-022X(01)00208-1
   BUENO SMA, 1995, J CHROMATOGR B, V667, P57, DOI 10.1016/0378-4347(94)00601-Z
   Castilho LR, 2000, J MEMBRANE SCI, V172, P269, DOI 10.1016/S0376-7388(00)00343-4
   Castilho LR, 2001, ESACT PROCEED, V1, P379
   CASTILHO LR, 2002, ADV BIOCHEM ENG BIOT, V74, P127
   CASTILHO LR, 2001, SERIES FORTSCHRITT B, V17
   Charcosset C, 1998, J CHEM TECHNOL BIOT, V71, P95, DOI 10.1002/(SICI)1097-4660(199802)71:2<95::AID-JCTB823>3.0.CO;2-J
   Dancette OP, 1999, J CHROMATOGR B, V723, P61, DOI 10.1016/S0378-4347(98)00470-8
   ELKAK A, 1991, J CHROMATOGR-BIOMED, V570, P29, DOI 10.1016/0378-4347(91)80198-L
   Fassina G, 1996, J MOL RECOGNIT, V9, P564, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<564::AID-JMR302>3.0.CO;2-F
   Fassina G, 2001, J BIOCHEM BIOPH METH, V49, P481, DOI 10.1016/S0165-022X(01)00215-9
   Gebauer KH, 1997, CHEM ENG SCI, V52, P405, DOI 10.1016/S0009-2509(96)00426-5
   Klein E, 2000, J MEMBRANE SCI, V179, P1, DOI 10.1016/S0376-7388(00)00514-7
   KOHLER G, 1975, NATURE, V256, P52
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   MALAKIAN A, 1993, AM LAB, V25
   Petsch D, 1997, J CHROMATOGR B, V693, P79, DOI 10.1016/S0378-4347(97)00013-3
   PORATH J, 1985, FEBS LETT, V185, P306, DOI 10.1016/0014-5793(85)80928-5
   ROPER DK, 1995, J CHROMATOGR A, V702, P3, DOI 10.1016/0021-9673(95)00010-K
   THOMMES J, 1995, BIOTECHNOL PROGR, V11, P357
   Thommes J, 1996, J CHROMATOGR A, V752, P111, DOI 10.1016/S0021-9673(96)00504-3
   van Reis R, 2001, CURR OPIN BIOTECH, V12, P208, DOI 10.1016/S0958-1669(00)00201-9
   Vancan S, 2002, PROCESS BIOCHEM, V37, P573, DOI 10.1016/S0032-9592(01)00242-4
   Ventura RCA, 2001, BIOMOL ENG, V17, P71, DOI 10.1016/S1389-0344(00)00069-1
   Zeng XF, 1999, BIOTECHNOL PROGR, V15, P1003, DOI 10.1021/bp990120e
NR 29
TC 62
Z9 64
U1 1
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0376-7388
J9 J MEMBRANE SCI
JI J. Membr. Sci.
PD SEP 15
PY 2002
VL 207
IS 2
BP 253
EP 264
AR PII S0376-7388(02)00257-0
DI 10.1016/S0376-7388(02)00257-0
PG 12
WC Engineering, Chemical; Polymer Science
SC Engineering; Polymer Science
GA 578FH
UT WOS:000177106400009
DA 2020-12-08
ER

PT J
AU Castilho, LR
   Anspach, FB
   Deckwer, WD
AF Castilho, LR
   Anspach, FB
   Deckwer, WD
TI An integrated process for mammalian cell perfusion cultivation and
   product purification using a dynamic filter
SO BIOTECHNOLOGY PROGRESS
LA English
DT Article
ID FILTRATION
AB In the present work, a dynamic filter was employed to develop an integrated perfusion/ purification process. A recombinant CHO cell line producing a human anti-HIV IgG was employed in the experiments. In the first part of this work, the dynamic filter was fitted with conventional microfiltration membranes and tested as a new external cell retention device for perfusion cultivations. The filter was connected to a running perfusion bioreactor and operated for approximately 400 h at an average cell concentration of 10 million cells mL(-1), whereby cell viability remained above 90% and no problems of sterility were experienced. In the second part of this work, the dynamic filter was employed to simultaneously carry out cell separation and product purification, using membrane adsorbers containing Protein A affinity ligands. An automated system was built, which integrated the features of an automated perfusion bioreactor and of a liquid chromatography system. The IgG was continuously adsorbed onto the affinity membranes and was periodically recovered through elution cycles. After connection of the filter, the system was operated for approximately 300 h, whereby three elution cycles were carried out. No progressive increase in transmembrane pressure was observed, indicating no membrane fouling problems, and the IgG was recovered practically free of contaminants in a 14-fold concentrated form, indicating that the integrated, one-step perfusion/purification process developed during this work is a promising alternative for the production of biologicals derived from mammalian cells.
C1 GBF, German Res Ctr Biotechnol, Div Biochem Engn, D-38124 Braunschweig, Germany.
RP Castilho, LR (corresponding author), Univ Fed Rio de Janeiro, COPPE, Chem Engn Program, Ctr Technol, Sala G-116,Ilha Fundao, BR-21945970 Rio De Janeiro, RJ, Brazil.
EM ledacastilho@ieg.com.br
RI Castilho, Leda/I-8939-2014
CR BELLGARDT KH, 1992, BIOENGINEERING, V8, P27
   Buntemeyer H, 1987, MODERN APPROACHES AN, P411
   CASTILHO LR, 2002, ADV BIOCHEM ENG BIOT, V74, P127
   CASTILHO LR, 2002, UNPUB BIOTECHNOL BIO
   CASTILHO LR, 2001, FORTSCHRITT BERICHTE, V17
   GOLLMER K, 1995, BIOSCOPE, V5, P57
   Kempken R, 1997, ANIMAL CELL TECHNOLOGY, P379
   KRAWINKEL U, 1976, EUR J IMMUNOL, V6, P529, DOI 10.1002/eji.1830060802
   Lehmann J, 1988, ANIMAL CELL BIOTECHN, V3, P221
   Lubiniecki AS, 1998, CYTOTECHNOLOGY, V28, P139, DOI 10.1023/A:1008094017583
   MATANGUIHAN C, 2000, P 11 WORLD C BIOT BI, V1, P469
   MERCILLE S, 1994, BIOTECHNOL BIOENG, V43, P833, DOI 10.1002/bit.260430902
   Scharfenberg K, 1995, ANIMAL CELL TECHNOLOGY: DEVELOPMENTS TOWARDS THE 21ST CENTURY, P619
   TENNANT JR, 1964, TRANSPLANTATION, V2, P685, DOI 10.1097/00007890-196411000-00001
   Tokashiki M, 1997, MAMMALIAN CELL BIOTECHNOLOGY IN PROTEIN PRODUCTION, P279
   Vogel JH, 2002, BIOTECHNOL BIOENG, V78, P805, DOI 10.1002/bit.10262
   Vogel JH, 1999, BIOTECHNOL BIOENG, V63, P663, DOI 10.1002/(SICI)1097-0290(19990620)63:6<663::AID-BIT4>3.0.CO;2-0
   VOGEL JH, 1999, FORTSCHRITT BERICHTE, V17
   Woodside SM, 1998, CYTOTECHNOLOGY, V28, P163, DOI 10.1023/A:1008050202561
NR 19
TC 21
Z9 23
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8756-7938
EI 1520-6033
J9 BIOTECHNOL PROGR
JI Biotechnol. Prog.
PD JUL-AUG
PY 2002
VL 18
IS 4
BP 776
EP 781
DI 10.1021/bp0255154
PG 6
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 581HE
UT WOS:000177285200015
PM 12153312
DA 2020-12-08
ER

PT J
AU Castilho, LR
   Deckwer, WD
   Anspach, FB
AF Castilho, LR
   Deckwer, WD
   Anspach, FB
TI Influence of matrix activation and polymer coating on the purification
   of human IgG with protein A affinity membranes
SO JOURNAL OF MEMBRANE SCIENCE
LA English
DT Article
DE affinity membranes; hydrophilic coating; protein adsorption; protein A;
   human immunoglobulin
ID MONOCLONAL-ANTIBODIES; SURFACE MODIFICATION; CHROMATOGRAPHY; SUPPORTS
AB Nylon microfiltration membranes were coated with dextrans (M(r)approximate to 6000 and 40,000) and poly(vinylalcohol) (PVA) (M(r)approximate to 72,000) to produce affinity matrices with adequate chemical functionality and low non-specific protein binding characteristics. In all cases, a considerable reduction of non-specific adsorption was attained, with PVA being most effective. Also, the permeability was reduced, indicating the presence of coating polymers in the flow-through pores. The extent of permeability reduction was related both to differences in the molar mass of dextran, as well as to polymer characteristics. The highest reduction was observed with the coil-forming high-molecular weight dextran. Protein A was immobilized to the different membranes for the adsorption of human immunoglobulin G (IgG). The highest apparent association constants were obtained with PVA-coated membranes, followed by membranes which were coated with low-molecular weight dextran, and then by membranes, which were coated twice with high-molecular weight dextran. It is concluded that multiple covalent binding of protein A occurs in the open network of dextran coils, restricting the accessibility of the various binding sites of this ligand for the large IgG molecule, and therefore, weakening the ligand-ligate association. With the film-forming PVA, a better accessibility was obtained with comparable ligand density to commercial protein A chromatography supports. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 GBF Gesell Biotechnol Forsch, Div Biochem Engn, D-38124 Braunschweig, Germany.
RP Anspach, FB (corresponding author), GBF Gesell Biotechnol Forsch, Div Biochem Engn, Mascheroder Weg 1, D-38124 Braunschweig, Germany.
RI Castilho, Leda/I-8939-2014
CR Anspach FB, 1996, BIOSEPARATION, V6, P165
   ARNOLD FH, 1985, CHEM ENG J B, V30, P9
   Beeskow T, 1997, J COLLOID INTERF SCI, V196, P278, DOI 10.1006/jcis.1997.5199
   BEESKOW T, 1996, THESIS TU BRAUNSCHWE
   BEESKOW TC, 1995, J CHROMATOGR A, V715, P49, DOI 10.1016/0021-9673(95)00540-4
   Biesheuvel PM, 1999, J MEMBRANE SCI, V156, P141
   BRANDT S, 1988, BIO-TECHNOL, V6, P779, DOI 10.1038/nbt0788-779
   Charcosset C, 1998, J CHEM TECHNOL BIOT, V71, P95, DOI 10.1002/(SICI)1097-4660(199802)71:2<95::AID-JCTB823>3.0.CO;2-J
   CHARCOSSET C, 1995, BIOTECHNOL BIOENG, V48, P415, DOI 10.1002/bit.260480414
   CHU TJ, 1992, J CHEM ENG JPN, V25, P660, DOI 10.1252/jcej.25.660
   Dancette OP, 1999, J CHROMATOGR B, V723, P61, DOI 10.1016/S0378-4347(98)00470-8
   Hermanson G. T., 1992, IMMOBILIZED AFFINITY
   JONSSON C, 1995, J MEMBRANE SCI, V108, P79, DOI 10.1016/0376-7388(95)00144-X
   KLEIN E, 1994, J MEMBRANE SCI, V95, P199, DOI 10.1016/0376-7388(94)00171-5
   KLEIN E, 1991, AFFINITY MEMBRANES T
   Koros WJ, 1996, J MEMBRANE SCI, V120, P149
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   MUELLER-SCHULTE D, 1991, Journal of Chromatography, V539, P307
   Ohlson S, 1997, J CHROMATOGR A, V758, P199, DOI 10.1016/S0021-9673(96)00733-9
   SANTARELLI X, 1988, J CHROMATOGR, V443, P55, DOI 10.1016/S0021-9673(00)94782-4
   THOMMES J, 1995, BIOTECHNOL PROGR, V11, P357
   Thommes J, 1996, J CHROMATOGR A, V752, P111, DOI 10.1016/S0021-9673(96)00504-3
   ZHOU FL, 1990, J CHROMATOGR, V510, P71, DOI 10.1016/S0021-9673(01)93740-9
NR 23
TC 44
Z9 47
U1 1
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0376-7388
J9 J MEMBRANE SCI
JI J. Membr. Sci.
PD JUL 1
PY 2000
VL 172
IS 1-2
BP 269
EP 277
DI 10.1016/S0376-7388(00)00343-4
PG 9
WC Engineering, Chemical; Polymer Science
SC Engineering; Polymer Science
GA 318NA
UT WOS:000087289200025
DA 2020-12-08
ER

PT J
AU Palma, MB
   Pinto, AL
   Gombert, AK
   Seitz, KH
   Kivatinitz, SC
   Castilho, LR
   Freire, DMG
AF Palma, MB
   Pinto, AL
   Gombert, AK
   Seitz, KH
   Kivatinitz, SC
   Castilho, LR
   Freire, DMG
TI Lipase production by Penicillium restrictum using solid waste of
   industrial babassu oil production as substrate
SO APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
LA English
DT Article; Proceedings Paper
CT 21st Sympsoium on Biotechnology for Fuels and Chemicals
CY MAY 02-06, 1999
CL FT COLLINS, COLORADO
SP US DOE Off Fuels Dev, US DOE Off Ind Technologies, Natl Renewable Energy Lab, Oak Ridge Natl Lab, Idaho Natl Engn & Environm Lab, Lockheed Martin Energy Res, AE Staley, Amer Chem Soc, Div Biochem Techn, BC Int, BF Goodrich, Cargill, Colorado Inst Res Biotechnol, Coors Brewing Co, EI DuPont Nemours & Co, Iogen Corp, Katzen Assoc Int Inc, Nat Resources, Canada, Pure Energy, Raphael Katzen, Tembec
DE lipase; protease; amylase; solid-state fermentation; Penicillium
   restrictum
ID STATE FERMENTATION SYSTEM; ASPERGILLUS-NIGER; RHIZOPUS-ORYZAE;
   OPTIMIZATION; TWEEN-80; PROTEASE; ACID; GLUCOAMYLASE; BIOREACTOR;
   RECOVERY
AB Lipase, protease, and amylase production by Penicillium restrictum in solid-state fermentation was investigated. The basal medium was an industrial waste of babassu oil (Orbignya oleifera) production. It was enriched with peptone, olive oil, and Tween-80. The supplementation positively influenced both enzyme production and fungal growth. Media enriched with Tween-80 provided the highest protease activity (8.6 U/g), whereas those enriched with peptone and olive oil led to the highest lipase (27.8 U/g) and amylase (31.8 U/g) activities, respectively.
C1 Univ Fed Rio de Janeiro, COPPE, Program Chem Engn, BR-21941 Rio De Janeiro, Brazil.
   Univ Sao Paulo, Dept Chem Engn, BR-05508 Sao Paulo, Brazil.
   Natl Univ Mar Del Plata, Dept Chem Engn, Mar Del Plata, Buenos Aires, Argentina.
   Natl Univ Cordoba, Dept Biochem, Cordoba, Argentina.
   Univ Fed Rio de Janeiro, Fac Pharm, BR-21941 Rio De Janeiro, Brazil.
RP Castilho, LR (corresponding author), BVT, Div Biochem Engn, GBF, D-38124 Braunschweig, Germany.
RI Castilho, Leda/I-8939-2014; FREIRE, Denise Maria/D-8699-2014; Gombert,
   Andreas/F-3764-2010
OI FREIRE, Denise Maria/0000-0002-8298-5936; Gombert,
   Andreas/0000-0001-9557-3773
CR AIDOO KE, 1981, EUR J APPL MICROBIOL, V12, P6, DOI 10.1007/BF00508111
   ASTHER M, 1987, ENZYME MICROB TECH, V9, P245, DOI 10.1016/0141-0229(87)90024-X
   BABU KR, 1993, FOLIA MICROBIOL, V38, P77, DOI 10.1007/BF02814555
   BANERJEE R, 1992, BIOPROCESS ENG, V7, P225, DOI 10.1007/BF00369550
   BANERJEE R, 1993, BIOTECHNOL BIOENG, V41, P67, DOI 10.1002/bit.260410109
   Castilho LR, 1999, PROCESS BIOCHEM, V34, P181, DOI 10.1016/S0032-9592(98)00089-2
   Castilho LR, 2000, BIORESOURCE TECHNOL, V71, P45, DOI 10.1016/S0960-8524(99)00058-9
   Castilho LR, 1999, PROCESS BIOCHEM, V34, P417, DOI 10.1016/S0032-9592(99)00061-8
   CHARNEY J, 1947, J BIOL CHEM, V171, P501
   CHRISTEN P, 1995, BIOTECHNOL TECH, V9, P597, DOI 10.1007/BF00152451
   CONSIDINE PJ, 1986, ANN NY ACAD SCI, V469, P304, DOI 10.1111/j.1749-6632.1986.tb26508.x
   ESPINOSA E, 1990, BIOTECHNOL LETT, V12, P209, DOI 10.1007/BF01026801
   Freire DM, 1997, APPL BIOCHEM BIOTECH, V63-5, P409, DOI 10.1007/BF02920442
   FREIRE DMG, 1990, APPL BIOCHEM BIOTECH, V26, P23, DOI 10.1007/BF02798390
   FREIRE DMG, 1997, REV MICROBIOL, V28, P6
   GEORGE S, 1995, PROCESS BIOCHEM, V30, P457, DOI 10.1016/0032-9592(94)00034-F
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   HENRIETTE C, 1993, J IND MICROBIOL, V12, P129, DOI 10.1007/BF01569913
   JACQUES NA, 1985, J GEN MICROBIOL, V131, P67
   Kamini NR, 1998, PROCESS BIOCHEM, V33, P505, DOI 10.1016/S0032-9592(98)00005-3
   LONSANE BK, 1985, ENZYME MICROB TECH, V7, P258, DOI 10.1016/0141-0229(85)90083-3
   MACRAE AR, 1985, BIOTECHNOL GENET ENG, V3, P193, DOI 10.1080/02648725.1985.10647813
   MALISZEWSKA I, 1992, ENZYME MICROB TECH, V14, P190, DOI 10.1016/0141-0229(92)90064-U
   NIGAM P, 1994, J BASIC MICROB, V34, P405, DOI 10.1002/jobm.3620340607
   OKEKE CN, 1990, BIOTECHNOL LETT, V12, P747, DOI 10.1007/BF01024733
   PANDEY A, 1992, PROCESS BIOCHEM, V27, P109, DOI 10.1016/0032-9592(92)80017-W
   Pandey A, 1996, PROCESS BIOCHEM, V31, P43, DOI 10.1016/0032-9592(94)00050-6
   PAREDESLOPEZ O, 1992, BIOCONSERVION WASTE, P117
   RIVERAMUNOZ G, 1991, BIOTECHNOL LETT, V13, P277, DOI 10.1007/BF01041484
   SAKURAI Y, 1977, AGR BIOL CHEM TOKYO, V41, P619, DOI 10.1080/00021369.1977.10862552
   SALLEH AB, 1993, CAN J MICROBIOL, V39, P978, DOI 10.1139/m93-147
   Sircar A, 1998, PROCESS BIOCHEM, V33, P283, DOI 10.1016/S0032-9592(97)00058-7
   Smits JP, 1996, PROCESS BIOCHEM, V31, P669, DOI 10.1016/S0032-9592(96)00019-2
   Tao S., 1998, PROCESS BIOCHEM, V33, P419
   THIES E, 1994, WORLD J MICROB BIOT, V10, P657, DOI 10.1007/BF00327954
   Trejo Hernandez M. R., 1993, Process Biochemistry, V28, P23, DOI 10.1016/0032-9592(94)80032-4
   Zakaria Z, 1998, PROCESS BIOCHEM, V33, P1, DOI 10.1016/S0032-9592(97)00069-1
NR 37
TC 47
Z9 49
U1 0
U2 11
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0273-2289
J9 APPL BIOCHEM BIOTECH
JI Appl. Biochem. Biotechnol.
PD SPR
PY 2000
VL 84-6
BP 1137
EP 1145
DI 10.1385/ABAB:84-86:1-9:1137
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 317DR
UT WOS:000087211500096
PM 10849864
DA 2020-12-08
ER

PT J
AU Castilho, LR
   Polato, CMS
   Baruque, EA
   Sant' Anna, GL
   Freire, DMG
AF Castilho, LR
   Polato, CMS
   Baruque, EA
   Sant' Anna, GL
   Freire, DMG
TI Economic analysis of lipase production by Penicillium restrictum in
   solid-state and submerged fermentations
SO BIOCHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE economic analysis; lipase; Penicillium restrictum; solid-state
   fermentation; submerged culture; enzyme production
ID ORYZAE
AB In the present work an economic analysis of the production of Penicillium restrictum lipase in both submerged (SF) and solid state fermentations (SSF) was performed. For a production scale of 100 m(3) lipase concentrate per year, total capital investment needed for the submerged process was 78% higher than that needed for the solid-state fermentation process. The submerged process proved to be economically unfeasible, as unitary product cost was 68% higher than the product selling price. Contrastingly, the solid-state fermentation process turned out to be very attractive from an economic point of view. Also for a scale of 100 m(3)/year, SSF unitary product cost was 47% lower than the selling price, payback time was 1.5 years, return on investment was 68% and internal return rate was 62% for a 5-year-project life. Furthermore, the profitability of this process remained high even with eventual increases of 40% in product concentration or total capital investment, or decreases of 20% in product price. The great advantage of the SSF process is the extremely cheap raw material it uses as main substrate. (C) 2000 Elsevier Science S.A. All rights reserved.
C1 Univ Fed Rio de Janeiro, COPPE, PEQ, BR-21945970 Rio De Janeiro, Brazil.
   Tocantins Babacu SA, BR-20031040 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Fac Pharm, CCS, BR-21944910 Rio De Janeiro, Brazil.
RP Castilho, LR (corresponding author), Gesell Biotechnol Forsch GmbH, Div Biochem Engn, Mascheroder Weg 1, D-38124 Braunschweig, Germany.
RI Castilho, Leda/I-8939-2014; FREIRE, Denise Maria/D-8699-2014
OI FREIRE, Denise Maria/0000-0002-8298-5936
CR Castilho LR, 1999, PROCESS BIOCHEM, V34, P181, DOI 10.1016/S0032-9592(98)00089-2
   Castilho LR, 2000, BIORESOURCE TECHNOL, V71, P45, DOI 10.1016/S0960-8524(99)00058-9
   Evangelista RL, 1998, BIOTECHNOL PROGR, V14, P607, DOI 10.1021/bp980047c
   FERREIRA JSG, 1995, PRODUCAO PECTINASES
   Freire DM, 1997, APPL BIOCHEM BIOTECH, V63-5, P409, DOI 10.1007/BF02920442
   FREIRE DMG, 1997, REV MICROBIOL, V28, P6
   GHILDYAL NP, 1985, J FOOD SCI TECH MYS, V22, P171
   Gombert AK, 1999, PROCESS BIOCHEM, V35, P85, DOI 10.1016/S0032-9592(99)00036-9
   HARSA S, 1993, PROCESS BIOCHEM, V28, P187, DOI 10.1016/0032-9592(93)80006-3
   Ikasari L, 1996, ENZYME MICROB TECH, V19, P171, DOI 10.1016/0141-0229(95)00227-8
   JAEGER KE, 1995, APPL ENVIRON MICROB, V61, P3113, DOI 10.1128/AEM.61.8.3113-3118.1995
   Lonsane B K, 1990, Adv Appl Microbiol, V35, P1, DOI 10.1016/S0065-2164(08)70242-9
   MITCHELL DA, 1998, ADV BIOTECHNOL, P17
   MOCHIZUKI M, 1995, J APPL POLYM SCI, V55, P289, DOI 10.1002/app.1995.070550212
   Murthy M. V. Ramana, 1993, ADV APPL MICROBIOL, V38, P99
   OHNISHI K, 1994, J FERMENT BIOENG, V77, P490, DOI 10.1016/0922-338X(94)90116-3
   OSULLIVAN TJ, 1984, CHEM ENG PROG, V80, P68
   Peters M.S., 1991, PLANT DESIGN EC CHEM
   RAO PV, 1993, PROCESS BIOCHEM, V28, P385
   SALLEH AB, 1993, CAN J MICROBIOL, V39, P978, DOI 10.1139/m93-147
   SAMAD MYA, 1990, WORLD J MICROB BIOT, V6, P390, DOI 10.1007/BF01202120
   SZTAJER H, 1989, BIOTECHNOL LETT, V11, P895, DOI 10.1007/BF01026848
   1999, CHEM MARKET REPORTER, V255, P30
NR 23
TC 137
Z9 149
U1 0
U2 26
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1369-703X
J9 BIOCHEM ENG J
JI Biochem. Eng. J.
PD FEB
PY 2000
VL 4
IS 3
BP 239
EP 247
DI 10.1016/S1369-703X(99)00052-2
PG 9
WC Biotechnology & Applied Microbiology; Engineering, Chemical
SC Biotechnology & Applied Microbiology; Engineering
GA 274KF
UT WOS:000084764500008
DA 2020-12-08
ER

PT J
AU Castilho, LR
   Medronho, RA
AF Castilho, LR
   Medronho, RA
TI A simple procedure for design and performance prediction of Bradley and
   Rietema hydrocyclones
SO MINERALS ENGINEERING
LA English
DT Article
DE hydrocyclones; thickening; fine particle processing
ID YEAST
AB Hydrocyclones were originally designed to promote solid-liquid separations but nowadays they are also used for solid-solid, liquid-liquid and gas-liquid separations. Although a hydrocyclone is a very simple equipment to build, the we of custom-made cyclones is not widely used. This is probably due to the lack of a simple procedure for hydrocyclone design. In the present work a procedure is presented which allows the design and performance prediction of hydrocyclones that follow Bradley and Rietema recommended geometries, that are the only two well-known families of geometrically similar hydrocyclones. The procedure proposed here resulted in little error, when the results were compared with experimental data. Additionally, a comparison of both families of hydrocyclones revealed that, for a given hydrocyclone diameter and at the same operational conditions, Bradley hydrocyclones provide higher efficiencies, while Rietema hydrocyclones give higher capacities. (C) 2000 Elsevier Science Ltd. All rights reserved.
C1 Univ Fed Rio de Janeiro, COPPE, Program Chem Engn, Ctr Tecnol, BR-21949900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Sch Chem, Dept Chem Engn, Ctr Tecnol, BR-21949900 Rio De Janeiro, Brazil.
RP Medronho, RA (corresponding author), Gesell Biotechnol Forsch mbH, Div Biochem Engn, Mascheroder Weg 1, D-38124 Braunschweig, Germany.
EM medronho@gbf.de
RI Castilho, Leda/I-8939-2014; Medronho, Ricardo/Q-1762-2015
OI Medronho, Ricardo/0000-0001-5603-9762
CR ANTUNES M, 1992, FLUID MEC A, V12, P3
   Bradley D., 1965, HYDROCYCLONE
   Bretney E, 1891, Patent No. [US, 453105, 453105]
   Cilliers JJ, 1997, CHEM ENG J, V65, P21, DOI 10.1016/S0923-0467(96)03100-4
   COELHO MAZ, 1994, P 22 BRAZ C PART SYS, V1, P273
   Concha F, 1996, HYDROCYCLONES '96, P63
   Devulapalli B, 1996, HYDROCYCLONES '96, P83
   DRIESSEN MG, 1951, REV IND MIN SPL, P449
   He P, 1999, CHEM ENG RES DES, V77, P429, DOI 10.1205/026387699526412
   Klima MS, 1998, J ENVIRON SCI HEAL A, V33, P1325, DOI 10.1080/10934529809376791
   Marti S, 1996, HYDROCYCLONES '96, P399
   Medronho R. A., 1984, P 2 INT C HYDR BHRA, P1
   MEDRONHO RA, 1984, THESIS U BRADFORD UK
   Moraes CAP, 1996, HYDROCYCLONES '96, P383
   Ortega-Rivas E, 1998, ADV POWDER TECHNOL, V9, P1, DOI 10.1016/S0921-8831(08)60590-7
   PLITT LR, 1976, CIM BULL, V69, P114
   RIETEMA K, 1961, CHEM ENG SCI, V15, P298, DOI 10.1016/0009-2509(61)85033-1
   Rosin P., 1933, Journal of the Institute of Fuel, V7, P29
   SILVA MAP, 1989, THESIS COPPE UFRJ RI
   SMYTH IC, 1996, HYDROCYCLONES 96, P357
   Svarovsky L., 1984, HYDROCYCLONES
   SVAROVSKY L, 1990, SOLID LIQUID SEPARAT, P43
   Yuan H, 1996, BIOSEPARATION, V6, P159
NR 23
TC 31
Z9 35
U1 0
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0892-6875
J9 MINER ENG
JI Miner. Eng.
PD FEB
PY 2000
VL 13
IS 2
BP 183
EP 191
DI 10.1016/S0892-6875(99)00164-8
PG 9
WC Engineering, Chemical; Mineralogy; Mining & Mineral Processing
SC Engineering; Mineralogy; Mining & Mineral Processing
GA 284AV
UT WOS:000085309300006
DA 2020-12-08
ER

PT J
AU Castilho, LR
   Medronho, RA
   Alves, TLM
AF Castilho, LR
   Medronho, RA
   Alves, TLM
TI Production and extraction of pectinases obtained by solid state
   fermentation of agroindustrial residues with Aspergillus niger
SO BIORESOURCE TECHNOLOGY
LA English
DT Article
DE pectinases; Aspergillus niger; wheat bran; soy bran; humidity;
   extraction
ID PECTINOLYTIC ENZYMES; WATER ACTIVITY; ACID PROTEASE; CULTURE;
   PURIFICATION; AMYLOGLUCOSIDASE; GROWTH
AB In this work soy and wheat bran were employed as raw materials for the production of pectinases by Aspergillus niger through solid-state fermentation. Several fermentation and recovery parameters were studied. The kinetics of enzyme synthesis was investigated in the range from 13 to 96 h with moisture contents varying from 25% to 70% (w/w). A medium moisture content of 40% and a fermentation time of 22 h were selected, as these conditions resulted in high pectolytic activity and enhanced polygalacturonase productivity. In order to optimise the recovery step, the best combination of temperature of extraction, contact time and solvent type was investigated. Acetate buffer (pH 4.4), 35 degrees C and 30 min provided the best recovery. The present results !;how that optimising the extraction conditions is a simple way of obtaining more concentrated enzyme extracts and could be a useful instrument to extract more selectively a desired biomolecule from fermented solids. (C) 1999 Elsevier Science Ltd. All rights reserved.
C1 Fed Univ Rio De Janeiro, Program Chem Engn, COPPE, Ctr Tecnol, BR-21945970 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Sch Chem, Ctr Tecnol, BR-21949900 Rio De Janeiro, Brazil.
RP Castilho, LR (corresponding author), Gesell Biotechnol Forsch GmbH, Div Biochem Engn, BVT PE, Mascheroder Weg 1, D-38124 Braunschweig, Germany.
RI Medronho, Ricardo/Q-1762-2015; Castilho, Leda/I-8939-2014
OI Medronho, Ricardo/0000-0001-5603-9762; 
CR ACUNAARGUELLES M, 1994, BIOTECHNOL LETT, V16, P23, DOI 10.1007/BF01022618
   ACUNAARGUELLES ME, 1995, APPL MICROBIOL BIOT, V43, P808, DOI 10.1007/s002530050489
   Archana A, 1997, ENZYME MICROB TECH, V21, P12, DOI 10.1016/S0141-0229(96)00207-4
   BATTAGLINO RA, 1991, APPL MICROBIOL BIOT, V35, P292, DOI 10.1007/BF00172714
   BEROVIC M, 1993, J CHEM TECHNOL BIOT, V56, P209
   Castilho LR, 1999, PROCESS BIOCHEM, V34, P181, DOI 10.1016/S0032-9592(98)00089-2
   CASTILHO LR, 1997, THESIS COPPE FEDERAL
   CASTILHO LR, 1996, P 11 BRAZ C CHEM ENG, V2, P1466
   Coelho MAZ, 1995, REV MICROBIOL, V26, P318
   Couri S, 1995, REV MICROBIOL, V26, P314
   GARZON CG, 1992, BIORESOURCE TECHNOL, V39, P93, DOI 10.1016/0960-8524(92)90061-2
   GHILDYAL NP, 1991, PROCESS BIOCHEM, V26, P235, DOI 10.1016/0032-9592(91)85005-9
   GONZALEZ JB, 1988, BIOTECHNOL LETT, V10, P793
   HESSELTINE CW, 1972, BIOTECHNOL BIOENG, V14, P517, DOI 10.1002/bit.260140402
   HOURS RA, 1988, BIOL WASTE, V23, P221, DOI 10.1016/0269-7483(88)90036-5
   Ikasari L, 1996, ENZYME MICROB TECH, V19, P171, DOI 10.1016/0141-0229(95)00227-8
   LAHORE HMF, 1995, PROCESS BIOCHEM, V30, P615, DOI 10.1016/0032-9592(94)00026-3
   LANGONE MAP, 1996, BRAZ J CHEM ENG, V13, P1
   Murthy M. V. Ramana, 1993, ADV APPL MICROBIOL, V38, P99
   NIGAM P, 1994, J BASIC MICROB, V34, P405, DOI 10.1002/jobm.3620340607
   PANDEY A, 1994, WORLD J MICROB BIOT, V10, P485, DOI 10.1007/BF00144481
   RAIMBAULT M, 1980, EUR J APPL MICROBIOL, V9, P199, DOI 10.1007/BF00504486
   Ramadas M, 1995, BIOTECHNOL TECH, V9, P901, DOI 10.1007/BF00158544
   Scopes RK, 1982, PROTEIN PURIFICATION
   SOLISPEREIRA S, 1993, APPL MICROBIOL BIOT, V39, P36, DOI 10.1007/BF00166845
   SOMOGYI M, 1952, J BIOL CHEM, V195, P19
   TRINDADE V, 1996, P 5 SEM HIDR ENZ BIO
NR 27
TC 148
Z9 159
U1 0
U2 19
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0960-8524
J9 BIORESOURCE TECHNOL
JI Bioresour. Technol.
PD JAN
PY 2000
VL 71
IS 1
BP 45
EP 50
DI 10.1016/S0960-8524(99)00058-9
PG 6
WC Agricultural Engineering; Biotechnology & Applied Microbiology; Energy &
   Fuels
SC Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels
GA 236UA
UT WOS:000082616300007
DA 2020-12-08
ER

PT J
AU Gombert, AK
   Pinto, AL
   Castilho, LR
   Freire, DMG
AF Gombert, AK
   Pinto, AL
   Castilho, LR
   Freire, DMG
TI Lipase production by Penicillium restrictum in solid-state fermentation
   using babassu oil cake as substrate
SO PROCESS BIOCHEMISTRY
LA English
DT Article
DE Penicillium restrictum; lipase; solid-stale fermentation; babassu cake;
   amylase; protease
ID ASPERGILLUS-NIGER; MICROBIAL LIPASES; PROCESS VARIABLES; CANDIDA-RUGOSA;
   SYSTEM; GLUCOAMYLASE; HYDROLYSIS; CITRINUM
AB Growth and enzyme production in SSF by a Brazilian strain of Penicillium restrictum was studied. Solid waste from the babassu oil industry was used as the basic nutrient source and was supplemented with peptone, olive oil or starch at different C/N ratios. The highest lipase activity (30.3 U/g initial dry weight) was achieved after 24 h of cultivation with 2% olive oil enrichment. Lipase activity a-as very sensitive to the kind and the level of supplementation, and decreased as protease level and pH in the media increased. Maximal levels of glucoamylase and protease were obtained with 4% starch enrichment, indicating that the type of carbon source supplemented to the basal medium determines the major enzymes produced. (C) 1999 Elsevier Science Ltd. All rights reserved.
C1 Univ Sao Paulo, Dept Chem Engn, BR-05424970 Sao Paulo, Brazil.
   Univ Fed Rio de Janeiro, COPPE, Program Chem Engn, BR-21945970 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Fac Pharm, CCS, BR-21944910 Rio De Janeiro, Brazil.
RP Castilho, LR (corresponding author), Gesell Biotechnol Forsch GmbH, Div Biochem Engn, Mascheroder Weg 1, D-38124 Braunschweig, Germany.
EM leda@gbf.de
RI Gombert, Andreas/F-3764-2010; FREIRE, Denise Maria/D-8699-2014;
   Castilho, Leda/I-8939-2014
OI Gombert, Andreas/0000-0001-9557-3773; FREIRE, Denise
   Maria/0000-0002-8298-5936; 
CR AIDOO KE, 1981, EUR J APPL MICROBIOL, V12, P6, DOI 10.1007/BF00508111
   Castilho LR, 1999, PROCESS BIOCHEM, V34, P181, DOI 10.1016/S0032-9592(98)00089-2
   CHARNEY J, 1947, J BIOL CHEM, V171, P501
   CHRISTEN P, 1995, BIOTECHNOL TECH, V9, P597, DOI 10.1007/BF00152451
   CONCON JM, 1973, ANAL BIOCHEM, V53, P35, DOI 10.1016/0003-2697(73)90405-3
   DRUET D, 1992, APPL MICROBIOL BIOT, V37, P745, DOI 10.1007/BF00174840
   Freire DM, 1997, APPL BIOCHEM BIOTECH, V63-5, P409, DOI 10.1007/BF02920442
   FREIRE DMG, 1990, APPL BIOCHEM BIOTECH, V26, P23, DOI 10.1007/BF02798390
   FREIRE DMG, 1997, REV MICROBIOL, V28, P6
   JAEGER KE, 1995, APPL ENVIRON MICROB, V61, P3113, DOI 10.1128/AEM.61.8.3113-3118.1995
   Kamini NR, 1998, PROCESS BIOCHEM, V33, P505, DOI 10.1016/S0032-9592(98)00005-3
   MOCHIZUKI M, 1995, J APPL POLYM SCI, V55, P289, DOI 10.1002/app.1995.070550212
   OHNISHI K, 1994, J FERMENT BIOENG, V77, P490, DOI 10.1016/0922-338X(94)90116-3
   Pandey A, 1996, PROCESS BIOCHEM, V31, P43, DOI 10.1016/0032-9592(94)00050-6
   PETROVIC SE, 1990, BIOTECHNOL LETT, V12, P299, DOI 10.1007/BF01093525
   PIMENTEL MCB, 1994, APPL BIOCHEM BIOTECH, V49, P59, DOI 10.1007/BF02888848
   RAO PV, 1993, PROCESS BIOCHEM, V28, P385
   RAO PV, 1993, PROCESS BIOCHEM, V28, P391
   RIVERAMUNOZ G, 1991, BIOTECHNOL LETT, V13, P277, DOI 10.1007/BF01041484
   SAKURAI Y, 1977, AGR BIOL CHEM TOKYO, V41, P619, DOI 10.1080/00021369.1977.10862552
   Smits JP, 1996, PROCESS BIOCHEM, V31, P669, DOI 10.1016/S0032-9592(96)00019-2
   SUGIURA M, 1984, LIPASES, P505
   SZTAJER H, 1989, BIOTECHNOL LETT, V11, P895, DOI 10.1007/BF01026848
NR 23
TC 170
Z9 179
U1 0
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-5113
EI 1873-3298
J9 PROCESS BIOCHEM
JI Process Biochem.
PD OCT
PY 1999
VL 35
IS 1-2
BP 85
EP 90
DI 10.1016/S0032-9592(99)00036-9
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering, Chemical
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering
GA 252UK
UT WOS:000083520500013
DA 2020-12-08
ER

PT J
AU Castilho, LR
   Alves, TLM
   Medronho, RA
AF Castilho, LR
   Alves, TLM
   Medronho, RA
TI Recovery of pectolytic enzymes produced by solid state culture of
   Aspergillus niger (vol 34, pg 181, 1999)
SO PROCESS BIOCHEMISTRY
LA English
DT Correction
C1 Univ Fed Rio de Janeiro, COPPE, Program Chem Engn, Ctr Tecnol, BR-21949900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Dept Chem Engn, Sch Chem, Ilha Fundao, BR-21949900 Rio De Janeiro, Brazil.
RP Alves, TLM (corresponding author), Univ Fed Rio de Janeiro, COPPE, Program Chem Engn, Ctr Tecnol, Sala G-116, BR-21949900 Rio De Janeiro, Brazil.
RI Castilho, Leda/I-8939-2014; Medronho, Ricardo/Q-1762-2015
OI Medronho, Ricardo/0000-0001-5603-9762
CR Castilho LR, 1999, PROCESS BIOCHEM, V34, P181, DOI 10.1016/S0032-9592(98)00089-2
NR 1
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-5113
J9 PROCESS BIOCHEM
JI Process Biochem.
PD JUN
PY 1999
VL 34
IS 4
BP 417
EP 417
DI 10.1016/S0032-9592(99)00061-8
PG 1
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering, Chemical
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering
GA 210DM
UT WOS:000081089900013
DA 2020-12-08
ER

PT J
AU Castilho, LR
   Alves, TLM
   Medronho, RA
AF Castilho, LR
   Alves, TLM
   Medronho, RA
TI Recovery of pectolytic enzymes produced by solid state culture of
   Aspergillus niger
SO PROCESS BIOCHEMISTRY
LA English
DT Article
DE pectinases; polygalacturonase; recovery; extraction; solid state
   fermentation; Aspergillus niger
ID MOLDY BRAN; AMYLOGLUCOSIDASE; EXTRACTION; PURIFICATION; FERMENTATION
AB Pectinases are enzymes with a wide range of applications in the food and drink industries. In the present work, the extraction of pectinases produced by Aspergillus niger in a solid state fermentation system was investigated. The purpose was to reduce enzyme losses in the fermented solids and at the same time obtain a crude extract as concentrated as possible. Initially the performances of stirred tank and fixed bed extractors were compared. Polygalacturonase activity and viscosity reducing capacity obtained in the stirred tank system were 105% and 15% superior, respectively. Repeated extractions and multiple stage countercurrent extraction were studied, employing stirred tanks. It was possible to observe that three stages were enough for total recovery of the enzymes contained in the solids. The final enzyme extract obtained by counter-current extraction with three stages showed a polygalacturonase activity 81% higher than the one obtained by one-stage extraction. (C) 1999 Published by Elsevier Science Ltd. All rights reserved.
C1 Univ Fed Rio de Janeiro, COPPE, Program Chem Engn, Ctr Tecnol, BR-21949900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Sch Chem, Dept Chem Engn, Ctr Tecnol, BR-21949900 Rio De Janeiro, Brazil.
RP Alves, TLM (corresponding author), Univ Fed Rio de Janeiro, COPPE, Program Chem Engn, Ctr Tecnol, Sala G-116, BR-21949900 Rio De Janeiro, Brazil.
RI Castilho, Leda/I-8939-2014; Medronho, Ricardo/Q-1762-2015
OI Medronho, Ricardo/0000-0001-5603-9762
CR CASTILHO LR, 1997, THESIS FEDERAL U RIO
   CASTILHO LR, 1996, P 11 BRAZ C CHEM ENG, V2, P1466
   Coelho MAZ, 1995, REV MICROBIOL, V26, P318
   COONEY CL, 1987, DOWNSTREAM PROCESSIN
   Couri S, 1995, REV MICROBIOL, V26, P314
   GHILDYAL NP, 1991, PROCESS BIOCHEM, V26, P235, DOI 10.1016/0032-9592(91)85005-9
   KUMAR PKR, 1987, PROCESS BIOCHEM, V22, P139
   LANGONE MAP, 1996, BRAZ J CHEM ENG, V13, P1
   McCabe W.L., 1985, UNIT OPERATIONS CHEM
   Ramadas M, 1995, BIOTECHNOL TECH, V9, P901, DOI 10.1007/BF00158544
   RAMAKRISHNA SV, 1982, INDIAN J TECHNOL, V20, P476
   SOMOGYI M, 1952, J BIOL CHEM, V195, P19
   WENZIG E, 1993, CHEM ENG TECHNOL, V16, P405
NR 13
TC 47
Z9 52
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-5113
J9 PROCESS BIOCHEM
JI Process Biochem.
PD FEB
PY 1999
VL 34
IS 2
BP 181
EP 186
DI 10.1016/S0032-9592(98)00089-2
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering, Chemical
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering
GA 182NY
UT WOS:000079506100012
DA 2020-12-08
ER

EF